"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A,US 1150744 A,160-153-060-399-711,1915-08-17,1915,US 3290815 A,1915-06-08,US 3290815 A,1915-06-08,SCREWLESS DOOR-HINGE.,,CARNEY PETER J,CARNEY PETER J,,https://lens.org/160-153-060-399-711,Granted Patent,no,0,1,1,1,0,E05D5/04;;E05D5/04,,,0,0,,,,EXPIRED
2,US,B1,US 8534934 B1,181-018-077-246-295,2013-09-17,2013,US 201213517846 A,2012-06-14,US 201213517846 A,2012-06-14,Camera stabilization device and method of use,"The present invention is a dynamically balanced, lightweight multifunctional, camera stabilization device that allows a film or digital video camera to be flown out of arms reach of the operator and maintain orientation toward the subject matter, while allowing the operator smooth control of rotation or pan of the camera.",CARNEY PETER L,CARNEY PETER L,,https://lens.org/181-018-077-246-295,Granted Patent,yes,2,30,1,1,0,F16M11/02;;F16M11/04;;F16M11/041;;F16M11/048;;F16M11/2078;;F16G13/04;;F16M2200/022;;F16M2200/04;;G03B17/563;;F16M11/02;;F16M11/048;;F16M2200/04;;F16M11/041;;F16G13/04;;F16M11/04;;F16M2200/022;;F16M11/2078;;G03B17/563,F16M11/02;;G03B17/48;;F16M11/04;;H04N5/225,396/428;;396/421;;352/197;;352/243;;348/373;;248/178.1;;248/187.1,0,0,,,,INACTIVE
3,CN,A,CN 114730256 A,123-966-504-807-058,2022-07-08,2022,CN 202080078455 A,2020-11-11,US 201962933831 P;;US 2020/0060006 W,2019-11-11,Computerized system and method for distributed low-code/code-free computing environment,"Systems and methods are disclosed for improving interactions with computers in a content generation, hosting, and/or provision system supported by or configured with a device, server, and/or platform, or among these computers. The disclosed systems and methods provide a novel low-code/code-free software development framework that enables the creation of software (e.g., applications) through graphical user interfaces and configurations rather than traditional manual coding programming. A low code (LC) model enables developers of different experience levels to create applications using a visual user interface in conjunction with model-driven logic. Similarly, the code-free model enables development of applications without coding on the client side. Thus, the disclosed LCNC framework reduces the amount of conventional manual coding, enabling accelerated delivery of business applications.",AVEVA SOFTWARE LLC,CARNEY DANIEL PETER,,https://lens.org/123-966-504-807-058,Patent Application,no,0,0,6,6,0,G06F8/34;;G06F8/35;;G06F8/34;;G06F8/77;;G06F8/33;;G06F8/35,G06F8/34,,0,0,,,,PENDING
4,GB,A,GB 2219489 A,191-638-849-064-425,1989-12-13,1989,GB 8907769 A,1987-10-19,GB 8625009 A;;GB 8626699 A;;GB 8700749 W,1986-10-18,APPARATUS FOR PREPARING AN INFUSION,"Apparatus for preparing an infusion from a liquid and an infusible ingredient comprises an infusion chamber (14) with a body and a movable base (36) provided with a filter (38), a receiver (44) for receiving infusion through the filter, means (34) for moving the base between closed and open positions, an air pump (16) arranged either to draw air upwardly through the filter during infusion or to pressurize the infusion chamber for discharging the infused liquid through the filter, and a rotary control member (20) which is arranged to control both the means for moving the base between its closed and open positions and the operation of the air pump. The air pump preferably is associated with a rotary valve (30) which connects either the suction or pressure side of the pump to the infusion chamber. Also described is a dispensing device (12) for delivering the infusible ingredient to the chamber, and a wiper device (40) for removing spent infusible ingredient from the filter, both of which also are operated by the rotary control member (20).",CARNEY PETER ANDREW,CARNEY PETER ANDREW,,https://lens.org/191-638-849-064-425,Patent Application,no,5,2,4,6,0,A47J31/401;;A47J31/32,A47J31/32;;A47J31/40,A4E E114          EZ;;A4E E128          EZ;;A4E E138          EZ;;A4E E166          EZ;;A4E E168          EZ,0,0,,,,EXPIRED
5,GB,B,GB 2219489 B,063-641-623-381-379,1990-06-13,1990,GB 8907769 A,1987-10-19,GB 8625009 A;;GB 8626699 A;;GB 8700749 W,1986-10-18,APPARATUS FOR PREPARING AN INFUSION,,CARNEY PETER ANDREW;;SANKEY VENDING LTD,CARNEY PETER ANDREW,,https://lens.org/063-641-623-381-379,Granted Patent,no,5,0,4,6,0,A47J31/401;;A47J31/32,A47J31/32;;A47J31/40,A4E E114          EZ;;A4E E128          EZ;;A4E E138          EZ;;A4E E166          EZ;;A4E E168          EZ,0,0,,,,EXPIRED
6,US,A,US 3209999 A,003-655-914-874-545,1965-10-05,1965,US 29103663 A,1963-06-27,US 29103663 A,1963-06-27,Analyzing instruments,,ROY CARNEY PETER,ROY CARNEY PETER,,https://lens.org/003-655-914-874-545,Granted Patent,no,4,1,1,1,0,G06G1/0073;;G06G1/0073,G06G1/00,,0,0,,,,EXPIRED
7,AU,A,AU 1994/072145 A,101-265-462-000-909,1995-02-06,1995,AU 1994/072145 A,1994-06-29,US 8473693 A;;US 9407289 W,1993-06-29,Watchband adaptor fitting for a wristwatch casing,,CHISCO INC,CARNEY PETER L,,https://lens.org/101-265-462-000-909,Patent Application,no,0,0,3,3,0,A44C5/14;;G04B37/1486;;G04B37/1493;;Y10T24/4782;;Y10T24/4782;;G04B37/1486;;A44C5/14;;G04B37/1493,A44C5/14;;G04B37/14,,0,0,,,,PENDING
8,WO,A1,WO 1995/002208 A1,129-278-056-331-971,1995-01-19,1995,US 9407289 W,1994-06-29,US 8473693 A,1993-06-29,WATCHBAND ADAPTOR FITTING FOR A WRISTWATCH CASING,"An adaptor (30) attachable to the watch casing of a watch is structured with attachment means (40) for being secured to the watchband securement means (12) of the watch casing, and is further structured with watchband retaining structure (48) which allows attachment of a watchband (16) by means different than is provided on the watch casing (10). Thus, the watch casing (10) may be converted for use with watchbands which are not configured to be attachable to that particular watch casing. Likewise, conventional watches employing pin means for attachment of the watchband may be converted to attach uniquely designed watchbands configured for attachment only to correspondingly unique watch casings.",CHISCO INC,CARNEY PETER L,,https://lens.org/129-278-056-331-971,Patent Application,yes,10,0,3,3,0,A44C5/14;;G04B37/1486;;G04B37/1493;;Y10T24/4782;;Y10T24/4782;;G04B37/1486;;A44C5/14;;G04B37/1493,A44C5/14;;G04B37/14,,0,0,,,,PENDING
9,US,A,US 5363351 A,020-193-461-403-777,1994-11-08,1994,US 8473693 A,1993-06-29,US 8473693 A,1993-06-29,Watchband adaptor fitting for a wristwatch casing,"An adaptor attachable to the watch casing of a watch is structured with attachment means for being secured to the watchband securement means of the watch casing, and is further structured with watchband retaining structure which allows attachment of a watchband by means different than is provided on the watch casing. Thus, the watch casing may be converted for use with watchbands which are not configured to be attachable to that particular watch casing. Likewise, conventional watches employing pin means for attachment of the watchband may be converted to attach uniquely designed watchbands configured for attachment only to correspondingly unique watch casings.",CHISCO INC,CARNEY PETER L,ETA SA FABRIQUES D'EBAUCHES (1999-06-30);;CLARK BARRY L (1999-06-30);;CHISCO INC (1993-08-24),https://lens.org/020-193-461-403-777,Granted Patent,yes,14,108,3,3,0,A44C5/14;;G04B37/1486;;G04B37/1493;;Y10T24/4782;;Y10T24/4782;;G04B37/1486;;A44C5/14;;G04B37/1493,A44C5/14;;G04B37/14,368/282;;X 24265WS;;224/164,0,0,,,,EXPIRED
10,WO,A1,WO 1988/002612 A1,181-245-770-078-816,1988-04-21,1988,GB 8700749 W,1987-10-19,GB 8625009 A;;GB 8626699 A,1986-10-18,APPARATUS FOR PREPARING AN INFUSION,"Apparatus for preparing an infusion from a liquid and an infusible ingredient comprises an infusion chamber (14) with a body and a movable base (36) provided with a filter (38), a receiver (44) for receiving infusion through the filter, means (34) for moving the base between closed and open positions, an air pump (16) arranged either to draw air upwardly through the filter during infusion or to pressurize the infusion chamber for discharging the infused liquid through the filter, and a rotary control member (20) which is arranged to control both the means for moving the base between its closed and open positions and the operation of the air pump. The air pump preferably is associated with a rotary valve (30) which connects either the suction or pressure side of the pump to the infusion chamber. Also described is a dispensing device (12) for delivering the infusible ingredient to the chamber, and a wiper device (40) for removing spent infusible ingredient from the filter, both of which also are operated by the rotary control member (20).",CARNEY PETER ANDREW,CARNEY PETER ANDREW,,https://lens.org/181-245-770-078-816,Patent Application,yes,5,32,4,6,0,A47J31/401;;A47J31/32,A47J31/32;;A47J31/40,A4E E114          EZ;;A4E E128          EZ;;A4E E138          EZ;;A4E E166          EZ;;A4E E168          EZ,0,0,,,,PENDING
11,US,A1,US 2013/0309650 A1,062-347-659-231-184,2013-11-21,2013,US 201313897335 A,2013-05-17,US 201313897335 A;;US 201261649298 P,2012-05-20,BINDER OF DRY ERASE PAGES,"A note taking binder gives the user the ability to take notes while dealing neither with the cumbersome tablet PC interface, nor with the fear of running out of battery life. The notes taken with the note taking binder can be photographed more easily than standard pencil and paper notes due to the thickness of the dry erase pages that make up the binder. The pages can also be erased more easily so that the pages can be reused numerous times. This gives the user practically all the benefits of taking and storing notes digitally on his or her digital device of choice. The binder is better than taking notes on a digital device because the notes can be taken and remain visible for extended periods of time without fear of battery depletion. Moreover, the binder allows the user to erase individual characters or diagrams as they are writing.",CARNEY PETER WILLIAM,CARNEY PETER WILLIAM,,https://lens.org/062-347-659-231-184,Patent Application,yes,6,13,1,1,0,B43L1/00;;B43L1/00;;B42D1/007;;B42D1/007;;B42D1/008;;B42D1/008;;B42D1/06;;B42D1/06;;B43L1/008;;B43L1/008,B43L1/00,434/414,0,0,,,,DISCONTINUED
12,US,A1,US 2014/0037281 A1,089-838-177-018-248,2014-02-06,2014,US 201313958535 A,2013-08-03,US 201313958535 A;;US 201261679070 P,2012-08-03,CAMERA STABILIZATION APPARATUS AND METHOD OF USE,"The present invention is a dynamically balanced, light weight multifunctional, camera stabilization device that allows a film or digital video camera to be flown out of arms reach of the operator while still maintaining orientation toward the subject matter and can easily be configured to allow the camera to be oriented, above or below, the stabilization assembly.",CARNEY PETER L,CARNEY PETER L,,https://lens.org/089-838-177-018-248,Patent Application,yes,8,39,1,1,0,F16M11/10;;F16M11/28;;F16M11/32;;F16M13/04;;G03B17/561;;G03B17/561;;F16M11/28;;F16M11/10;;F16M13/04;;F16M11/32,G03B17/56,396/421,0,0,,,,DISCONTINUED
13,US,A,US 1722902 A,177-464-408-630-589,1929-07-30,1929,US 28110328 A,1928-05-28,US 28110328 A,1928-05-28,Head scutcher,,CARNEY PETER A,CARNEY PETER A,,https://lens.org/177-464-408-630-589,Granted Patent,no,0,4,1,1,0,A22B5/10;;A22B5/10,A22B5/10,,0,0,,,,EXPIRED
14,EP,A1,EP 3803949 A1,100-743-938-254-486,2021-04-14,2021,EP 19730463 A,2019-05-31,GB 201808890 A;;GB 2019051500 W,2018-05-31,BENCH-TOP TIME OF FLIGHT MASS SPECTROMETER,,MICROMASS LTD,CARNEY PETER;;CHUMMAR SOJI,,https://lens.org/100-743-938-254-486,Patent Application,yes,0,0,9,9,0,H01J49/02;;H01J49/40;;H01J49/40;;H01J49/0013;;H01J49/063;;H01J49/24;;H01J49/405,H01J49/40;;H01J49/02,,0,0,,,,PENDING
15,WO,A1,WO 2009/047530 A1,159-342-060-030-540,2009-04-16,2009,GB 2008003452 W,2008-10-13,GB 0719917 A,2007-10-11,REGENERATIVE ADSORPTION GAS DRYER,"A regenerative adsorption gas dryer having a wet gas inlet, first and second drying towers, and a dried gas outlet, the inlet, towers and outlet being arranged such that, in use, a flow of purge gas regenerates an off-stream one of the towers, while a stream of wet gas from the wet gas inlet enters an on-stream one of the towers to exit that tower as a stream of dried gas which then continues to the dried gas outlet, the roles of the off -stream and on-stream towers being reversible, -wherein the dryer further has:a first check valve (20) for controlling a stream of dried gas between the first drying tower and the dried gas outlet, and a second check valve (20) for controlling a stream of dried gas between the second drying tower and the dried gas outlet, he first and second check valves being arranged such that the pressure of the stream of dried gas exiting the on-stream tower opens the check valve of that tower to allow the stream of dried gas to continue to the dried gas outlet, and such that the pressure of the stream of dried gas from the on-stream tower closes the check valve of the off-stream tower; and a first by-pass (28) to the first check valve and a second by-pass (28) to the second check valve, each by-pass allowing a restricted flow of gas to be extracted from the stream of dried gas from the on-stream tower to form the flow of purge gas for the off -stream tower. Each check valve may have a valve body (24) which moves relative to a valve seat (22) to open and close the valve, the respective by-pass being formed as a gas passage through the valve body.",WALKER FILTRATION LTD;;WALKER BRIAN;;CARNEY PETER,WALKER BRIAN;;CARNEY PETER,,https://lens.org/159-342-060-030-540,Patent Application,yes,5,0,6,6,0,B01D53/261;;B01D2259/40001;;B01D2259/40003;;B01D2259/40086;;B01D53/261;;B01D2259/40003;;B01D2259/40086;;B01D2259/40001,B01D53/26;;B01D53/04,,0,0,,,,PENDING
16,EP,A1,EP 2205339 A1,037-644-901-618-243,2010-07-14,2010,EP 08806584 A,2008-10-13,GB 2008003452 W;;GB 0719917 A,2007-10-11,REGENERATIVE ADSORPTION GAS DRYER,,WALKER FILTRATION LTD,WALKER BRIAN;;CARNEY PETER,WALKER FILTRATION LIMITED (2013-07-10),https://lens.org/037-644-901-618-243,Patent Application,yes,0,2,6,6,0,B01D53/261;;B01D2259/40001;;B01D2259/40003;;B01D2259/40086;;B01D53/261;;B01D2259/40003;;B01D2259/40086;;B01D2259/40001,B01D53/26;;B01D53/04,,0,0,,,,ACTIVE
17,US,B2,US 8262784 B2,000-920-138-373-304,2012-09-11,2012,US 68271908 A,2008-10-13,GB 0719917 A;;GB 2008003452 W,2007-10-11,Regenerative adsorption gas dryer,"A regenerative adsorption gas dryer has a wet gas inlet, first and second drying towers, and a dried gas outlet. The inlet, towers and outlet are arranged such that, in use, a flow of purge gas regenerates an off-stream one of the towers, while a stream of wet gas from the wet gas inlet enters an on-stream one of the towers to exit that tower as a stream of dried gas which then continues to the dried gas outlet. The roles of the off-stream and on-stream towers are reversible. The dryer further has a first check valve for controlling a stream of dried gas between the first drying tower and the dried gas outlet, and a second check valve for controlling a stream of dried gas between the second drying tower and the dried gas outlet.",WALKER BRIAN;;CARNEY PETER;;WALKER FILTRATION LTD,WALKER BRIAN;;CARNEY PETER,WALKER FILTRATION LIMITED (2008-11-11),https://lens.org/000-920-138-373-304,Granted Patent,yes,12,4,6,6,0,B01D53/261;;B01D2259/40001;;B01D2259/40003;;B01D2259/40086;;B01D53/261;;B01D2259/40003;;B01D2259/40086;;B01D2259/40001,B01D53/02,96/110;;96/116;;96/121;;96/133;;96/134;;96/144,0,0,,,,ACTIVE
18,GB,A,GB 2594076 A,101-657-285-277-589,2021-10-20,2021,GB 202005528 A,2020-04-16,GB 202005528 A,2020-04-16,Vacuum interface,"An analytical instrument comprises a first vacuum region, a second vacuum region, and an annular interface 202 arranged between the first vacuum region and the second vacuum region. The annular interface comprises a main body 202 surrounding an aperture 204. The annular interface comprises one or more coil springs 234, 236 arranged in an annular configuration so as to surround the aperture 204. The one or more springs 234, 236 may be configured to act as an electromagnetic compatibility (EMC) or electromagnetic interference (EMI) shield. Beneficially this can prevent electric fields from being transmitted into the vacuum chamber where sensitive optics may be housed.",MICROMASS LTD,PETER CARNEY;;JAMES BETHELL,,https://lens.org/101-657-285-277-589,Patent Application,no,4,0,2,2,0,H01J49/24;;F16L23/18;;F16J15/127;;F16L23/18;;H01J49/02;;H01J49/24,H01J49/24;;F16L23/18;;H01J49/02,,3,1,024-552-600-366-417,10.1016/0042-207x(92)90200-g,"WURSCHING ET AL: ""Residual gas analysis in a space simulation facility"", VACUUM, PERGAMON PRESS, GB, vol. 43, no. 1-2, 1 January 1992 (1992-01-01), pages 137 - 141, XP025733921, ISSN: 0042-207X, [retrieved on 19920101], DOI: 10.1016/0042-207X(92)90200-G;;ANONYMOUS: ""Bal Spring(TM) canted coil spring Solutions for EMI/RFI Shielding Applications"", 1 January 2015 (2015-01-01), XP055756436, Retrieved from the Internet <URL:https://www.balseal.com/technical-library/catalogs/product-catalogs/> [retrieved on 20201203];;ANONYMOUS: ""EMI Gasket Catalog DM8 BalShield (TM) Solutions for EMI Applications"", 1 January 2001 (2001-01-01), XP055756370, Retrieved from the Internet <URL:https://docplayer.net/33163378-Balshield-solutions-for-emi-applications-emi-gasket-catalog-dm8-simply-better-shielding.html> [retrieved on 20201203]",DISCONTINUED
19,US,A1,US 2010/0212505 A1,097-989-636-031-870,2010-08-26,2010,US 68271908 A,2008-10-13,GB 0719917 A;;GB 2008003452 W,2007-10-11,REGENERATIVE ADSORPTION GAS DRYER,"A regenerative adsorption gas dryer has a wet gas inlet, first and second drying towers, and a dried gas outlet. The inlet, towers and outlet are arranged such that, in use, a flow of purge gas regenerates an off-stream one of the towers, while a stream of wet gas from the wet gas inlet enters an on-stream one of the towers to exit that tower as a stream of dried gas which then continues to the dried gas outlet. The roles of the off-stream and on-stream towers are reversible. The dryer further has a first check valve for controlling a stream of dried gas between the first drying tower and the dried gas outlet, and a second check valve for controlling a stream of dried gas between the second drying tower and the dried gas outlet.",WALKER FILTRATION LTD,WALKER BRIAN;;CARNEY PETER,,https://lens.org/097-989-636-031-870,Patent Application,yes,5,4,6,6,0,B01D53/261;;B01D2259/40001;;B01D2259/40003;;B01D2259/40086;;B01D53/261;;B01D2259/40003;;B01D2259/40086;;B01D2259/40001,B01D53/26;;B01D53/04,96/110;;96/118,0,0,,,,ACTIVE
20,WO,A1,WO 2019/229459 A1,044-692-988-870-707,2019-12-05,2019,GB 2019051500 W,2019-05-31,GB 201808890 A,2018-05-31,BENCH-TOP TIME OF FLIGHT MASS SPECTROMETER,"An assembly for a mass spectrometer, comprising a housing (106) and a Time of Flight analyser (110), wherein the housing (106) is configured to enclose at least the Time of Flight analyser (110), and the Time of Flight analyser comprises a pusher assembly (120) and a flight tube (160), wherein the Time of Flight mass analyser (110) is cantilevered from the housing.",MICROMASS LTD,CARNEY PETER;;CHUMMAR SOJI,,https://lens.org/044-692-988-870-707,Patent Application,yes,4,4,9,9,0,H01J49/02;;H01J49/40;;H01J49/40;;H01J49/0013;;H01J49/063;;H01J49/24;;H01J49/405,H01J49/02;;H01J49/40,,1,0,,,"BORIS KOZLOV ET AL: ""Time-of-flight mass spectrometer for investigations of laser ablation"", ASMS 1999 AT DALLAS, 1 May 1999 (1999-05-01), XP055607207, Retrieved from the Internet <URL:https://www.researchgate.net/publication/330202298_Time-of-flight_mass_spectrometer_for_investigations_of_laser_ablation> [retrieved on 20190719]",PENDING
21,CN,A,CN 112204701 A,012-564-222-863-717,2021-01-08,2021,CN 201980036585 A,2019-05-31,GB 201808890 A;;GB 2019051500 W,2018-05-31,BENCH-TOP TIME OF FLIGHT MASS SPECTROMETER,"An assembly for a mass spectrometer, comprising a housing (106) and a Time of Flight analyser (110), wherein the housing (106) is configured to enclose at least the Time of Flight analyser (110), andthe Time of Flight analyser comprises a pusher assembly (120) and a flight tube (160), wherein the Time of Flight mass analyser (110) is cantilevered from the housing.",MICROMASS LTD,CARNEY PETER;;CHUMMAR SOJI,,https://lens.org/012-564-222-863-717,Patent Application,no,9,0,9,9,0,H01J49/02;;H01J49/40;;H01J49/40;;H01J49/0013;;H01J49/063;;H01J49/24;;H01J49/405,H01J49/40;;H01J49/02,,0,0,,,,PENDING
22,EP,B1,EP 2205339 B1,110-485-004-103-207,2013-08-14,2013,EP 08806584 A,2008-10-13,GB 2008003452 W;;GB 0719917 A,2007-10-11,REGENERATIVE ADSORPTION GAS DRYER,,WALKER FILTRATION LTD,WALKER BRIAN;;CARNEY PETER,WALKER FILTRATION LIMITED (2013-07-10),https://lens.org/110-485-004-103-207,Granted Patent,yes,5,0,6,6,0,B01D53/261;;B01D2259/40001;;B01D2259/40003;;B01D2259/40086;;B01D53/261;;B01D2259/40003;;B01D2259/40086;;B01D2259/40001,B01D53/26;;B01D53/04,,0,0,,,,ACTIVE
23,GB,A,GB 2574723 A,114-909-236-435-157,2019-12-18,2019,GB 201907730 A,2019-05-31,GB 201808890 A,2018-05-31,Bench-top time of flight mass spectrometer,"An assembly for a mass spectrometer comprising: a housing; and, a time of flight (ToF) analyser 110 enclosed within and cantilevered from the housing. The ToF analyser comprises a pusher assembly 120 and a flight tube 160, which are preferably mounted to a support assembly 130 of the ToF analyser, the support being cantilevered from the housing. The support may have a main body 142, to which the flight tube and pusher are attached, and a connecting member 132, for fastening to the housing. The connecting member may be a horseshoe or U-shaped bracket connected to the housing by thermally and/or electrically insulating fasteners, preferably extending through apertures 138. A reflectron 170 may be mounted to the flight tube with insulating fasteners. The insulating fasteners may be formed of ceramic or plastic, such as polyether ether ketone (PEEK).",MICROMASS LTD,PETER CARNEY;;SOJI CHUMMAR,,https://lens.org/114-909-236-435-157,Patent Application,no,2,1,9,9,0,H01J49/02;;H01J49/40;;H01J49/40;;H01J49/0013;;H01J49/063;;H01J49/24;;H01J49/405,H01J49/40,,0,0,,,,ACTIVE
24,AT,T1,AT E423217 T1,108-558-731-250-994,2009-03-15,2009,AT 03711275 T,2003-02-27,US 36121902 P;;US 36865802 P,2002-03-01,ASSAYS ZUR ÜBERWACHUNG VON KREBSPATIENTEN AUF GRUNDLAGE DER SPIEGEL VON ANALYTENKOMPONENTEN DES PLASMINOGEN-AKTIVATOR-SYSTEMS IN PROBEN VON KÖRPERFLÜSSIGKEITEN,"The present invention describes methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. An increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression.",SIEMENS HEALTHCARE DIAGNOSTICS,CARNEY WALTER;;HAMER PETER,,https://lens.org/108-558-731-250-994,Granted Patent,no,0,0,14,14,0,G01N33/57484;;G01N33/86;;G01N2333/8132;;G01N2333/9723;;G01N2800/52;;Y10T436/25;;A61P35/00;;Y10T436/25;;G01N33/57484;;G01N2333/9723;;G01N33/86;;G01N2333/8132;;G01N2800/52,G01N33/574;;G01N33/86,,0,0,,,,EXPIRED
25,US,B2,US 11437226 B2,118-261-756-252-908,2022-09-06,2022,US 201917057012 A,2019-05-31,GB 201808890 A;;GB 2019051500 W,2018-05-31,Bench-top time of flight mass spectrometer,"An assembly for a mass spectrometer, comprising a housing ( 106 ) and a Time of Flight analyser ( 110 ), wherein the housing ( 106 ) is configured to enclose at least the Time of Flight analyser ( 110 ), and the Time of Flight analyser comprises a pusher assembly ( 120 ) and a flight tube ( 160 ), wherein the Time of Flight mass analyser ( 110 ) is cantilevered from the housing.",MICROMASS LTD,CARNEY PETER;;CHUMMAR SOJI,MICROMASS UK LIMITED (2021-03-19),https://lens.org/118-261-756-252-908,Granted Patent,yes,263,0,9,9,0,H01J49/02;;H01J49/40;;H01J49/40;;H01J49/0013;;H01J49/063;;H01J49/24;;H01J49/405,H01J49/40;;H01J49/00;;H01J49/06;;H01J49/24,,78,5,002-875-246-112-868;;004-471-982-018-484;;022-561-862-885-681;;119-779-971-342-191;;062-933-196-688-541,11523084;;10.1002/jms.207;;10.1002/rcm.1074;;12820206;;10.1021/ac0518811;;16579588;;10.1016/j.ijms.2013.02.010;;10.1063/1.4922913;;pmc4482810;;26133872,"Combined Search and Examination Report under Sections 17 and 18(3), for Application No. GB1907724 7, dated Sep. 25, 2019, 7 pages.;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fee for International application No. PCT/3B2019/051494, dated Sep. 19, 2019.;;Combined Search and Examination Report under Sections 17 and 18(3), dated Sep. 27, 2019, for Application No. GB1907736.1, 6 pages.;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fees, for International application No. PCT/GB2019/051499, dated Sep. 4, 2019.;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fee, for International Application No. PCT/GB2019/051496, dated Aug. 29, 2019.;;Anonymous, “Time-of-flight mass spectrometry”, Wikipedia, Apr. 28, 2018 (Apr. 28, 2018), XP055614063, Retrieved from the Internet:URL:https://en.wikipedia.org/w/index.php title=Time-of-flight_mass_spectrometry oldid=838663844 [retrieved on Aug. 20, 2019].;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fees for International application No. PCT/GB2019/051497, dated Sep. 2, 2019.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1907745.2, dated Aug. 13, 2019, 7 pages.;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fee, for International application No. PCT/GB2019/051501, dated Jul. 29, 2019, 14 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051497, dated Nov. 5, 2019, 19 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051503, dated Sep. 25, 2019, 17 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051496, dated Oct. 23, 2019, 29 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051506, dated Sep. 25, 2019, 14 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051494, dated Nov. 18, 2019, 20 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051507, dated Oct. 15, 2019, 17 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051508, dated Oct. 23, 2019, 16 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051499, dated Nov. 5, 2019, 19 pages.;;Examination Report under Section 18(3) for Application No. GB1907719.7, dated Jul. 28, 2021, 9 pages.;;Parkes, S. SpaceWire User Guide, STAR-Dundee [online] 2012 [retrieved on Aug. 13, 2021], Retrieved from Internet URL: https://www.star-dundee.com/wp-content/star_uploads/general/SpaceWire-Users-Guide.pdf, 117 pages.;;SCIEX, “3200 Series of Instruments System User Guide” [online], published Apr. 2018, available from: https://sciex.com/content/dam/SCIEX/pdf/customer-docs/user-guide/3200-system-user-guide-en.pdf, 241 pages.;;Combined Search and Examination Report under Sections 17 and 18(3), for Application No. GB2100898.2, dated Jun. 21, 2021, 7 pages.;;Combined Search and Examination Report under Sections 17 and 18(3), for Application No. GB2001530.1, dated Aug. 5, 2020, 7 pages.;;Thermo Fisher Scientific, Inc, Feb. 2015, Orbitrap Fusion Hardware Manual [online]. Retrieved from Internet URL: http://www.unitylabservices.eu/content/dam/tfs/ATG/CMD/cmddocuments/oper/oper/ms/lc-ms/sys/Man-80000-97016-Orbitrap-Fusion-Hardware-Man8000097016-A-EN.pdf, 122 pages.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 BioPharma Analytical Summit BioAccord Abstract. ASMS MS-in-QC, PowerPoint 24 pages.;;International Preliminary Report on Patentability for International application No. PCT/GB2019/051510, dated Dec. 1, 2020, 7 pages.;;Examination Report under Section 18(3) for Application No. GB1907739.5, dated Nov. 3, 2020, 5 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808932 6, dated Nov. 21, 2018, 4 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808890 6, dated Nov. 28, 2018, 7 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808912 8, dated Nov. 30, 2018, 10 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808942.5, dated Dec. 3, 2018, 7 pages.;;Chernushevich, I. V., et al., “An introduction to quadrupole-time-of-flight mass spectrometry”, Journal of Mass Spectrometry, 36(8):849-65 (2001) Abstract only.;;Chernushevich, I.V., et al., “Charge state separation for protein applications using a quadrupole time-of-flight mass spectrometer”, Rapid Communications in Mass Spectrometry 17(13):1416-1424 (2003). Abstract only.;;Makarov, A. et al., “Performance evaluation of a hybrid linear ion trap/orbitrap mass spectrometer,” Analytical Chemistry, 78(7):2113-20 (2006).;;Combined Search and Examination Report under Sections 117 and 18(3) for Application No. GB1808948.2 dated Nov. 21, 2018, 7 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808893.0 dated Nov. 27, 2018, 8 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808936.7 dated Nov. 20, 2018, 10 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808892.2, dated Dec. 3, 2018, 6 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Applicaton No. GB1808894.8 dated Dec. 3, 2018, 7 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808949.0 dated Oct. 31, 2018, 8 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1907722.1 dated Jun. 28, 2019, 8 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808889.8 dated Nov. 30, 2018, 7 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051504, dated Jul. 23, 2019, 11 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1818003.4, dated May 2, 2019, 6 pages.;;Invitation to pay additional fees and, where applicable, protest fee for PCT/GB2019/051508, dated Aug. 28, 2019.;;Author unknown, “Operating Manual and Programming Reference, Models RGA100, RGA200, and RGA300 Residual Gas Analyzer,” Stanford Research Systems Revision 1.8 (May 2009).;;Jungmann, J. H., et al., “An in-vacuum, pixelated detection system for mass spectrometric analysis and imaging of macromolecules,” International Journal of Mass Spectrometry, 341-342:34-44 (2013).;;Invitation to pay additional fees and, where applicable, protest fee for International application No. PCT/GB2019/051507, dated Aug. 20, 2019, 16 pages.;;Fang, C., and Hanley, L., “ChiMS: Open-source instrument control software platform on LabVIEW for imaging/depth profiling mass spectrometers,” Review of Scientific Instruments, 86:065106-1 through 065016-7 (2015).;;Invitation to pay additional fees and, where applicable, protest fee for International application No. PCT/GB2019/051506, dated Jul. 22, 2019,13 pages.;;Invitation to pay addition al fees and, where applicable, protest fee for PCT/GB2019/051503, dated Jul. 25, 2019, 17 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051500, dated Aug. 5, 2019, 9 pages.;;Kozlov, B., et al., “Time-of-flight mass spectrometer for investigations of laser ablation,” ASMS Conference paper, Dallas, TX (May 1999). [Retrieved from the Internet URL: https//www.researchgate.net/publication/330202298_Time-of-flight_mass_spectrometer_for_investigations_of_laser_ablation]. Abstract.;;Shion, H., et al., “Towards Overcoming the Challenges of Implementing Accurate Mass MS for Routine Biotherapeutic Analysis” 2018 ASMS Prototype oa-TOF Abstract HYS Final.;;Shion, S., et al., “Towards Overcoming the Challenges of Implementing Accurate Mass MS for Routine Biotherapeutic Analysis” 2018 ASMS Prototype oa-TOF WP699 HYS Final Poster.;;Shion, H., et al., “A Fit-for-purpose Accurate Mass MS for Routine Biotherapeutic Analysis”, 2018 CASSS Mass Spec HYS Final Poster.;;Shion, H., et al., “A Fit-for-purpose Accurate Mass MS for Routine Biotherapeutic Analysis”, 2018 CASSS Mass Spec BioTof HYS Final, Abstract.;;Shion, H., et al., “Progress Towards Implementing Simple Time-of-flight Accurate Mass MS for Routine Biotherapeutic Analysis”, XXII (IMSC) International Mass Spectrometry Conference Florence, Italy (2018) Abstract.;;Shion, H., et al., “Progress Towards Implementing Simple Time-of-flight Accurate Mass MS for Routine Biotherapeutic Analysis”, XXII International Mass Spectrometry Conference Florence, Italy (2018) poster.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 ASMS BioAccord Oral Session PowerPoint.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 ASMS BioAccord Abstract.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments” 2019 ATEurope BioAccord, Abstract.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments” 2019 ATEurope BioAccord, Poster.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 BioPharma Analytical Summit BioAccord, abstract.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 Bio Pharma Summit BioAccord, Poster.;;Shion, H., “Enabling Routine and Reproducible Biotherapeutic Analysis when Data Integrity Matters”, 2019 15th Annual PEGs Boston Waters BioAccord, PowerPoint 29 pages.;;Shion, H., “Enabling Routine and Reproducible Biotherapeutic Analysis when Data Integrity Matters”, 2019 15th Annual PEGs Boston Waters BioAccord, Abstract.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 Pitt Con Bio Accord, Poster.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 Pitt Con Bio Accord, Abstract.;;Combined Search and Exam Report from IPO for GB Application No. 1907739.5, dated Nov. 27, 2019, 8 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051510, dated Aug. 29, 2019, 13 pages.;;Combined Search and Exam Report from IPO for GB Application No. 1907735.3, dated Nov. 25, 2019, 7 pages.;;Combined Sand E Report under Sections 17 and 18(3) for Application No. GB1907734.6, dated Oct. 31, 2019, 7 pages.;;International Search Report and Written Opinion for International Application No. PCT/GB2019/051498, dated Nov. 6, 2019, 21 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1907719.7, dated Nov. 15, 2019, 11 pages.;;Author unknown, “Waters Xevo G2-S QTof Operators Overview and Maintenance Guide”, Feb. 11, 2013 (Feb. 11, 2013), XP55606374, Retrieved from the Internet: URL:https://www.waters.eom/webassets/cms/support/docs/kevo_g2-s_qtof_715003596rb.pdf [retrieved on Jul. 17, 2019].;;International Search Report and Written Opinion for International application No. PCT/GB2019/051501, dated Sep. 25, 2019, 17 pages.;;Examination Report under Section 18(3) for Application No. GB1907722.1, dated Oct. 26, 2021, 4 pages.;;Examination Report under Section 18(3) for Application No. GB2020743.7, dated Jan. 28, 2022, 6 pages.",ACTIVE
26,US,A1,US 2021/0210329 A1,040-352-483-310-636,2021-07-08,2021,US 201917057012 A,2019-05-31,GB 201808890 A;;GB 2019051500 W,2018-05-31,BENCH-TOP TIME OF FLIGHT MASS SPECTROMETER,"An assembly for a mass spectrometer, comprising a housing ( 106 ) and a Time of Flight analyser ( 110 ), wherein the housing ( 106 ) is configured to enclose at least the Time of Flight analyser ( 110 ), and the Time of Flight analyser comprises a pusher assembly ( 120 ) and a flight tube ( 160 ), wherein the Time of Flight mass analyser ( 110 ) is cantilevered from the housing.",MICROMASS LTD,CARNEY PETER;;CHUMMAR SOJI,MICROMASS UK LIMITED (2021-03-19),https://lens.org/040-352-483-310-636,Patent Application,yes,0,4,9,9,0,H01J49/02;;H01J49/40;;H01J49/40;;H01J49/0013;;H01J49/063;;H01J49/24;;H01J49/405,H01J49/40;;H01J49/00;;H01J49/06;;H01J49/24,,0,0,,,,ACTIVE
27,GB,B,GB 2574723 B,185-592-255-327-672,2020-10-28,2020,GB 201907730 A,2019-05-31,GB 201808890 A,2018-05-31,Bench-top time of flight mass spectrometer,,MICROMASS LTD,PETER CARNEY;;SOJI CHUMMAR,,https://lens.org/185-592-255-327-672,Granted Patent,no,2,3,9,9,0,H01J49/02;;H01J49/40;;H01J49/40;;H01J49/0013;;H01J49/063;;H01J49/24;;H01J49/405,H01J49/40,,0,0,,,,ACTIVE
28,CN,C,CN 1309269 C,032-631-692-676-732,2007-04-04,2007,CN 00107578 A,2000-05-18,US 31481999 A,1999-05-19,Method and arrangement for starting extended spectrum radio telephone receiver,,MOTOROLA INC,CARNEY CHRISTOPHER PETER RAROS,"MOTOROLA MOBILITY CO., LTD. (2011-01-27)",https://lens.org/032-631-692-676-732,Granted Patent,no,4,0,14,30,0,H04B1/70752;;H04B1/70752;;H04B7/26;;H04B1/70751;;H04B1/70751;;H04B1/70753;;H04B1/70753;;H04B1/70756;;H04B1/70756;;H04B2201/70701;;H04B2201/70701;;H04B2201/70702;;H04B2201/70702;;H04B2201/70707;;H04B2201/70707;;H04B2201/70709;;H04B2201/70709,H04Q7/32;;H04B1/16;;H04B1/7075;;H04B7/26;;H04M1/00;;H04M1/73,,0,0,,,,EXPIRED
29,US,S,US D1011941 S,034-869-476-842-903,2024-01-23,2024,US 202229857936 F,2022-10-26,GB 6205108 F,2022-04-29,Mass spectrometer,,MICROMASS LTD,BLAKE ARTHUR;;PAWSON ANDREW;;CARNEY PETER,MICROMASS UK LIMITED (2023-01-05),https://lens.org/034-869-476-842-903,Design Right,no,20,0,1,1,0,,,1004;;D10/81;;D24/216,2,0,,,"Thermo Fisher, Scientific Introduces Groundbreaking Mass Spectrometer to Revolutionize Biological Discovery, Date first available Jun. 5, 2023, [online]retrieved Jul. 24, 2023, available from https://ir.thermofisher.com/investors/news-events/news/news-details/2023/Thermo-Fisher-Scientific-Introduces-Groundb (Year: 2023).;;Labcompare, Buyer's Guide:Best Buys for Mass Spectroscopy, Date first available Mar. 22, 2021, [online]retrieved Jul. 24, 2023, available from https://www.labcompare.com/10-Featured-Articles/574418-Buyers-Guide-Mass-Spectroscopy/ (Year: 2021).",ACTIVE
30,EP,A1,EP 3584474 A1,039-281-264-073-350,2019-12-25,2019,EP 19190542 A,2015-06-04,GB 201410359 A;;EP 15170638 A,2014-06-11,FLOW CONTROL DEVICE,"An adjustable flow control device is provided which has a valve body containing a series of orifices of varying diameter and an indexable valve cover which includes at least one flow conduit which can be positioned and locked in a sealable manner over a chosen orifice whilst the remaining part of the valve cover closes off the other orifices of the valve body. Due to the device having fixed size orifices, each orifice will provide a fixed specific fluid flow rate for any predetermined pressure loss across the orifice. The device is suitable for use on all types of gas and liquid fluids.
",WALKER FILTRATION LTD,WALKER BRIAN;;WISE SIMON;;CARNEY PETER,,https://lens.org/039-281-264-073-350,Patent Application,yes,6,1,8,8,0,B01D53/26;;F16K3/085;;F16K11/074;;B01D53/0446;;B01D2259/40005;;B01D53/047;;F16K3/08;;B01D2259/40003;;B01D53/26;;F16K3/085;;F16K11/074;;B01D53/0446;;B01D2259/40005;;B01D53/047;;B01D2259/40043;;F16K3/08,F16K3/08;;B01D53/04;;B01D53/047;;B01D53/26;;F16K11/074,,0,0,,,,PENDING
31,US,A1,US 2002/0119937 A1,064-446-576-631-875,2002-08-29,2002,US 93216701 A,2001-08-17,US 93216701 A;;US 22659500 P,2000-08-21,Fermentation and purification of migrastatin and analog,"
    Migrastatin and a migrastatin analog can be produced by fermentation of Streptomyces platensis NRRL 18993 and used in pharmaceutical formulations to treat cancer and/or inhibit metastasis of cancer cells. 
",KHOSLA CHAITAN;;LICARI PETER;;CARNEY JOHN,KHOSLA CHAITAN;;LICARI PETER;;CARNEY JOHN,KOSAN BIOSCIENCES INC (2001-11-09),https://lens.org/064-446-576-631-875,Patent Application,yes,0,19,4,4,0,C12P17/16;;C12P17/16;;C07K14/36;;C07K14/36,C07K14/36;;C12P17/16,514/28;;435/76,0,0,,,,EXPIRED
32,US,A1,US 2013/0052026 A1,111-008-964-134-339,2013-02-28,2013,US 201113220656 A,2011-08-29,US 201113220656 A,2011-08-29,AXIAL RETENTION SYSTEM FOR A BLADED ROTOR WITH MULTIPLE BLADE TYPES,A bladed rotor includes a blade lock mountable to a rotor hub adjacent to a multiple of blade slots. The blade lock includes at least one interface feature adjacent to a first of the multiple of blade slots. A first rotor blade includes a blade feature which interfaces with the interface feature to permit the first rotor blade to be axially mounted within the first of the multiple of blade slots but not within a remainder of the multiple of blade slots.,ANDERSON CARNEY R;;TOMEO PETER V,ANDERSON CARNEY R;;TOMEO PETER V,RAYTHEON TECHNOLOGIES CORPORATION (2011-08-29),https://lens.org/111-008-964-134-339,Patent Application,yes,1,2,4,4,0,F01D5/326;;F01D5/326;;Y02T50/60;;Y02T50/60;;Y10T29/49316;;Y10T29/49316,F01D5/32;;B21D53/78,416220 R;;29/889,0,0,,,,INACTIVE
33,US,A1,US 2004/0209336 A1,103-474-531-068-389,2004-10-21,2004,US 83889504 A,2004-05-03,US 83889504 A;;US 93216701 A;;US 22659500 P,2000-08-21,Fermentation and purification of migrastatin and analog,"
    Migrastatin and a migrastatin analog can be produced by fermentation of Streptomyces platensis NRRL 18993 and used in pharmaceutical formulations to treat cancer and/or inhibit metastasis of cancer cells. 
",KHOSLA CHAITAN;;LICARI PETER;;CARNEY JOHN,KHOSLA CHAITAN;;LICARI PETER;;CARNEY JOHN,,https://lens.org/103-474-531-068-389,Patent Application,yes,3,0,4,4,0,C12P17/16;;C12P17/16;;C07K14/36;;C07K14/36,C07K14/36;;C12P17/16,435/135;;514/548,0,0,,,,EXPIRED
34,US,A1,US 2011/0176925 A1,071-590-322-794-498,2011-07-21,2011,US 68942310 A,2010-01-19,US 68942310 A,2010-01-19,TORSIONAL FLEXING ENERGY ABSORBING BLADE LOCK,"A lock for constraining blades in a hub includes a flexible ring for constraining the blades from moving axially in the hub, a finger attached to the hub for preventing the ring from rotating relative to the hub and whereby the ring flexes about at least a partial circumference thereof if urged axially by the blades.",ANDERSON CARNEY R;;TOMEO PETER V,ANDERSON CARNEY R;;TOMEO PETER V,RTX CORPORATION (2010-01-15),https://lens.org/071-590-322-794-498,Patent Application,yes,17,13,5,5,0,F01D5/3015;;F01D5/3015;;F01D5/326;;F01D5/326;;F05D2230/64;;F05D2230/64;;Y10T29/49316;;Y10T29/49316;;Y10T29/49321;;Y10T29/49321,F01D5/32;;B23P15/04,416/221;;29/889,0,0,,,,ACTIVE
35,US,B2,US 7732159 B2,103-493-379-378-852,2010-06-08,2010,US 96532307 A,2007-12-27,US 96532307 A;;US 37564603 A;;US 36121902 P;;US 36865802 P,2002-03-01,Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples,"The present invention describes clinically and medically important methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. As a result of performing the method, an increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression and/or a lack of treatment effectiveness for the patient.",SIEMENS HEALTHCARE DIAGNOSTICS,CARNEY WALTER P;;HAMER PETER J,SIEMENS HEALTHCARE DIAGNOSTICS INC (2007-08-17);;BAYER CORPORATION (2003-04-30);;BAYER HEALTHCARE LLC (2003-01-01),https://lens.org/103-493-379-378-852,Granted Patent,yes,20,0,14,14,0,G01N33/57484;;G01N33/86;;G01N2333/8132;;G01N2333/9723;;G01N2800/52;;Y10T436/25;;A61P35/00;;Y10T436/25;;G01N33/57484;;G01N2333/9723;;G01N33/86;;G01N2333/8132;;G01N2800/52,C12Q1/00;;A01N37/18;;A01N61/00;;A61K31/00;;A61K38/00;;A61K38/28;;A61K49/00;;A61K51/00;;A61M36/14;;G01N33/574;;G01N33/86,435/7.92;;435/4;;435/7.1;;435/7.4;;436/63;;436/64;;436/86;;436/174;;514/1;;514/2;;514/4;;424/1.11;;424/9.1;;424/9.21,52,47,033-990-808-114-75X;;034-134-907-055-024;;047-416-668-164-924;;028-969-327-729-326;;011-783-571-203-307;;035-783-764-342-216;;026-302-592-004-58X;;007-178-707-944-260;;108-323-686-515-562;;070-130-046-842-153;;002-292-577-326-743;;047-960-474-836-226;;106-753-778-592-300;;020-026-345-586-213;;022-580-168-937-799;;011-871-798-991-598;;018-826-014-553-250;;081-414-742-933-634;;018-547-918-765-81X;;022-115-319-245-703;;007-363-367-081-378;;006-335-428-330-899;;062-690-953-950-33X;;041-138-531-537-253;;035-631-914-297-455;;041-041-038-442-209;;019-029-281-233-870;;021-615-903-484-695;;003-249-033-814-813;;056-002-770-711-257;;031-177-911-764-844;;010-559-134-960-542;;025-087-523-019-336;;086-477-987-043-373;;041-863-374-864-841;;181-448-152-035-827;;055-542-669-483-094;;064-741-687-897-846;;035-081-115-342-527;;077-903-001-903-019;;017-077-300-427-35X;;101-395-260-712-954;;011-699-709-349-99X;;094-495-688-845-199;;014-713-113-374-219;;086-483-972-437-207;;012-585-244-632-306,10.1093/aje/kwj063;;16410346;;pmc1444894;;1563002;;11410515;;10024688;;10.3892/ijo.14.3.535;;10.1002/1097-0215(20000920)89:5<431::aid-ijc6>3.0.co;2-v;;11008205;;10676647;;11792750;;10.1093/jnci/94.2.116;;pmc2362331;;10408864;;10.1038/sj.bjc.6690389;;10.1177/107602969700300403;;11062719;;10430786;;10.1093/clinchem/45.8.1206;;11005561;;10.1007/bf02725342;;1172191;;10.1038/256495a0;;25291284;;10.1016/0167-5699(83)90123-8;;10.1002/(sici)1097-0215(19970703)72:1<1::aid-ijc1>3.0.co;2-z;;9212216;;pmc2362263;;10098758;;10.1038/sj.bjc.6690191;;6309368;;10.1007/bf00124213;;10.1016/s0065-230x(08)60028-7;;2930999;;8419965;;10.1152/physrev.1993.73.1.161;;pmc1886060;;1702928;;1855221;;pmc50406;;1279689;;10.1073/pnas.89.22.10686;;1582084;;10.1007/bf00132746;;1950706;;10.1016/s0065-230x(08)61002-7;;1333882;;2151734;;9330876;;10.1016/s0955-0674(97)80126-3;;10.1055/s-0038-1642654;;8578527;;7515053;;10.1016/s0021-9258(17)36595-x;;10.1038/nm0898-923;;9701244;;2109745;;10.1007/bf00272198;;pmc551782;;10.1002/j.1460-2075.1990.tb08213.x;;2157592;;6193874;;pmc1886028;;1850957;;10.1016/0022-1759(95)00016-4;;7769243;;7658022;;10.1016/0022-1759(95)00086-p;;10.1002/eji.1830240426;;8149964;;10.1016/s0378-1119(96)00627-0;;10.1016/s0065-2776(08)60674-4;;7872158;;6186024;;10.1126/science.6186024;;6204768;;10.1016/0092-8674(84)90412-4;;2997370;;10.1099/0022-1317-66-11-2347;;10.1016/0378-1119(86)90137-x;;3023199;;10.1038/nbt0790-662;;1369995;;3086313;;10.1016/s0021-9258(19)57447-6;;10.1093/clinchem/29.3.549;;6825270;;6199316;;10.1002/ijc.2910330310,"Perkins and Schisterman, ""The inconsistency of 'optimal' cutpoints obtained using two criteria based on the receiver operating characteristic curve,"" Am J Epidemiol., 163(7): 670-675 (Apr. 1, 2006; epub Jan. 12, 2006) Abstract.;;Tockman et al., ""Considerations in Bringing a Cancer Biomarker to Clinical Application,"" Cancer Research(Suppl.). 52: 2711s-2718s (May 1, 1992).;;Konecny et al., ""Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer,"" Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, Jun. 2001, 7(6), pp. 1743-1749.;;Miyake et al., ""Elevation of urokinase-type plasminogen activator its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer,"" International Journal of Oncology, Mar. 1999, 14(3), pp. 535-541.;;Yang et al., ""Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets,"" International Journal of Cancer, Sep. 20, 2000, 89(5), pp. 431-439; Abstract.;;Foekens et al., ""The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients,"" Cancer Research, Feb. 1, 2000, 60(3), pp. 636-643; Abstract.;;Look et al., ""Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients,"" Journal of the National Cancer Institute, Jan. 16, 2002, 94(2), pp. 116-128; Abstract.;;Broet et al., ""Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study,"" British Journal of Cancer, May 1999, 80(3-4), pp. 536-545; Abstract.;;Lox et al., ""Tamoxifen-induced changes in the plasma fibrinolytic factors in menopausal women with breast cancer,"" Clinical and Applied Thrombosis/Hemostasis, 1997, 3(4), pp. 234-238; Abstract.;;Morii et al., ""Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma,"" Anticancer Research, Sep. 2000, 20(5A), pp. 3031-3036; Abstract.;;Pedersen et al., ""Determination of the complex between urokinase and its type-1 inhibitor in plasma from healthy donors and breast cancer patients,"" Clinical Chemistry, Aug. 1999, 45(8), pp. 1206-1213; Abstract.;;Nielsen et al., ""Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer,"" Annals of Surgical Oncology, Sep. 2000, 7(8),Lippincott Williams & Wilkins, pp. 617-623; Abstract.;;Supplemental European Search Report Dated Jul. 4, 2006 Corresponding to European Patent Application No. 03 71 1275.;;Köhler et al., ""Continuous cultures of fused cells secreting antibody of predefined specificity."" Nature, Aug. 7, 1975, 256(5517), pp. 495-497.;;Kozbor et al., ""The production of monoclonal antibodies from human lymphocytes,"" Immunology Today, 1983, 4(3), pp. 72-79.;;Cole et al., ""The EBV-Gybridoma technique and its application to human lung cancer,"" Monoclonal Antibodies and Cancer Therapy, 1985, Alan R. Liss, Inc., New York, pp. 77-96.;;Andreasen et al., ""The Urokinase-type plasminogen activator system in cancer metastasis: a review,"" International Journal of Cancer, Jul. 3, 1997, 72(1), pp. 1-22.;;Dewitte et al., ""Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients,"" British Journal of Cancer, Mar. 1999, 79(7/8), pp. 1190-1198.;;Liotta et al., ""Role of collagenases in tumor cell invasión,"" Cancer Metastasis Review, 1982, 1(1), Martinus Nijhoff Publishers, the Hague, the Netherlands, pp. 277-288.;;Danø et al., ""Plasminogen activators, tissue degradation, and cancer,"" Advances in Cancer Research, Klein et al. (eds.), 1985, 44, Academic Press, Inc., pp. 139-266.;;Mignatti et al., ""Biology and biochemistry of proteinases in tumor invasion,"" Physiological Reviews., Jan. 1993, 73(1), The American Physiological Society, pp. 161-195.;;Grondahl-Hansen et al., ""Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans,"" American Journal of Pathology, Jan. 1991, 138(1), pp. 111-117.;;Pyke et al., ""The plasminogen activation system in human colon cancer: Messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma,"" Cancer Research, Aug. 1, 1991, 51(15), pp. 4067-4071.;;Bacharach et al., ""In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis,"" Proceedings of the National Academy of Sciences of the USA, Nov. 5, 1992, 89(22), pp. 10686-10690.;;Duffy, ""The role of proteolytic enzymes in cancer invasion and metastasis,"" Clinical Experimental Metastasis, May 1992, 10(3), Rapid Communications of Oxford, pp. 145-155.;;Pöllänen et al., ""Directed plasminogen activation at the surface of normal and malignant cells,"" Advances in Cancer Research, 1991, 57, Academic Press, Inc., pp. 273-328.;;Ossowski, ""Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase,"" Cancer Research, Dec. 15, 1992, 52(24), pp. 6754-6760.;;Blasi et al., ""Urokinase-dependent cell surface proteolysis and cancer,"" Seminars in Cancer Biology: The Role of Proteases in Cancer, Apr. 1990, 1 (2), pp. 117-126.;;Chapman et al., ""Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration,"" Current Opinion in Cell Biology, Oct. 1997, 9(5), Current Biology, Ltd., pp. 714-724.;;Deng et al., ""The PAI-1/vitronectin interaction: two cats in a bag?"" Thrombosis and Haemostasis, Jul. 1995, 74(1), pp. 66-70.;;Lawrence et al., ""Localization of vitronectin binding domain in plasminogen activator inhibitor-1,"" Journal of Biological Chemistry, May 27, 1994, 269(21), pp. 15223-15228.;;Bajou et al., ""Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization,"" Nature Medicine, Aug. 1998, 4(8), pp. 923-928.;;Kristensen et al., ""Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma,"" Histochemistry, Apr. 1990, 93(6), Springer International, pp. 559-566.;;Cubellis et al., ""Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1,"" The EMBO Journal, Apr. 1990, 9(4), IRL Press at Oxford University Press, pp. 1079-1085.;;Markus et al., ""Plasminogen activator secretion of human tumors in short-term organ culture, including a comparison of primary and metastatic colon tumors,"" Cancer Research, Nov. 1983, 43(11), American Association for Cancer Research, pp. 5517-5525.;;Pyke et al., ""Rapid communication: urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas,"" American Journal of Pathology, May 1991, 138(5), pp. 1059-1067.;;Setyono-Han et al., ""Anti-tumor and anti-metastatic activity of the urokinase/plasmin inhibitor, WX-UK1, as single agent or in combination with epirubicin in the rat BN-472 mammary carcinoma model,"" Proceedings of American Association for Cancer Research: 92nd Annual Meeting, Mar. 24-28, 2001, 42, New Orleans, LA, p. 69 (Abstract #371).;;Probst et al., ""Small molecule approach to inhibit the urokinase-type plasminogen activator system,"" Proceedings of American Association for Cancer Research: 92nd Annual Meeting, Mar. 24-28, 2001, 42, New Orleans, LA, p. 69 (Abstract #370).;;Brinkman et al., ""Phage display of disulfide-stabilized Fv fragments,"" Journal of Immunological Methods, 1995, 182(1), Elsevier Science B.V., pp. 41-50.;;Ames et al., ""Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins,"" Journal of Immunological Methods, 1995, 184(2), Elsevier Science B.V., pp. 177-186.;;Kettleborough et al., ""Isolation of tumor cell-specific single-chain Fv from immunized mice using phage-antibody libraries and the re-construction of whole antibodies from these antibody fragments,"" European Journal of Immunology, Apr. 1994, 24(4), pp. 952-958.;;Persic et al., ""An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries,"" Gene: an International Journal on Genes and Genomes, 1997, 187(1), Elsevier Science B.V., pp. 9-18.;;Burton et al., ""Human antibodies from combinatorial libraries,"" Advances in Immunology, 1994, 57, Academic Press, Inc. pp. 191-280.;;Sutcliffe et al., ""Antibodies that react with predetermined sites on proteins,"" Science, Feb. 11, 1983, 219(4585), pp. 660-666.;;Wilson et al., ""The structure of an antigenic determinant in a protein,"" Cell, Jul. 1984, 37(3), pp. 767-778.;;Francis et al., ""Immunological priming with synthetic peptides of foot-and-mouth disease virus,"" Journal of General Virology, Nov. 1985, 66(11), the Society for General Microbiology, Great Britain, pp. 2347-2354.;;Foecking et al., ""Powerful and versatile enhancer-promoter unit for mammalian expression vectors,"" Gene: an international journal focusing on gene cloning and gene structure and function, 1986, 45(1), Elsevier Science Publishers B.V. (Biomedical Division), pp. 101-105.;;Cockett et al., ""High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine synthetase gene amplification,"" Bio/Technology: The International Monthly for Industrial Biology, Jul. 1990, 8(1), pp. 662-667.;;Andreasen et al., ""Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme,"" The Journal of Biological Chemistry, Jun. 15, 1986, 261(17), The American Society of Biological Chemists, Inc., pp. 7644-7651.;;Del Villano et al., ""Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9,"" Clinical Chemistry, Mar. 1983, 29(3), pp. 549-552.;;Ritts Jr. et al., ""Initial clinical evaluation of an immunoradiometric assay for CA 19-9 using the NCI serum bank,"" International Journal of Cancer, Mar. 15, 1984, 33(3), pp. 339-345.;;Rule, ""Carcinoembryonic antigens (CEA),"" Methods in Clinical Chemistry, Chapter 90, 1987, The C.V. Mosby Company, pp. 702-713.",EXPIRED
36,GB,A,GB 2527082 A,022-841-811-553-931,2015-12-16,2015,GB 201410359 A,2014-06-11,GB 201410359 A,2014-06-11,Flow control device,"An adjustable flow control device has a valve body 1, an orifice plate 2 containing a series of orifices 21 of varying diameter, and an indexable valve cover 3 which includes at least one flow conduit 31 which can be positioned and locked in a sealable manner over a chosen orifice 21 whilst the remaining part of the valve cover 3 closes off the other orifices. Because the device has fixed size orifices 21, each orifice will provide a fixed specific fluid flow rate for any predetermined pressure loss across the orifice. The device is suitable for use on all types of gas and liquid fluids.",WALKER FILTRATION LTD,WALKER BRIAN;;WISE SIMON;;CARNEY PETER,,https://lens.org/022-841-811-553-931,Patent Application,no,5,0,8,8,0,B01D53/26;;F16K3/085;;F16K11/074;;B01D53/0446;;B01D2259/40005;;B01D53/047;;F16K3/08;;B01D2259/40003;;B01D53/26;;F16K3/085;;F16K11/074;;B01D53/0446;;B01D2259/40005;;B01D53/047;;B01D2259/40043;;F16K3/08,F16K3/08,,0,0,,,,ACTIVE
37,US,A1,US 2017/0367322 A1,179-703-320-107-716,2017-12-28,2017,US 201715481692 A,2017-04-07,US 201715481692 A;;US 201662319651 P,2016-04-07,Reconstitution Solution For Spray-Dried Plasma,"The present invention relates to a reconstitution solution for spray dried plasma having a non-anticoagulant compound that does not bind calcium. When the reconstitution solution of the present invention is mixed with spray dry plasma, the reconstituted plasma mediates platelet adhesion and aggregation about the same as or greater than the starting plasma prior to spray drying. The present invention also relates to an assay for determining platelet adhesion and aggregation using microfluidic flow cell system having a shear flow. The assay assesses labeled whole blood samples having reconstituted plasma having spray dried plasma and a reconstitution solution; platelets; and red blood cells. After inducing a shear flow under conditions suitable for clot formation, coverage area of the platelets, intensity of the platelets, morphology, or a combination thereof is detected to determine platelet accumulation (e.g., platelet adhesion and aggregation).",VELICO MEDICAL INC,LIU QIYONG PETER;;CARNEY RYAN CHRISTOPHER,VELICO MEDICAL INC (2017-04-07),https://lens.org/179-703-320-107-716,Patent Application,yes,0,9,2,2,0,A61K31/191;;A61K31/198;;A61K31/375;;A61K35/16;;A61K45/06;;A61P7/08;;A61K35/16;;A61K31/375;;A61K31/191;;A61K31/198;;A61K45/06;;A01N1/0205;;A01N1/0278;;G01N33/86,A01N1/02;;A61K35/16;;G01N33/86,,0,0,,,,DISCONTINUED
38,EP,A2,EP 1489968 A2,075-302-840-486-205,2004-12-29,2004,EP 03711275 A,2003-02-27,US 0305957 W;;US 36121902 P;;US 36865802 P,2002-03-01,ASSAYS FOR CANCER PATIENT MONITORING BASED ON LEVELS OF ANALYTE COMPONENTS OF THE PLASMINOGEN ACTIVATOR SYSTEM IN BODY FLUID SAMPLES,"The present invention describes methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. An increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression.",BAYER AG,CARNEY WALTER P;;HAMER PETER J,SIEMENS HEALTHCARE DIAGNOSTICS INC. (2008-04-23),https://lens.org/075-302-840-486-205,Patent Application,yes,0,0,14,14,0,G01N33/57484;;G01N33/86;;G01N2333/8132;;G01N2333/9723;;G01N2800/52;;Y10T436/25;;A61P35/00;;Y10T436/25;;G01N33/57484;;G01N2333/9723;;G01N33/86;;G01N2333/8132;;G01N2800/52,G01N33/574;;G01N33/86,,0,0,,,,EXPIRED
39,US,B2,US 9376926 B2,159-225-160-233-537,2016-06-28,2016,US 201213677470 A,2012-11-15,US 201213677470 A,2012-11-15,Gas turbine engine fan blade lock assembly,"A gas turbine engine fan blade lock assembly includes a fan hub that has blade slots each configured to receive a root of a fan blade. The fan hub includes circumferentially spaced first slots. A lock ring is configured to move between unlocked and locked positions. The lock ring includes circumferentially spaced second slots aligned with the first slots in the locked position, and multiple discrete pins. Each pin is configured to be slidably received in paired first and second slots in the locked position to prevent rotational movement of the lock ring relative the fan hub.",UNITED TECHNOLOGIES CORP,ANDERSON CARNEY R;;TOMEO PETER V,RTX CORPORATION (2012-11-14),https://lens.org/159-225-160-233-537,Granted Patent,yes,13,9,2,2,0,F01D5/3015;;F01D5/3015;;F01D5/323;;F01D5/323;;Y02T50/60;;Y02T50/60,F01D5/30;;F01D5/32,,0,0,,,,ACTIVE
40,US,A1,US 2012/0220524 A1,032-010-594-794-899,2012-08-30,2012,US 201213407641 A,2012-02-28,US 201213407641 A;;US 50773709 A;;US 37564603 A;;US 36865802 P;;US 36121902 P,2002-03-01,ASSAYS FOR CANCER PATIENT MONITORING BASED ON LEVELS OF ANALYTE COMPONENTS OF THE PLASMINOGEN ACTIVATOR SYSTEM IN BODY FLUID SAMPLES,"The present invention describes methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. An increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression.",CARNEY WALTER P;;HAMER PETER J;;SIEMENS HEALTHCARE DIAGNOSTICS,CARNEY WALTER P;;HAMER PETER J,,https://lens.org/032-010-594-794-899,Patent Application,yes,0,1,14,14,0,G01N33/57484;;G01N33/86;;G01N2333/8132;;G01N2333/9723;;G01N2800/52;;Y10T436/25;;A61P35/00;;Y10T436/25;;G01N33/57484;;G01N2333/9723;;G01N33/86;;G01N2333/8132;;G01N2800/52,A61K38/22;;A61P35/00;;G01N33/574;;G01N33/86,514/9.7,0,0,,,,DISCONTINUED
41,US,A1,US 2009/0286268 A1,026-037-113-659-358,2009-11-19,2009,US 50773709 A,2009-07-22,US 50773709 A;;US 37564603 A;;US 36121902 P;;US 36865802 P,2002-03-01,Assays for Cancer Patient Monitoring Based on Levels of Analyte Components of the Plasminogen Activator System in Body Fluid Samples,"The present invention describes clinically and medically important methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. As a result of performing the method, an increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression and/or a lack of treatment effectiveness for the patient.",CARNEY WALTER P;;HAMER PETER J,CARNEY WALTER P;;HAMER PETER J,SIEMENS HEALTHCARE DIAGNOSTICS INC (2007-01-01);;BAYER CORPORATION (2003-01-02),https://lens.org/026-037-113-659-358,Patent Application,yes,17,1,14,14,0,G01N33/57484;;G01N33/86;;G01N2333/8132;;G01N2333/9723;;G01N2800/52;;Y10T436/25;;A61P35/00;;Y10T436/25;;G01N33/57484;;G01N2333/9723;;G01N33/86;;G01N2333/8132;;G01N2800/52,G01N33/53;;G01N33/574;;G01N33/86,435/7.92,0,0,,,,DISCONTINUED
42,EP,A4,EP 1489968 A4,049-477-538-913-60X,2006-08-02,2006,EP 03711275 A,2003-02-27,US 0305957 W;;US 36121902 P;;US 36865802 P,2002-03-01,ASSAYS FOR CANCER PATIENT MONITORING BASED ON LEVELS OF ANALYTE COMPONENTS OF THE PLASMINOGEN ACTIVATOR SYSTEM IN BODY FLUID SAMPLES,"The present invention describes methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. An increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression.",BAYER CORP,CARNEY WALTER P;;HAMER PETER J,SIEMENS HEALTHCARE DIAGNOSTICS INC. (2008-04-23),https://lens.org/049-477-538-913-60X,Search Report,no,2,0,14,14,0,G01N33/57484;;G01N33/86;;G01N2333/8132;;G01N2333/9723;;G01N2800/52;;Y10T436/25;;A61P35/00;;Y10T436/25;;G01N33/57484;;G01N2333/9723;;G01N33/86;;G01N2333/8132;;G01N2800/52,G01N33/574;;G01N33/86,,10,10,047-416-668-164-924;;028-969-327-729-326;;011-783-571-203-307;;035-783-764-342-216;;026-302-592-004-58X;;007-178-707-944-260;;108-323-686-515-562;;070-130-046-842-153;;002-292-577-326-743;;047-960-474-836-226,11410515;;10024688;;10.3892/ijo.14.3.535;;10.1002/1097-0215(20000920)89:5<431::aid-ijc6>3.0.co;2-v;;11008205;;10676647;;11792750;;10.1093/jnci/94.2.116;;pmc2362331;;10408864;;10.1038/sj.bjc.6690389;;10.1177/107602969700300403;;11062719;;10430786;;10.1093/clinchem/45.8.1206;;11005561;;10.1007/bf02725342,"KONECNY G ET AL: ""Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer."", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. JUN 2001, vol. 7, no. 6, June 2001 (2001-06-01), pages 1743 - 1749, XP002386406, ISSN: 1078-0432;;MIYAKE H ET AL: ""ELEVATION OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR AND ITS RECEPTOR DENSITIES AS NEW PREDICTORS OF DISEASE PROGRESSION AND PROGNOSIS IN MEN WITH PROSTATE CANCER"", INTERNATIONAL JOURNAL OF ONCOLOGY, EDITORIAL ACADEMY OF THE INTERNATIONAL JOURNAL OF ONCOLOGY,, GR, vol. 14, no. 3, March 1999 (1999-03-01), pages 535 - 541, XP008034948, ISSN: 1019-6439;;YANG JIA-LIN ET AL: ""Urokinase-type plasminogen activator and its receptor in colorectal cancer: Independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets"", INTERNATIONAL JOURNAL OF CANCER, vol. 89, no. 5, 20 September 2000 (2000-09-20), pages 431 - 439, XP002386407, ISSN: 0020-7136;;FOEKENS JOHN A ET AL: ""The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients"", CANCER RESEARCH, vol. 60, no. 3, 1 February 2000 (2000-02-01), pages 636 - 643, XP002386408, ISSN: 0008-5472;;LOOK MAXIME P ET AL: ""Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients"", JOURNAL OF THE NATIONAL CANCER INSTITUTE (BETHESDA), vol. 94, no. 2, 16 January 2002 (2002-01-16), pages 116 - 128, XP002386409, ISSN: 0027-8874;;BROET P ET AL: ""Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: A multicentre study"", BRITISH JOURNAL OF CANCER, vol. 80, no. 3-4, May 1999 (1999-05-01), pages 536 - 545, XP002386410, ISSN: 0007-0920;;LOX C D ET AL: ""Tamoxifen-induced changes in the plasma fibrinolytic factors in menopausal women with breast cancer"", CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS 1997 UNITED STATES, vol. 3, no. 4, 1997, pages 234 - 238, XP008065623, ISSN: 1076-0296;;MORII TAKESHI ET AL: ""Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma"", ANTICANCER RESEARCH, vol. 20, no. 5A, September 2000 (2000-09-01), pages 3031 - 3036, XP008065628, ISSN: 0250-7005;;PEDERSEN A N ET AL: ""Determination of the complex between urokinase and its type-I inhibitor in plasma from healthy donors and breast cancer patients"", CLINICAL CHEMISTRY, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY, WASHINGTON, DC, US, vol. 45, no. 8, 1999, pages 1206 - 1213, XP002968350, ISSN: 0009-9147;;NIELSEN H J ET AL: ""Preoperative plasma plasminogen activator inhibitor type-I and serum C-reactive protein levels in patients with colorectal cancer"", ANNALS OF SURGICAL ONCOLOGY, RAVEN PRESS, NEW YORK, NY, US, vol. 7, no. 8, 2000, pages 617 - 623, XP002968351, ISSN: 1068-9265",EXPIRED
43,US,B2,US 6750047 B2,183-412-010-122-077,2004-06-15,2004,US 93216701 A,2001-08-17,US 93216701 A;;US 22659500 P,2000-08-21,Fermentation and purification of migrastatin and analog,"
    Migrastatin and a migrastatin analog can be produced by fermentation of Streptomyces platensis NRRL 18993 and used in pharmaceutical formulations to treat cancer and/or inhibit metastasis of cancer cells. 
",KOSAN BIOSCIENCES INC,KHOSLA CHAITAN;;LICARI PETER;;CARNEY JOHN,KOSAN BIOSCIENCES INC (2001-11-09),https://lens.org/183-412-010-122-077,Granted Patent,yes,5,0,4,4,0,C12P17/16;;C12P17/16;;C07K14/36;;C07K14/36,C07K14/36;;C12P17/16,435/119;;435/117;;435/118;;435/244,10,8,041-981-985-487-624;;009-129-497-904-27X;;031-731-951-977-68X;;018-611-726-407-448;;080-726-136-003-097;;062-552-020-884-195;;031-095-008-794-896;;013-732-025-529-855,10.7164/antibiotics.47.870;;7928672;;2272925;;10.7164/antibiotics.43.1502;;7928673;;10.7164/antibiotics.47.875;;10.7164/antibiotics.47.862;;7928671;;10.7164/antibiotics.53.1130;;11132958;;10.7164/antibiotics.53.1228;;11132973;;10.7164/antibiotics.49.234;;8626236;;10.1002/(sici)1097-0142(19971015)80:8+<1529::aid-cncr2>3.3.co;2-#;;9362419;;10.1002/(sici)1097-0142(19971015)80:8+<1529::aid-cncr2>3.0.co;2-f,"Hochlowski et al., J. Antibiotics (1994) 47:870-874.;;Hondo et al., Transplantation Proceedings XIX (1987) Supp.6:17-22.;;Jarvis et al., J. Antibiotics (1990) 43:1502-1504.;;Kadam and McAlpine, J. Antibiotics (1994) 47:875-880.;;Karwowski et al., J. Antibiotics (1994) 47:862-869.;;Marshall et al. J. Industrial Microbiology (1990) 5:283-288.;;Nakae et al., J. Antibiotics (2000) 53:1130-1136.;;Nakae et al., J. Antibiotics (2000) 53:1228-1230.;;Warr et al., J. Antibiotics (1996) 49:234-240.;;Woodhouse et al., Cancer (1997) 80:1529-1537.",EXPIRED
44,US,A1,US 2019/0112928 A1,008-353-174-263-279,2019-04-18,2019,US 201715787478 A,2017-10-18,US 201715787478 A,2017-10-18,TUNED RETENTION RING FOR ROTOR DISK,"A rotor disk assembly may include a rotor disk and a retention ring coupled to the rotor disk. Generally, the retention ring is tuned to adjust a modal frequency response of the rotor disk/rotor disk assembly. In various embodiments, dimensions of the retention ring vary circumferentially. In various embodiments, the retention ring includes an axially extending flange and a radially extending flange. A radial thickness of the axially extending flange may vary circumferentially and/or an axial thickness of the radially extending flange may vary circumferentially.",UNITED TECHNOLOGIES CORP,TOMEO PETER V;;ANDERSON CARNEY R,RTX CORPORATION (2017-10-17),https://lens.org/008-353-174-263-279,Patent Application,yes,4,0,4,4,0,F01D5/10;;F01D5/16;;F01D5/26;;F01D5/3023;;F01D5/326;;F01D9/041;;F01D11/006;;F01D25/04;;F01D25/06;;F05D2260/96;;F05D2260/30;;F01D5/3015;;Y02T50/60;;F01D5/027;;F04D29/662;;F04D29/325;;F04D29/321;;F05D2260/96;;F04D29/34;;F05D2220/32;;F05D2230/60;;F05D2260/30;;F01D5/3015;;F01D25/06;;F01D25/04;;F01D11/006;;F01D5/10;;F01D5/16;;F01D5/326;;F01D9/041;;F01D5/3023;;F01D5/26,F01D5/02;;F01D5/30;;F04D29/32;;F04D29/34;;F04D29/66,,0,0,,,,ACTIVE
45,US,A,US 3354396 A,085-503-824-751-543,1967-11-21,1967,US 41132464 A,1964-11-16,GB 4623963 A,1963-11-22,Device for generating an electric signal composed of at least two interlaced signals of different but relating frequencies,,ELLIOTT BROTHERS LONDON LTD,WHITTAKER JOHN N;;CARNEY PETER W,,https://lens.org/085-503-824-751-543,Granted Patent,no,6,1,2,2,0,H04B14/08;;H04L15/22;;H04B14/08;;H04L15/22,H04B14/08;;H04L15/22,,0,0,,,,EXPIRED
46,EP,A1,EP 2565384 A1,127-462-620-550-284,2013-03-06,2013,EP 12182029 A,2012-08-28,US 201113220656 A,2011-08-29,Bladed rotor and corresponding assembling method,"A bladed rotor (72) includes a blade lock (76) mountable to a rotor hub (70) adjacent to a multiple of blade slots (68). The blade lock (76) includes at least one interface feature (82) adjacent to a first of the multiple of blade slots (68). A first rotor blade (60A) includes a blade feature (84) which interfaces with the interface feature (82) to permit the first rotor blade (60A) to be axially mounted within the first of the multiple of blade slots (68) but not within a remainder of the multiple of blade slots (68). A corresponding method of assembling a bladed rotor is also provided.
",UNITED TECHNOLOGIES CORP,ANDERSON CARNEY R;;TOMEO PETER V,"RAYTHEON TECHNOLOGIES CORPORATION (N.D.GES.D.S, US (2022-09-23);;UNITED TECHNOLOGIES CORPORATION (2016-10-26)",https://lens.org/127-462-620-550-284,Patent Application,yes,4,1,4,4,0,F01D5/326;;F01D5/326;;Y02T50/60;;Y02T50/60;;Y10T29/49316;;Y10T29/49316,F01D5/32,,0,0,,,,ACTIVE
47,EP,A1,EP 2955423 A1,016-619-967-857-179,2015-12-16,2015,EP 15170638 A,2015-06-04,GB 201410359 A,2014-06-11,FLOW CONTROL DEVICE,"An adjustable flow control device is provided which has a valve body containing a series of orifices of varying diameter and an indexable valve cover which includes at least one flow conduit which can be positioned and locked in a sealable manner over a chosen orifice whilst the remaining part of the valve cover closes off the other orifices of the valve body. Due to the device having fixed size orifices, each orifice will provide a fixed specific fluid flow rate for any predetermined pressure loss across the orifice. The device is suitable for use on all types of gas and liquid fluids.
",WALKER FILTRATION LTD,WALKER BRIAN;;WISE SIMON;;CARNEY PETER,,https://lens.org/016-619-967-857-179,Patent Application,yes,5,3,8,8,0,B01D53/26;;F16K3/085;;F16K11/074;;B01D53/0446;;B01D2259/40005;;B01D53/047;;F16K3/08;;B01D2259/40003;;B01D53/26;;F16K3/085;;F16K11/074;;B01D53/0446;;B01D2259/40005;;B01D53/047;;B01D2259/40043;;F16K3/08,F16K3/08;;B01D53/26;;F16K11/074,,0,0,,,,ACTIVE
48,ZA,B,ZA 95978 B,094-194-364-555-049,1995-10-10,1995,ZA 95978 A,1995-02-07,US 21675194 A,1994-03-23,Method and apparatus for determining signal quality,,MOTOROLA INC,LAROSA CHRISTOPHER PETER;;CARNEY MICHAEL JOHN,,https://lens.org/094-194-364-555-049,Granted Patent,no,0,0,4,4,0,H04L1/24;;H04L27/22;;H04L27/22;;H04L1/24,H04L1/24;;H04L27/22,,0,0,,,,EXPIRED
49,ES,T3,ES 2320115 T3,106-736-635-465-895,2009-05-19,2009,ES 03711275 T,2003-02-27,US 36121902 P;;US 36865802 P,2002-03-01,ENSAYOS PARA MONITOREAR A UN PACIENTE CON CANCER CON BASE EN LOS NIVELES DE LOS COMPONENTES ANALITOS DEL SISTEMA ACTIVADOR DE PLASMINOGENO EN MUESTRAS DE FLUIDO CORPORAL.,"The present invention describes methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. An increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression.",SIEMENS HEALTHCARE DIAGNOSTICS,CARNEY WALTER P;;HAMER PETER J,,https://lens.org/106-736-635-465-895,Granted Patent,no,0,0,14,14,0,G01N33/57484;;G01N33/86;;G01N2333/8132;;G01N2333/9723;;G01N2800/52;;Y10T436/25;;A61P35/00;;Y10T436/25;;G01N33/57484;;G01N2333/9723;;G01N33/86;;G01N2333/8132;;G01N2800/52,C12Q1/00;;G01N33/574;;G01N33/86,,0,0,,,,EXPIRED
50,US,A1,US 2011/0049035 A1,191-491-523-211-807,2011-03-03,2011,US 85201210 A,2010-08-06,GB 0913961 A,2009-08-07,FILTER ASSEMBLY,"A filter assembly is provided for removing entrained material from a fluid stream. The assembly includes a manifold with a port through which the fluid is received into or removed from the assembly, and a housing into which is inserted a tubular filter element having walls of a filtration medium. The housing and the manifold have joining formations which allow them to be joined together and separated apart by relative rotation. The filter element has an end cap thereon which sealingly engages with the manifold. The end cap has an opening therein which accepts fluid received through the port and feeds the fluid into the interior of the filter element or which accepts fluid received from the interior of the filter element and feeds the fluid to the port. The filter element is insertable into the housing along the axial direction of the filter element.",WALKER FILTRATION LTD,WISE SIMON;;CARNEY PETER;;CHALMERS ANDREW,WALKER FILTRATION LIMITED (2010-10-25),https://lens.org/191-491-523-211-807,Patent Application,yes,6,7,3,3,0,B01D46/0004;;B01D46/0005;;B01D2201/295;;B01D2201/30;;B01D2201/4015;;B01D2265/022;;B01D46/0004;;B01D2201/295;;B01D2201/4015;;B01D2265/022;;B01D46/0005;;B01D2201/30,B01D35/30;;B01D29/11,210/236;;210/497.01,0,0,,,,DISCONTINUED
51,US,B2,US 8961141 B2,033-511-300-438-197,2015-02-24,2015,US 201113220656 A,2011-08-29,US 201113220656 A,2011-08-29,Axial retention system for a bladed rotor with multiple blade types,A bladed rotor includes a blade lock mountable to a rotor hub adjacent to a multiple of blade slots. The blade lock includes at least one interface feature adjacent to a first of the multiple of blade slots. A first rotor blade includes a blade feature which interfaces with the interface feature to permit the first rotor blade to be axially mounted within the first of the multiple of blade slots but not within a remainder of the multiple of blade slots.,ANDERSON CARNEY R;;TOMEO PETER V;;UNITED TECHNOLOGIES CORP,ANDERSON CARNEY R;;TOMEO PETER V,RAYTHEON TECHNOLOGIES CORPORATION (2011-08-29),https://lens.org/033-511-300-438-197,Granted Patent,yes,21,9,4,4,0,F01D5/326;;F01D5/326;;Y02T50/60;;Y02T50/60;;Y10T29/49316;;Y10T29/49316,F01D5/32,416/203;;X416220 R,1,0,,,"European Search Report completed Dec. 14, 2012 for European Patent Application No. 12182029.4.",INACTIVE
52,WO,A3,WO 2003/073910 A3,067-619-061-231-92X,2003-10-16,2003,US 0305957 W,2003-02-27,US 36121902 P;;US 36865802 P,2002-03-01,ASSAYS FOR CANCER PATIENT MONITORING BASED ON LEVELS OF ANALYTE COMPONENTS OF THE PLASMINOGEN ACTIVATOR SYSTEM IN BODY FLUID SAMPLES,"The present invention describes clinically and medically important methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. As a result of performing the method, an increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression and/or a lack of treatment effectiveness for the patient.",BAYER AG,CARNEY WALTER P;;HAMER PETER J,,https://lens.org/067-619-061-231-92X,Search Report,yes,0,0,14,14,0,G01N33/57484;;G01N33/86;;G01N2333/8132;;G01N2333/9723;;G01N2800/52;;Y10T436/25;;A61P35/00;;Y10T436/25;;G01N33/57484;;G01N2333/9723;;G01N33/86;;G01N2333/8132;;G01N2800/52,G01N33/574;;G01N33/86,,2,2,002-292-577-326-743;;047-960-474-836-226,10430786;;10.1093/clinchem/45.8.1206;;11005561;;10.1007/bf02725342,"PEDERSEN ET AL.: ""Determination of the complex between urokinase and its type-I inhibitor in plasma from healthy donors and breast cancer patients"", CLINICAL CHEMISTRY, vol. 45, no. 8, 1999, pages 1206 - 1213, XP002968350;;NIELSEN ET AL.: ""Preoperative plasma plasminogen activator inhibitor type-I and serum C-reactive protein levels in patients with colorectal cancer"", ANNALS OF SURGICAL ONCOLOGY, vol. 7, no. 8, pages 617 - 623, XP002968351",PENDING
53,AU,A1,AU 2003/213594 A1,077-535-217-975-584,2003-09-16,2003,AU 2003/213594 A,2003-02-27,US 36121902 P;;US 36865802 P;;US 0305957 W,2002-03-01,ASSAYS FOR CANCER PATIENT MONITORING BASED ON LEVELS OF ANALYTE COMPONENTS OF THE PLASMINOGEN ACTIVATOR SYSTEM IN BODY FLUID SAMPLES,"The present invention describes methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. An increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression.",BAYER AG,CARNEY WALTER P;;HAMER PETER J,,https://lens.org/077-535-217-975-584,Patent Application,no,0,0,14,14,0,G01N33/57484;;G01N33/86;;G01N2333/8132;;G01N2333/9723;;G01N2800/52;;Y10T436/25;;A61P35/00;;Y10T436/25;;G01N33/57484;;G01N2333/9723;;G01N33/86;;G01N2333/8132;;G01N2800/52,G01N33/574;;G01N33/86,,0,0,,,,DISCONTINUED
54,US,B2,US 9682450 B2,116-002-805-244-009,2017-06-20,2017,US 201313739294 A,2013-01-11,US 201313739294 A,2013-01-11,Gas turbine engine nose cone attachment configuration,A gas turbine engine fan section includes a fan hub configured to rotate about an axis. A nose cone includes a spinner operatively mounted to the fan hub. The spinner supports a first fastening element and the nose cone includes an annular cover arranged over the fastening element. The spinner and annular cover provide an aerodynamic exterior surface of the nose cone without exposed fasteners. A second fastening element cooperates with the first fastening element to secure the spinner relative to the fan hub. The first and second fastening elements are oriented transversely to the axis.,UNITED TECHNOLOGIES CORP,TOMEO PETER V;;ANDERSON CARNEY R,RTX CORPORATION (2013-01-09),https://lens.org/116-002-805-244-009,Granted Patent,yes,34,6,2,2,0,F01D5/025;;F01D5/282;;F01D11/008;;F02C7/04;;F05D2220/36;;F05D2220/3216;;Y10T29/49327;;Y02T50/60;;B23P15/04;;Y10T29/49327;;F01D5/025;;F01D5/282;;F01D11/008;;F02C7/04;;F05D2220/36;;F05D2220/3216;;Y02T50/60,B23P15/04;;F01D5/02;;F01D5/28;;F01D11/00;;F02C7/04,,0,0,,,,ACTIVE
55,WO,A1,WO 2019/229460 A1,133-612-430-310-704,2019-12-05,2019,GB 2019051501 W,2019-05-31,US 201862678843 P,2018-05-31,BENCH-TOP TIME OF FLIGHT MASS SPECTROMETER,"Disclosed herein is a bench-top time of flight mass spectrometer (100). In embodiments, there is provided a solvent bottle mounting assembly configured so that a user can press a solvent bottle (201) onto the solvent bottle mounting assembly in order to mount the solvent bottle to the mass spectrometer. Other embodiments relate to a vacuum arrangement comprising first and second vacuum chambers with respective first and second vacuum pumps wherein a backing line (1401) for the second vacuum pump is connected to the first vacuum chamber such that the second vacuum pump is backed to the first vacuum chamber. Also disclosed in a method of manufacturing a lens plate or electrode wherein a substrate is chemically etched to reduce a sharp cusp (1803) to provide a smoother edge profile (1804).",MICROMASS LTD,CARNEY PETER;;MURRAY HAYDN;;WILDGOOSE JASON,,https://lens.org/133-612-430-310-704,Patent Application,yes,1,0,2,2,0,H01J49/0013;;H01J49/04;;G01N2035/0405;;G01N2035/041;;G01N35/04;;H01J49/0013;;H01J49/067;;H01J49/24;;H01J49/40,G01N1/00;;H01J49/04;;H01J49/00,,1,0,,,"715003596 REVISION: ""Waters Xevo G2-S QTof Operator's Overview and Maintenance Guide"", 11 February 2013 (2013-02-11), XP055606374, Retrieved from the Internet <URL:https://www.waters.com/webassets/cms/support/docs/xevo_g2-s_qtof_715003596rb.pdf> [retrieved on 20190717]",PENDING
56,EP,B1,EP 3473810 B1,130-564-547-388-836,2020-12-16,2020,EP 18200956 A,2018-10-17,US 201715787478 A,2017-10-18,TUNED RETENTION RING FOR ROTOR DISK,,UNITED TECHNOLOGIES CORP,TOMEO PETER V;;ANDERSON CARNEY R,RAYTHEON TECHNOLOGIES CORPORATION (2021-03-24),https://lens.org/130-564-547-388-836,Granted Patent,yes,1,0,4,4,0,F01D5/10;;F01D5/16;;F01D5/26;;F01D5/3023;;F01D5/326;;F01D9/041;;F01D11/006;;F01D25/04;;F01D25/06;;F05D2260/96;;F05D2260/30;;F01D5/3015;;Y02T50/60;;F01D5/027;;F04D29/662;;F04D29/325;;F04D29/321;;F05D2260/96;;F04D29/34;;F05D2220/32;;F05D2230/60;;F05D2260/30;;F01D5/3015;;F01D25/06;;F01D25/04;;F01D11/006;;F01D5/10;;F01D5/16;;F01D5/326;;F01D9/041;;F01D5/3023;;F01D5/26,F01D5/26;;F01D5/10;;F01D5/16;;F01D5/30;;F01D5/32;;F01D9/04;;F01D11/00;;F01D25/04;;F01D25/06,,0,0,,,,ACTIVE
57,US,B2,US 10458244 B2,045-595-752-237-093,2019-10-29,2019,US 201715787478 A,2017-10-18,US 201715787478 A,2017-10-18,Tuned retention ring for rotor disk,"A rotor disk assembly may include a rotor disk and a retention ring coupled to the rotor disk. Generally, the retention ring is tuned to adjust a modal frequency response of the rotor disk/rotor disk assembly. In various embodiments, dimensions of the retention ring vary circumferentially. In various embodiments, the retention ring includes an axially extending flange and a radially extending flange. A radial thickness of the axially extending flange may vary circumferentially and/or an axial thickness of the radially extending flange may vary circumferentially.",UNITED TECHNOLOGIES CORP,TOMEO PETER V;;ANDERSON CARNEY R,RTX CORPORATION (2017-10-17),https://lens.org/045-595-752-237-093,Granted Patent,yes,14,0,4,4,0,F01D5/10;;F01D5/16;;F01D5/26;;F01D5/3023;;F01D5/326;;F01D9/041;;F01D11/006;;F01D25/04;;F01D25/06;;F05D2260/96;;F05D2260/30;;F01D5/3015;;Y02T50/60;;F01D5/027;;F04D29/662;;F04D29/325;;F04D29/321;;F05D2260/96;;F04D29/34;;F05D2220/32;;F05D2230/60;;F05D2260/30;;F01D5/3015;;F01D25/06;;F01D25/04;;F01D11/006;;F01D5/10;;F01D5/16;;F01D5/326;;F01D9/041;;F01D5/3023;;F01D5/26,F01D5/02;;F01D5/30;;F04D29/32;;F04D29/34;;F04D29/66,,1,0,,,"European Patent Office, European Search Report dated Mar. 15, 2019 in Application No. 18200956.3.",ACTIVE
58,US,B2,US 8459954 B2,054-499-069-559-350,2013-06-11,2013,US 68942310 A,2010-01-19,US 68942310 A,2010-01-19,Torsional flexing energy absorbing blade lock,"A lock for constraining blades in a hub includes a flexible ring for constraining the blades from moving axially in the hub, a finger attached to the hub for preventing the ring from rotating relative to the hub and whereby the ring flexes about at least a partial circumference thereof if urged axially by the blades.",ANDERSON CARNEY R;;TOMEO PETER V;;UNITED TECHNOLOGIES CORP,ANDERSON CARNEY R;;TOMEO PETER V,RTX CORPORATION (2010-01-15),https://lens.org/054-499-069-559-350,Granted Patent,yes,20,12,5,5,0,F01D5/3015;;F01D5/3015;;F01D5/326;;F01D5/326;;F05D2230/64;;F05D2230/64;;Y10T29/49316;;Y10T29/49316;;Y10T29/49321;;Y10T29/49321,F01D5/32,416/221;;X416220 R;;29/889.21,2,0,,,"International Preliminary Report on Patentability dated Aug. 2, 2012.;;International Search Report dated Apr. 18, 2011.",ACTIVE
59,US,A,US 5661433 A,055-754-758-582-427,1997-08-26,1997,US 67103696 A,1996-06-27,US 67103696 A,1996-06-27,Digital FM demodulator,"In the digital FM demodulator (330), a hard limiter (333) receives a modulated analog IF signal and limits the voltage of the IF signal to two levels. Next, a direct phase digitizer (336) uses zero-crossings of the limited IF signal to generate N-bit digital words. A phase differential circuit (340) computes the phase shift of the signal from the direct phase digitizer over a predetermined time interval. The dynamic range of the phase differential signal can be increased by replacing the phase differential circuit (340) with a high-resolution phase differential circuit (700). After digital demodulation and filtering and gain control by audio processor (360), the recovered signal is forwarded to a speaker (390) to produce an audio output. Thus, the digital FM demodulator both avoids problems common to analog discriminator circuitry and offers a reduced complexity, size, and power consumption alternative to conventional digital FM demodulators.",MOTOROLA INC,LAROSA CHRISTOPHER PETER;;CARNEY MICHAEL JOHN,MOTOROLA MOBILITY LLC (2012-06-22);;GOOGLE TECHNOLOGY HOLDINGS LLC (2014-10-28);;MOTOROLA INC (1996-06-27),https://lens.org/055-754-758-582-427,Granted Patent,yes,12,29,6,6,0,H03D3/006;;H03D3/006,H03D3/00,329/341;;455/214;;455/337,0,0,,,,EXPIRED
60,US,A1,US 2003/0180819 A1,071-681-718-681-557,2003-09-25,2003,US 37564603 A,2003-02-27,US 37564603 A;;US 36121902 P;;US 36865802 P,2002-03-01,Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples,"
   The present invention describes clinically and medically important methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. As a result of performing the method, an increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression and/or a lack of treatment effectiveness for the patient. 
",CARNEY WALTER P.;;HAMER PETER J.,CARNEY WALTER P;;HAMER PETER J,SIEMENS HEALTHCARE DIAGNOSTICS INC (2007-08-17);;BAYER CORPORATION (2003-04-30);;BAYER HEALTHCARE LLC (2003-01-01),https://lens.org/071-681-718-681-557,Patent Application,yes,18,2,14,14,0,G01N33/57484;;G01N33/86;;G01N2333/8132;;G01N2333/9723;;G01N2800/52;;Y10T436/25;;A61P35/00;;Y10T436/25;;G01N33/57484;;G01N2333/9723;;G01N33/86;;G01N2333/8132;;G01N2800/52,G01N33/574;;G01N33/86,435/7.23;;514/43;;435/7.92,0,0,,,,DISCONTINUED
61,EP,B1,EP 1489968 B1,137-220-353-939-965,2009-02-18,2009,EP 03711275 A,2003-02-27,US 0305957 W;;US 36121902 P;;US 36865802 P,2002-03-01,ASSAYS FOR CANCER PATIENT MONITORING BASED ON LEVELS OF ANALYTE COMPONENTS OF THE PLASMINOGEN ACTIVATOR SYSTEM IN BODY FLUID SAMPLES,"The present invention describes methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. An increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression.",SIEMENS HEALTHCARE DIAGNOSTICS,CARNEY WALTER P;;HAMER PETER J,SIEMENS HEALTHCARE DIAGNOSTICS INC. (2008-04-23),https://lens.org/137-220-353-939-965,Granted Patent,yes,2,0,14,14,0,G01N33/57484;;G01N33/86;;G01N2333/8132;;G01N2333/9723;;G01N2800/52;;Y10T436/25;;A61P35/00;;Y10T436/25;;G01N33/57484;;G01N2333/9723;;G01N33/86;;G01N2333/8132;;G01N2800/52,C12Q1/00;;G01N33/574;;G01N33/86,,12,0,,,"KONECNY G ET AL: ""Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer."" CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. JUN 2001, vol. 7, no. 6, June 2001 (2001-06), pages 1743-1749, XP002386406 ISSN: 1078-0432;;MIYAKE H ET AL: ""ELEVATION OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR AND ITS RECEPTOR DENSITIES AS NEW PREDICTORS OF DISEASE PROGRESSION AND PROGNOSIS IN MEN WITH PROSTATE CANCER"" INTERNATIONAL JOURNAL OF ONCOLOGY, EDITORIAL ACADEMY OF THE INTERNATIONAL JOURNAL OF ONCOLOGY,, GR, vol. 14, no. 3, March 1999 (1999-03), pages 535-541, XP008034948 ISSN: 1019-6439;;YANG JIA-LIN ET AL: ""Urokinase-type plasminogen activator and its receptor in colorectal cancer: Independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets"" INTERNATIONAL JOURNAL OF CANCER, vol. 89, no. 5, 20 September 2000 (2000-09-20), pages 431-439, XP002386407 ISSN: 0020-7136;;FOEKENS JOHN A ET AL: ""The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients"" CANCER RESEARCH, vol. 60, no. 3, 1 February 2000 (2000-02-01), pages 636-643, XP002386408 ISSN: 0008-5472;;LOOK MAXIME P ET AL: ""Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients"" JOURNAL OF THE NATIONAL CANCER INSTITUTE (BETHESDA), vol. 94, no. 2, 16 January 2002 (2002-01-16), pages 116-128, XP002386409 ISSN: 0027-8874;;BROET P ET AL: ""Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: A multicentre study"" BRITISH JOURNAL OF CANCER, vol. 80, no. 3-4, May 1999 (1999-05), pages 536-545, XP002386410 ISSN: 0007-0920;;LOX C D ET AL: ""Tamoxifen-induced changes in the plasma fibrinolytic factors in menopausal women with breast cancer"" CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS 1997 UNITED STATES, vol. 3, no. 4, 1997, pages 234-238, XP008065623 ISSN: 1076-0296;;MORII TAKESHI ET AL: ""Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma"" ANTICANCER RESEARCH, vol. 20, no. 5A, September 2000 (2000-09), pages 3031-3036, XP008065628 ISSN: 0250-7005;;PEDERSEN A N ET AL: ""Determination of the complex between urokinase and its type-I inhibitor in plasma from healthy donors and breast cancer patients"" CLINICAL CHEMISTRY, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY, WASHINGTON, DC, US, vol. 45, no. 8, 1999, pages 1206-1213, XP002968350 ISSN: 0009-9147;;NIELSEN H J ET AL: ""Preoperative plasma plasminogen activator inhibitor type-I and serum C-reactive protein levels in patients with colorectal cancer"" ANNALS OF SURGICAL ONCOLOGY, RAVEN PRESS, NEW YORK, NY, US, vol. 7, no. 8, 2000, pages 617-623, XP002968351 ISSN: 1068-9265;;PEDERSEN ET AL.: 'Determination of the complex between urokinase and its type-I inhibitor in plasma from healthy donors and breast cancer patients' CLINICAL CHEMISTRY vol. 45, no. 8, 1999, pages 1206 - 1213, XP002968350;;NIELSEN ET AL.: 'Preoperative plasma plasminogen activator inhibitor type-I and serum C-reactive protein levels in patients with colorectal cancer' ANNALS OF SURGICAL ONCOLOGY vol. 7, no. 8, pages 617 - 623, XP002968351",EXPIRED
62,US,A1,US 2008/0113392 A1,170-623-815-744-20X,2008-05-15,2008,US 96532307 A,2007-12-27,US 96532307 A;;US 37564603 A;;US 36121902 P;;US 36865802 P,2002-03-01,ASSAYS FOR CANCER PATIENT MONITORING BASED ON LEVELS OF ANALYTE COMPONENTS OF THE PLASMINOGEN ACTIVATOR SYSTEM IN BODY FLUID SAMPLES,"The present invention describes clinically and medically important methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. As a result of performing the method, an increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression and/or a lack of treatment effectiveness for the patient.",CARNEY WALTER P;;HAMER PETER J,CARNEY WALTER P;;HAMER PETER J,SIEMENS HEALTHCARE DIAGNOSTICS INC (2007-08-17);;BAYER CORPORATION (2003-04-30);;BAYER HEALTHCARE LLC (2003-01-01),https://lens.org/170-623-815-744-20X,Patent Application,yes,16,0,14,14,0,G01N33/57484;;G01N33/86;;G01N2333/8132;;G01N2333/9723;;G01N2800/52;;Y10T436/25;;A61P35/00;;Y10T436/25;;G01N33/57484;;G01N2333/9723;;G01N33/86;;G01N2333/8132;;G01N2800/52,G01N33/53;;G01N33/48;;G01N33/574;;G01N33/86,435/7.92;;435/7.1;;436/64,0,0,,,,EXPIRED
63,WO,A1,WO 2011/090970 A1,177-155-514-728-679,2011-07-28,2011,US 2011/0021633 W,2011-01-19,US 68942310 A,2010-01-19,TORSIONAL FLEXING ENERGY ABSORBING BLADE LOCK,"A lock for constraining blades in a hub includes a flexible ring (15) for constraining the blades from moving axially in the hub, a finger (125) attached to the hub (10) for preventing the ring from rotating relative to the hub and whereby the ring flexes about at least a partial circumference thereof if urged axially by the blades (35).",UNITED TECHNOLOGIES CORP;;ANDERSON CARNEY R;;TOMEO PETER V,ANDERSON CARNEY R;;TOMEO PETER V,,https://lens.org/177-155-514-728-679,Patent Application,yes,3,3,5,5,0,F01D5/3015;;F01D5/326;;F05D2230/64;;Y10T29/49321;;Y10T29/49316;;Y10T29/49321;;Y10T29/49316;;F01D5/3015;;F01D5/326;;F05D2230/64,F01D5/30,,0,0,,,,PENDING
64,GB,A,GB 1108564 A,107-374-547-903-016,1968-04-03,1968,GB 4623963 A,1963-11-22,GB 4623963 A,1963-11-22,Improvements in or relating to electric signal generating devices,"1,108,564. Radio signalling. ELLIOTT BROS (LONDON) Ltd. 18 Nov., 1964 [22 Nov., 1963], No. 46239/63. Heading H4L. A signal generator, e.g. a V.H.F./U.H.F. beacon for emitting a distress signal is arranged to produce an output signal consisting of two interlaced signals comprising two different but related carrier frequencies. This enables the beacon to be used with receiving equipment which operates on one or other of the two frequencies. As shown, a beacon comprises a crystal-controlled oscillator 1 producing a carrier frequency of 121À5 Mc/s. which is applied via an amplifier 2 to driver and power amplifier stages 3, 4 where it is amplitude modulated by a 1 kc./s. signal supplied via amplifier 5 from oscillator 6. This modulated carrier wave is supplied to serially connected filters 7, 8, filter 7 rejecting the second harmonic of the carrier wave and filter 8 rejecting the carrier wave. A frequency-doubler circuit including a varactor diode 10 is connected to the junction of filters 7, 8. A generator 11 produces a ¢ c./s. square wave which operates a transistor switch 12 so that a bias supply at 13 is applied for periods of one second with intervals of one second to a diode 9 connected across filters 7, 8. When diode 9 is conducting the filters are short-circuited so that the 121À5 Mc/s. modulated signal is supplied via diode 9 to the aerial 14, the frequency-doubling circuit being inoperative. With diode 9 non-conducting the 121À5 Mc/s. signal is supplied via filter 7 to the frequency-doubling circuit and a 243 Mc/s. modulated signal is supplied via filter 8 to the aerial, the filter -7 preventing the frequency-doubled signal from circulating through the varactor circuit.",ELLIOTT BROTHERS LONDON LTD,WHITTAKER JOHN NORMAN;;CARNEY PETER WILLIAM,,https://lens.org/107-374-547-903-016,Granted Patent,no,0,0,2,2,0,H04B14/08;;H04L15/22;;H04B14/08;;H04L15/22,H04B14/08;;H04L15/22,H4L LETD          LETD;;H4L LW            LW;;H4L LWE           LWE;;H4L L11D          -;;H4L L7            -,0,0,,,,EXPIRED
65,US,A1,US 2014/0133991 A1,132-612-079-366-72X,2014-05-15,2014,US 201213677470 A,2012-11-15,US 201213677470 A,2012-11-15,GAS TURBINE ENGINE FAN BLADE LOCK ASSEMBLY,"A gas turbine engine fan blade lock assembly includes a fan hub that has blade slots each configured to receive a root of a fan blade. The fan hub includes circumferentially spaced first slots. A lock ring is configured to move between unlocked and locked positions. The lock ring includes circumferentially spaced second slots aligned with the first slots in the locked position, and multiple discrete pins. Each pin is configured to be slidably received in paired first and second slots in the locked position to prevent rotational movement of the lock ring relative the fan hub.",UNITED TECHNOLOGIES CORP,ANDERSON CARNEY R;;TOMEO PETER V,RTX CORPORATION (2012-11-14),https://lens.org/132-612-079-366-72X,Patent Application,yes,6,6,2,2,0,F01D5/3015;;F01D5/3015;;F01D5/323;;F01D5/323;;Y02T50/60;;Y02T50/60,F01D5/30,416220 R,0,0,,,,ACTIVE
66,US,A1,US 2013/0156584 A1,136-782-283-374-863,2013-06-20,2013,US 201113328040 A,2011-12-16,US 201113328040 A,2011-12-16,COMPRESSOR ROTOR WITH INTERNAL STIFFENING RING OF DISTINCT MATERIAL,"A compressor rotor has a hub at a radially outer location, and a leg extending from an inner ring at a radially inner location to the hub. The hub has an inner bore at a location spaced from the leg. A stiffening ring is force fit into the inner bore of the hub.",ANDERSON CARNEY R;;TOMEO PETER V,ANDERSON CARNEY R;;TOMEO PETER V,UNITED TECHNOLOGIES CORPORATION (2011-12-15),https://lens.org/136-782-283-374-863,Patent Application,yes,42,2,2,2,0,F01D5/02;;F05D2260/37;;F05D2260/94;;F01D5/02;;F05D2260/37;;F05D2260/94,F01D5/30,416210 A,0,0,,,,DISCONTINUED
67,EP,B1,EP 2565384 B1,196-920-470-621-195,2017-10-04,2017,EP 12182029 A,2012-08-28,US 201113220656 A,2011-08-29,Bladed rotor and corresponding assembling method,,UNITED TECHNOLOGIES CORP,ANDERSON CARNEY R;;TOMEO PETER V,"RAYTHEON TECHNOLOGIES CORPORATION (N.D.GES.D.S, US (2022-09-23);;UNITED TECHNOLOGIES CORPORATION (2016-10-26)",https://lens.org/196-920-470-621-195,Granted Patent,yes,4,0,4,4,0,Y10T29/49316;;F01D5/326;;Y02T50/60;;Y10T29/49316;;Y02T50/60;;F01D5/326,F01D5/32,,0,0,,,,ACTIVE
68,GB,B,GB 2527082 B,017-766-879-322-795,2020-08-26,2020,GB 201410359 A,2014-06-11,GB 201410359 A,2014-06-11,Flow control device,,WALKER FILTRATION LTD,BRIAN WALKER;;SIMON WISE;;PETER CARNEY,,https://lens.org/017-766-879-322-795,Granted Patent,no,5,0,8,8,0,B01D53/26;;F16K3/085;;F16K11/074;;B01D53/0446;;B01D2259/40005;;B01D53/047;;F16K3/08;;B01D2259/40003;;B01D53/26;;F16K3/085;;F16K11/074;;B01D53/0446;;B01D2259/40005;;B01D53/047;;B01D2259/40043;;F16K3/08,F16K3/08,,0,0,,,,ACTIVE
69,WO,A1,WO 2017/177104 A1,069-602-902-318-790,2017-10-12,2017,US 2017/0026546 W,2017-04-07,US 201715481692 A;;US 201662319651 P,2016-04-07,RECONSTITUTION SOLUTION FOR SPRAY-DRIED PLASMA,"The present invention relates to a reconstitution solution for spray dried plasma having a non-anticoagulant compound that does not bind calcium. When the reconstitution solution of the present invention is mixed with spray dry plasma, the reconstituted plasma mediates platelet adhesion and aggregation about the same as or greater than the starting plasma prior to spray drying. The present invention also relates to an assay for determining platelet adhesion and aggregation using microfluidic flow cell system having a shear flow. The assay assesses labeled whole blood samples having reconstituted plasma having spray dried plasma and a reconstitution solution; platelets; and red blood cells. After inducing a shear flow under conditions suitable for clot formation, coverage area of the platelets, intensity of the platelets, morphology, or a combination thereof is detected to determine platelet accumulation (e.g., platelet adhesion and aggregation).",VELICO MEDICAL INC,LIU QIYONG PETER;;CARNEY RYAN CHRISTOPHER,,https://lens.org/069-602-902-318-790,Patent Application,yes,27,0,2,2,0,A61K31/191;;A61K31/198;;A61K31/375;;A61K35/16;;A61K45/06;;A61P7/08;;A61K35/16;;A61K31/375;;A61K31/191;;A61K31/198;;A61K45/06;;A01N1/0205;;A01N1/0278;;G01N33/86,A61K31/191;;A61K31/198;;A61K31/375;;A61K35/16;;A61P7/08,,2,2,079-632-389-520-364;;033-681-763-273-896,10.1111/trf.12039;;23301977;;10.1001/archsurg.2009.154;;19797107,"TIM H. LEE ET AL: ""The use of lyophilized plasma in a severe multi-injury pig model : Lyophilized Plasma in Pig Model"", TRANSFUSION., vol. 53, 1 January 2013 (2013-01-01), US, pages 72S - 79S, XP055379858, ISSN: 0041-1132, DOI: 10.1111/trf.12039;;NICHOLAS SPOERKE ET AL: ""Lyophilized Plasma for Resuscitation in a Swine Model of Severe Injury"", ARCHIVES OF SURGERY, vol. 144, no. 9, 21 September 2009 (2009-09-21), US, pages 829, XP055379860, ISSN: 0004-0010, DOI: 10.1001/archsurg.2009.154",PENDING
70,WO,A2,WO 2003/073910 A2,105-403-148-262-343,2003-09-12,2003,US 0305957 W,2003-02-27,US 36121902 P;;US 36865802 P,2002-03-01,ASSAYS FOR CANCER PATIENT MONITORING BASED ON LEVELS OF ANALYTE COMPONENTS OF THE PLASMINOGEN ACTIVATOR SYSTEM IN BODY FLUID SAMPLES,"The present invention describes clinically and medically important methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. As a result of performing the method, an increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression and/or a lack of treatment effectiveness for the patient.",BAYER AG,CARNEY WALTER P;;HAMER PETER J,,https://lens.org/105-403-148-262-343,Patent Application,yes,0,0,14,14,0,G01N33/57484;;G01N33/86;;G01N2333/8132;;G01N2333/9723;;G01N2800/52;;Y10T436/25;;A61P35/00;;Y10T436/25;;G01N33/57484;;G01N2333/9723;;G01N33/86;;G01N2333/8132;;G01N2800/52,G01N33/574;;G01N33/86,,0,0,,,,PENDING
71,US,A1,US 2014/0199176 A1,185-997-664-870-698,2014-07-17,2014,US 201313739294 A,2013-01-11,US 201313739294 A,2013-01-11,GAS TURBINE ENGINE NOSE CONE ATTACHMENT CONFIGURATION,A gas turbine engine fan section includes a fan hub configured to rotate about an axis. A nose cone includes a spinner operatively mounted to the fan hub. The spinner supports a first fastening element and the nose cone includes an annular cover arranged over the fastening element. The spinner and annular cover provide an aerodynamic exterior surface of the nose cone without exposed fasteners. A second fastening element cooperates with the first fastening element to secure the spinner relative to the fan hub. The first and second fastening elements are oriented transversely to the axis.,UNITED TECHNOLOGIES CORP,TOMEO PETER V;;ANDERSON CARNEY R,RTX CORPORATION (2013-01-09),https://lens.org/185-997-664-870-698,Patent Application,yes,27,11,2,2,0,F01D5/025;;F01D5/282;;F01D11/008;;F02C7/04;;F05D2220/36;;F05D2220/3216;;Y10T29/49327;;Y02T50/60;;B23P15/04;;Y10T29/49327;;F01D5/025;;F01D5/282;;F01D11/008;;F02C7/04;;F05D2220/36;;F05D2220/3216;;Y02T50/60,B23P15/04;;F01D5/02,416245 R;;29/889.3,0,0,,,,ACTIVE
72,US,B2,US 9790803 B2,087-908-723-561-992,2017-10-17,2017,US 201414185962 A,2014-02-21,US 201414185962 A;;US 201361774743 P,2013-03-08,Double split blade lock ring,A rotor assembly for a gas turbine engine includes a plurality of blades including a root portion and an airfoil portion. The rotor includes a plurality of slots that receive the root portion of a corresponding blade. The rotor includes an annular groove for a first and second retaining ring. The retaining rings are received within a common annular groove for holding each of the plurality of blades within the slots of the rotor.,UNITED TECHNOLOGIES CORP,ANDERSON CARNEY R;;TOMEO PETER V,RTX CORPORATION (2013-06-04),https://lens.org/087-908-723-561-992,Granted Patent,yes,11,2,2,2,0,F01D5/326;;F01D5/326;;F01D5/3015;;F01D5/3015;;Y10T29/49321;;Y10T29/49321,F01D5/32;;F01D5/30,,0,0,,,,ACTIVE
73,DE,D1,DE 60326214 D1,184-220-298-031-907,2009-04-02,2009,DE 60326214 T,2003-02-27,US 36121902 P;;US 36865802 P;;US 0305957 W,2002-03-01,ASSAYS ZUR ÜBERWACHUNG VON KREBSPATIENTEN AUF GRUNDLAGE DER SPIEGEL VON ANALYTENKOMPONENTEN DES PLASMINOGEN-AKTIVATOR-SYSTEMS IN PROBEN VON KÖRPERFLÜSSIGKEITEN,"The present invention describes methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. An increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression.",SIEMENS HEALTHCARE DIAGNOSTICS,CARNEY WALTER P;;HAMER PETER J,,https://lens.org/184-220-298-031-907,Granted Patent,no,0,0,14,14,0,G01N33/57484;;G01N33/86;;G01N2333/8132;;G01N2333/9723;;G01N2800/52;;Y10T436/25;;A61P35/00;;Y10T436/25;;G01N33/57484;;G01N2333/9723;;G01N33/86;;G01N2333/8132;;G01N2800/52,C12Q1/00;;G01N33/574;;G01N33/86,,0,0,,,,EXPIRED
74,EP,A1,EP 2526262 A1,036-329-324-748-93X,2012-11-28,2012,EP 11701429 A,2011-01-19,US 68942310 A;;US 2011/0021633 W,2010-01-19,TORSIONAL FLEXING ENERGY ABSORBING BLADE LOCK,,UNITED TECHNOLOGIES CORP,ANDERSON CARNEY R;;TOMEO PETER V,"UNITED TECHNOLOGIES CORP. (N.D.GES.D. STAATES , US (2017-07-24);;RAYTHEON TECHNOLOGIES CORPORATION (N.D.GES.D.S, US (2022-09-23)",https://lens.org/036-329-324-748-93X,Patent Application,yes,0,0,5,5,0,F01D5/3015;;F01D5/3015;;F01D5/326;;F01D5/326;;F05D2230/64;;F05D2230/64;;Y10T29/49316;;Y10T29/49316;;Y10T29/49321;;Y10T29/49321,F01D5/32;;F01D5/30,,1,0,,,See references of WO 2011090970A1,ACTIVE
75,CN,A,CN 114730316 A,103-958-949-026-865,2022-07-08,2022,CN 202080078361 A,2020-11-11,US 201962933826 P;;US 2020/0059990 W,2019-11-11,Computerized system and method for electronically generating dynamic visual hierarchical representation of electronic information,"Systems and methods are disclosed for improving interactions with and between computers in a content providing, displaying, and/or hosting system supported or configured by devices, servers, and/or platforms. The disclosed systems and methods provide a novel framework that enables multiple alternative hierarchies to be organized, reconstructed and/or created based on the same set of assets, where each hierarchie is different on ontology and meets various relationships that may exist between assets. The framework configures and displays hierarchical representations of assets, as well as various attributes of each asset, in a dynamically generated and displayed interface. Visualization and analysis of the framework may be modified in response to the request, where reconstruction of the hierarchy or new generation of the hierarchy may be implemented and displayed depending on the type of the request or the type of action included in the request.",AVEVA SOFTWARE LLC,MADDEN JOHN JOSEPH;;CARNEY DANIEL PETER,,https://lens.org/103-958-949-026-865,Patent Application,no,0,0,6,6,0,G06F16/953;;G06F16/287;;G06F3/0484;;G06F9/451;;G06F16/2246;;G06F3/0482;;G06F16/26,G06F16/28,,0,0,,,,PENDING
76,US,A1,US 2015/0362082 A1,182-571-593-952-137,2015-12-17,2015,US 201514729759 A,2015-06-03,GB 201410359 A,2014-06-11,FLOW CONTROL DEVICE,"An adjustable flow control device is provided which has a valve body containing a series of orifices of varying diameter and an indexable valve cover which includes at least one flow conduit which can be positioned and locked in a sealable manner over a chosen orifice whilst the remaining part of the valve cover closes off the other orifices of the valve body. Due to the device having fixed size orifices, each orifice will provide a fixed specific fluid flow rate for any predetermined pressure loss across the orifice. The device is suitable for use on all types of gas and liquid fluids.",WALKER FILTRATION LTD,WALKER BRIAN;;WISE SIMON;;CARNEY PETER,WALKER FILTRATION LTD (2015-07-03),https://lens.org/182-571-593-952-137,Patent Application,yes,10,3,8,8,0,B01D53/26;;F16K3/085;;F16K11/074;;B01D53/0446;;B01D2259/40005;;B01D53/047;;F16K3/08;;B01D2259/40003;;B01D53/26;;F16K3/085;;F16K11/074;;B01D53/0446;;B01D2259/40005;;B01D53/047;;B01D2259/40043;;F16K3/08,F16K3/08;;B01D53/047,,0,0,,,,ACTIVE
77,EP,B1,EP 2526262 B1,074-041-421-938-976,2015-06-03,2015,EP 11701429 A,2011-01-19,US 68942310 A;;US 2011/0021633 W,2010-01-19,TORSIONAL FLEXING ENERGY ABSORBING BLADE LOCK,,UNITED TECHNOLOGIES CORP,ANDERSON CARNEY R;;TOMEO PETER V,"UNITED TECHNOLOGIES CORP. (N.D.GES.D. STAATES , US (2017-07-24);;RAYTHEON TECHNOLOGIES CORPORATION (N.D.GES.D.S, US (2022-09-23)",https://lens.org/074-041-421-938-976,Granted Patent,yes,3,0,5,5,0,F01D5/3015;;F01D5/3015;;F01D5/326;;F01D5/326;;F05D2230/64;;F05D2230/64;;Y10T29/49316;;Y10T29/49316;;Y10T29/49321;;Y10T29/49321,F01D5/32;;F01D5/30,,0,0,,,,ACTIVE
78,DE,T1,DE 4293441 T1,132-168-143-862-405,1997-07-31,1997,DE 4293441 T,1992-08-26,US 76152791 A;;US 9207193 W,1991-09-18,Phasenkombinationsverfahren und Vorrichtung zur Verwendung in einem Diversity-Empfänger,,MOTOROLA INC,LAROSA CHRISTOPHER PETER;;CARNEY MICHAEL JOHN,,https://lens.org/132-168-143-862-405,Patent Application,no,2,0,24,24,0,H04B7/0802;;H04B7/0857;;H04B7/0871;;H04B7/0874;;H04B7/08;;H04B7/0874;;H04B7/0857;;H04B7/0802;;H04B7/0871,H04B7/08;;H04B7/26,,0,0,,,,DISCONTINUED
79,US,B2,US 9568112 B2,147-349-091-747-575,2017-02-14,2017,US 201514729759 A,2015-06-03,GB 201410359 A,2014-06-11,Flow control device,"An adjustable flow control device is provided which has a valve body containing a series of orifices of varying diameter and an indexable valve cover which includes at least one flow conduit which can be positioned and locked in a sealable manner over a chosen orifice while the remaining part of the valve cover closes off the other orifices of the valve body. Due to the device having fixed size orifices, each orifice will provide a fixed specific fluid flow rate for any predetermined pressure loss across the orifice. The device is suitable for use on all types of gas and liquid fluids.",WALKER FILTRATION LTD,WALKER BRIAN;;WISE SIMON;;CARNEY PETER,WALKER FILTRATION LTD (2015-07-03),https://lens.org/147-349-091-747-575,Granted Patent,yes,11,5,8,8,0,B01D53/26;;F16K3/085;;F16K11/074;;B01D53/0446;;B01D2259/40005;;B01D53/047;;F16K3/08;;B01D2259/40003;;B01D53/26;;F16K3/085;;F16K11/074;;B01D53/0446;;B01D2259/40005;;B01D53/047;;B01D2259/40043;;F16K3/08,F16K3/08;;B01D53/04;;B01D53/047;;B01D53/26;;F16K11/074,,0,0,,,,ACTIVE
80,EP,A2,EP 2604793 A2,146-721-684-649-198,2013-06-19,2013,EP 12197264 A,2012-12-14,US 201113328040 A,2011-12-16,Rotor with Internal Stiffening Ring,"A compressor rotor (44) has a hub (144) at a radially outer location, and a leg (48) extending from an inner ring (46) at a radially inner location to the hub (144). The hub (144) has an inner bore (52) at a location spaced from the leg (48). A stiffening ring (52) is force fit into the inner bore of the hub (144).
",UNITED TECHNOLOGIES CORP,ANDERSON CARNEY R;;TOMEO PETER V,,https://lens.org/146-721-684-649-198,Patent Application,yes,0,1,2,2,0,F01D5/02;;F05D2260/37;;F05D2260/94;;F01D5/02;;F05D2260/37;;F05D2260/94,F01D5/02,,0,0,,,,DISCONTINUED
81,US,A1,US 2014/0255196 A1,022-985-644-339-470,2014-09-11,2014,US 201414185962 A,2014-02-21,US 201414185962 A;;US 201361774743 P,2013-03-08,DOUBLE SPLIT BLADE LOCK RING,A rotor assembly for a gas turbine engine includes a plurality of blades including a root portion and an airfoil portion. The rotor includes a plurality of slots that receive the root portion of a corresponding blade. The rotor includes an annular groove for a first and second retaining ring. The retaining rings are received within a common annular groove for holding each of the plurality of blades within the slots of the rotor.,UNITED TECHNOLOGIES CORP,ANDERSON CARNEY R;;TOMEO PETER V,RTX CORPORATION (2013-06-04),https://lens.org/022-985-644-339-470,Patent Application,yes,4,7,2,2,0,F01D5/326;;F01D5/326;;F01D5/3015;;F01D5/3015;;Y10T29/49321;;Y10T29/49321,F01D5/30;;B23P15/00,416/218;;29/889.21,0,0,,,,ACTIVE
82,US,A,US 3626149 A,075-941-188-178-324,1971-12-07,1971,US 3626149D A,1970-01-02,US 6570 A,1970-01-02,THERMALLY CONDUCTIVE CONCRETE WITH HEATING MEANS,,SUPERIOR GRAPHITE CO,CARNEY PETER R;;STEVENS RAYMOND F,,https://lens.org/075-941-188-178-324,Granted Patent,no,4,50,1,1,0,C04B28/04;;C04B28/04;;C04B2111/00465;;C04B2111/00465;;E01C7/145;;E01C7/145;;E01C11/265;;E01C11/265;;F24D13/02;;F24D13/02;;Y02B30/00;;Y02B30/00;;Y10S165/905;;Y10S165/905,E01C7/14;;E01C11/26;;F24D13/02,219/213,0,0,,,,EXPIRED
83,EP,A1,EP 2292310 A1,096-842-607-034-690,2011-03-09,2011,EP 10251418 A,2010-08-09,GB 0913961 A,2009-08-07,Filter assembly,"A filter assembly is provided for removing entrained material from a fluid stream. The assembly comprises a manifold with a port through which the fluid is received into or removed from the assembly, and a housing into which is inserted a tubular filter element having walls of a filtration medium. The housing and the manifold have joining formations which allow them to be joined together and separated apart by relative rotation. The filter element has an end cap thereon which sealingly engages with the manifold. The end cap has an opening therein which accepts fluid received through the port and feeds the fluid into the interior of the filter element or which accepts fluid received from the interior of the filter element and feeds the fluid to the port. The filter element is insertable into the housing along the axial direction of the filter element. The end cap has a plurality of circumferentially spaced, outwardly directed projections which rest on a seat formation of the housing to determine the axial position of the inserted filter element relative to the housing. The housing further has an overhang formation with a plurality of channels formed therein. The channels are arranged such that, on insertion of the filter element, the projections align with and travel along respective of the channels to arrive at the seat formation. When the projections rest on the seat formation the inserted filter element is angularly displaceable about its axial direction relative to the housing such that the overhang formation traps the projections to prevent withdrawal of the filter element in its axial direction from the housing.
",WALKER FILTRATION LTD,WISE SIMON;;CARNEY PETER;;CHALMERS ANDREW,,https://lens.org/096-842-607-034-690,Patent Application,yes,5,3,3,3,0,B01D46/0004;;B01D46/0005;;B01D2201/295;;B01D2201/30;;B01D2201/4015;;B01D2265/022;;B01D46/0004;;B01D2201/295;;B01D2201/4015;;B01D2265/022;;B01D46/0005;;B01D2201/30,B01D46/00,,0,0,,,,DISCONTINUED
84,EP,B1,EP 2955423 B1,191-762-213-047-695,2019-09-18,2019,EP 15170638 A,2015-06-04,GB 201410359 A,2014-06-11,FLOW CONTROL DEVICE,,WALKER FILTRATION LTD,WALKER BRIAN;;WISE SIMON;;CARNEY PETER,,https://lens.org/191-762-213-047-695,Granted Patent,yes,5,0,8,8,0,B01D53/26;;F16K3/085;;F16K11/074;;B01D53/0446;;B01D2259/40005;;B01D53/047;;F16K3/08;;B01D2259/40003;;B01D53/26;;F16K3/085;;F16K11/074;;B01D53/0446;;B01D2259/40005;;B01D53/047;;B01D2259/40043;;F16K3/08,F16K3/08;;B01D53/04;;B01D53/047;;B01D53/26;;F16K11/074,,0,0,,,,ACTIVE
85,EP,A1,EP 3473810 A1,199-513-205-523-675,2019-04-24,2019,EP 18200956 A,2018-10-17,US 201715787478 A,2017-10-18,TUNED RETENTION RING FOR ROTOR DISK,"A rotor disk assembly (100) may include a rotor disk (110) and a retention ring (120) coupled to the rotor disk (110). Generally, the retention ring (120) is tuned to adjust a modal frequency response of the rotor disk (110)/rotor disk assembly (100). In various embodiments, dimensions of the retention ring (120) vary circumferentially. In various embodiments, the retention ring (120) includes an axially extending flange (121) and a radially extending flange (123). A radial thickness of the axially extending flange (121) may vary circumferentially and/or an axial thickness of the radially extending flange (123) may vary circumferentially.
",UNITED TECHNOLOGIES CORP,TOMEO PETER V;;ANDERSON CARNEY R,RAYTHEON TECHNOLOGIES CORPORATION (2021-03-24),https://lens.org/199-513-205-523-675,Patent Application,yes,5,0,4,4,0,F01D5/10;;F01D5/16;;F01D5/26;;F01D5/3023;;F01D5/326;;F01D9/041;;F01D11/006;;F01D25/04;;F01D25/06;;F05D2260/96;;F05D2260/30;;F01D5/3015;;Y02T50/60;;F01D5/027;;F04D29/662;;F04D29/325;;F04D29/321;;F05D2260/96;;F04D29/34;;F05D2220/32;;F05D2230/60;;F05D2260/30;;F01D5/3015;;F01D25/06;;F01D25/04;;F01D11/006;;F01D5/10;;F01D5/16;;F01D5/326;;F01D9/041;;F01D5/3023;;F01D5/26,F01D5/26;;F01D5/10;;F01D5/16;;F01D5/30;;F01D5/32;;F01D9/04;;F01D11/00;;F01D25/04;;F01D25/06,,0,0,,,,ACTIVE
86,EP,A2,EP 2223112 A2,016-234-776-615-436,2010-09-01,2010,EP 08867472 A,2008-12-17,US 2008/0087128 W;;US 1588107 P,2007-12-21,CIRCULATING EPHA2 RECEPTOR,,SIEMENS HEALTHCARE DIAGNOSTICS,HAMER PETER;;BRADLEY STEPHEN P;;CARNEY WALTER,,https://lens.org/016-234-776-615-436,Patent Application,yes,0,0,4,4,0,G01N33/573;;G01N33/57415;;G01N33/57419;;G01N33/57423;;G01N33/57434;;G01N33/57438;;G01N33/57488;;G01N2333/91215;;G01N2800/56;;G01N33/573;;G01N2800/56;;G01N33/57438;;G01N33/57419;;G01N33/57423;;G01N2333/91215;;G01N33/57434;;G01N33/57488;;G01N33/57415,G01N33/53,,0,0,,,,DISCONTINUED
87,WO,A1,WO 2009/085811 A1,065-537-526-112-145,2009-07-09,2009,US 2008/0087142 W,2008-12-17,US 1570007 P,2007-12-21,CIRCULATING RET RECEPTOR,"Provided are compositions, methods, and kits relating to the detection of a circulating or soluble form of the KET receptor tyrosine kinase.",SIEMENS HEATHCARE DIAGNOSTICS;;HAMER PETER;;BRADLEY STEPHEN P;;CARNEY WALTER,HAMER PETER;;BRADLEY STEPHEN P;;CARNEY WALTER,,https://lens.org/065-537-526-112-145,Patent Application,yes,3,2,4,4,0,G01N33/566;;G01N33/566;;G01N33/57488;;G01N33/57488;;G01N2333/91215;;G01N2333/91215,G01N33/53,,5,3,011-016-624-525-450;;049-066-126-047-075;;084-829-277-141-917,10.1016/j.cytogfr.2005.05.010;;15982921;;10.1038/381785a0;;8657281;;15331579;;10.1210/en.2004-0922,"ARIGHI ET AL.: ""RET tyrosine kinase signaling in development and cancer."", CYTOKINE & GROWTH FACTOR REVIEWS, vol. 16, 2005, pages 441 - 467;;TRUPP ET AL.: ""Functional receptor for GDNF encoded by the c-ret proto-oncogene"", NATURE, vol. 381, no. 6585, 1996, pages 785 - 789;;See also references of EP 2223113A4;;KODAMA Y. ET AL., CANCER SCL, vol. 96, no. 3, March 2005 (2005-03-01), pages 143 - 8;;SANTORO M ET AL., ENDOCRINOLOGY, vol. 145, no. 12, December 2004 (2004-12-01), pages 5448 - 51",PENDING
88,US,A1,US 2018/0322507 A1,083-468-475-211-19X,2018-11-08,2018,US 201815971847 A,2018-05-04,US 201815971847 A;;US 201762502265 P,2017-05-05,WARRANTY MANAGEMENT SYSTEM AND METHODS OF PERFORMING THE SAME,"The present disclosure relates to a warranty management system. In an embodiment, the warranty management system includes an information gathering unit that gathers information on a medical device, a warranty tracking unit that gathers warranty information on the medical device, submits a warranty claim and tracks the status of the warranty claim, a credit calculation unit that determines the amount of a credit for the warranty claim, and a payment distribution unit that generates a list of payees based on the warranty information and generates a payment to each payee.",CHAMPION MEDICAL TECH INC,CASADY PETER I;;CASADY TOM;;CARNEY CHARITY,CHAMPION MEDICAL TECHNOLOGIES INC (2018-06-06),https://lens.org/083-468-475-211-19X,Patent Application,yes,0,0,1,1,0,G16H40/20;;G06Q30/012;;G06Q30/0283;;G06Q10/10;;G16H40/40;;G06Q30/012;;G06Q30/0283;;G16H40/40;;G06Q10/10;;G16H40/20,G06Q30/00;;G06Q10/10;;G06Q30/02;;G16H40/40,,0,0,,,,DISCONTINUED
89,EP,A4,EP 2223113 A4,103-573-072-675-449,2011-04-06,2011,EP 08868641 A,2008-12-17,US 2008/0087142 W;;US 1570007 P,2007-12-21,CIRCULATING RET RECEPTOR,,SIEMENS HEALTHCARE DIAGNOSTICS,HAMER PETER;;BRADLEY STEPHEN P;;CARNEY WALTER,,https://lens.org/103-573-072-675-449,Search Report,no,3,0,4,4,1,G01N33/566;;G01N33/566;;G01N33/57488;;G01N33/57488;;G01N2333/91215;;G01N2333/91215,G01N33/53,,1,0,,,See also references of WO 2009085811A1,DISCONTINUED
90,US,A1,US 2019/0371584 A1,182-403-036-355-206,2019-12-05,2019,US 201916428151 A,2019-05-31,US 201916428151 A;;US 201862678843 P,2018-05-31,BENCH-TOP TIME OF FLIGHT MASS SPECTROMETER,"Disclosed herein is a bench-top time of flight mass spectrometer. In embodiments, there is provided a solvent bottle mounting assembly configured so that a user can press a solvent bottle onto the solvent bottle mounting assembly in order to mount the solvent bottle to the mass spectrometer. Other embodiments relate to a vacuum arrangement comprising first and second vacuum chambers with respective first and second vacuum pumps wherein a backing line for the second vacuum pump is connected to the first vacuum chamber such that the second vacuum pump is backed to the first vacuum chamber. Also disclosed in a method of manufacturing a lens plate or electrode wherein a substrate is chemically etched to reduce a sharp cusp to provide a smoother edge profile.",MICROMASS LTD,CARNEY PETER;;MURRAY HAYDN;;WILDGOOSE JASON L,MICROMASS UK LIMITED (2019-04-02),https://lens.org/182-403-036-355-206,Patent Application,yes,0,9,2,2,0,H01J49/0013;;H01J49/04;;G01N2035/0405;;G01N2035/041;;G01N35/04;;H01J49/0013;;H01J49/067;;H01J49/24;;H01J49/40,H01J49/00;;H01J49/06;;H01J49/24;;H01J49/40,,0,0,,,,DISCONTINUED
91,WO,A3,WO 2009/085805 A3,033-975-633-257-787,2016-05-26,2016,US 2008/0087128 W,2008-12-17,US 1588107 P,2007-12-21,CIRCULATING EPHA2 RECEPTOR,"Provided are compositions, methods, and kits relating to the detection of a circulating or soluble form of the EphA2 receptor tyrosine kinase.",SIEMENS HEATHCARE DIAGNOSTICS INC;;HAMER PETER;;BRADLEY STEPHEN P;;CARNEY WALTER,HAMER PETER;;BRADLEY STEPHEN P;;CARNEY WALTER,,https://lens.org/033-975-633-257-787,Search Report,yes,4,0,4,4,0,G01N33/573;;G01N33/57415;;G01N33/57419;;G01N33/57423;;G01N33/57434;;G01N33/57438;;G01N33/57488;;G01N2333/91215;;G01N2800/56;;G01N33/573;;G01N2800/56;;G01N33/57438;;G01N33/57419;;G01N33/57423;;G01N2333/91215;;G01N33/57434;;G01N33/57488;;G01N33/57415,A61K39/00;;G01N33/00;;C07K16/00,,0,0,,,,PENDING
92,US,A1,US 2010/0267058 A1,143-140-708-218-41X,2010-10-21,2010,US 80870808 A,2008-12-17,US 80870808 A;;US 1570007 P;;US 2008/0087142 W,2007-12-21,CIRCULATING RET RECEPTOR,"Provided are compositions, methods, and kits relating to the detection of a circulating or soluble form of the KET receptor tyrosine kinase.",SIEMENS HEALTHCARE DIAGNOSTICS,HAMER PETER;;BRADLEY STEPHEN P;;CARNEY WALTER,,https://lens.org/143-140-708-218-41X,Patent Application,yes,1,0,4,4,0,G01N33/566;;G01N33/566;;G01N33/57488;;G01N33/57488;;G01N2333/91215;;G01N2333/91215,G01N33/574;;C07K16/30,435/7.23;;530/389.7,2,1,026-343-185-135-567,9177201;;10.1073/pnas.94.12.6238;;pmc21033,"Sanicola et al. Glial cell line-derived neurotrophic factor-dependent RET activation can be mediated by two different cell-surface accessory proteins. Proc. Natl. Acad. Sci. USA 94: 6238-6243, June 1997.;;Written Opinion International Searching Report for PCT/JP2006/321184, English translation. 2006.",DISCONTINUED
93,EP,A1,EP 2223113 A1,003-148-696-796-967,2010-09-01,2010,EP 08868641 A,2008-12-17,US 2008/0087142 W;;US 1570007 P,2007-12-21,CIRCULATING RET RECEPTOR,,SIEMENS HEALTHCARE DIAGNOSTICS,HAMER PETER;;BRADLEY STEPHEN P;;CARNEY WALTER,,https://lens.org/003-148-696-796-967,Patent Application,yes,0,0,4,4,1,G01N33/566;;G01N33/566;;G01N33/57488;;G01N33/57488;;G01N2333/91215;;G01N2333/91215,G01N33/53,,0,0,,,,DISCONTINUED
94,WO,A2,WO 2009/085805 A2,052-813-546-637-615,2009-07-09,2009,US 2008/0087128 W,2008-12-17,US 1588107 P,2007-12-21,CIRCULATING EPHA2 RECEPTOR,"Provided are compositions, methods, and kits relating to the detection of a circulating or soluble form of the EphA2 receptor tyrosine kinase.",SIEMENS HEATHCARE DIAGNOSTICS;;HAMER PETER;;BRADLEY STEPHEN P;;CARNEY WALTER,HAMER PETER;;BRADLEY STEPHEN P;;CARNEY WALTER,,https://lens.org/052-813-546-637-615,Patent Application,yes,0,1,4,4,0,G01N33/573;;G01N33/57415;;G01N33/57419;;G01N33/57423;;G01N33/57434;;G01N33/57438;;G01N33/57488;;G01N2333/91215;;G01N2800/56;;G01N33/573;;G01N2800/56;;G01N33/57438;;G01N33/57419;;G01N33/57423;;G01N2333/91215;;G01N33/57434;;G01N33/57488;;G01N33/57415,G01N33/53,,0,0,,,,PENDING
95,US,A1,US 2011/0281279 A1,091-951-494-490-200,2011-11-17,2011,US 80847008 A,2008-12-17,US 80847008 A;;US 1588107 P;;US 2008/0087128 W,2007-12-21,CIRCULATING Epha2 RECEPTOR,"Provided are compositions, methods, and kits relating to the detection of a circulating or soluble form of the EphA2 receptor tyrosine kinase.",HAMER PETER;;BRADLEY STEPHEN P;;CARNEY WALTER;;SIEMENS HEALTHCARE DIAGNOSTICS,HAMER PETER;;BRADLEY STEPHEN P;;CARNEY WALTER,,https://lens.org/091-951-494-490-200,Patent Application,yes,0,5,4,4,1,G01N33/573;;G01N33/57415;;G01N33/57419;;G01N33/57423;;G01N33/57434;;G01N33/57438;;G01N33/57488;;G01N2333/91215;;G01N2800/56;;G01N33/573;;G01N2800/56;;G01N33/57438;;G01N33/57419;;G01N33/57423;;G01N2333/91215;;G01N33/57434;;G01N33/57488;;G01N33/57415,G01N33/573;;C07K16/40;;C12Q1/48;;G01N21/64;;G01N21/75;;G01N33/82,435/7.4;;435/15;;530/388.22;;530/389.1,0,0,,,,DISCONTINUED
96,EP,A1,EP 2913090 A1,014-669-863-840-607,2015-09-02,2015,EP 15152454 A,2015-01-26,GB 201401351 A,2014-01-27,PURIFICATION COLUMN,"A purification column is provided in which fluid is purified by flow through a purifying component. The column includes an annular wall defining a bore which, in use, contains the purifying component. The column further includes an inlet port to the bore comprising a first aperture through the annular wall, the inlet port being adjacent one end of the column. The column further includes an outlet port from the bore comprising a second aperture through the annular wall, the outlet port being adjacent the same end of the column as the inlet port. The column further includes a flow guidance device within the bore and removably connected to the inlet and outlet ports for guiding the fluid to the purifying component from the inlet port and for guiding the fluid from the purifying component to the outlet port. The flow guidance device maintains separation of the fluid flows to and from the purifying component.
",WALKER FILTRATION LTD,WALKER BRIAN;;WISE SIMON;;CARNEY PETER;;MCHUGH PETER;;NIXON CHRIS,,https://lens.org/014-669-863-840-607,Patent Application,yes,6,4,11,11,0,B01D35/30;;B01D29/114;;B01D29/96;;B01D2201/301;;B01D2201/302;;B01D2201/306;;B01D15/00;;B01D35/30;;B01D46/0002;;B01D53/00;;B01D35/30;;B01D29/114;;B01D29/96;;B01D2201/301;;B01D2201/302;;B01D2201/306;;B01D46/58;;B01D46/62;;B01D50/20;;B01D45/12;;B01D46/30,B01D35/30;;B01D29/11;;B01D29/96,,0,0,,,,ACTIVE
97,GB,A,GB 2524625 A,010-561-496-232-748,2015-09-30,2015,GB 201501226 A,2015-01-26,GB 201401351 A,2014-01-27,Purification column,"A purification column 2 in which fluid is purified by flow through a purifying component, the column includes an annular wall 10 defining a bore 12 which, in use, contains the purifying component, such as a filter. The annular wall is an extruded body and the column further includes an inlet port to the bore comprising a first aperture 14 through the annular wall, the inlet port being adjacent one end of the column. The column further includes an outlet port from the bore comprising a second aperture 16 through the annular wall. The outlet port being adjacent the same end of the column as the inlet port. The column further includes a flow guidance device 18 within the bore and removably connected to the inlet and outlet ports for guiding the fluid to the purifying component from the inlet port and for guiding the fluid from the purifying component to the outlet port. The flow guidance device maintains separation of the fluid flows to and from the purifying component.",WALKER FILTRATION LTD,WALKER BRIAN;;WISE SIMON;;CARNEY PETER;;MCHUGH PETER;;NIXON CHRIS,,https://lens.org/010-561-496-232-748,Patent Application,no,1,0,11,11,0,B01D35/30;;B01D29/114;;B01D29/96;;B01D2201/301;;B01D2201/302;;B01D2201/306;;B01D15/00;;B01D35/30;;B01D46/0002;;B01D53/00;;B01D35/30;;B01D29/114;;B01D29/96;;B01D2201/301;;B01D2201/302;;B01D2201/306;;B01D46/58;;B01D46/62;;B01D50/20;;B01D45/12;;B01D46/30,B01D35/30;;B01D15/00;;B01D46/00;;B01D53/00,,0,0,,,,ACTIVE
98,GB,B,GB 2524625 B,105-873-036-882-245,2017-05-10,2017,GB 201501226 A,2015-01-26,GB 201401351 A,2014-01-27,Purification column,,WALKER FILTRATION LTD,BRIAN WALKER;;SIMON WISE;;PETER CARNEY;;PETER MCHUGH;;CHRIS NIXON,,https://lens.org/105-873-036-882-245,Granted Patent,no,1,0,11,11,0,B01D35/30;;B01D29/114;;B01D29/96;;B01D2201/301;;B01D2201/302;;B01D2201/306;;B01D15/00;;B01D35/30;;B01D46/0002;;B01D53/00;;B01D35/30;;B01D29/114;;B01D29/96;;B01D2201/301;;B01D2201/302;;B01D2201/306;;B01D46/58;;B01D46/62;;B01D50/20;;B01D45/12;;B01D46/30,B01D35/30;;B01D15/00;;B01D46/00;;B01D53/00,,0,0,,,,ACTIVE
99,ES,T3,ES 2732451 T3,133-910-052-895-201,2019-11-22,2019,ES 15152454 T,2015-01-26,GB 201401351 A,2014-01-27,Columna de purificación,"Una columna de purificación (2, 4, 6), en la que se purifica fluido por flujo a través de un componente purificador (8, 60a-d), incluyendo la columna: una pared anular (10), que define un taladro (12) que, en uso, contiene el componente purificador, un orificio de entrada al taladro, que comprende una primera abertura (14) a través de la pared anular, siendo el orificio de entrada adyacente a un extremo de la columna, un orificio de salida desde el taladro, que comprende una segunda abertura (16) a través de la pared anular, siendo el orificio de salida adyacente al mismo extremo de la columna que el orificio de entrada, y un dispositivo de guía de flujo (18) dentro del taladro y conectado de manera extraíble a los orificios de entrada y de salida, para guiar el fluido al componente purificador desde el orificio de entrada y para guiar el fluido desde el componente purificador al orificio de salida, manteniendo el dispositivo de guía de flujo la separación de los flujos de fluido hacia y desde el componente purificador; y caracterizada por que la pared anular es un cuerpo extruido.",WALKER FILTRATION LTD,WALKER BRIAN;;WISE SIMON;;CARNEY PETER;;MCHUGH PETER;;NIXON CHRIS,,https://lens.org/133-910-052-895-201,Granted Patent,no,0,0,11,11,0,B01D35/30;;B01D29/114;;B01D29/96;;B01D2201/301;;B01D2201/302;;B01D2201/306;;B01D15/00;;B01D35/30;;B01D46/0002;;B01D53/00;;B01D35/30;;B01D29/114;;B01D29/96;;B01D2201/301;;B01D2201/302;;B01D2201/306;;B01D46/58;;B01D46/62;;B01D50/20;;B01D45/12;;B01D46/30,B01D35/30;;B01D29/11;;B01D29/96,,0,0,,,,ACTIVE
100,US,B2,US 9604173 B2,094-693-686-576-869,2017-03-28,2017,US 201514605635 A,2015-01-26,GB 201401351 A,2014-01-27,Purification column,"A purification column is provided in which fluid is purified by flow through a purifying component. The column includes an annular wall defining a bore which, in use, contains the purifying component. The column further includes an inlet port to the bore comprising a first aperture through the annular wall, the inlet port being adjacent one end of the column. The column further includes an outlet port from the bore comprising a second aperture through the annular wall, the outlet port being adjacent the same end of the column as the inlet port. The column further includes a flow guidance device within the bore and removably connected to the inlet and outlet ports for guiding the fluid to the purifying component from the inlet port and for guiding the fluid from the purifying component to the outlet port. The flow guidance device maintains separation of the fluid flows to and from the purifying component.",WALKER FILTRATION LTD,WALKER BRIAN;;WISE SIMON;;CARNEY PETER;;MCHUGH PETER;;NIXON CHRIS,WALKER FILTRATION LTD (2015-03-13),https://lens.org/094-693-686-576-869,Granted Patent,yes,12,1,11,11,0,B01D35/30;;B01D29/114;;B01D29/96;;B01D2201/301;;B01D2201/302;;B01D2201/306;;B01D15/00;;B01D35/30;;B01D46/0002;;B01D53/00;;B01D35/30;;B01D29/114;;B01D29/96;;B01D2201/301;;B01D2201/302;;B01D2201/306;;B01D46/58;;B01D46/62;;B01D50/20;;B01D45/12;;B01D46/30,B01D53/02;;B01D29/11;;B01D29/96;;B01D35/30;;B01D45/12;;B01D46/00;;B01D46/30;;B01D50/00,,0,0,,,,ACTIVE
101,US,A1,US 2018/0147524 A1,179-759-356-580-508,2018-05-31,2018,US 201715409094 A,2017-01-18,US 201715409094 A;;GB 201401351 A;;US 201514605635 A,2014-01-27,PURIFICATION COLUMN,"A purification column is provided in which fluid is purified by flow through a purifying component. The column includes an annular wall defining a bore which, in use, contains the purifying component. The column further includes an inlet port to the bore comprising a first aperture through the annular wall, the inlet port being adjacent one end of the column. The column further includes an outlet port from the bore comprising a second aperture through the annular wall, the outlet port being adjacent the same end of the column as the inlet port. The column further includes a flow guidance device within the bore and removably connected to the inlet and outlet ports for guiding the fluid to the purifying component from the inlet port and for guiding the fluid from the purifying component to the outlet port. The flow guidance device maintains separation of the fluid flows to and from the purifying component.",WALKER FILTRATION LTD,WALKER BRIAN;;WISE SIMON;;CARNEY PETER;;MCHUGH PETER;;NIXON CHRIS,WALKER FILTRATION LTD (2015-03-13),https://lens.org/179-759-356-580-508,Patent Application,yes,0,1,11,11,0,B01D35/30;;B01D29/114;;B01D29/96;;B01D2201/301;;B01D2201/302;;B01D2201/306;;B01D15/00;;B01D35/30;;B01D46/0002;;B01D53/00;;B01D35/30;;B01D29/114;;B01D29/96;;B01D2201/301;;B01D2201/302;;B01D2201/306;;B01D46/58;;B01D46/62;;B01D50/20;;B01D45/12;;B01D46/30,B01D50/00;;B01D29/11;;B01D29/96;;B01D35/30;;B01D45/12;;B01D46/00;;B01D46/30,,0,0,,,,ACTIVE
102,US,B2,US 10112141 B2,003-398-573-480-438,2018-10-30,2018,US 201715409094 A,2017-01-18,US 201715409094 A;;GB 201401351 A;;US 201514605635 A,2014-01-27,Purification column,"A purification column is provided in which fluid is purified by flow through a purifying component. The column includes an annular wall defining a bore which, in use, contains the purifying component. The column further includes an inlet port to the bore comprising a first aperture through the annular wall, the inlet port being adjacent one end of the column. The column further includes an outlet port from the bore comprising a second aperture through the annular wall, the outlet port being adjacent the same end of the column as the inlet port. The column further includes a flow guidance device within the bore and removably connected to the inlet and outlet ports for guiding the fluid to the purifying component from the inlet port and for guiding the fluid from the purifying component to the outlet port. The flow guidance device maintains separation of the fluid flows to and from the purifying component.",WALKER FILTRATION LTD,WALKER BRIAN;;WISE SIMON;;CARNEY PETER;;MCHUGH PETER;;NIXON CHRIS,WALKER FILTRATION LTD (2015-03-13),https://lens.org/003-398-573-480-438,Granted Patent,yes,4,0,11,11,0,B01D35/30;;B01D29/114;;B01D29/96;;B01D2201/301;;B01D2201/302;;B01D2201/306;;B01D15/00;;B01D35/30;;B01D46/0002;;B01D53/00;;B01D35/30;;B01D29/114;;B01D29/96;;B01D2201/301;;B01D2201/302;;B01D2201/306;;B01D46/58;;B01D46/62;;B01D50/20;;B01D45/12;;B01D46/30,B01D53/02;;B01D29/11;;B01D29/96;;B01D35/30;;B01D45/12;;B01D46/00;;B01D46/30;;B01D50/00,,0,0,,,,ACTIVE
103,EP,B1,EP 2913090 B1,124-666-922-946-108,2019-05-08,2019,EP 15152454 A,2015-01-26,GB 201401351 A,2014-01-27,PURIFICATION COLUMN,,WALKER FILTRATION LTD,WALKER BRIAN;;WISE SIMON;;CARNEY PETER;;MCHUGH PETER;;NIXON CHRIS,,https://lens.org/124-666-922-946-108,Granted Patent,yes,6,0,11,11,0,B01D35/30;;B01D29/114;;B01D29/96;;B01D2201/301;;B01D2201/302;;B01D2201/306;;B01D15/00;;B01D35/30;;B01D46/0002;;B01D53/00;;B01D35/30;;B01D29/114;;B01D29/96;;B01D2201/301;;B01D2201/302;;B01D2201/306;;B01D46/58;;B01D46/62;;B01D50/20;;B01D45/12;;B01D46/30,B01D35/30;;B01D29/11;;B01D29/96,,0,0,,,,ACTIVE
104,US,A1,US 2015/0209711 A1,145-815-900-790-42X,2015-07-30,2015,US 201514605635 A,2015-01-26,GB 201401351 A,2014-01-27,PURIFICATION COLUMN,"A purification column is provided in which fluid is purified by flow through a purifying component. The column includes an annular wall defining a bore which, in use, contains the purifying component. The column further includes an inlet port to the bore comprising a first aperture through the annular wall, the inlet port being adjacent one end of the column. The column further includes an outlet port from the bore comprising a second aperture through the annular wall, the outlet port being adjacent the same end of the column as the inlet port. The column further includes a flow guidance device within the bore and removably connected to the inlet and outlet ports for guiding the fluid to the purifying component from the inlet port and for guiding the fluid from the purifying component to the outlet port. The flow guidance device maintains separation of the fluid flows to and from the purifying component.",WALKER FILTRATION LTD,WALKER BRIAN;;WISE SIMON;;CARNEY PETER;;MCHUGH PETER;;NIXON CHRIS,WALKER FILTRATION LTD (2015-03-13),https://lens.org/145-815-900-790-42X,Patent Application,yes,1,6,11,11,0,B01D35/30;;B01D29/114;;B01D29/96;;B01D2201/301;;B01D2201/302;;B01D2201/306;;B01D15/00;;B01D35/30;;B01D46/0002;;B01D53/00;;B01D35/30;;B01D29/114;;B01D29/96;;B01D2201/301;;B01D2201/302;;B01D2201/306;;B01D46/58;;B01D46/62;;B01D50/20;;B01D45/12;;B01D46/30,B01D50/00;;B01D45/12;;B01D46/00;;B01D46/30,,0,0,,,,ACTIVE
105,EP,B1,EP 2848297 B1,057-113-055-794-397,2016-11-02,2016,EP 14183116 A,2014-09-02,GB 201315625 A;;GB 201407442 A,2013-09-03,Filter assembly and filter element for use in the assembly,,WALKER FILTRATION LTD,WALKER BRIAN;;NIXON CHRIS;;WISE SIMON;;CARNEY PETER,,https://lens.org/057-113-055-794-397,Granted Patent,yes,3,0,4,6,0,B01D46/0004;;B01D46/0041;;B01D46/2414;;B01D46/0004;;B01D46/0041;;B01D46/2414;;B01D46/0005,B01D46/24;;B01D46/00,,0,0,,,,ACTIVE
106,WO,A9,WO 2002/012533 A9,080-311-057-644-051,2003-10-02,2003,US 0124383 W,2001-08-03,US 22264900 P,2000-08-03,FERMENTATION AND PURIFICATION OF MYCOLACTONES,"Fermentation based methods for producing mycolactones allows one to produce large quantities of mycolactones, which can be purified by extraction and chromatography to yield pure preparations of mycolactones A, B, C, and D.",KOSAN BIOSCIENCES INC,LICARI PETER;;ARSLANIAN ROBERT;;CADAPAN LAWRENCE;;CARNEY JOHN,,https://lens.org/080-311-057-644-051,Patent Application,no,0,0,7,7,0,C12P17/08;;C12P17/08,C12P17/08,,0,0,,,,PENDING
107,US,A1,US 2015/0128546 A1,124-936-346-372-544,2015-05-14,2015,US 201414476162 A,2014-09-03,GB 201315625 A;;GB 201407442 A,2013-09-03,FILTER ASSEMBLY AND FILTER ELEMENT FOR USE IN THE ASSEMBLY,"A filter assembly for collecting material entrained in a fluid stream includes a filter element having a tubular filter and an end cap providing a flow conduit which extends between first and second conduit openings communicating with the internal void of the tubular filter. A housing for the filter element has inlet and outlet ports for the fluid stream, a housing bowl in which the tubular filter is located, and a housing head which provides at least one of the ports as a docking port for the first conduit opening. The housing head and end cap are arranged such that the end cap is inserted into the housing head, and then rotated relative to the housing head about an axis perpendicular to the axis of the tubular filter and to the axis of the first conduit",WALKER FILTRATION LTD,WALKER BRIAN;;NIXON CHRIS;;WISE SIMON;;CARNEY PETER,WALKER FILTRATION LTD (2014-09-26),https://lens.org/124-936-346-372-544,Patent Application,yes,0,3,4,6,0,B01D46/0004;;B01D46/0041;;B01D46/2414;;B01D46/0004;;B01D46/0041;;B01D46/2414;;B01D46/0005,B01D46/00,55/502,0,0,,,,ACTIVE
108,AU,A1,AU 2006/312059 A1,033-038-473-862-390,2007-05-18,2007,AU 2006/312059 A,2006-11-01,US 73309805 P;;US 2006/0042661 W,2005-11-02,"Methods for prediction and prognosis of cancer, and monitoring cancer therapy",,BAYER HEALTHCARE LLC,CARNEY WALTER P;;HAMER PETER J;;BIGWOOD DOUGLAS,,https://lens.org/033-038-473-862-390,Patent Application,no,0,0,16,16,0,G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N2800/52;;G01N33/57492;;G01N2333/71;;G01N2333/475,G01N33/574,,0,0,,,,DISCONTINUED
109,BR,A2,BR PI0618564 A2,025-881-613-968-197,2011-09-06,2011,BR PI0618564 A,2006-11-01,US 73309805 P;;US 2006/0042661 W,2005-11-02,métodos para predição e prognóstico de cáncer e para monitoração de terapia contra cáncer,"MéTODOS PARA PREDIçãO E PROGNóSTICO DE CáNCER E PARA MONITORAçãO DE TERAPIA CONTRA CáNCER. A presente invenção refere-se a biomarcadores e o uso de biomarcadores para a predição e prognóstico de câncer, bem como o uso de biomarcadores para monitorar a eficácia de tratamento contra câncer. Especificamente, esta invenção refere-se ao uso de VEGF-R2 solúvel como biomarcador para inibidores de múltiplas quinases.",BAYER HEALTHCARE LLC,CARNEY WALTER P;;HAMER PETER J;;BIGWOOD DOUGLAS,,https://lens.org/025-881-613-968-197,Patent Application,no,0,0,16,16,0,G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N2800/52;;G01N33/57492;;G01N2333/71;;G01N2333/475,G01N33/574,,0,0,,,,DISCONTINUED
110,US,B2,US 6562602 B2,039-552-682-838-573,2003-05-13,2003,US 92166601 A,2001-08-03,US 92166601 A;;US 22264900 P,2000-08-03,Fermentation and purification of mycolactones,"
    Fermentation based methods for producing mycolactones allows one to produce large quantities of mycolactones, which can be purified by extraction and chromatography to yield pure preparations of mycolactones A, B, C, and D. 
",KOSAN BIOSCIENCES INC,LICARI PETER;;ARSLANIAN ROBERT;;CADAPAN LAWRENCE;;CARNEY JOHN,KOSAN BIOSCIENCES INC (2001-10-25),https://lens.org/039-552-682-838-573,Granted Patent,yes,0,2,7,7,0,C12P17/08;;C12P17/08,C12P17/08,435/123,13,11,014-438-762-019-029;;128-457-555-922-415;;053-261-459-547-623;;053-261-459-547-623;;023-221-927-579-534;;027-399-976-595-710;;059-132-816-940-560;;003-060-278-659-621;;049-864-376-271-543;;020-246-527-793-496;;094-310-216-638-462,10.1016/s0378-1097(01)00502-x;;10.1111/j.1574-6968.2001.tb10977.x;;11750832;;10.1128/iai.66.2.587-593.1998;;pmc107944;;9453613;;10.1126/science.283.5403.854;;9933171;;10.1126/science.283.5403.854;;9933171;;10.1021/ja990017l;;10564801;;10.1016/s0378-1097(99)00528-5;;10.1111/j.1574-6968.1999.tb08838.x;;10.1016/0092-1157(88)90013-3;;3058708;;pmc105348;;10.1128/jcm.36.11.3420-3422.1998;;9774612;;pmc104550;;10.1128/jcm.36.2.402-408.1998;;9466749;;10.1093/infdis/157.3.577;;2963867;;4830529;;10.1128/iai.9.6.1114-1122.1974;;pmc414941,"Cadapan, L. et al. (2001) FEMS Microbiology Letters 205(2):385-389.;;George, K. et al. (1998) Infection and Immunity 66(2):587-593.;;George, K. et al. (1999) Science 283(5403):854-857.;;Report of the 3rd WHO Advisory Group Meeting on Buruli Ulcer (Mar., 2000), On Line!, XP002201041. Retrieved from the Internet: <URL:http:/www.who.int/gtb-buruli/activities/PDF/2000_meeting_report_(BU).pdf> retrieved on Jun. 3, 2002! pp. 59-60.;;Report of the 4th WHO Advisory Group Meeting on Buruli Ulcer (Mar., 2001), On Line!, XP002201042. Retrieved from the Internet: >URL:http:/www.who.int/gtb-buruli/activities/PDF/2001_Final_Report.pdf> retrieved on Jun. 3, 2002! pp. 57-59.;;George et al., Science (1999) 283:854-857.;;Gunawardana et al., JACS (1999) 121:6092-6093.;;Mve-Obiang et al., FEMS Microbiol. Lett. (1999) 181:153-157.;;Nyabenda et al., J. Biol. Standard (1988) 16:259-267.;;Palomino et al., J. Clin. Microbiol. (1998) 36(11):3420-3422.;;Palomino and Portaels, J. Clin. Microbiol. (1998) 36(2):402-408.;;Pimsler et al., J. Infect. Dis. (1988) 157(3):577-580.;;Read et al., Infection & Immun. (1974) 9(6):1114-1122.",EXPIRED
111,EP,A4,EP 1943521 A4,154-357-344-483-023,2009-12-30,2009,EP 06827287 A,2006-11-01,US 2006/0042661 W;;US 73309805 P,2005-11-02,"METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY",,BAYER HEALTHCARE LLC,CARNEY WALTER P;;HAMER PETER J;;BIGWOOD DOUGLAS,,https://lens.org/154-357-344-483-023,Search Report,no,1,0,16,16,0,G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N2800/52;;G01N33/57492;;G01N2333/71;;G01N2333/475,G01N33/574,,3,0,,,"MILOJKOVIC DRAGANA ET AL: ""Immunohistochemical characterisation of vascular endothelial growth factor (VEGF) and its receptors Flt-1 and KDR in chronic myeloid leukaemia (CML) patients treated with imatinib mesylate."", November 2004, BLOOD, VOL. 104, NR. 11, PART 1, PAGE(S) 551A-552A, 46TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 04 -07, 2004, ISSN: 0006-4971, XP002555803;;LIANG AIBIN ET AL: ""Differential expression of VEGF and its receptors in the primary cells of various risk classified acute lymphoblastic leukemia patients"", BLOOD, vol. 104, no. 11, Part 2, November 2004 (2004-11-01), & 46TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 04 -07, 2004, pages 194B, XP002555802, ISSN: 0006-4971;;ELTING JAMES ET AL: ""Biomarkers associated with clinical outcomes in TARGETs, a Phase III single-agent, placebo-controlled study of sorafenib in advanced renal cell carcinoma"", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 47, 1 April 2006 (2006-04-01), pages 683 - 684, XP001245679, ISSN: 0197-016X",DISCONTINUED
112,AT,T1,AT E493652 T1,187-479-771-220-714,2011-01-15,2011,AT 06801170 T,2006-08-10,US 70780605 P;;US 2006/0031245 W,2005-08-11,QUANTITATIVE ASSAYS FÜR PDGFR-BETA- IN KÖRPERFLÜSSIGKEITEN,"The present invention is directed to the detection and quantification of total PDGFR-beta in body fluids, particularly serial changes of total PDGFR-beta levels in a subject's body fluids. Further, the invention is directed to detecting and quantitatiing total PDGFR-beta in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for diseases, and useful to select therapies for patients with diseases, preferably preneoplastic/neoplastic diseases. The disclosed methods are particularly useful to monitor the status of a patient's disease, and/or to monitor how a patient is responding to a therapy.",SIEMENS HEALTHCARE DIAGNOSTICS,HAMER PETER;;CARNEY WALTER;;MORRIS LETICIA;;ELTING JAMES,,https://lens.org/187-479-771-220-714,Granted Patent,no,0,0,9,9,0,G01N33/57415;;G01N33/57419;;G01N33/57434;;G01N33/57449;;G01N33/57488;;G01N33/57492;;G01N2333/49;;G01N2333/71;;G01N2800/52;;G01N33/57488;;G01N2333/71;;G01N2800/52;;G01N33/57419;;G01N2333/49;;G01N33/57434;;G01N33/57449;;G01N33/57415;;G01N33/57492,,,0,0,,,,INACTIVE
113,US,A1,US 2002/0086375 A1,141-317-344-822-576,2002-07-04,2002,US 92166601 A,2001-08-03,US 92166601 A;;US 22264900 P,2000-08-03,Fermentation and purification of mycolactones,"
   Fermentation based methods for producing mycolactones allows one to produce large quantities of mycolactones, which can be purified by extraction and chromatography to yield pure preparations of mycolactones A, B, C, and D. 
",LICARI PETER;;ARSLANIAN ROBERT;;CADAPAN LAWRENCE;;CARNEY JOHN,LICARI PETER;;ARSLANIAN ROBERT;;CADAPAN LAWRENCE;;CARNEY JOHN,KOSAN BIOSCIENCES INC (2001-10-25),https://lens.org/141-317-344-822-576,Patent Application,yes,0,0,7,7,0,C12P17/08;;C12P17/08,C12P17/08,435/123;;549/263,0,0,,,,EXPIRED
114,MX,B,MX 166901 B,185-795-434-979-553,1993-02-11,1993,MX 2479491 A,1991-03-06,US 58707290 A,1990-09-24,MODULO PROTECTOR DE CIRCUITO TELEFONICO QUE TIENE ELEMENTOS DE TIERRA DE CIRCUITOS PLULARES,"La presente invención se refiere a un módulo protector telefónico de circuito de suscriptor que incluye un alojamiento, elementos protectores de voltaje excesivo y de corriente dispuesto dentro de este alojamiento para poner tierrra las corrientes que tienen un voltaje y un flujo de corriente arriba de los niveles previamente determinados, la mejora que incluye; estos tres elementos que tiene un electrodo central y primero y un segundo electrodos de extremo, un dispositivo contra fallas del tubo de gas que incluye un sujetador metálico alargado que hace contacto con el electrodo central, y mantenido em una relación aislada en relación con los electodos de tierra que incluye un perno de tierra alargado que se extiende de extremo interior, un miembro plano de tierra que se extiende de manera transversal llevado por este extremo interior; un miembro plano de tierra que se extiende de una manera transversal llevado por extremo interior, el electrodo central tiene un perno de contacto que se extiende de una manera lateral el cual penetra en el miembro de tierra para su comunicación eléctrica con el mismo, siendo este sujetador alargado llevado por el perno de contacto; un par de contactos de punto de prueba haciendo cada uno contacto con un electrodo de extremo respectivo, indpendientemente de los elementos fusibles en un primer extremo del mismo, y que tienen elementos fusibles en un primer extremo del mismo, y que tienen un segundo extremo que se extiende de una maneratransversal, encima del miembro plano de tierra, elementos aisladores cilíndricos que separan el segundo extremo del miembro plano de tierra; un par de con- tactos largos que tienen cada uno primero y segundo extremos, haciendo contacto este primer extremo con el segundo extremo del miembro plano de tierra; un par de contactos largos que tienen cada uno primer y segundo extremo haciendo contacto este primer extremo con el segundo extremo de un contaco de punto de prueba respectivo, donde los orificios correspondientes de cada uno de los puntos de prueba hacen contacto con el contacto largo y quedan alineados y un par de bobinas de calor termicamente activadas, llevadas cada una por un contacto respectivo, y que tiene elementos de contacto de punto extensible que penetran en los orificios alineados para hacer contacto con el miembro plano de tierrra sobre la activación de la bobina de calor, con lo que cada uno del tubo de gas de tres elementos y el dispositivo contra fallas están en un contacto constante con el miembro plano de tierra, y las bobinas de calor están selectivamente en contacto con el miembro plano de tierra; soirviendo el tubo de gas para poner a tierra las oleadas de voltaje en el margen de 200 a 300 voltios, sirviendo el dispositivo contra fallas para poner a tierra las oleadas de corriente sostenidas, y llegando a ser las bobinas de calor operativas en la presencia de corrientes arrastradas en la escala de menos de un amper.",PORTA SYSTEMS CORP,VISCONTI PETER;;NEUWIRTH HELMUTH;;MEYERHOEFER CARL;;CARNEY WILLIAM,,https://lens.org/185-795-434-979-553,Granted Patent,no,0,0,2,2,0,H01T1/14;;H01T4/06;;H04M3/18;;H01T4/06;;H04M3/18;;H01T1/14,H01T1/14;;H01T4/06;;H04M3/18,,0,0,,,,EXPIRED
115,WO,A3,WO 2002/012533 A3,074-381-530-931-109,2003-01-03,2003,US 0124383 W,2001-08-03,US 22264900 P,2000-08-03,FERMENTATION AND PURIFICATION OF MYCOLACTONES,"Fermentation based methods for producing mycolactones allows one to produce large quantities of mycolactones, which can be purified by extraction and chromatography to yield pure preparations of mycolactones A, B, C, and D.",KOSAN BIOSCIENCES INC,LICARI PETER;;ARSLANIAN ROBERT;;CADAPAN LAWRENCE;;CARNEY JOHN,,https://lens.org/074-381-530-931-109,Search Report,yes,0,0,7,7,0,C12P17/08;;C12P17/08,C12P17/08,,7,5,027-399-976-595-710;;128-457-555-922-415;;053-261-459-547-623;;049-864-376-271-543;;014-438-762-019-029,10564801;;10.1016/s0378-1097(99)00528-5;;10.1111/j.1574-6968.1999.tb08838.x;;10.1128/iai.66.2.587-593.1998;;pmc107944;;9453613;;10.1126/science.283.5403.854;;9933171;;pmc104550;;10.1128/jcm.36.2.402-408.1998;;9466749;;10.1016/s0378-1097(01)00502-x;;10.1111/j.1574-6968.2001.tb10977.x;;11750832,"MVE-OBIANG ARMAND ET AL: ""Growth and cytotoxic activity by Mycobacterium ulcerans in protein-free media."", FEMS MICROBIOLOGY LETTERS, vol. 181, no. 1, 1 December 1999 (1999-12-01), pages 153 - 157, XP002201039, ISSN: 0378-1097;;GEORGE KATHLEEN M ET AL: ""Partial purification and characterization of biological effects of a lipid toxin produced by Mycobacterium ulcerans."", INFECTION AND IMMUNITY, vol. 66, no. 2, February 1998 (1998-02-01), pages 587 - 593, XP000918628, ISSN: 0019-9567;;GEORGE K M ET AL: ""Mycolactone. A Polyketide Toxin from Mycobacterium ulcerans Required for Virulence"", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 283, no. 5403, 5 February 1999 (1999-02-05), pages 854 - 857, XP002148650, ISSN: 0036-8075;;PALOMINO J C ET AL: ""Effects of decontamination method and culture conditions on viability of Mycobacterium ulcerans in the BACTEC system."", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 36, no. 2, February 1998 (1998-02-01), pages 402 - 408, XP002201040, ISSN: 0095-1137;;ANONYMOUS, REPORT OF 3RD WHO ADVISORY GROUP MEETING ON BURULI ULCER (MARCH 2000), March 2000 (2000-03-01), XP002201041, Retrieved from the Internet <URL:http://www.who.int/gtb-buruli/activities/PDF/2000_meeting_report_(BU).pdf> [retrieved on 20020603];;ANONYMOUS, REPORT OF 4TH WHO ADVISORY GROUP MEETING ON BURULI ULCER (MARCH 2001), March 2001 (2001-03-01), XP002201042, Retrieved from the Internet <URL:http://www.who.int/gtb-buruli/activities/PDF/2001_Final_REPORT.pdf> [retrieved on 20020603];;CADAPAN L D ET AL: ""Suspension cultivation of Mycobacterium ulcerans for the production of mycolactones."", FEMS MICROBIOLOGY LETTERS, vol. 205, no. 2, 2001, pages 385 - 389, XP002201043, ISSN: 0378-1097",PENDING
116,WO,A2,WO 2002/012533 A2,078-587-279-393-193,2002-02-14,2002,US 0124383 W,2001-08-03,US 22264900 P,2000-08-03,FERMENTATION AND PURIFICATION OF MYCOLACTONES,"Fermentation based methods for producing mycolactones allows one to produce large quantities of mycolactones, which can be purified by extraction and chromatography to yield pure preparations of mycolactones A, B, C, and D.",KOSAN BIOSCIENCES INC,LICARI PETER;;ARSLANIAN ROBERT;;CADAPAN LAWRENCE;;CARNEY JOHN,,https://lens.org/078-587-279-393-193,Patent Application,yes,0,12,7,7,0,C12P17/08;;C12P17/08,C12P17/08,,0,0,,,,PENDING
117,US,B2,US 7375230 B2,198-686-357-523-737,2008-05-20,2008,US 83889504 A,2004-05-03,US 83889504 A;;US 93216701 A;;US 22659500 P,2000-08-21,Fermentation and purification of migrastatin and analog,Migrastatin and a migrastatin analog can be produced by fermentation of Streptomyces platensis NRRL 18993 and used in pharmaceutical formulations to treat cancer and/or inhibit metastasis of cancer cells.,KOSAN BIOSCIENCES INC,KHOSLA CHAITAN;;LICARI PETER J;;CARNEY JOHN R,,https://lens.org/198-686-357-523-737,Granted Patent,yes,5,0,4,4,0,C12P17/16;;C12P17/16;;C07K14/36;;C07K14/36,C07C257/00;;A61K31/445;;C07K14/36;;C12P17/00;;C12P17/16,546/243;;514/327;;435/117,10,9,041-981-985-487-624;;009-129-497-904-27X;;031-731-951-977-68X;;018-611-726-407-448;;082-853-645-359-045;;080-726-136-003-097;;062-552-020-884-195;;031-095-008-794-896;;013-732-025-529-855,10.7164/antibiotics.47.870;;7928672;;2272925;;10.7164/antibiotics.43.1502;;7928673;;10.7164/antibiotics.47.875;;10.7164/antibiotics.47.862;;7928671;;10.1007/bf01578202;;1366609;;10.7164/antibiotics.53.1130;;11132958;;10.7164/antibiotics.53.1228;;11132973;;10.7164/antibiotics.49.234;;8626236;;10.1002/(sici)1097-0142(19971015)80:8+<1529::aid-cncr2>3.3.co;2-#;;9362419;;10.1002/(sici)1097-0142(19971015)80:8+<1529::aid-cncr2>3.0.co;2-f,"Hochlowski et al., ""Dorrigocins: novel antifungal antibiotics that change the morphology of ras-transformed NIH/3T3 cells to that of normal cells. II. Isolation and elucidation of structures,"" J. Antibiot., 47(8):870-874 (1994).;;Hondo et al., Transplantation Proceedings XIX, Supp. 6:17-22 (1987).;;Jarvis et al., ""Use of resins for trichothecene production in liquid cultures,"" J. Antibiot., 43(11):1502-1504.;;Kadam et al., ""Dorrigocins: novel antifungal antibodies that change the morphology of ras-transformed NIH/3T3 cells to that of normal cells. III. Biological properties and mechanism of action,"" J. Antibiot., 47(8):875-880 (1994).;;Karwowski et al., ""Dorrigocins: novel antifungal antibodies that change the morphology of ras-transformed NIH/3T3 cells to that of normal cells. I. Taxonomy of the producing organism, fermentation and biological activity,"" J. Antibiot., 47(8):862-869 (1994).;;Marshall et al., ""The effect of neutral resins on the fermentation production of rubradirin,"" J. Ind. Microbiol., 5(5):283-287 (1990).;;Nakae et al., ""Migrastatin, a new inhibitor of tumor cell migration from Streptomyces sp. MK929-43F1. Taxonomy, fermentation, isolation and biological activities,"" J. Antibiot., 53(10):1130-1136 (2000).;;Nakae et al., ""Migrastatin, a novel 14-membered lactone from Streptomyces sp. MK929-43F1,"" J. Antibiot., 53(10):1228-1230 (2000).;;Warr et al., ""BMS-182123, a fungal metabolite that inhibits the production of TNF-alpha by macrophages and monocytes,"" J. Antibiot., 49(3):234-240 (1996).;;Woodhouse et al., ""General mechanisms of metastasis,"" Cancer, 80(8 suppol.):1529-1537 (1997).",EXPIRED
118,EP,A1,EP 2848297 A1,107-576-057-791-117,2015-03-18,2015,EP 14183116 A,2014-09-02,GB 201315625 A;;GB 201407442 A,2013-09-03,Filter assembly and filter element for use in the assembly,"A filter assembly is provided for collecting material that is entrained in a fluid stream. The assembly includes a removable filter element having a tubular filter through which, in use, the fluid stream flows, and an end cap providing a flow conduit which extends between a first conduit opening and a second conduit opening communicating with the internal void of the tubular filter, the axis of the first conduit opening being at an angle to the axis of the tubular filter. The assembly further includes a housing for the filter element, the housing having inlet and outlet ports for the fluid stream, a housing bowl in which the tubular filter is located, and a housing head which provides at least one of the ports as a docking port for the first conduit opening. The housing head and the end cap are arranged such that the end cap is inserted into the housing head, and then rotated relative to the housing head about an axis perpendicular to the axis of the tubular filter and to the axis of the first conduit opening to bring the first conduit opening and the docking port into sealed communication.
",WALKER FILTRATION LTD,WALKER BRIAN;;NIXON CHRIS;;WISE SIMON;;CARNEY PETER,,https://lens.org/107-576-057-791-117,Patent Application,yes,3,3,4,6,0,B01D46/0004;;B01D46/0041;;B01D46/2414;;B01D46/0004;;B01D46/0041;;B01D46/2414;;B01D46/0005,B01D46/24;;B01D46/00,,0,0,,,,ACTIVE
119,AU,A,AU 2001/078155 A,121-629-975-898-785,2002-02-18,2002,AU 2001/078155 A,2001-08-03,US 22264900 P;;US 0124383 W,2000-08-03,Fermentation and purification of mycolactones,,KOSAN BIOSCIENCES INC,LICARI PETER;;ARSLANIAN ROBERT;;CADAPAN LAWRENCE;;CARNEY JOHN,,https://lens.org/121-629-975-898-785,Patent Application,no,0,0,7,7,0,C12P17/08;;C12P17/08,C12P17/08,,0,0,,,,PENDING
120,US,B2,US 9895639 B2,176-300-338-686-116,2018-02-20,2018,US 201414476162 A,2014-09-03,GB 201315625 A;;GB 201407442 A,2013-09-03,Filter assembly and filter element for use in the assembly,"A filter assembly for collecting material entrained in a fluid stream includes a filter element having a tubular filter and an end cap providing a flow conduit which extends between first and second conduit openings communicating with the internal void of the tubular filter. A housing for the filter element has inlet and outlet ports for the fluid stream, a housing bowl in which the tubular filter is located, and a housing head which provides at least one of the ports as a docking port for the first conduit opening. The housing head and end cap are arranged such that the end cap is inserted into the housing head, and then rotated relative to the housing head about an axis perpendicular to the axis of the tubular filter and to the axis of the first conduit.",WALKER FILTRATION LTD,WALKER BRIAN;;NIXON CHRIS;;WISE SIMON;;CARNEY PETER,WALKER FILTRATION LTD (2014-09-26),https://lens.org/176-300-338-686-116,Granted Patent,yes,7,0,4,6,0,B01D46/0004;;B01D46/0041;;B01D46/2414;;B01D46/0004;;B01D46/0041;;B01D46/2414;;B01D46/0005,B01D46/00;;B01D46/24,,0,0,,,,ACTIVE
121,WO,A2,WO 2007/056012 A2,119-676-439-808-766,2007-05-18,2007,US 2006/0042661 W,2006-11-01,US 73309805 P,2005-11-02,"METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY","The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of soluble VEGF-R2 as a biomarker for multi-kinase inhibitors.",BAYER HEALTHCARE LLC;;ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J;;BIGWOOD DOUGLAS,CARNEY WALTER P;;HAMER PETER J;;BIGWOOD DOUGLAS,,https://lens.org/119-676-439-808-766,Patent Application,yes,0,6,16,16,0,G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N2800/52;;G01N33/57492;;G01N2333/71;;G01N2333/475,G01N33/574,,0,0,,,,PENDING
122,CN,C,CN 1154259 C,019-596-776-638-993,2004-06-16,2004,CN 00807732 A,2000-05-10,US 31481999 A;;US 55812100 A,1999-05-19,Method and apparatus for acquisition of a spread spectrum signal,一种用于码分多址CDMA无线电话(104)捕获伪随机噪声PN序列定时的装置(114)。一缓冲器(230)存储至少一个导频信号的样本。一耦合到缓冲器(230)的相关器(202)可操作以将所述样本的至少一部分与在多个不同的PN偏移之一上的PN序列相关，以产生对应的相关能量。一旦在一特定PN偏移的所述PN序列产生一至少等于能量阈值的相关能量，耦合到相关器(202)的控制器(116)，就中断相关器(202)。,MOTOROLA INC,LAROSA CHRISTOPHER PETER;;STORM BRIAN DAVID;;CARNEY MICHAEL JOHN,"MOTOROLA MOBILE CO., LTD. (2011-01-07)",https://lens.org/019-596-776-638-993,Granted Patent,no,0,0,16,30,0,H04B1/70752;;H04B1/70752;;H04B1/7077;;H04B1/70751;;H04B1/70751;;H04B1/70753;;H04B1/70753;;H04B1/70756;;H04B1/70756;;H04B1/709;;H04B1/709;;H04B2201/70701;;H04B2201/70701;;H04B2201/70702;;H04B2201/70702;;H04B2201/70707;;H04B2201/70707;;H04B2201/70709;;H04B2201/70709,H04B1/7075;;H04B1/709,,0,0,,,,EXPIRED
123,US,A,US 5008772 A,138-751-776-703-523,1991-04-16,1991,US 58707290 A,1990-09-24,US 58707290 A,1990-09-24,Telephone circuit protector module having plural circuit grounding means,"An improved telephone subscriber circuit protector module providing plural surge voltage and excess current protection elements including so-called sneak current protection. The module includes a three-element gas tube which protects against voltage surges in the range of 200 to 300 volts, and includes fail safe protection relative to the gas tube should the gas tube become non-conductive over its intended range of protection. The fail safe protection is thermally operated under the influence of high current. Secondary air gap protection supplements the operation of the gas tube in the event of gas tube failure, and is operative to ground momentary voltage surges in the area of 1500 volts. Separate sneak current protection employing heat coils are operative in a range below one ampere flow, and an alternate form provides for the opening of the subscriber side of the line rather than the grounding of it. All of the protective elements communicate with a common ground plane forming part of a ground assembly.",PORTA SYSTEMS CORP,NEUWIRTH HELMUTH;;MEYERHOEFER CARL;;CARNEY WILLIAM V;;VISCONTI PETER,PORTA SYSTEMS CORPORATION (1990-06-22),https://lens.org/138-751-776-703-523,Granted Patent,yes,4,14,2,2,0,H01T1/14;;H01T4/06;;H04M3/18;;H01T4/06;;H04M3/18;;H01T1/14,H01T1/14;;H01T4/06;;H04M3/18,361/119;;361/120;;361/124;;337/32,0,0,,,,EXPIRED
124,GB,A,GB 2591343 A,171-941-405-711-667,2021-07-28,2021,GB 202020743 A,2019-05-31,GB 201808893 A;;GB 201907735 A,2018-05-31,Bench-top time of flight mass spectrometer,"A pusher assembly 120 for a time of flight mass analyser comprises a pusher electrode 200 and a double grid electrode 202 to provide a field-free region for focusing ions accelerated by the pusher electrode. Ring electrodes 204 and an exit grid electrode 206 may be provided downstream of the double grid electrode. A double grid electrode structure is formed by applying adhesive to an upper and lower surface of an annular member 232, and winding metal strands or wires across the annular member to form two grid electrodes attached to the two surfaces. The adhesive may be applied before or after the strands are wound. Also disclosed are (i) a time-of-flight analyser comprising a flight tube and a reflectron, wherein the reflectron is compressed against the flight tube; and (ii) an ion inlet device and control system configured to introduce an analyte sample or lock mass substance into a mass spectrometer and switch between the analyte sample and the lock mass substance during an analytical run.",MICROMASS LTD,PETER CARNEY;;SOJI CHUMMAR;;JASON LEE WILDGOOSE;;RUTH WAMSLEY,,https://lens.org/171-941-405-711-667,Patent Application,no,8,0,12,12,0,H01J49/068;;H01J49/405;;H01J49/0009;;H01J49/04;;H01J49/06;;H01J49/401;;H01J49/405;;H01J49/0031;;H01J49/04;;H01J49/065;;H01J49/068;;H01J49/401;;H01J49/405,H01J49/06;;H01J49/00;;H01J49/04;;H01J49/40,,0,0,,,,ACTIVE
125,ES,T3,ES 2349660 T3,164-148-570-595-113,2011-01-10,2011,ES 06785512 T,2006-06-23,US 69408205 P,2005-06-23,ENSAYOS CUANTITATIVOS PARA RAS P21 EN FLUIDOS CORPORALES.,"The present invention is directed to the detection and quantification of total ras p21 in body fluids, particularly serial changes of total ras p21 levels in a subject's body fluids. Further, the invention is directed to detecting and quantitating total ras p21 in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for preneoplastic/neoplastic diseases, and useful to select therapies for patients with preneoplastic/neoplastic diseases. The disclosed methods are further useful to monitor the status of a patient's preneoplastic/neoplastic disease, and/or to monitor how a patient is responding to an anticancer therapy.",SIEMENS HEALTHCARE DIAGNOSTICS,HAMER PETER;;BROWN-SHIMER SHERYL;;CARNEY WALTER;;PIERCE KAREN,,https://lens.org/164-148-570-595-113,Granted Patent,no,0,0,13,13,0,G01N33/5748;;G01N2333/82;;G01N2800/44;;G01N33/5748;;G01N2800/44;;G01N2333/82;;G01N33/574,G01N33/48;;G01N1/00;;G01N33/00,,0,0,,,,ACTIVE
126,EP,B1,EP 2964522 B1,027-909-016-243-31X,2021-06-16,2021,EP 14760886 A,2014-02-26,US 201361773687 P;;US 2014/0018567 W,2013-03-06,GAS TURBINE ENGINE NOSE CONE ATTACHMENT,,RAYTHEON TECH CORP,HUBBERT COREY L;;TOMEO PETER V;;ANDERSON CARNEY R,RAYTHEON TECHNOLOGIES CORPORATION (2021-03-24);;UNITED TECHNOLOGIES CORPORATION (2016-10-26),https://lens.org/027-909-016-243-31X,Granted Patent,yes,7,0,6,6,0,F01D5/066;;F01D5/30;;F02K3/06;;Y10T29/49323;;F01D5/32;;Y02T50/60;;F01D5/30;;F02K3/06;;F01D5/066;;Y02T50/60;;Y10T29/49323;;F01D5/02;;F01D5/12;;F01D5/3007;;F01D5/32;;F01D9/04;;F05D2220/32;;F05D2230/60,B64C11/14;;F01D5/02;;F01D5/06;;F01D5/12;;F01D5/30;;F01D5/32;;F01D9/04;;F02C7/04;;F02K3/06,,0,0,,,,ACTIVE
127,GB,A,GB 2609096 A,081-612-666-431-890,2023-01-25,2023,GB 202211820 A,2019-05-31,GB 201808893 A;;GB 202020743 A,2018-05-31,Bench-top Time of Flight mass spectrometer,"A method of time of flight mass analysis comprises mass analysing an analytical sample to obtain analytical data, mass analysing two different lock mass compounds, and applying a correction factor to the analytical data based on the difference between recorded and known masses of the lock mass compounds. The two different lock mass compounds may be mass analysed immediately before and immediately after the analytical run. A single sprayer may be used to introduce the analytical sample and the lock mass compounds. Also disclosed are (i) a time of flight analyser having a reflectron that is compressed against the flight tube; (ii) a pusher assembly comprising a double grid electrode to provide a field-free region; (iii) a method of forming two grid electrodes, comprising applying adhesive to an annular member and winding metal strands across the annular member; and (iv) an ion inlet device and control system configured to introduce an analyte sample or lock mass substance into a mass spectrometer and switch between the analyte sample and the lock mass substance during an analytical run.",MICROMASS LTD,RUTH WAMSLEY;;SOJI CHUMMAR;;PETER CARNEY;;JASON LEE WILDGOOSE,,https://lens.org/081-612-666-431-890,Patent Application,no,10,0,12,12,0,H01J49/068;;H01J49/405;;H01J49/0009;;H01J49/04;;H01J49/06;;H01J49/401;;H01J49/405;;H01J49/0031;;H01J49/04;;H01J49/065;;H01J49/068;;H01J49/401;;H01J49/405,H01J49/00;;H01J49/04;;H01J49/06;;H01J49/40,,0,0,,,,ACTIVE
128,WO,A2,WO 2007/047955 A2,084-460-464-256-106,2007-04-26,2007,US 2006/0041090 W,2006-10-20,US 72941005 P,2005-10-21,"METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY","The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of VEGF-165 as a biomarker for multi-kinase inhibitors.",BAYER HEALTHCARE LLC;;ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J,ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J,,https://lens.org/084-460-464-256-106,Patent Application,yes,0,10,15,15,0,G01N33/57488;;G01N2800/52;;A61P35/00;;A61P35/02;;A61P43/00;;G01N33/57488;;G01N2800/52;;G01N33/57488;;G01N2800/52,G01N33/574,,0,0,,,,PENDING
129,US,A1,US 2014/0056713 A1,140-180-234-644-720,2014-02-27,2014,US 201213593587 A,2012-08-24,US 201213593587 A,2012-08-24,TURBINE ENGINE ROTOR ASSEMBLY,"A turbine engine rotor assembly includes a turbine engine rotor disk that extends axially along a centerline between a first disk end and a second disk end, and radially to an outer disk surface. The rotor disk includes one or more blade retention slots arranged circumferentially around the centerline. A first of the blade retention slots extends axially into the rotor disk from a disk end surface at the first disk end to a slot end surface, and radially into the rotor disk from the outer disk surface to a slot base surface.",TOMEO PETER V;;ANDERSON CARNEY R;;GANOE WILLIAM RICHARD;;UNITED TECHNOLOGIES CORP,TOMEO PETER V;;ANDERSON CARNEY R;;GANOE WILLIAM RICHARD,RTX CORPORATION (2012-08-22),https://lens.org/140-180-234-644-720,Patent Application,yes,5,9,2,2,0,B23C3/30;;B23C3/30;;B23C2220/366;;B23C2220/366;;B24B19/02;;B24B19/02;;F01D5/3007;;F01D5/3007;;Y10T29/49316;;Y10T29/49316,F01D5/30;;B21D53/00,416219 R;;29/889,0,0,,,,ACTIVE
130,US,A1,US 2021/0126487 A1,192-472-956-760-724,2021-04-29,2021,US 202017082628 A,2020-10-28,US 202017082628 A;;US 201962926594 P,2019-10-28,UNINTERRUPTIBLE POWER SUPPLY SYSTEM HAVING STRANDED POWER RECOVERY,"An uninterruptible power supply (UPS) system with stranded power recovery has a plurality of UPS modules with one or more of the UPS modules usable to provide stranded power to a recovered power bus. When a UPS module is used to provide stranded power to the recovered power bus, the AC/AC converter associated with that UPS module provides AC power that is synchronized with AC power being provided to the recovered power bus by each of the other AC/AC converters that are providing AC power. In this manner all of the AC/AC converters that are providing AC power to the recovered power bus have the same voltage, the same frequency and are in phase.",VERTIV CORP,BUSH TERRY D;;CARNEY KEVIN B;;PANFIL PETER A,VERTIV CORPORATION (2021-04-28),https://lens.org/192-472-956-760-724,Patent Application,yes,0,0,8,8,0,H02J9/062;;H02J9/068;;H02J9/062;;H02J3/40;;H02J2310/16;;G06F1/30;;G06F11/2015;;H02J9/068;;H02J9/062,H02J9/06,,0,0,,,,ACTIVE
131,US,B2,US 10072509 B2,019-396-966-602-418,2018-09-11,2018,US 201414768228 A,2014-02-26,US 201414768228 A;;US 201361773687 P;;US 2014/0018567 W,2013-03-06,Gas turbine engine nose cone attachment,"A fan section for a gas turbine engine includes a fan hub having blade slots for receiving a root of a fan blade. A lock ring is configured to move rotatably from an unlocked position to a locked position for securing the blade root in the blade slot. A nose cone is secured to the lock ring, and thereby secured to the fan section.",UNITED TECHNOLOGIES CORP,HUBBERT COREY L;;TOMEO PETER V;;ANDERSON CARNEY R,RTX CORPORATION (2023-07-14),https://lens.org/019-396-966-602-418,Granted Patent,yes,23,2,6,6,0,F01D5/32;;F01D5/32;;F01D5/02;;F01D5/066;;F01D5/066;;F01D5/12;;F01D5/30;;F01D5/30;;F01D5/3007;;F01D9/04;;F02K3/06;;F02K3/06;;F05D2220/32;;F05D2230/60;;Y02T50/60;;Y02T50/60;;Y10T29/49323;;Y10T29/49323,F01D5/32;;F01D5/02;;F01D5/06;;F01D5/12;;F01D5/30;;F01D9/04;;F02K3/06,,3,0,,,"International Search Report for PCT Application No. PCT/US2014/018567, dated May 28, 2014.;;International Preliminary Report on Patentability for International Application No. PCT/US2014/018567 dated Sep. 17, 2015.;;Extended European Search Report for European Application No. 14760886.3 dated Sep. 20, 2016.",ACTIVE
132,AT,T1,AT E73735 T1,052-431-370-869-645,1992-04-15,1992,AT 87300021 T,1987-01-05,EP 87300021 A,1987-01-05,THERMISCHE REINIGUNG VON MINERALISCHEN NATURKOHLENSTOFFEN.,"Properties of naturally occurring C materials are modified by treatment in a fludised bed at a temp. of at least about 2500 deg. C, using a primer charge of a C material, pref. a conductive, non-sticky, granular solid, esp. petroleum coke, fluidised using a fluidising medium. Bed residence time of the C material being treated is sufficient to increase the resiliency of the material 100%. Pref. the bed is fluidised using an inert gas, pref. N2, at a pref. flow rate of 7-8 scfm.",SUPERIOR GRAPHITE CO,GOLDBERGER WILLIAM MORGAN;;CARNEY PETER R;;REED ALLAN K,,https://lens.org/052-431-370-869-645,Granted Patent,no,0,0,2,5,0,,B01J8/24;;C01B31/04,,0,0,,,,DISCONTINUED
133,US,B2,US 11611231 B2,184-694-326-084-956,2023-03-21,2023,US 202217675257 A,2022-02-18,US 202217675257 A;;US 202017082628 A;;US 201962926594 P,2019-10-28,Uninterruptible power supply system having stranded power recovery,"An uninterruptible power supply (UPS) system with stranded power recovery has a plurality of UPS modules with one or more of the UPS modules usable to provide stranded power to a recovered power bus. When a UPS module is used to provide stranded power to the recovered power bus, the AC/AC converter associated with that UPS module provides AC power that is synchronized with AC power being provided to the recovered power bus by each of the other AC/AC converters that are providing AC power. In this manner all of the AC/AC converters that are providing AC power to the recovered power bus have the same voltage, the same frequency, and are in phase.",VERTIV CORP,BUSH TERRY D;;CARNEY KEVIN B;;PANFIL PETER A,VERTIV CORPORATION (2021-04-28),https://lens.org/184-694-326-084-956,Granted Patent,yes,13,0,8,8,0,H02J9/062;;H02J9/068;;H02J9/062;;H02J3/40;;H02J2310/16;;G06F1/30;;G06F11/2015;;H02J9/068;;H02J9/062,H02J9/00;;H02J9/06,,2,1,086-261-620-714-748,10.1109/icmcs.2014.6911208,"International Search Report and Written Opinion dated Jan. 15, 2021 for PCT/US2020/057717.;;Kissaoui, M. et al., “Adaptive control of uninterruptible power supply based on AC/AC Power Converter”, 2014 International Conference on Multimedia Computing and Systems (ICMCS), Marrakech, Morocco, 2014, pp. 1557-1562, doi: 10.1109/ICMCS.2014.6911208.",ACTIVE
134,CN,A,CN 114616742 A,090-140-431-244-648,2022-06-10,2022,CN 202080075014 A,2020-10-28,US 201962926594 P;;US 2020/0057717 W,2019-10-28,Uninterruptible power supply system with shelving power recovery,"An uninterruptible power supply (UPS) system with rest power recovery has a plurality of UPS modules, wherein one or more of the UPS modules may be used to provide rest power to a recovered power bus. When a UPS module is used to provide shelving power to the recovered power bus, an AC/AC converter associated with the UPS module provides AC power synchronized with AC power provided to the recovered power bus by each of the other AC/AC converters that provide AC power. In this manner, all AC/AC converters that provide AC power to the recovered power bus have the same voltage, the same frequency, and are in phase.",CORP COMPANY,BUSH TERRY D;;CARNEY KEVIN B;;PANFIL PETER A,,https://lens.org/090-140-431-244-648,Patent Application,no,0,0,8,8,0,H02J9/062;;H02J9/068;;H02J9/062;;H02J3/40;;H02J2310/16;;G06F1/30;;G06F11/2015;;H02J9/068;;H02J9/062,H02J9/06,,0,0,,,,PENDING
135,US,A1,US 2021/0202222 A1,189-062-808-178-61X,2021-07-01,2021,US 201917056999 A,2019-05-31,GB 201808893 A;;GB 2019051498 W,2018-05-31,BENCH-TOP TIME OF FLIGHT MASS SPECTROMETER,"A Time of Flight analyser comprising a flight tube ( 160 ) and a reflectron ( 170 ), wherein the reflectron comprises a stack of electrodes ( 172 ) that are compressed against the flight tube such that they remain parallel to each other under compression.",MICROMASS LTD,CARNEY PETER;;CHUMMAR SOJI;;WILDGOOSE JASON LEE;;WAMSLEY RUTH,MICROMASS UK LIMITED (2021-03-03),https://lens.org/189-062-808-178-61X,Patent Application,yes,10,1,12,12,0,H01J49/068;;H01J49/405;;H01J49/0009;;H01J49/04;;H01J49/06;;H01J49/401;;H01J49/405;;H01J49/0031;;H01J49/04;;H01J49/065;;H01J49/068;;H01J49/401;;H01J49/405,H01J49/00;;H01J49/04;;H01J49/06;;H01J49/40,,1,0,,,"CN-103400742-A, machine translation, FIT (Year: 2023)",PENDING
136,US,A1,US 2022/0173610 A1,195-943-965-814-234,2022-06-02,2022,US 202217675257 A,2022-02-18,US 202217675257 A;;US 202017082628 A;;US 201962926594 P,2019-10-28,UNINTERRUPTIBLE POWER SUPPLY SYSTEM HAVING STRANDED POWER RECOVERY,"An uninterruptible power supply (UPS) system with stranded power recovery has a plurality of UPS modules with one or more of the UPS modules usable to provide stranded power to a recovered power bus. When a UPS module is used to provide stranded power to the recovered power bus, the AC/AC converter associated with that UPS module provides AC power that is synchronized with AC power being provided to the recovered power bus by each of the other AC/AC converters that are providing AC power. In this manner all of the AC/AC converters that are providing AC power to the recovered power bus have the same voltage, the same frequency, and are in phase.",VERTIV CORP,BUSH TERRY D;;CARNEY KEVIN B;;PANFIL PETER A,VERTIV CORPORATION (2021-04-28),https://lens.org/195-943-965-814-234,Patent Application,yes,4,0,8,8,0,H02J9/062;;H02J9/068;;H02J9/062;;H02J3/40;;H02J2310/16;;G06F1/30;;G06F11/2015;;H02J9/068;;H02J9/062,H02J9/06,,0,0,,,,ACTIVE
137,WO,A3,WO 2007/047955 A3,046-003-456-076-373,2008-08-07,2008,US 2006/0041090 W,2006-10-20,US 72941005 P,2005-10-21,"METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY","The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of VEGF-165 as a biomarker for multi-kinase inhibitors.",BAYER HEALTHCARE LLC;;ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J,ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J,,https://lens.org/046-003-456-076-373,Search Report,yes,1,0,15,15,0,G01N33/57488;;G01N2800/52;;A61P35/00;;A61P35/02;;A61P43/00;;G01N33/57488;;G01N2800/52;;G01N33/57488;;G01N2800/52,C12N5/06,,1,1,051-970-733-485-20X,10.1158/1078-0432.ccr-0951-3;;15014023,"KONECNY G.E.: ""Association between HER-2/neu and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients"", CLINICAL CANCER RESEARCH, vol. 10, March 2004 (2004-03-01), pages 1706 - 1716, XP002478339",PENDING
138,US,B2,US 9366145 B2,096-702-977-711-527,2016-06-14,2016,US 201213593587 A,2012-08-24,US 201213593587 A,2012-08-24,Turbine engine rotor assembly,"A turbine engine rotor assembly includes a turbine engine rotor disk that extends axially along a centerline between a first disk end and a second disk end, and radially to an outer disk surface. The rotor disk includes one or more blade retention slots arranged circumferentially around the centerline. A first of the blade retention slots extends axially into the rotor disk from a disk end surface at the first disk end to a slot end surface, and radially into the rotor disk from the outer disk surface to a slot base surface.",TOMEO PETER V;;ANDERSON CARNEY R;;GANOE WILLIAM RICHARD;;UNITED TECHNOLOGIES CORP,TOMEO PETER V;;ANDERSON CARNEY R;;GANOE WILLIAM RICHARD,RTX CORPORATION (2012-08-22),https://lens.org/096-702-977-711-527,Granted Patent,yes,14,2,2,2,0,B23C3/30;;B23C3/30;;B23C2220/366;;B23C2220/366;;B24B19/02;;B24B19/02;;F01D5/3007;;F01D5/3007;;Y10T29/49316;;Y10T29/49316,F01D5/30;;B21D53/00;;B23C3/30;;B24B19/02,,0,0,,,,ACTIVE
139,WO,A1,WO 2021/086951 A1,056-827-051-999-326,2021-05-06,2021,US 2020/0057717 W,2020-10-28,US 201962926594 P,2019-10-28,UNINTERRUPTIBLE POWER SUPPLY SYSTEM HAVING STRANDED POWER RECOVERY,"An uninterruptible power supply (UPS) system with stranded power recovery has a plurality of UPS modules with one or more of the UPS modules usable to provide stranded power to a recovered power bus. When a UPS module is used to provide stranded power to the recovered power bus, the AC/AC converter associated with that UPS module provides AC power that is synchronized with AC power being provided to the recovered power bus by each of the other AC/AC converters that are providing AC power. In this manner all of the AC/AC converters that are providing AC power to the recovered power bus have the same voltage, the same frequency and are in phase.",VERTIV CORP,BUSH TERRY D;;CARNEY KEVIN B;;PANFIL PETER A,,https://lens.org/056-827-051-999-326,Patent Application,yes,3,0,8,8,0,H02J9/062;;H02J9/068;;H02J9/062;;H02J3/40;;H02J2310/16;;G06F1/30;;G06F11/2015;;H02J9/068;;H02J9/062,H02J9/06;;G06F1/30;;G06F11/20;;H02J3/40,,0,0,,,,PENDING
140,US,A1,US 2015/0361804 A1,077-320-955-640-972,2015-12-17,2015,US 201414768228 A,2014-02-26,US 201414768228 A;;US 201361773687 P;;US 2014/0018567 W,2013-03-06,GAS TURBINE ENGINE NOSE CONE ATTACHMENT,"A fan section for a gas turbine engine includes a fan hub having blade slots for receiving a root of a fan blade. A lock ring is configured to move rotatably from an unlocked position to a locked position for securing the blade root in the blade slot. A nose cone is secured to the lock ring, and thereby secured to the fan section.",UNITED TECHNOLOGIES CORP,HUBBERT COREY L;;TOMEO PETER V;;ANDERSON CARNEY R,RTX CORPORATION (2023-07-14),https://lens.org/077-320-955-640-972,Patent Application,yes,9,7,6,6,0,F01D5/32;;F01D5/32;;F01D5/02;;F01D5/066;;F01D5/066;;F01D5/12;;F01D5/30;;F01D5/30;;F01D5/3007;;F01D9/04;;F02K3/06;;F02K3/06;;F05D2220/32;;F05D2230/60;;Y02T50/60;;Y02T50/60;;Y10T29/49323;;Y10T29/49323,F01D5/32;;F01D5/02;;F01D5/12;;F01D5/30;;F01D9/04,,0,0,,,,ACTIVE
141,GB,B,GB 2576076 B,152-248-661-466-651,2021-02-24,2021,GB 201907735 A,2019-05-31,GB 201808893 A,2018-05-31,Bench-top time of flight mass spectrometer,,MICROMASS LTD,PETER CARNEY;;SOJI CHUMMAR;;JASON LEE WILDGOOSE;;RUTH WAMSLEY,,https://lens.org/152-248-661-466-651,Granted Patent,no,5,0,12,12,0,H01J49/068;;H01J49/405;;H01J49/0009;;H01J49/04;;H01J49/06;;H01J49/401;;H01J49/405;;H01J49/0031;;H01J49/04;;H01J49/065;;H01J49/068;;H01J49/401;;H01J49/405,H01J49/40;;H01J49/00;;H01J49/04;;H01J49/06,,0,0,,,,ACTIVE
142,EP,B1,EP 4052350 B1,080-379-940-344-438,2023-12-06,2023,EP 20808248 A,2020-10-28,US 201962926594 P;;US 2020/0057717 W,2019-10-28,UNINTERRUPTIBLE POWER SUPPLY SYSTEM HAVING STRANDED POWER RECOVERY,,VERTIV CORP,BUSH TERRY D;;CARNEY KEVIN B;;PANFIL PETER A,,https://lens.org/080-379-940-344-438,Granted Patent,yes,3,0,8,8,0,H02J9/062;;H02J9/068;;H02J9/062;;H02J3/40;;H02J2310/16;;G06F1/30;;G06F11/2015;;H02J9/068;;H02J9/062,H02J9/06;;G06F1/30;;G06F11/20;;H02J3/40,,0,0,,,,ACTIVE
143,EP,A4,EP 2964522 A4,153-313-579-486-543,2016-10-19,2016,EP 14760886 A,2014-02-26,US 201361773687 P;;US 2014/0018567 W,2013-03-06,GAS TURBINE ENGINE NOSE CONE ATTACHMENT,,UNITED TECHNOLOGIES CORP,HUBBERT COREY L;;TOMEO PETER V;;ANDERSON CARNEY R,RAYTHEON TECHNOLOGIES CORPORATION (2021-03-24);;UNITED TECHNOLOGIES CORPORATION (2016-10-26),https://lens.org/153-313-579-486-543,Search Report,no,2,0,6,6,0,F01D5/32;;F01D5/32;;F01D5/02;;F01D5/066;;F01D5/066;;F01D5/12;;F01D5/30;;F01D5/30;;F01D5/3007;;F01D9/04;;F02K3/06;;F02K3/06;;F05D2220/32;;F05D2230/60;;Y02T50/60;;Y02T50/60;;Y10T29/49323;;Y10T29/49323,B64C11/14;;F01D5/02;;F01D5/06;;F01D5/12;;F01D5/30;;F01D5/32;;F01D9/04;;F02C7/04;;F02K3/06,,1,0,,,See also references of WO 2014137688A1,ACTIVE
144,EP,A1,EP 4052350 A1,167-708-123-605-246,2022-09-07,2022,EP 20808248 A,2020-10-28,US 201962926594 P;;US 2020/0057717 W,2019-10-28,UNINTERRUPTIBLE POWER SUPPLY SYSTEM HAVING STRANDED POWER RECOVERY,,VERTIV CORP,BUSH TERRY D;;CARNEY KEVIN B;;PANFIL PETER A,,https://lens.org/167-708-123-605-246,Patent Application,yes,0,0,8,8,0,H02J9/062;;H02J9/068;;H02J9/062;;H02J3/40;;H02J2310/16;;G06F1/30;;G06F11/2015;;H02J9/068;;H02J9/062,H02J9/06;;G06F1/30;;G06F11/20;;H02J3/40,,0,0,,,,ACTIVE
145,GB,B,GB 2591343 B,191-456-666-405-947,2023-01-04,2023,GB 202020743 A,2019-05-31,GB 201808893 A;;GB 201907735 A,2018-05-31,Bench-top time of flight mass spectrometer,,MICROMASS LTD,PETER CARNEY;;SOJI CHUMMAR;;JASON LEE WILDGOOSE;;RUTH WAMSLEY,,https://lens.org/191-456-666-405-947,Granted Patent,no,11,0,12,12,0,H01J49/068;;H01J49/405;;H01J49/0009;;H01J49/04;;H01J49/06;;H01J49/401;;H01J49/405;;H01J49/0031;;H01J49/04;;H01J49/065;;H01J49/068;;H01J49/401;;H01J49/405,H01J49/06;;H01J49/00;;H01J49/04;;H01J49/40,,0,0,,,,ACTIVE
146,BR,A,BR 8701516 A,144-510-384-746-145,1988-10-11,1988,BR 8701516 A,1987-04-02,BR 8701516 A;;EP 87300021 A,1987-01-05,PROCESSO TERMICO APERFEICOADO PARA MODIFICAR AS PROPRIEDADES MATERIAIS DO CARBONO QUE OCORREM NATURALMENTE,,SUPERIOR GRAPHITE CO,GOLDBERG WILLIAM MORGAN;;CARNEY PETER R;;REED ALLAN K,,https://lens.org/144-510-384-746-145,Patent Application,no,0,0,3,5,0,C01B32/215,C01B31/04,,0,0,,,,EXPIRED
147,DE,D1,DE 3777595 D1,070-288-551-834-066,1992-04-23,1992,DE 3777595 T,1987-01-05,EP 87300021 A,1987-01-05,THERMISCHE REINIGUNG VON MINERALISCHEN NATURKOHLENSTOFFEN.,"Properties of naturally occurring C materials are modified by treatment in a fludised bed at a temp. of at least about 2500 deg. C, using a primer charge of a C material, pref. a conductive, non-sticky, granular solid, esp. petroleum coke, fluidised using a fluidising medium. Bed residence time of the C material being treated is sufficient to increase the resiliency of the material 100%. Pref. the bed is fluidised using an inert gas, pref. N2, at a pref. flow rate of 7-8 scfm.",SUPERIOR GRAPHITE CO,GOLDBERGER WILLIAM MORGAN;;CARNEY PETER R;;REED ALLAN K,,https://lens.org/070-288-551-834-066,Granted Patent,no,0,0,2,5,0,,B01J8/24;;C01B31/04,,0,0,,,,EXPIRED
148,CN,A,CN 1352833 A,177-906-951-884-72X,2002-06-05,2002,CN 00807732 A,2000-05-10,US 31481999 A;;US 55812100 A,1999-05-19,Method and apparatus for acquisition of a spread spectrum signal,,MOTOROLA INC,LAROSA CHRISTOPHER PETER;;STORM BRIAN DAVID;;CARNEY MICHAEL JOHN,"MOTOROLA MOBILE CO., LTD. (2011-01-07)",https://lens.org/177-906-951-884-72X,Patent Application,no,0,0,16,30,0,H04B1/70752;;H04B1/70752;;H04B1/7077;;H04B1/70751;;H04B1/70751;;H04B1/70753;;H04B1/70753;;H04B1/70756;;H04B1/70756;;H04B1/709;;H04B1/709;;H04B2201/70701;;H04B2201/70701;;H04B2201/70702;;H04B2201/70702;;H04B2201/70707;;H04B2201/70707;;H04B2201/70709;;H04B2201/70709,H04B1/7075;;H04B1/709,,0,0,,,,EXPIRED
149,BR,A2,BR PI0617488 A2,002-295-569-548-585,2011-07-26,2011,BR PI0617488 A,2006-10-20,US 72941005 P;;US 2006/0041090 W,2005-10-21,"mÉtodo para a monitoraÇço do estado de uma doenÇa associada a uma via de vegf-165 ativada por ultra-expressço ou por mutaÇço de proteÍna vegf-165 em um paciente, mÉtodo de seleÇço de terapia para um paciente humano com uma doenÇa e mÉtodo de dignàstico para detectar uma doenÇa associada a uma via de vegf-165 ativada por ultra-expressço ou por mutaÇço de proteÍna vegf-165 em um paciente","<B>MÉTODO PARA A MONITORAÇçO DO ESTADO DE UMA DOENÇA ASSOCIADA A UMA VIA DE VEGF-165 ATIVADA POR ULTRA-EXPRESSçO OU POR MUTAÇçO DE PROTEÍNA VEGF-165 EM UM PACIENTE, MÉTODO DE SELEÇçO DE TERAPIA PARA UM PACIENTE HUMANO COM UMA DOENÇA E MÉTODO DE DIAGNÕSTICO PA- RA DETECTAR UMA DOENÇA ASSOCIADA A UMA VIA DE VEGF-165 ATIVADA POR ULTRA-EXPRESSçO OU POR MUTAÇçO DE PROTEÍNA VEGF-165EM UM PACIENTE<D>A presente invenção refere-se a biomarcadores e ao uso de biomarcadores para a previsão e prognóstico de câncer bem como o uso de biomarcadores para monitorar a eficácia do tratamento de câncer. Especificamente, essa invenção refere-se ao uso de VEGF-165 como um biomarcador para inibidores de multicinases.",BAYER HEALTHCARE LLC,ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J,,https://lens.org/002-295-569-548-585,Patent Application,no,0,0,15,15,0,G01N33/57488;;G01N2800/52;;A61P35/00;;A61P35/02;;A61P43/00;;G01N33/57488;;G01N2800/52;;G01N33/57488;;G01N2800/52,,,0,0,,,,DISCONTINUED
150,GB,A,GB 2576076 A,070-113-094-301-445,2020-02-05,2020,GB 201907735 A,2019-05-31,GB 201808893 A,2018-05-31,Bench-top time of flight mass spectrometer,"A Time of Flight analyser comprises a flight tube 160 and a reflectron 170, wherein the reflectron is compressed against the flight tube. The reflectron may comprise a stack of electrodes 172 (e.g. ring electrodes) that remains parallel to each other under compression. Rods 178 may extend through the stack of electrodes, and resilient members 182 may be biased between the rods and the stack of electrodes to compress them towards the flight tube. Also disclosed are (i) a pusher assembly comprising a double grid electrode to provide a field-free region; (ii) a method of forming two grid electrodes, comprising applying adhesive to an upper and lower surface of an annular member and winding metal strands across the annular member so as to form two grid electrodes attached to the two surfaces; and (iii) an ion inlet device and control system configured to introduce an analyte sample or lock mass substance into a mass spectrometer and switch between the analyte sample and the lock mass substance during an analytical run.",MICROMASS LTD,PETER CARNEY;;SOJI CHUMMAR;;JASON LEE WILDGOOSE;;RUTH WAMSLEY,,https://lens.org/070-113-094-301-445,Patent Application,no,5,0,12,12,0,H01J49/068;;H01J49/405;;H01J49/0009;;H01J49/04;;H01J49/06;;H01J49/401;;H01J49/405;;H01J49/0031;;H01J49/04;;H01J49/065;;H01J49/068;;H01J49/401;;H01J49/405,H01J49/40;;H01J49/00;;H01J49/04;;H01J49/06,,0,0,,,,ACTIVE
151,EP,B1,EP 0274165 B1,108-263-708-508-127,1992-03-18,1992,EP 87300021 A,1987-01-05,EP 87300021 A;;BR 8701516 A,1987-01-05,THERMAL PURIFICATION OF NATURAL MINERAL CARBONS,,SUPERIOR GRAPHITE CO.,"GOLDBERGER, WILLIAM MORGAN;;CARNEY, PETER R.;;REED, ALLAN K.",,https://lens.org/108-263-708-508-127,Granted Patent,yes,2,1,3,5,0,C01B32/215,C01B31/04,,2,0,,,"CHEMICAL ABSTRACTS, vol. 79, no. 4, 30th July 1973, page 142, abstract no. 20974e, Columbus, Ohio, US, M.A. AVDEENKO et al.: ""Purification of graphite to a high degree of purity"", & TSVET. METAL. 1973, (2), 48-50;;CHEMICAL ABSTRACTS, vol. 92, no. 2, 14th January 1980, page 104, abstract no. 8351k, Columbus, Ohio, US; G.A. PERKOVA et al.: ""Study of thermal and gas-thermal refining of carbon phases"", & KHIM. TVERD. TOPL.(MOSCOW) 1979, (4), 37-43",EXPIRED
152,EP,A2,EP 1946115 A2,164-189-741-182-075,2008-07-23,2008,EP 06826373 A,2006-10-20,US 2006/0041090 W;;US 72941005 P,2005-10-21,"METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY",,BAYER HEALTHCARE LLC,ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J,,https://lens.org/164-189-741-182-075,Patent Application,yes,0,0,15,15,0,G01N33/57488;;G01N2800/52;;A61P35/00;;A61P35/02;;A61P43/00;;G01N33/57488;;G01N2800/52;;G01N33/57488;;G01N2800/52,C12N5/06,,0,0,,,,DISCONTINUED
153,KR,A,KR 20080073711 A,005-262-255-382-795,2008-08-11,2008,KR 20087011699 A,2008-05-16,US 72941005 P,2005-10-21,"METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY","The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of VEGF-165 as a biomarker for multi-kinase inhibitors.",BAYER HEALTHCARE LLC,ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J,,https://lens.org/005-262-255-382-795,Patent Application,no,0,0,15,15,0,G01N33/57488;;G01N2800/52;;A61P35/00;;A61P35/02;;A61P43/00;;G01N33/57488;;G01N2800/52;;G01N33/57488;;G01N2800/52,G01N33/574,,0,0,,,,DISCONTINUED
154,AT,T1,AT E476652 T1,004-208-254-466-598,2010-08-15,2010,AT 06785512 T,2006-06-23,US 69408205 P;;US 2006/0024647 W,2005-06-23,QUANTITATIVE ASSAYS FÜR RAS P21 IN KÖRPERFLÜSSIGKEITEN,"The present invention is directed to the detection and quantification of total ras p21 in body fluids, particularly serial changes of total ras p21 levels in a subject's body fluids. Further, the invention is directed to detecting and quantitating total ras p21 in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for preneoplastic/neoplastic diseases, and useful to select therapies for patients with preneoplastic/neoplastic diseases. The disclosed methods are further useful to monitor the status of a patient's preneoplastic/neoplastic disease, and/or to monitor how a patient is responding to an anticancer therapy.",SIEMENS HEALTHCARE DIAGNOSTICS,CARNEY WALTER;;HAMER PETER;;PIERCE KAREN;;BROWN-SHIMER SHERYL,,https://lens.org/004-208-254-466-598,Granted Patent,no,0,0,13,13,0,G01N33/5748;;G01N2333/82;;G01N2800/44;;G01N33/5748;;G01N2800/44;;G01N2333/82;;G01N33/574,,,0,0,,,,INACTIVE
155,EP,A1,EP 2964522 A1,140-545-753-859-263,2016-01-13,2016,EP 14760886 A,2014-02-26,US 201361773687 P;;US 2014/0018567 W,2013-03-06,GAS TURBINE ENGINE NOSE CONE ATTACHMENT,,UNITED TECHNOLOGIES CORP,HUBBERT COREY L;;TOMEO PETER V;;ANDERSON CARNEY R,RAYTHEON TECHNOLOGIES CORPORATION (2021-03-24);;UNITED TECHNOLOGIES CORPORATION (2016-10-26),https://lens.org/140-545-753-859-263,Patent Application,yes,0,0,6,6,0,F01D5/32;;F01D5/32;;F01D5/02;;F01D5/066;;F01D5/066;;F01D5/12;;F01D5/30;;F01D5/30;;F01D5/3007;;F01D9/04;;F02K3/06;;F02K3/06;;F05D2220/32;;F05D2230/60;;Y02T50/60;;Y02T50/60;;Y10T29/49323;;Y10T29/49323,B64C11/14;;F01D5/02;;F01D5/06;;F01D5/12;;F01D5/30;;F01D5/32;;F01D9/04;;F02C7/04;;F02K3/06,,0,0,,,,ACTIVE
156,US,B1,US 6243410 B1,016-267-646-383-682,2001-06-05,2001,US 8999298 A,1998-06-03,US 8999298 A;;US 80833197 A;;US 62432996 A,1996-03-29,Demodulator having an infinite-duration impulse response filter with dynamic coeffiecient scaling,"By time-sharing demodulator hardware between a primary data path (165), a power control data path (161), and a received signal strength indicator (RSSI) path (163), an entire power control data path (161) can be implemented in a demodulator (140) of a spread spectrum subscriber unit receiver with a low increase in gate count. The primary data path (165) and the power control data path (161) time-share a complex conjugate generator (270), a complex multiplier (280), and a real component extractor (290). Due to timing requirements, though, the channel estimation filter (240) of the primary data path cannot be time-shared with the power control data path. Instead, dynamic coefficient scaling is added to an infinite-duration impulse response (IIR) filter in the RSSI path (163) so that the IIR filter (250) with dynamic coefficient scaling can be time-shared between the RSSI path (163) and the power control data path (161).",MOTOROLA INC,LAROSA CHRISTOPHER PETER;;CARNEY MICHAEL JOHN;;BECKER CHRISTOPHER JOHN,APPLE INC (2011-04-11);;FREESCALE SEMICONDUCTOR INC (2004-04-04),https://lens.org/016-267-646-383-682,Granted Patent,yes,11,10,13,13,0,H04B1/707;;H04J13/00;;H04L25/0214;;H04L25/0226;;H04W52/42;;H04W52/60;;H04B1/7117;;H04B1/7113;;H04B1/7093;;H04W52/42;;H04L25/0214;;H04B1/707;;H04L25/0226;;H04J13/00;;H04W52/60,H04B1/707;;H04B7/005;;H04B7/26;;H04J11/00;;H04J13/00;;H04L25/02,375/148;;375/233;;375/350,1,0,,,"Andrew J. Viterbi, CDMA: Principles of Spread Spectrum Communication 86-93 (1995).",EXPIRED
157,CN,A,CN 1275043 A,083-865-805-458-283,2000-11-29,2000,CN 00107578 A,2000-05-18,US 31481999 A,1999-05-19,Method and arrangement for starting extended spectrum radio telephone receiver,,MOTOROLA INC,RAROSA CHRISTOPHER PETER;;STORM BLAIN DAVID;;CARNEY MICHAEL JOHN,"MOTOROLA MOBILITY CO., LTD. (2011-01-27)",https://lens.org/083-865-805-458-283,Patent Application,no,0,0,14,30,0,H04B1/70752;;H04B1/70752;;H04B7/26;;H04B1/70751;;H04B1/70751;;H04B1/70753;;H04B1/70753;;H04B1/70756;;H04B1/70756;;H04B2201/70701;;H04B2201/70701;;H04B2201/70702;;H04B2201/70702;;H04B2201/70707;;H04B2201/70707;;H04B2201/70709;;H04B2201/70709,H04B1/16;;H04B1/7075;;H04B7/26;;H04M1/00;;H04M1/73,,0,0,,,,EXPIRED
158,WO,A1,WO 2019/229457 A1,129-167-368-559-770,2019-12-05,2019,GB 2019051498 W,2019-05-31,GB 201808893 A,2018-05-31,BENCH-TOP TIME OF FLIGHT MASS SPECTROMETER,"A Time of Flight analyser comprising a flight tube (160) and a reflectron (170), wherein the reflectron comprises a stack of electrodes (172) that are compressed against the flight tube such that they remain parallel to each other under compression.",MICROMASS LTD,CARNEY PETER;;CHUMMAR SOJI;;WILDGOOSE JASON LEE;;WAMSLEY RUTH,,https://lens.org/129-167-368-559-770,Patent Application,yes,6,1,12,12,0,H01J49/068;;H01J49/405;;H01J49/0009;;H01J49/04;;H01J49/06;;H01J49/401;;H01J49/405;;H01J49/0031;;H01J49/04;;H01J49/065;;H01J49/068;;H01J49/401;;H01J49/405,H01J49/06;;H01J49/40,,0,0,,,,PENDING
159,WO,A1,WO 2014/137688 A1,162-503-290-167-449,2014-09-12,2014,US 2014/0018567 W,2014-02-26,US 201361773687 P,2013-03-06,GAS TURBINE ENGINE NOSE CONE ATTACHMENT,"A fan section for a gas turbine engine includes a fan hub having blade slots for receiving a root of a fan blade. A lock ring is configured to move rotatably from an unlocked position to a locked position for securing the blade root in the blade slot. A nose cone is secured to the lock ring, and thereby secured to the fan section.",UNITED TECHNOLOGIES CORP,HUBBERT COREY L;;TOMEO PETER V;;ANDERSON CARNEY R,,https://lens.org/162-503-290-167-449,Patent Application,yes,6,1,6,6,0,F01D5/066;;F01D5/30;;F02K3/06;;Y10T29/49323;;F01D5/32;;Y02T50/60;;F01D5/30;;F02K3/06;;F01D5/066;;Y02T50/60;;Y10T29/49323;;F01D5/02;;F01D5/12;;F01D5/3007;;F01D5/32;;F01D9/04;;F05D2220/32;;F05D2230/60,B64C11/14;;F02C7/04,,0,0,,,,PENDING
160,US,B2,US 11283289 B2,172-119-074-685-82X,2022-03-22,2022,US 202017082628 A,2020-10-28,US 202017082628 A;;US 201962926594 P,2019-10-28,Uninterruptible power supply system having stranded power recovery,"An uninterruptible power supply (UPS) system with stranded power recovery has a plurality of UPS modules with one or more of the UPS modules usable to provide stranded power to a recovered power bus. When a UPS module is used to provide stranded power to the recovered power bus, the AC/AC converter associated with that UPS module provides AC power that is synchronized with AC power being provided to the recovered power bus by each of the other AC/AC converters that are providing AC power. In this manner all of the AC/AC converters that are providing AC power to the recovered power bus have the same voltage, the same frequency and are in phase.",VERTIV CORP,BUSH TERRY D;;CARNEY KEVIN B;;PANFIL PETER A,VERTIV CORPORATION (2021-04-28),https://lens.org/172-119-074-685-82X,Granted Patent,yes,11,0,8,8,0,H02J9/062;;H02J9/068;;H02J9/062;;H02J3/40;;H02J2310/16;;G06F1/30;;G06F11/2015;;H02J9/068;;H02J9/062,H02J7/00;;H02J9/00;;H02J9/06,,2,1,086-261-620-714-748,10.1109/icmcs.2014.6911208,"M. Kissaoui, F. Z. Chaoui, A. Abouloifa, F. Giri and Y. Abouelmahjoub, “Adaptive control of uninterruptible power supply based on AC/AC Power Converter,” 2014 International Conference on Multimedia Computing and Systems (ICMCS), Marrakech, Morocco, 2014, pp. 1557-1562, doi: 10.1109/ICMCS.2014.6911208.;;International Search Report and Written Opinion regarding International Application No. PCT/US2020/057717, dated Jan. 15, 2021.",ACTIVE
161,EP,A1,EP 0274165 A1,065-821-490-048-054,1988-07-13,1988,EP 87300021 A,1987-01-05,EP 87300021 A;;BR 8701516 A,1987-01-05,Thermal purification of natural mineral carbons.,"A method for modifying the properties of naturally occurring carbon materials, which comprises the steps of: introducing a charge of carbonaceous primer material into a fluidizing zone; passing a fluidizing medium through said carbonaceous primer material within the fluidizing zone at a velocity sufficient to fluidize substantially uniformly said carbonaceous primer material; heating said carbonaceous primer material while in such fluidized state to at least approximately 2500°C; introducing within the fluidizing zone a carbon material to be thermally treated; maintaining said material within such fluidizing zone for an average residence time sufficient to increase resiliency of the treatment material at least approximately 100%, while simultaneously maintaining such fluidizing and heating conditions; and withdrawing and cooling said material.  ",SUPERIOR GRAPHITE CO,GOLDBERGER WILLIAM MORGAN;;CARNEY PETER R;;REED ALLAN K,,https://lens.org/065-821-490-048-054,Patent Application,yes,2,5,3,5,0,C01B32/215,C01B31/04,,2,0,,,"CHEMICAL ABSTRACTS, vol. 79, no. 4, 30th July 1973, page 142, abstract no. 20974e, Columbus, Ohio, US, M.A. AVDEENKO et al.: ""Purification of graphite to a high degree of purity"", & TSVET. METAL. 1973, (2), 48-50;;CHEMICAL ABSTRACTS, vol. 92, no. 2, 14th January 1980, page 104, abstract no. 8351k, Columbus, Ohio, US; G.A. PERKOVA et al.: ""Study of thermal and gas-thermal refining of carbon phases"", & KHIM. TVERD. TOPL.(MOSCOW) 1979, (4), 37-43",EXPIRED
162,US,A1,US 2009/0221010 A1,079-214-503-434-573,2009-09-03,2009,US 9040806 A,2006-10-20,US 9040806 A;;US 72941005 P;;US 2006/0041090 W,2005-10-21,"Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy","The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of VEGF-165 as a biomarker for multi-kinase inhibitors.",ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J,ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J,BATER HEALTHCARE LLC (2008-05-08),https://lens.org/079-214-503-434-573,Patent Application,yes,8,13,15,15,0,G01N33/57488;;G01N2800/52;;A61P35/00;;A61P35/02;;A61P43/00;;G01N33/57488;;G01N2800/52;;G01N33/57488;;G01N2800/52,G01N33/53;;C12Q1/00;;G01N33/68,435/7.94;;436/86;;435/4,0,0,,,,DISCONTINUED
163,AU,A1,AU 2006/304764 A1,114-912-009-182-310,2007-04-26,2007,AU 2006/304764 A,2006-10-20,US 72941005 P;;US 2006/0041090 W,2005-10-21,"Methods for prediction and prognosis of cancer, and monitoring cancer therapy",,BAYER HEALTHCARE LLC,ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J,,https://lens.org/114-912-009-182-310,Patent Application,no,0,0,15,15,0,G01N33/57488;;G01N2800/52;;A61P35/00;;A61P35/02;;A61P43/00;;G01N33/57488;;G01N2800/52;;G01N33/57488;;G01N2800/52,G01N33/574,,0,0,,,,DISCONTINUED
164,CA,A1,CA 2626019 A1,133-665-698-894-658,2007-04-26,2007,CA 2626019 A,2006-10-20,US 72941005 P;;US 2006/0041090 W,2005-10-21,"METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY",,BAYER HEALTHCARE LLC,HAMER PETER J;;ELTING JAMES J;;CARNEY WALTER P,,https://lens.org/133-665-698-894-658,Patent Application,no,0,0,15,15,0,G01N33/57488;;G01N2800/52;;A61P35/00;;A61P35/02;;A61P43/00;;G01N33/57488;;G01N2800/52;;G01N33/57488;;G01N2800/52,G01N33/574,,0,0,,,,DISCONTINUED
165,GB,B,GB 2609096 B,067-087-651-417-770,2023-04-26,2023,GB 202211820 A,2019-05-31,GB 201808893 A;;GB 202020743 A,2018-05-31,Bench-top time of flight mass spectrometer,,MICROMASS LTD,RUTH WAMSLEY;;SOJI CHUMMAR;;PETER CARNEY;;JASON LEE WILDGOOSE,,https://lens.org/067-087-651-417-770,Granted Patent,no,10,0,12,12,0,H01J49/068;;H01J49/405;;H01J49/0009;;H01J49/04;;H01J49/06;;H01J49/401;;H01J49/405;;H01J49/0031;;H01J49/04;;H01J49/065;;H01J49/068;;H01J49/401;;H01J49/405,H01J49/00;;H01J49/04;;H01J49/06;;H01J49/40,,0,0,,,,ACTIVE
166,EP,A4,EP 1946115 A4,172-047-971-614-108,2009-12-02,2009,EP 06826373 A,2006-10-20,US 2006/0041090 W;;US 72941005 P,2005-10-21,"METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY",,BAYER HEALTHCARE LLC,ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J,,https://lens.org/172-047-971-614-108,Search Report,no,1,0,15,15,0,G01N33/57488;;G01N2800/52;;A61P35/00;;A61P35/02;;A61P43/00;;G01N33/57488;;G01N2800/52;;G01N33/57488;;G01N2800/52,C12N5/06,,20,19,135-087-595-841-634;;085-408-934-318-147;;110-015-859-414-135;;022-596-410-848-265;;034-454-612-642-734;;031-615-395-036-337;;025-600-663-600-303;;133-019-720-411-610;;015-260-158-749-94X;;039-648-467-050-034;;148-755-843-001-283;;025-712-631-297-094;;023-012-707-230-575;;056-598-879-214-422;;004-337-690-593-033;;001-991-672-259-83X;;007-281-591-338-896;;075-793-153-464-812;;010-813-243-896-587,11192826;;10.1177/172460080001500405;;12131083;;pmc1422546;;10.1097/00000658-200207000-00007;;15070666;;10.1182/blood-2003-10-3443;;12841685;;10.1177/172460080301800209;;10.5301/jbm.2008.1731;;10.2739/kurumemedj.48.43;;11402619;;10.1067/msy.2002.123011;;12019409;;12843001;;10.1182/blood-2002-10-2998;;11501971;;14976047;;10.1182/blood-2003-08-2695;;10.1016/s0022-5347(05)68049-4;;10.1097/00005392-200001000-00092;;10604387;;9831387;;10.1016/s0022-1759(98)00131-8;;10.1093/annonc/mdf270;;12377642;;10.1016/s0959-8049(98)00282-2;;10070308;;pmc2063176;;10.1038/bjc.1998.688;;9823983;;10762747;;10.1016/s0959-8049(00)00003-4;;10.1002/(sici)1097-0215(20000120)89:1<51::aid-ijc9>3.3.co;2-#;;10.1002/(sici)1097-0215(20000120)89:1<51::aid-ijc9>3.0.co;2-8;;10719731;;10.1200/jco.2000.18.7.1423;;10735889;;10.1023/b:brea.0000004357.92232.cb;;14703061;;11687953;;10.1038/sj.neo.7900186;;pmc1506210,"LISSONI P ET AL: ""CHEMOTHERAPY AND ANGIOGENESIS IN ADVANCED CANCER: VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) DECLINE AS PREDICTOR OF DISEASE CONTROL DURING TAXOL THERAPY IN METASTATIC BREAST CANCER"", INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, WICHTIG EDITORE, MILAN, IT, vol. 15, no. 4, 1 October 2000 (2000-10-01), pages 308 - 311, XP009066941, ISSN: 0393-6155;;KARAYIANNAKIS ANASTASIOS J ET AL: ""Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery."", ANNALS OF SURGERY JUL 2002, vol. 236, no. 1, July 2002 (2002-07-01), pages 37 - 42, XP002550925, ISSN: 0003-4932;;BONO PETRI ET AL: ""Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib"", BLOOD, vol. 103, no. 8, 15 April 2004 (2004-04-15), pages 2929 - 2935, XP002550926, ISSN: 0006-4971;;LISSONI P ET AL: ""Changes in circulating VEGF levels in relation to clinical response during chemotherapy for metastatic cancer."", INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, vol. 18, no. 2, April 2003 (2003-04-01), pages 152 - 155, XP008113442, ISSN: 0393-6155;;KIDO YASUKO: ""Vascular endothelial growth factor (VEGF) serum concentration changes during chemotherapy in patients with lung cancer"", KURUME MEDICAL JOURNAL, vol. 48, no. 1, 2001, pages 43 - 47, XP008113450, ISSN: 0023-5679;;KARAYIANNAKIS ANASTASIOS J ET AL: ""Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery"", SURGERY (ST LOUIS), vol. 131, no. 5, May 2002 (2002-05-01), pages 548 - 555, XP002550928, ISSN: 0039-6060;;FIEDLER WALTER ET AL: ""A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia."", BLOOD, vol. 102, no. 8, 15 October 2003 (2003-10-15), pages 2763 - 2767, XP002550938, ISSN: 0006-4971;;LISSONI P ET AL: ""Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1"", JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, vol. 15, no. 2, April 2001 (2001-04-01), pages 140 - 144, XP008113318, ISSN: 0393-974X;;LEGROS LAURENCE ET AL: ""Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia."", BLOOD 15 JUL 2004, vol. 104, no. 2, 15 July 2004 (2004-07-15), pages 495 - 501, XP002550927, ISSN: 0006-4971;;JACOBSEN ET AL: ""VASCULAR ENDOTHELIAL GROWTH FACTOR AS PROGNOSTIC FACTOR IN RENAL CELL CARCINOMA"", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 163, no. 1, 1 January 2000 (2000-01-01), pages 343 - 347, XP005556268, ISSN: 0022-5347;;RODRIGUEZ C R ET AL: ""A sensitive fluorometric enzyme-linked immunosorbent assay that measures vascular endothelial growth factor165 in human plasma"", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 219, no. 1-2, 1 October 1998 (1998-10-01), pages 45 - 55, XP004142540, ISSN: 0022-1759;;LAACK E ET AL: ""Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer."", ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY / ESMO OCT 2002, vol. 13, no. 10, October 2002 (2002-10-01), pages 1550 - 1557, XP002550929, ISSN: 0923-7534;;HYODO I ET AL: ""Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer"", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 34, no. 13, 1 December 1998 (1998-12-01), pages 2041 - 2045, XP004285698, ISSN: 0959-8049;;ISHIGAMI S-I ET AL: ""Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer"", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, LONDON, GB, vol. 78, no. 10, 1 January 1998 (1998-01-01), pages 1379 - 1384, XP002960008, ISSN: 0007-0920;;LEE J C ET AL: ""Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients."", EUROPEAN JOURNAL OF CANCER (OXFORD, ENGLAND : 1990) APR 2000, vol. 36, no. 6, April 2000 (2000-04-01), pages 748 - 753, XP008113308, ISSN: 0959-8049;;LINDERHOLM B ET AL: ""p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma."", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER 20 JAN 2000, vol. 89, no. 1, 20 January 2000 (2000-01-20), pages 51 - 62, XP002550930, ISSN: 0020-7136;;LINDERHOLM BARBRO ET AL: ""Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment"", JOURNAL OF CLINICAL ONCOLOGY, vol. 18, no. 7, April 2000 (2000-04-01), pages 1423 - 1431, XP002550935, ISSN: 0732-183X;;RYDÉN LISA ET AL: ""Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer."", BREAST CANCER RESEARCH AND TREATMENT DEC 2003, vol. 82, no. 3, December 2003 (2003-12-01), pages 147 - 154, XP002550936, ISSN: 0167-6806;;GEORGE M L ET AL: ""VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression."", NEOPLASIA (NEW YORK, N.Y.) 2001 SEP-OCT, vol. 3, no. 5, September 2001 (2001-09-01), pages 420 - 427, XP002550937, ISSN: 1522-8002;;R&D SYSTEMS: ""Quantikine - Human VEGF immunoassay"", Retrieved from the Internet <URL:http://www.rndsystems.com/pdf/dve00.pdf> [retrieved on 20110126]",DISCONTINUED
167,ZA,B,ZA 200803430 B,197-489-394-222-74X,2009-08-26,2009,ZA 200803430 A,2008-04-17,US 72941005 P,2005-10-21,"Methods for prediction and prognosis of cancer, and monitoring cancer therapy",,BAYER HEALTHCARE LLC,ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J,,https://lens.org/197-489-394-222-74X,Granted Patent,no,0,0,15,15,0,G01N33/57488;;G01N2800/52;;A61P35/00;;A61P35/02;;A61P43/00;;G01N33/57488;;G01N2800/52;;G01N33/57488;;G01N2800/52,G01N/,,0,0,,,,ACTIVE
168,US,A1,US 2017/0370952 A1,083-732-427-504-879,2017-12-28,2017,US 201715481573 A,2017-04-07,US 201715481573 A;;US 201662319584 P,2016-04-07,Reconstitution Solution for Spray-Dried Plasma,"The present invention relates to a reconstitution solution for spray dried plasma having a non-anticoagulant compound that does not bind calcium. When the reconstitution solution of the present invention is mixed with spray dry plasma, the reconstituted plasma mediates platelet adhesion and aggregation about the same as or greater than the starting plasma prior to spray drying. The present invention also relates to an assay for determining platelet adhesion and aggregation using microfluidic flow cell system having a shear flow. The assay assesses labeled whole blood samples having reconstituted plasma having spray dried plasma and a reconstitution solution; platelets; and red blood cells. After inducing a shear flow under conditions suitable for clot formation, coverage area of the platelets, intensity of the platelets, morphology, or a combination thereof is detected to determine platelet accumulation (e.g., platelet adhesion and aggregation).",VELICO MEDICAL INC;;THE GOVERNMENT OF THE UNITED STATES,LIU QIYONG PETER;;CARNEY RYAN CHRISTOPHER;;CAP ANDREW PETER;;MELEDEO MICHAEL ADAM,VELICO MEDICAL INC (2017-04-10);;THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE ARMY (2017-10-16),https://lens.org/083-732-427-504-879,Patent Application,yes,0,0,1,1,0,A01N1/0205;;A01N1/0205;;A01N1/0278;;A61K35/16;;A61K35/16;;G01N33/86;;G01N33/86,G01N33/86;;A01N1/02;;A61K35/16,,0,0,,,,DISCONTINUED
169,US,B2,US 11073027 B2,145-132-641-941-103,2021-07-27,2021,US 201815982648 A,2018-05-17,US 201815982648 A,2018-05-17,Mold tool and methods for airfoil bonding,An airfoil bonding system may comprise a mold tool configured to support an airfoil assembly during a bonding process. The bonding process may include applying heat and pressure to the airfoil assembly. A surface of the mold tool may complement a preselected airfoil parameter. The mold tool may maintain the airfoil assembly in the preselected airfoil parameter during the application of heat and pressure to the airfoil assembly.,UNITED TECHNOLOGIES CORP;;RAYTHEON TECH CORP,ROBERTSON JR THOMAS J;;ANDERSON CARNEY R;;SCHUTTE PETER T,RTX CORPORATION (2018-05-16),https://lens.org/145-132-641-941-103,Granted Patent,yes,18,0,3,3,0,B29C66/81455;;B23P15/04;;B29C33/12;;B29C70/342;;B29C70/44;;B29C70/541;;B29C70/682;;B29L2031/08;;B32B2603/00;;B64C27/48;;F01D5/288;;F01D5/147;;F01D5/282;;F05D2220/32;;F05D2230/20;;F05D2230/23;;F05D2230/40;;Y02T50/60,F01D5/28;;B29C33/12;;B29C70/34;;B29C70/44;;B29C70/54;;B29C70/68;;B29L31/08;;B64C27/48,,1,0,,,"European Patent Office, European Search Report dated Oct. 28, 2019 in Application No. 19174762.5.",ACTIVE
170,AT,T1,AT E441107 T1,004-206-908-205-663,2009-09-15,2009,AT 03709354 T,2003-02-27,US 36067802 P;;US 42948702 P;;US 0305831 W,2002-03-01,"ASSAYS ZUR ÜBERWACHUNG VON KREBSPATIENTEN AUF GRUNDLAGE DER SPIEGEL DES ANALYTEN FÜR DIE EXTRAZELLULÄRE DOMÄNE (ECD) DES EPIDERMALEN WACHSTUMSFAKTOR-REZEPTORS (EGFR), ALLEIN ODER IN KOMBINATION MIT ANDEREN ANALYTEN, IN PROBEN VON KÍRPERFLÜSSIGKEITEN",,SIEMENS HEALTHCARE DIAGNOSTICS,CARNEY WALTER;;HAMER PETER;;LIPTON ALLAN;;LEITZEL KIM;;ALI SUHAIL,,https://lens.org/004-206-908-205-663,Granted Patent,no,0,0,12,12,0,G01N33/57407;;G01N33/57415;;G01N33/57419;;G01N33/57423;;G01N33/57434;;G01N33/57449;;G01N33/57488;;G01N2333/485;;G01N2333/71;;G01N2800/52;;G01N33/57488;;G01N33/57434;;G01N2333/485;;G01N2800/52;;G01N33/57415;;G01N33/57423;;G01N33/57407;;G01N33/57419;;G01N33/57449;;G01N2333/71,A61B/;;G01N33/48;;G01N33/53;;G01N33/566;;G01N33/574,,0,0,,,,EXPIRED
171,WO,A1,WO 2019/229465 A1,071-123-766-291-565,2019-12-05,2019,GB 2019051506 W,2019-05-31,GB 201808948 A,2018-05-31,BENCH-TOP TIME OF FLIGHT MASS SPECTROMETER,"A mass spectrometer comprising: a vacuum chamber housing an electronic component therein; a voltage supply module for supplying a voltage to said electronic component; a pressure sensor for determining the pressure in the vacuum chamber; and a control module configured to cut power to the voltage supply module when the pressure sensor determines that the pressure in the vacuum chamber is at or above a predetermined threshold pressure, such that the voltage supply module is incapable of supplying a voltage to the electronic component.",MICROMASS LTD,MCIVER PAUL;;WAMSLEY RUTH;;CARNEY PETER;;CHUMMAR SOJI;;MURRAY HAYDN,,https://lens.org/071-123-766-291-565,Patent Application,yes,3,4,5,5,0,H01J49/0013;;H01J49/0431;;H01J49/10;;H01J49/24;;H01J49/022;;H01J49/0031;;H01J49/022;;H01J49/24,H01J49/10;;F04C28/00;;H01J49/00;;H01J49/02;;H01J49/04;;H01J49/24,,0,0,,,,PENDING
172,GB,A,GB 2575353 A,166-512-691-077-858,2020-01-08,2020,GB 201907734 A,2019-05-31,GB 201808948 A,2018-05-31,Bench-top time of flight mass spectrometer,"A mass spectrometer 1700 comprising: a vacuum chamber housing an electronic component therein; a voltage supply module 1717, 1718 for supplying a voltage to said electronic component; a pressure sensor for determining the pressure in the vacuum chamber; and a control module 1715 configured to cut power to the voltage supply module when the sensor determines that the pressure in the vacuum chamber is at or above a predetermined threshold, such that the voltage supply module is incapable of supplying a voltage to the component. This mitigates the risk of damage to the electronics inside the vacuum housing in the even of a vacuum failure. The electronic component may, for example, be an ion guide, or a pusher assembly, reflectron or ion detector in a time of flight mass analyser. The predetermined threshold pressure may be set based upon the maximum amplitude of the voltage that the voltage supply module is designed to supply.",MICROMASS LTD,RUTH WAMSLEY;;SOJI CHUMMAR;;PETER CARNEY;;PAUL MCIVER;;HAYDN MURRAY,,https://lens.org/166-512-691-077-858,Patent Application,no,3,1,5,5,0,H01J49/0013;;H01J49/0431;;H01J49/10;;H01J49/24;;H01J49/022;;H01J49/0031;;H01J49/022;;H01J49/24,H01J49/02;;H01J49/24,,0,0,,,,ACTIVE
173,EP,A4,EP 1913391 A4,012-374-787-489-673,2009-02-18,2009,EP 06801170 A,2006-08-10,US 2006/0031245 W;;US 70780605 P,2005-08-11,QUANTITATIVE ASSAYS FOR PDGFR-beta IN BODY FLUIDS,"The present invention is directed to the detection and quantification of total PDGFR-beta in body fluids, particularly serial changes of total PDGFR-beta levels in a subject's body fluids. Further, the invention is directed to detecting and quantitatiing total PDGFR-beta in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for diseases, and useful to select therapies for patients with diseases, preferably preneoplastic/neoplastic diseases. The disclosed methods are particularly useful to monitor the status of a patient's disease, and/or to monitor how a patient is responding to a therapy.",SIEMENS HEALTHCARE DIAGNOSTICS,HAMER PETER J;;CARNEY WALTER P;;MORRIS LETICIA;;ELTING JAMES,SIEMENS HEALTHCARE DIAGNOSTICS INC. (2008-07-09),https://lens.org/012-374-787-489-673,Search Report,no,4,0,9,9,0,G01N33/57415;;G01N33/57419;;G01N33/57434;;G01N33/57449;;G01N33/57488;;G01N33/57492;;G01N2333/49;;G01N2333/71;;G01N2800/52;;G01N33/57488;;G01N2333/71;;G01N2800/52;;G01N33/57419;;G01N2333/49;;G01N33/57434;;G01N33/57449;;G01N33/57415;;G01N33/57492,G01N33/53,,0,0,,,,ACTIVE
174,EP,A2,EP 1913391 A2,104-260-154-217-184,2008-04-23,2008,EP 06801170 A,2006-08-10,US 2006/0031245 W;;US 70780605 P,2005-08-11,QUANTITATIVE ASSAYS FOR PDGFR-beta IN BODY FLUIDS,"The present invention is directed to the detection and quantification of total PDGFR-beta in body fluids, particularly serial changes of total PDGFR-beta levels in a subject's body fluids. Further, the invention is directed to detecting and quantitatiing total PDGFR-beta in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for diseases, and useful to select therapies for patients with diseases, preferably preneoplastic/neoplastic diseases. The disclosed methods are particularly useful to monitor the status of a patient's disease, and/or to monitor how a patient is responding to a therapy.",BAYER HEALTHCARE LLC,HAMER PETER J;;CARNEY WALTER P;;MORRIS LETICIA;;ELTING JAMES,SIEMENS HEALTHCARE DIAGNOSTICS INC. (2008-07-09),https://lens.org/104-260-154-217-184,Patent Application,yes,0,0,9,9,0,G01N33/57415;;G01N33/57419;;G01N33/57434;;G01N33/57449;;G01N33/57488;;G01N33/57492;;G01N2333/49;;G01N2333/71;;G01N2800/52;;G01N33/57488;;G01N2333/71;;G01N2800/52;;G01N33/57419;;G01N2333/49;;G01N33/57434;;G01N33/57449;;G01N33/57415;;G01N33/57492,G01N33/53,,0,0,,,,ACTIVE
175,WO,B1,WO 2007/021860 B1,169-336-010-436-368,2008-02-28,2008,US 2006/0031245 W,2006-08-10,US 70780605 P,2005-08-11,QUANTITATIVE ASSAYS FOR PDGFR-ß IN BODY FLUIDS,"The present invention is directed to the detection and quantification of total PDGFR-ß in body fluids, particularly serial changes of total PDGFR-ß levels in a subject's body fluids. Further, the invention is directed to detecting and quantitatiing total PDGFR-ß in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for diseases, and useful to select therapies for patients with diseases, preferably preneoplastic/neoplastic diseases. The disclosed methods are particularly useful to monitor the status of a patient's disease, and/or to monitor how a patient is responding to a therapy.",BAYER HEALTHCARE LLC;;HAMER PETER J;;CARNEY WALTER P;;MORRIS LETICIA;;ELTING JAMES,HAMER PETER J;;CARNEY WALTER P;;MORRIS LETICIA;;ELTING JAMES,,https://lens.org/169-336-010-436-368,Patent Application,no,0,0,9,9,0,G01N33/57415;;G01N33/57419;;G01N33/57434;;G01N33/57449;;G01N33/57488;;G01N33/57492;;G01N2333/49;;G01N2333/71;;G01N2800/52;;G01N33/57488;;G01N2333/71;;G01N2800/52;;G01N33/57419;;G01N2333/49;;G01N33/57434;;G01N33/57449;;G01N33/57415;;G01N33/57492,G01N33/53,,0,0,,,,PENDING
176,EP,A1,EP 3572214 A1,185-570-358-532-09X,2019-11-27,2019,EP 19174762 A,2019-05-15,US 201815982648 A,2018-05-17,TOOL AND METHODS FOR AIRFOIL BONDING,"An airfoil bonding system (200) may comprise a mold tool (146) configured to support an airfoil assembly (100; 300) during a bonding process. The bonding process may include applying heat and pressure to the airfoil assembly (100; 300). A surface (148) of the mold tool (146) may complement a preselected airfoil parameter. The mold tool (146) may maintain the airfoil assembly (100; 300) in the preselected airfoil parameter during the application of heat and pressure to the airfoil assembly (100; 300).
",UNITED TECHNOLOGIES CORP,ROBERTSON THOMAS J JR;;ANDERSON CARNEY R;;SCHUTTE PETER T,RAYTHEON TECHNOLOGIES CORPORATION (2021-03-24);;RTX CORPORATION (2023-11-01),https://lens.org/185-570-358-532-09X,Patent Application,yes,4,0,3,3,0,F01D5/147;;F01D5/282;;F05D2230/20;;B29C66/81455;;Y02T50/60;;B23P15/04;;B29C33/12;;B29L2031/08;;F01D5/288;;F05D2220/32;;F05D2230/23;;F05D2230/40;;B29C70/44;;B29C70/342;;B29C70/541;;B64C27/48;;B29C70/682;;B32B2603/00,B29C65/00;;F01D5/14;;F01D5/28,,0,0,,,,PENDING
177,CA,A1,CA 2619380 A1,191-591-247-954-329,2008-08-05,2008,CA 2619380 A,2008-02-24,US 67113507 A,2007-02-05,METHODS FOR EXTRACTING OIL FROM TAR SAND,,SUPERIOR GRAPHITE CO,WAWZROS FRANK;;RADFORD JEFF;;BARSUKOV IGOR V;;CARNEY PETER R,,https://lens.org/191-591-247-954-329,Patent Application,no,0,1,4,4,0,E21B43/2401;;E21B43/2401,E21B43/24;;E21C41/24,,0,0,,,,INACTIVE
178,WO,A3,WO 2007/021860 A3,057-847-001-772-54X,2007-10-04,2007,US 2006/0031245 W,2006-08-10,US 70780605 P,2005-08-11,QUANTITATIVE ASSAYS FOR PDGFR-ß IN BODY FLUIDS,"The present invention is directed to the detection and quantification of total PDGFR-β in body fluids, particularly serial changes of total PDGFR-β levels in a subject's body fluids. Further, the invention is directed to detecting and quantitatiing total PDGFR-β in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for diseases, and useful to select therapies for patients with diseases, preferably preneoplastic/neoplastic diseases. The disclosed methods are particularly useful to monitor the status of a patient's disease, and/or to monitor how a patient is responding to a therapy.",BAYER HEALTHCARE LLC;;HAMER PETER J;;CARNEY WALTER P;;MORRIS LETICIA;;ELTING JAMES,HAMER PETER J;;CARNEY WALTER P;;MORRIS LETICIA;;ELTING JAMES,,https://lens.org/057-847-001-772-54X,Search Report,yes,2,0,9,9,0,G01N33/57415;;G01N33/57419;;G01N33/57434;;G01N33/57449;;G01N33/57488;;G01N33/57492;;G01N2333/49;;G01N2333/71;;G01N2800/52;;G01N33/57488;;G01N2333/71;;G01N2800/52;;G01N33/57419;;G01N2333/49;;G01N33/57434;;G01N33/57449;;G01N33/57415;;G01N33/57492,G01N33/53,,1,1,067-786-714-274-221,10.1038/nbt0502-448;;11981554,"FAMULOK M.: ""Bringing Picomolar Protein Detection into Proximity"", NATURE BIOTECHNOLOGY, vol. 20, May 2002 (2002-05-01), pages 448 - 449, XP002375041",PENDING
179,GB,B,GB 2575353 B,079-442-402-512-485,2023-01-25,2023,GB 201907734 A,2019-05-31,GB 201808948 A,2018-05-31,Bench-top time of flight mass spectrometer,,MICROMASS LTD,RUTH WAMSLEY;;SOJI CHUMMAR;;PETER CARNEY;;PAUL MCIVER;;HAYDN MURRAY,,https://lens.org/079-442-402-512-485,Granted Patent,no,3,0,5,5,0,H01J49/0013;;H01J49/0431;;H01J49/10;;H01J49/24;;H01J49/022;;H01J49/0031;;H01J49/022;;H01J49/24,H01J49/02;;H01J49/24,,0,0,,,,ACTIVE
180,US,B2,US 7617869 B2,150-096-374-357-10X,2009-11-17,2009,US 67113507 A,2007-02-05,US 67113507 A,2007-02-05,Methods for extracting oil from tar sand,Hydrocarbon containing formations can be processed using an in-situ liquefaction technique. This new technique embodies systematic temperature elevation applied to subsurface formation allowing recoverable hydrocarbons to reach a Newtonian fluid viscosity suitable for extraction.,SUPERIOR GRAPHITE CO,CARNEY PETER R;;BARSUKOV IGOR V;;WAWRZOS FRANK;;RADFORD JEFF,SUPERIOR GRAPHITE CO (2008-02-19),https://lens.org/150-096-374-357-10X,Granted Patent,yes,33,5,4,4,0,E21B43/2401;;E21B43/2401,E21B43/24;;E21B36/04;;E21B43/30,166/248;;166/245;;166/302,0,0,,,,INACTIVE
181,WO,A2,WO 2007/021860 A2,065-008-823-782-942,2007-02-22,2007,US 2006/0031245 W,2006-08-10,US 70780605 P,2005-08-11,QUANTITATIVE ASSAYS FOR PDGFR-ß IN BODY FLUIDS,"The present invention is directed to the detection and quantification of total PDGFR-β in body fluids, particularly serial changes of total PDGFR-β levels in a subject's body fluids. Further, the invention is directed to detecting and quantitatiing total PDGFR-β in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for diseases, and useful to select therapies for patients with diseases, preferably preneoplastic/neoplastic diseases. The disclosed methods are particularly useful to monitor the status of a patient's disease, and/or to monitor how a patient is responding to a therapy.",BAYER HEALTHCARE LLC;;HAMER PETER J;;CARNEY WALTER P;;MORRIS LETICIA;;ELTING JAMES,HAMER PETER J;;CARNEY WALTER P;;MORRIS LETICIA;;ELTING JAMES,,https://lens.org/065-008-823-782-942,Patent Application,yes,5,5,9,9,0,G01N33/57415;;G01N33/57419;;G01N33/57434;;G01N33/57449;;G01N33/57488;;G01N33/57492;;G01N2333/49;;G01N2333/71;;G01N2800/52;;G01N33/57488;;G01N2333/71;;G01N2800/52;;G01N33/57419;;G01N2333/49;;G01N33/57434;;G01N33/57449;;G01N33/57415;;G01N33/57492,G01N33/574;;G01N33/567,,36,27,033-930-922-879-110;;026-860-237-671-907;;058-101-458-172-566;;008-067-357-138-940;;073-231-717-607-843;;010-547-675-269-81X;;052-984-805-402-260;;002-513-729-619-980;;009-538-091-125-900;;058-026-217-248-366;;006-632-943-642-783;;005-165-879-313-670;;106-753-778-592-300;;034-331-211-704-877;;020-855-322-534-259;;030-607-398-087-475;;006-574-964-805-278;;162-646-650-680-173;;021-485-212-364-595;;055-474-976-935-722;;184-992-937-861-545;;012-082-881-196-098;;076-459-135-210-395;;050-081-885-967-236;;049-471-679-950-765;;126-540-620-594-177;;026-817-898-917-720,16039137;;10.1016/j.cyto.2005.06.005;;10.1038/labinvest.3700094;;15077122;;1322795;;11740804;;10.1053/sonc.2001.29185;;10.1016/s0093-7754(01)90100-9;;16425993;;10.3816/cgc.2005.n.028;;10.1126/science.2836952;;2836952;;15583853;;10.1007/s00018-004-4272-z;;10.1016/j.cytogfr.2004.03.010;;15207814;;10.1038/ng731;;11544480;;12359756;;10850862;;10.1093/jnen/59.6.495;;8486649;;10.1016/s0021-9258(18)98395-x;;1172191;;10.1038/256495a0;;10.1038/352624a0;;1907718;;1748994;;10.1016/0022-2836(91)90498-u;;pmc392030;;10.1073/pnas.81.21.6851;;6436822;;10.1038/321522a0;;3713831;;10.1016/0959-440x(92)90091-k;;10.1093/protein/8.10.1057;;8771187;;440114;;10.1016/0076-6879(79)62235-8;;10.1016/b978-0-08-016876-0.50102-x;;10.1093/clinchem/29.8.1474;;6191885;;10.1677/erc.0.0080219;;11566613;;10.2174/1389557043487349;;15032674;;10.1200/jco.2005.01.032;;15466784;;16648571;;10.1158/1535-7163.mct-05-0410;;pmc99786;;10.1128/mcb.21.19.6387-6394.2001;;11533228,"BREITKOPF, CYTOKINE, vol. 31, no. 5, 2005, pages 349 - 357;;BORKHAM-KAMPHORST ET AL., LAB. INVEST., vol. 84, 26 April 2004 (2004-04-26), pages 766 - 777;;CZOCHRA ET AL., J HEPATOL., 30 May 2006 (2006-05-30);;FLEMING ET AL., CANCER RES., vol. 52, 1992, pages 4550 - 4553;;GEORGE, D., SEMIN. ONCOL., vol. 28, 2001, pages 27 - 33;;GOLLOB, CLIN GENITOURIN. CANCER, vol. 4, no. 3, 2005, pages 167 - 174;;HART ET AL., SCIENCE, vol. 240, 10 June 1988 (1988-06-10), pages 1529 - 1531;;JONES; CROSS, CELL MOL LIFE SCI., vol. 61, no. 23, December 2004 (2004-12-01), pages 2912 - 23;;LEVITSKI, A., CYTOKINE GROWTH FACTOR REV., vol. 15, no. 4, August 2004 (2004-08-01), pages 229 - 35;;MACDONALD ET AL., NAT. GENET., vol. 29, 2001, pages 143 - 152;;PIETRAS ET AL., CANCER RES., vol. 62, 2002, pages 5476 - 5484;;SMITH ET AL., J. NEUROPATHOL. EXP. NEUROL., vol. 59, 2000, pages 495 - 503;;TIESMAN; HART, JOURNAL OF BIOLOQICAL CHEMISTRY, vol. 268, no. 13, 5 May 1993 (1993-05-05), pages 9621 - 9628;;KOHLER ET AL., NATURE, vol. 256, 1975, pages 495;;CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597;;MORRISON ET AL., PROC. NATL. ACAD. SCI., USA, vol. 81, 1984, pages 6851 - 6855;;JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;REICHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329;;PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596;;HOLLINGER ET AL., PROC. NATL. ACAD. SCI., USA, vol. 90, 1993, pages 6444 - 6448;;ZAPATA ET AL., PROTEIN ENG., vol. 8, no. 10, 1995, pages 1057 - 1062;;AVARMEAS ET AL., SCAN. J. IMMUNOL., vol. 8, no. 7, 1978, pages 7;;BAYER ET AL., METH. ENZVMOL, vol. 62, 1979, pages 308;;CHANDLER ET AL., J. IMMUNOL. METH., vol. 53, 1982, pages 187;;EKEKE; ABUKNESHA, J. STEROID BIOCHEM., vol. 11, 1979, pages 1579;;ENGVALL; PERLMANN, J. IMMUNOL., vol. 109, 1972, pages 129;;GEOGHEGAN ET AL., IMMUNOL. COMM., vol. 7, 1978, pages 1;;WEEKS ET AL., CLINICAL CHEMISTRY, vol. 29, no. 8, 1983, pages 1474 - 1479;;LYONS ET AL., ENDOCRINE-RELATED CANCER, vol. 8, 2001, pages 219 - 225;;BANSAI ET AL., J. NEUROSCIENCE RES., vol. 74, no. 4, 23 October 2003 (2003-10-23), pages 486 - 493;;GARCIA-ECHEVERA; FABBRO: ""Therapeutically Targeted Anti-cancer Agents: Inhibition of Receptor Tyrosine Kinases"", MINI REVIEWS IN MEDICINAL CHEMISTRV, vol. 4, no. 3, March 2004 (2004-03-01), pages 273 - 283;;REICHARDT ET AL., J. CLIN. ONCOL., vol. 23, no. 16S, 2005, pages 3016;;JAYSON ET AL., J. CLIN. ONCOL., vol. 23, no. 5, 10 February 2005 (2005-02-10), pages 973 - 981;;ALBERT ET AL., MOL CANCER THER., vol. 5, no. 4, 2006, pages 995 - 1006;;SAITO ET AL., MOL. CELL BIOL., vol. 21, no. 19, 2001, pages 6387 - 6394",PENDING
182,DE,D1,DE 602006019262 D1,097-662-564-431-108,2011-02-10,2011,DE 602006019262 T,2006-08-10,US 70780605 P;;US 2006/0031245 W,2005-08-11,QUANTITATIVE ASSAYS FÜR PDGFR-beta- IN KÖRPERFLÜSSIGKEITEN,"The present invention is directed to the detection and quantification of total PDGFR-beta in body fluids, particularly serial changes of total PDGFR-beta levels in a subject's body fluids. Further, the invention is directed to detecting and quantitatiing total PDGFR-beta in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for diseases, and useful to select therapies for patients with diseases, preferably preneoplastic/neoplastic diseases. The disclosed methods are particularly useful to monitor the status of a patient's disease, and/or to monitor how a patient is responding to a therapy.",SIEMENS HEALTHCARE DIAGNOSTICS,HAMER PETER J;;CARNEY WALTER P;;MORRIS LETICIA;;ELTING JAMES,,https://lens.org/097-662-564-431-108,Granted Patent,no,0,0,9,9,0,G01N33/57415;;G01N33/57419;;G01N33/57434;;G01N33/57449;;G01N33/57488;;G01N33/57492;;G01N2333/49;;G01N2333/71;;G01N2800/52;;G01N33/57488;;G01N2333/71;;G01N2800/52;;G01N33/57419;;G01N2333/49;;G01N33/57434;;G01N33/57449;;G01N33/57415;;G01N33/57492,G01N33/53,,0,0,,,,ACTIVE
183,US,A1,US 2007/0037224 A1,121-851-712-606-063,2007-02-15,2007,US 50201306 A,2006-08-10,US 50201306 A;;US 70780605 P,2005-08-11,Quantitative assays for PDGFR-beta in body fluids,"The present invention is directed to the detection and quantification of total PDGFR-β in body fluids, particularly serial changes of total PDGFR-β levels in a subject's body fluids. Further, the invention is directed to detecting and quantitatiing total PDGFR-β in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for diseases, and useful to select therapies for patients with diseases, preferably preneoplastic/neoplastic diseases. The disclosed methods are particularly useful to monitor the status of a patient's disease, and/or to monitor how a patient is responding to a therapy.",HAMER PETER J;;CARNEY WALTER P;;MORRIS LETICIA;;ELTING JAMES,HAMER PETER J;;CARNEY WALTER P;;MORRIS LETICIA;;ELTING JAMES,,https://lens.org/121-851-712-606-063,Patent Application,yes,7,31,9,9,0,G01N33/57415;;G01N33/57419;;G01N33/57434;;G01N33/57449;;G01N33/57488;;G01N33/57492;;G01N2333/49;;G01N2333/71;;G01N2800/52;;G01N33/57488;;G01N2333/71;;G01N2800/52;;G01N33/57419;;G01N2333/49;;G01N33/57434;;G01N33/57449;;G01N33/57415;;G01N33/57492,G01N33/574;;G01N33/567,435/7.21;;435/7.23,0,0,,,,DISCONTINUED
184,CA,C,CA 2619380 C,061-808-391-776-10X,2010-11-09,2010,CA 2619380 A,2008-02-24,US 67113507 A,2007-02-05,METHODS FOR EXTRACTING OIL FROM TAR SAND,Hydrocarbon containing formations can be processed using an in-situ liquefaction technique. This new technique embodies systematic temperature elevation applied to subsurface formation allowing recoverable hydrocarbons to reach a Newtonian fluid viscosity suitable for extraction.,SUPERIOR GRAPHITE CO,CARNEY PETER R;;BARSUKOV IGOR V;;WAWZROS FRANK;;RADFORD JEFF,,https://lens.org/061-808-391-776-10X,Granted Patent,no,0,0,4,4,0,E21B43/2401;;E21B43/2401,E21B43/24;;E21C41/24,,0,0,,,,INACTIVE
185,EP,B1,EP 1913391 B1,101-553-878-297-714,2010-12-29,2010,EP 06801170 A,2006-08-10,US 2006/0031245 W;;US 70780605 P,2005-08-11,QUANTITATIVE ASSAYS FOR PDGFR-beta IN BODY FLUIDS,"The present invention is directed to the detection and quantification of total PDGFR-beta in body fluids, particularly serial changes of total PDGFR-beta levels in a subject's body fluids. Further, the invention is directed to detecting and quantitatiing total PDGFR-beta in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for diseases, and useful to select therapies for patients with diseases, preferably preneoplastic/neoplastic diseases. The disclosed methods are particularly useful to monitor the status of a patient's disease, and/or to monitor how a patient is responding to a therapy.",SIEMENS HEALTHCARE DIAGNOSTICS,HAMER PETER J;;CARNEY WALTER P;;MORRIS LETICIA;;ELTING JAMES,SIEMENS HEALTHCARE DIAGNOSTICS INC. (2008-07-09),https://lens.org/101-553-878-297-714,Granted Patent,yes,6,1,9,9,0,G01N33/57415;;G01N33/57419;;G01N33/57434;;G01N33/57449;;G01N33/57488;;G01N33/57492;;G01N2333/49;;G01N2333/71;;G01N2800/52;;G01N33/57488;;G01N2333/71;;G01N2800/52;;G01N33/57419;;G01N2333/49;;G01N33/57434;;G01N33/57449;;G01N33/57415;;G01N33/57492,G01N33/53,,1,0,,,"FAMULOK M.: 'Bringing Picomolar Protein Detection into Proximity' NATURE BIOTECHNOLOGY vol. 20, May 2002, pages 448 - 449, XP002375041",ACTIVE
186,US,A1,US 2019/0353040 A1,039-910-146-696-126,2019-11-21,2019,US 201815982648 A,2018-05-17,US 201815982648 A,2018-05-17,MOLD TOOL AND METHODS FOR AIRFOIL BONDING,An airfoil bonding system may comprise a mold tool configured to support an airfoil assembly during a bonding process. The bonding process may include applying heat and pressure to the airfoil assembly. A surface of the mold tool may complement a preselected airfoil parameter. The mold tool may maintain the airfoil assembly in the preselected airfoil parameter during the application of heat and pressure to the airfoil assembly.,UNITED TECHNOLOGIES CORP,ROBERTSON JR THOMAS J;;ANDERSON CARNEY R;;SCHUTTE PETER T,RTX CORPORATION (2018-05-16),https://lens.org/039-910-146-696-126,Patent Application,yes,7,3,3,3,0,B29C66/81455;;B23P15/04;;B29C33/12;;B29C70/342;;B29C70/44;;B29C70/541;;B29C70/682;;B29L2031/08;;B32B2603/00;;B64C27/48;;F01D5/288;;F01D5/147;;F01D5/282;;F05D2220/32;;F05D2230/20;;F05D2230/23;;F05D2230/40;;Y02T50/60,F01D5/28;;B29C33/12,,0,0,,,,ACTIVE
187,US,A1,US 2008/0185145 A1,136-801-634-343-446,2008-08-07,2008,US 67113507 A,2007-02-05,US 67113507 A,2007-02-05,METHODS FOR EXTRACTING OIL FROM TAR SAND,Hydrocarbon containing formations can be processed using an in-situ liquefaction technique. This new technique embodies systematic temperature elevation applied to subsurface formation allowing recoverable hydrocarbons to reach a Newtonian fluid viscosity suitable for extraction.,CARNEY PETER R;;BARSUKOV IGOR V;;WAWRZOS FRANK;;RADFORD JEFF,CARNEY PETER R;;BARSUKOV IGOR V;;WAWRZOS FRANK;;RADFORD JEFF,SUPERIOR GRAPHITE CO (2008-02-19),https://lens.org/136-801-634-343-446,Patent Application,yes,33,6,4,4,0,E21B43/2401;;E21B43/2401,E21B43/24,166/272.1;;166/302;;166/60,0,0,,,,INACTIVE
188,US,A,US 5799011 A,030-878-064-338-849,1998-08-25,1998,US 80833197 A,1997-02-28,US 80833197 A;;US 62432996 A,1996-03-29,CDMA power control channel estimation using dynamic coefficient scaling,"By time-sharing demodulator hardware between a primary data path (165), a power control data path (161), and a received signal strength indicator (RSSI) path (163), an entire power control data path (161) can be implemented in a demodulator (140) of a spread spectrum subscriber unit receiver with a low increase in gate count. The primary data path (165) and the power control data path (161) time-share a complex conjugate generator (270), a complex multiplier (280), and a real component extractor (290). Due to timing requirements, though, the channel estimation filter (240) of the primary data path cannot be time-shared with the power control data path. Instead, dynamic coefficient scaling is added to an infinite-duration impulse response (IIR) filter in the RSSI path (163) so that the IIR filter (250) with dynamic coefficient scaling can be time-shared between the RSSI path (163) and the power control data path (161).",MOTOROLA INC,LAROSA CHRISTOPHER PETER;;CARNEY MICHAEL JOHN;;BECKER CHRISTOPHER JOHN;;LING FUYUN,APPLE INC (2011-04-11);;FREESCALE SEMICONDUCTOR INC (2004-04-04);;MOTOROLA INC (1997-02-28),https://lens.org/030-878-064-338-849,Granted Patent,yes,6,30,13,13,0,H04B1/707;;H04J13/00;;H04L25/0214;;H04L25/0226;;H04W52/42;;H04W52/60;;H04B1/7117;;H04B1/7113;;H04B1/7093;;H04W52/42;;H04L25/0214;;H04B1/707;;H04L25/0226;;H04J13/00;;H04W52/60,H04B1/707;;H04B7/005;;H04B7/26;;H04J11/00;;H04J13/00;;H04L25/02,370/335;;370/318;;370/342;;370/522;;375/206;;375/343,1,0,,,"Viterbi, Andrew J., CDMA: Principles of Spread Spectrum Communication , Addison Wesley Publishing Co., pp. 86 93, 1995.",EXPIRED
189,KR,A,KR 20080073729 A,150-862-366-136-083,2008-08-11,2008,KR 20087013325 A,2008-06-02,US 73310005 P,2005-11-02,"METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY","The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of VEGF as a biomarker for multi-kinase inhibitors.",BAYER HEALTHCARE LLC,ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J;;BIGWOOD DOUGLAS,,https://lens.org/150-862-366-136-083,Patent Application,no,0,0,14,14,0,G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N2800/52;;A61P35/00;;A61P43/00;;G01N33/57492;;G01N2800/52;;G01N2333/71;;G01N2333/475;;G01N33/57492;;G01N2333/475;;G01N2800/52;;G01N2333/71,G01N33/574,,0,0,,,,DISCONTINUED
190,US,A1,US 2008/0311604 A1,130-519-761-484-439,2008-12-18,2008,US 9189906 A,2006-11-01,US 9189906 A;;US 73309805 P;;US 2006/0042661 W,2005-11-02,"Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy","The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of soluble VEGF-R2 as a biomarker for multi-kinase inhibitors.",ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J;;BIGWOOD DOUGLAS,ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J;;BIGWOOD DOUGLAS,BAYER HEALTHCARE LLC (2008-05-08),https://lens.org/130-519-761-484-439,Patent Application,yes,7,50,16,16,0,G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N2800/52;;G01N33/57492;;G01N2333/71;;G01N2333/475,C12Q1/00;;G01N33/53,435/7.94;;435/4,0,0,,,,DISCONTINUED
191,ZA,B,ZA 200803516 B,055-208-312-434-114,2009-02-25,2009,ZA 200803516 A,2008-04-22,US 73310005 P,2005-11-02,"Methods for prediction and prognosis of cancer, and monitoring cancer therapy",,BAYER HEALTHCARE LLC,ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J;;DOUGLAS BIGWOOD,,https://lens.org/055-208-312-434-114,Granted Patent,no,0,0,14,14,0,G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N2800/52;;A61P35/00;;A61P43/00;;G01N33/57492;;G01N2800/52;;G01N2333/71;;G01N2333/475;;G01N33/57492;;G01N2333/475;;G01N2800/52;;G01N2333/71,G01N/,,0,0,,,,ACTIVE
192,WO,A8,WO 2007/056012 A8,084-561-425-286-25X,2008-08-07,2008,US 2006/0042661 W,2006-11-01,US 73309805 P,2005-11-02,"METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY","The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of soluble VEGF-R2 as a biomarker for multi-kinase inhibitors.",BAYER HEALTHCARE LLC;;ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J;;BIGWOOD DOUGLAS,ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J;;BIGWOOD DOUGLAS,,https://lens.org/084-561-425-286-25X,Patent Application,no,0,0,16,16,0,G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N2800/52;;G01N33/57492;;G01N2333/71;;G01N2333/475,G01N33/574,,0,0,,,,PENDING
193,WO,A3,WO 2007/056012 A3,001-930-427-762-838,2008-05-22,2008,US 2006/0042661 W,2006-11-01,US 73309805 P,2005-11-02,"METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY","The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of soluble VEGF-R2 as a biomarker for multi-kinase inhibitors.",BAYER HEALTHCARE LLC;;ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J;;BIGWOOD DOUGLAS,ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J;;BIGWOOD DOUGLAS,,https://lens.org/001-930-427-762-838,Search Report,yes,3,0,16,16,0,G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N2800/52;;G01N33/57492;;G01N2333/71;;G01N2333/475,G01N35/574,,2,2,062-532-271-839-067;;025-712-631-297-094,15788677;;10.1158/1078-0432.ccr-04-0572;;10.1093/annonc/mdf270;;12377642,"ARORA S. ET AL.: ""Stromelysin-3, Ets-1, and Vascular Endothelial Growth Factor Expression in Oral Precancerous Lesions: Correlations with Microvessel Density, Progression and Prognosis"", CLIN. CANCER RES., vol. 11, no. 6, March 2005 (2005-03-01), pages 2272 - 2284, XP008127275;;LAACK E. ET AL.: ""Pretreatment Serum Levels of Matrix Metalloproteinase-9 and Vascular Endothelial Growth Factor in Non-Small-Cell Lung Cancer"", vol. 13, no. 10, October 2002 (2002-10-01), pages 1550 - 1557, XP002550929",PENDING
194,US,A1,US 2010/0167324 A1,074-413-703-892-894,2010-07-01,2010,US 91747106 A,2006-06-23,US 91747106 A;;US 69408205 P;;US 2006/0024647 W,2005-06-23,Quantitative Assays for Ras p21 in Body Fluids,"The present invention is directed to the detection and quantification of total ras p21 in body fluids, particularly serial changes of total ras p21 levels in a subject's body fluids. Further, the invention is directed to detecting and quantitatiing total ras p21 in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for preneoplastic/neoplastic diseases, and useful to select therapies for patients with preneoplastic/neoplastic diseases. The disclosed methods are further useful to monitor the status of a patient's preneoplastic/neoplastic disease, and/or to monitor how a patient is responding to an anticancer therapy.",CARNEY WALTER P;;HAMER PETER J;;PIERCE KAREN;;BROWN-SHIMER SHERYL,CARNEY WALTER P;;HAMER PETER J;;PIERCE KAREN;;BROWN-SHIMER SHERYL,SIEMENS HEALTHCARE DIAGNOSTICS INC (2008-03-03),https://lens.org/074-413-703-892-894,Patent Application,yes,5,0,13,13,0,G01N33/5748;;G01N2333/82;;G01N2800/44;;G01N33/5748;;G01N2800/44;;G01N2333/82;;G01N33/574,C12Q1/34;;G01N33/53,435/7.94;;435/18,0,0,,,,DISCONTINUED
195,CA,A1,CA 2626054 A1,183-290-868-505-121,2007-05-18,2007,CA 2626054 A,2006-11-01,US 73310005 P;;US 2006/0042660 W,2005-11-02,"METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY",,BAYER HEALTHCARE LLC,ELTING JAMES J;;BIGWOOD DOUGLAS;;CARNEY WALTER P;;HAMER PETER J,,https://lens.org/183-290-868-505-121,Patent Application,no,0,0,14,14,0,G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N2800/52;;A61P35/00;;A61P43/00;;G01N33/57492;;G01N2800/52;;G01N2333/71;;G01N2333/475;;G01N33/57492;;G01N2333/475;;G01N2800/52;;G01N2333/71,G01N33/574,,0,0,,,,DISCONTINUED
196,US,A1,US 2008/0311601 A1,056-267-108-752-015,2008-12-18,2008,US 9188906 A,2006-11-01,US 9188906 A;;US 73310005 P;;US 2006/0042660 W,2005-11-02,"Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy","The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of VEGF as a biomarker for multi-kinase inhibitors.",ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J;;BIGWOOD DOUGLAS,ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J;;BIGWOOD DOUGLAS,BAYER HEALTHCARE LLC (2008-05-08),https://lens.org/056-267-108-752-015,Patent Application,yes,6,7,14,14,0,G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N2800/52;;A61P35/00;;A61P43/00;;G01N33/57492;;G01N2800/52;;G01N2333/71;;G01N2333/475;;G01N33/57492;;G01N2333/475;;G01N2800/52;;G01N2333/71,G01N33/574;;C12Q1/02,435/7.92;;435/29,0,0,,,,DISCONTINUED
197,WO,A8,WO 2007/056012 A8,127-001-986-905-439,2008-06-26,2008,US 2006/0042661 W,2006-11-01,US 73309805 P,2005-11-02,"METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY","The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of soluble VEGF-R2 as a biomarker for multi-kinase inhibitors.",BAYER HEALTHCARE LLC;;ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J;;BIGWOOD DOUGLAS,ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J;;BIGWOOD DOUGLAS,,https://lens.org/127-001-986-905-439,Patent Application,no,0,0,16,16,0,G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N2800/52;;G01N33/57492;;G01N2333/71;;G01N2333/475,G01N33/574,,0,0,,,,PENDING
198,EP,A1,EP 3073194 A1,010-242-664-540-750,2016-09-28,2016,EP 15000860 A,2015-03-24,EP 15000860 A,2015-03-24,HEAT EXCHANGING SYSTEM FOR A FURNACE,"The invention relates to a heat exchanging system for a furnace (300) with a supply pipe (120, 130) adapted to supply a medium to a burner (310a, 310b) of the furnace (300), an exhaust flue (100) adapted to exhaust combustion waste gases (101) from the furnace (300), the exhaust flue (100) comprising a refractory element (110), wherein the supply pipe (120, 130) is arranged at least partially inside or on the refractory element (110) of the exhaust flue (100).
",LINDE AG,MIETH RAINER;;GÖRISCH MATTHIAS;;CARNEY STEPHEN;;RICHARDSON ANDREW PETER;;KOEDER HORST,,https://lens.org/010-242-664-540-750,Patent Application,yes,5,2,3,3,0,C03B5/237;;F23L15/02;;F27B3/266;;F27D99/0033;;F27B3/263;;Y02E20/34;;Y02P40/50,F23L15/02;;C03B5/237,,0,0,,,,DISCONTINUED
199,KR,A,KR 20080077360 A,103-820-565-756-218,2008-08-22,2008,KR 20087013169 A,2008-05-30,US 73309805 P,2005-11-02,"METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY","The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of soluble VEGF-R2 as a biomarker for multi-kinase inhibitors.",BAYER HEALTHCARE LLC,ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J;;BIGWOOD DOUGLAS,,https://lens.org/103-820-565-756-218,Patent Application,no,0,0,16,16,0,G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N2800/52;;G01N33/57492;;G01N2333/71;;G01N2333/475,G01N33/574;;G01N33/48;;G01N33/53,,0,0,,,,DISCONTINUED
200,EP,A4,EP 1893997 A4,171-209-247-050-906,2009-02-18,2009,EP 06785512 A,2006-06-23,US 2006/0024647 W;;US 69408205 P,2005-06-23,QUANTITATIVE ASSAYS FOR RAS P21 IN BODY FLUIDS,"The present invention is directed to the detection and quantification of total ras p21 in body fluids, particularly serial changes of total ras p21 levels in a subject's body fluids. Further, the invention is directed to detecting and quantitating total ras p21 in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for preneoplastic/neoplastic diseases, and useful to select therapies for patients with preneoplastic/neoplastic diseases. The disclosed methods are further useful to monitor the status of a patient's preneoplastic/neoplastic disease, and/or to monitor how a patient is responding to an anticancer therapy.",SIEMENS HEALTHCARE DIAGNOSTICS,CARNEY WALTER P;;HAMER PETER J;;PIERCE KAREN;;BROWN-SHIMER SHERYL,SIEMENS HEALTHCARE DIAGNOSTICS INC. (2008-07-09),https://lens.org/171-209-247-050-906,Search Report,no,4,0,13,13,0,G01N33/5748;;G01N2333/82;;G01N2800/44;;G01N33/5748;;G01N2800/44;;G01N2333/82;;G01N33/574,G01N33/48;;G01N1/00;;G01N33/00,,3,3,009-045-673-374-880;;019-745-154-005-784;;005-691-855-066-935,10.1016/s0304-3835(02)00236-7;;12142081;;6287003;;pmc256120;;10.1128/jvi.43.1.294-304.1982;;10.1016/0046-8177(93)90260-n;;8276374,"RUNDLE ANDREW ET AL: ""Association between the ras p21 oncoprotein in blood samples and breast cancer"", CANCER LETTERS, vol. 185, no. 1, 8 November 2002 (2002-11-08), pages 71 - 78, XP002486942, ISSN: 0304-3835;;FURTH M E ET AL: ""MONOCLONAL ANTIBODIES TO THE P21 PRODUCTS OF THE TRANSFORMING GENE OF HARVEY MURINE SARCOMA VIRUS AND OF THE CELLULAR RAS GENE FAMILY"", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 43, no. 1, 1 July 1982 (1982-07-01), pages 294 - 304, XP008041021, ISSN: 0022-538X;;GULBIS BEATRICE ET AL: ""Immunodetection of the p21-ras products in human normal and preneoplastic tissues and solid tumors: A review"", HUMAN PATHOLOGY, vol. 24, no. 12, 1993, pages 1271 - 1285, XP002486943, ISSN: 0046-8177",ACTIVE
201,EP,B1,EP 1893997 B1,066-167-337-642-615,2010-08-04,2010,EP 06785512 A,2006-06-23,US 2006/0024647 W;;US 69408205 P,2005-06-23,QUANTITATIVE ASSAYS FOR RAS P21 IN BODY FLUIDS,"The present invention is directed to the detection and quantification of total ras p21 in body fluids, particularly serial changes of total ras p21 levels in a subject's body fluids. Further, the invention is directed to detecting and quantitating total ras p21 in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for preneoplastic/neoplastic diseases, and useful to select therapies for patients with preneoplastic/neoplastic diseases. The disclosed methods are further useful to monitor the status of a patient's preneoplastic/neoplastic disease, and/or to monitor how a patient is responding to an anticancer therapy.",SIEMENS HEALTHCARE DIAGNOSTICS,CARNEY WALTER P;;HAMER PETER J;;PIERCE KAREN;;BROWN-SHIMER SHERYL,SIEMENS HEALTHCARE DIAGNOSTICS INC. (2008-07-09),https://lens.org/066-167-337-642-615,Granted Patent,yes,4,0,13,13,0,G01N33/5748;;G01N2333/82;;G01N2800/44;;G01N33/5748;;G01N2800/44;;G01N2333/82;;G01N33/574,G01N33/48;;G01N1/00;;G01N33/00,,4,0,,,"RUNDLE ANDREW ET AL: ""Association between the ras p21 oncoprotein in blood samples and breast cancer"" CANCER LETTERS, vol. 185, no. 1, 8 November 2002 (2002-11-08), pages 71-78, XP002486942 ISSN: 0304-3835;;FURTH M E ET AL: ""MONOCLONAL ANTIBODIES TO THE P21 PRODUCTS OF THE TRANSFORMING GENE OF HARVEY MURINE SARCOMA VIRUS AND OF THE CELLULAR RAS GENE FAMILY"" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 43, no. 1, 1 July 1982 (1982-07-01), pages 294-304, XP008041021 ISSN: 0022-538X;;GULBIS BEATRICE ET AL: ""Immunodetection of the p21-ras products in human normal and preneoplastic tissues and solid tumors: A review"" HUMAN PATHOLOGY, vol. 24, no. 12, 1993, pages 1271-1285, XP002486943 ISSN: 0046-8177;;RUNDLE A. ET AL.: 'Association between the ras p21 oncoprotein in blood samples and breast cancer' CANCER LETTERS vol. 185, 2002, pages 71 - 78",ACTIVE
202,US,S,US D0897874 S,020-891-666-567-589,2020-10-06,2020,US 201829671897 F,2018-11-30,GB 6036377 F,2018-05-31,Mass spectrometer,,MICROMASS LTD;;257 LTD,CARNEY PETER;;HENDERSON MATTHEW J;;MURRAY HAYDN;;BLAKE ARTHUR;;PAWSON ANDREW,MICROMASS UK LIMITED (2019-03-01);;257 LTD (2019-03-01),https://lens.org/020-891-666-567-589,Design Right,no,4,3,2,2,0,,,1004;;D10/81,0,0,,,,ACTIVE
203,CA,C,CA 2612693 C,029-567-261-528-648,2012-05-08,2012,CA 2612693 A,2006-06-23,US 69408205 P;;US 2006/0024647 W,2005-06-23,QUANTITATIVE ASSAYS FOR RAS P21 IN BODY FLUIDS,"The present invention is directed to the detection and quantification of total ras p21 in body fluids, particularly serial changes of total ras p21 levels in a subject's body fluids. Further, the invention is directed to detecting and quantitatiing total ras p21 in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for preneoplastic/neoplastic diseases, and useful to select therapies for patients with preneoplastic/neoplastic diseases. The disclosed methods are further useful to monitor the status of a patient's preneoplastic/neoplastic disease, and/or to monitor how a patient is responding to an anticancer therapy.",BAYER HEALTHCARE LLC,CARNEY WALTER P;;HAMER PETER J;;PIERCE KAREN;;BROWN-SHIMER SHERYL,,https://lens.org/029-567-261-528-648,Granted Patent,no,0,0,13,13,0,G01N33/5748;;G01N2333/82;;G01N2800/44;;G01N33/5748;;G01N2800/44;;G01N2333/82;;G01N33/574,G01N33/48;;G01N1/00;;G01N33/00,,0,0,,,,INACTIVE
204,ZA,B,ZA 200803517 B,163-036-057-275-319,2009-02-25,2009,ZA 200803517 A,2008-04-22,US 73309805 P,2005-11-02,"Methods for prediction and prognosis of cancer, and monitoring cancer therapy",,BAYER HEALTHCARE LLC,ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J;;DOUGLAS BIGWOOD,,https://lens.org/163-036-057-275-319,Granted Patent,no,0,0,16,16,0,G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N2800/52;;G01N33/57492;;G01N2333/71;;G01N2333/475,G01N/,,0,0,,,,ACTIVE
205,WO,A2,WO 2007/056011 A2,008-794-361-097-476,2007-05-18,2007,US 2006/0042660 W,2006-11-01,US 73310005 P,2005-11-02,"METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY","The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of VEGF as a biomarker for multi-kinase inhibitors.",BAYER HEALTHCARE LLC;;ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J;;BIGWOOD DOUGLAS,ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J;;BIGWOOD DOUGLAS,,https://lens.org/008-794-361-097-476,Patent Application,yes,0,8,14,14,0,G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N2800/52;;A61P35/00;;A61P43/00;;G01N33/57492;;G01N2800/52;;G01N2333/71;;G01N2333/475;;G01N33/57492;;G01N2333/475;;G01N2800/52;;G01N2333/71,G01N33/574,,0,0,,,,PENDING
206,EP,A1,EP 1893997 A1,011-107-307-202-299,2008-03-05,2008,EP 06785512 A,2006-06-23,US 2006/0024647 W;;US 69408205 P,2005-06-23,QUANTITATIVE ASSAYS FOR RAS P21 IN BODY FLUIDS,"The present invention is directed to the detection and quantification of total ras p21 in body fluids, particularly serial changes of total ras p21 levels in a subject's body fluids. Further, the invention is directed to detecting and quantitating total ras p21 in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for preneoplastic/neoplastic diseases, and useful to select therapies for patients with preneoplastic/neoplastic diseases. The disclosed methods are further useful to monitor the status of a patient's preneoplastic/neoplastic disease, and/or to monitor how a patient is responding to an anticancer therapy.",BAYER HEALTHCARE LLC,CARNEY WALTER P;;HAMER PETER J;;PIERCE KAREN;;BROWN-SHIMER SHERYL,SIEMENS HEALTHCARE DIAGNOSTICS INC. (2008-07-09),https://lens.org/011-107-307-202-299,Patent Application,yes,0,0,13,13,0,G01N33/5748;;G01N2333/82;;G01N2800/44;;G01N33/5748;;G01N2800/44;;G01N2333/82;;G01N33/574,G01N33/48;;G01N1/00;;G01N33/00,,0,0,,,,ACTIVE
207,WO,A3,WO 2007/056011 A3,072-798-122-389-403,2007-12-06,2007,US 2006/0042660 W,2006-11-01,US 73310005 P,2005-11-02,"METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY","The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of VEGF as a biomarker for multi-kinase inhibitors.",BAYER HEALTHCARE LLC;;ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J;;BIGWOOD DOUGLAS,ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J;;BIGWOOD DOUGLAS,,https://lens.org/072-798-122-389-403,Search Report,yes,3,0,14,14,0,G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N2800/52;;A61P35/00;;A61P43/00;;G01N33/57492;;G01N2800/52;;G01N2333/71;;G01N2333/475;;G01N33/57492;;G01N2333/475;;G01N2800/52;;G01N2333/71,G01N33/574,,2,2,062-532-271-839-067;;025-712-631-297-094,15788677;;10.1158/1078-0432.ccr-04-0572;;10.1093/annonc/mdf270;;12377642,"ARORA S. ET AL.: ""Stromelysin-3, Ets-1, and Vascular Endothelial Growth Factor Expression in Oral Precancerous Lesions: Correlations with Microvessel Density, Progression and Prognosis"", CLIN. CANCER RES., vol. 11, no. 6, March 2005 (2005-03-01), pages 2272 - 2284, XP008127275;;LAACK E. ET AL.: ""Pretreatment Serum Levels of Matrix Metalloproteinase-9 and Vascular Endothelial Growth Factor in Non-Small-Cell Lung Cancer"", vol. 13, no. 10, October 2002 (2002-10-01), pages 1550 - 1557, XP002550929",PENDING
208,EP,A4,EP 1946116 A4,129-290-844-085-080,2010-01-06,2010,EP 06827286 A,2006-11-01,US 2006/0042660 W;;US 73310005 P,2005-11-02,"METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY",,BAYER HEALTHCARE LLC,ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J;;BIGWOOD DOUGLAS,,https://lens.org/129-290-844-085-080,Search Report,no,1,0,14,14,0,G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N2800/52;;A61P35/00;;A61P43/00;;G01N33/57492;;G01N2800/52;;G01N2333/71;;G01N2333/475;;G01N33/57492;;G01N2333/475;;G01N2800/52;;G01N2333/71,G01N33/574,,5,2,030-881-310-124-836;;035-908-956-212-21X,10.1002/bjs.4398;;14760675;;10.1097/01.coc.0000199882.53545.ac;;16601426,"MILOJKOVIC DRAGANA ET AL: ""Immunohistochemical characterisation of vascular endothelial growth factor (VEGF) and its receptors Flt-1 and KDR in chronic myeloid leukaemia (CML) patients treated with imatinib mesylate."", November 2004, BLOOD, VOL. 104, NR. 11, PART 1, PAGE(S) 551A-552A, 46TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 04 -07, 2004, ISSN: 0006-4971, XP002555803;;LIANG AIBIN ET AL: ""Differential expression of VEGF and its receptors in the primary cells of various risk classified acute lymphoblastic leukemia patients"", BLOOD, vol. 104, no. 11, Part 2, November 2004 (2004-11-01), & 46TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 04 -07, 2004, pages 194B, XP002555802, ISSN: 0006-4971;;HAYES A J ET AL: ""Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma."", THE BRITISH JOURNAL OF SURGERY FEB 2004, vol. 91, no. 2, February 2004 (2004-02-01), pages 242 - 247, XP002555819, ISSN: 0007-1323;;ELTING JAMES ET AL: ""Biomarkers associated with clinical outcomes in TARGETs, a Phase III single-agent, placebo-controlled study of sorafenib in advanced renal cell carcinoma"", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 47, 1 April 2006 (2006-04-01), pages 683 - 684, XP001245679, ISSN: 0197-016X;;LOCKHART A C ET AL: ""Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer"", AMERICAN JOURNAL OF CLINICAL ONCOLOGY (CANCER CLINICAL TRIALS), RAVEN PRESS LTD., NEW YORK NY, US, vol. 29, no. 2, 1 April 2006 (2006-04-01), pages 109 - 115, XP008087910, ISSN: 0277-3732",DISCONTINUED
209,US,S,US D0955246 S,123-838-755-958-567,2022-06-21,2022,US 202029752064 F,2020-09-24,US 202029752064 F;;GB 6036377 F;;US 201829671897 F,2018-05-31,Mass spectrometer,,MICROMASS LTD,CARNEY PETER;;HENDERSON MATTHEW J;;MURRAY HAYDN;;BLAKE ARTHUR;;PAWSON ANDREW,MICROMASS UK LIMITED (2019-03-01);;257 LTD (2019-01-03),https://lens.org/123-838-755-958-567,Design Right,no,6,3,2,2,0,,,1004;;D10/81,0,0,,,,ACTIVE
210,US,A1,US 2014/0093890 A1,100-039-011-099-960,2014-04-03,2014,US 201314051589 A,2013-10-11,US 201314051589 A;;US 91747106 A;;US 2006/0024647 W;;US 69408205 P,2005-06-23,QUANTITATIVE ASSAYS FOR RAS P21 IN BODY FLUIDS,"The present invention is directed to the detection and quantification of total ras p21 in body fluids, particularly serial changes of total ras p21 levels in a subject's body fluids. Further, the invention is directed to detecting and quantitating total ras p21 in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for preneoplastic/neoplastic diseases, and useful to select therapies for patients with preneoplastic/neoplastic diseases. The disclosed methods are further useful to monitor the status of a patient's preneoplastic/neoplastic disease, and/or to monitor how a patient is responding to an anticancer therapy.",CARNEY WALTER P;;HAMER PETER J;;PIERCE KAREN;;BROWN-SHIMER SHERYL;;SIEMENS HEALTHCARE DIAGNOSTICS,CARNEY WALTER P;;HAMER PETER J;;PIERCE KAREN;;BROWN-SHIMER SHERYL,,https://lens.org/100-039-011-099-960,Patent Application,yes,0,0,13,13,0,G01N33/5748;;G01N2333/82;;G01N2800/44;;G01N33/5748;;G01N2800/44;;G01N2333/82;;G01N33/574,G01N33/574,435/7.23;;435/7.94,0,0,,,,DISCONTINUED
211,EP,A2,EP 1946116 A2,025-943-240-429-326,2008-07-23,2008,EP 06827286 A,2006-11-01,US 2006/0042660 W;;US 73310005 P,2005-11-02,"METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY",,BAYER HEALTHCARE LLC,ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J;;BIGWOOD DOUGLAS,,https://lens.org/025-943-240-429-326,Patent Application,yes,0,0,14,14,0,G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N2800/52;;A61P35/00;;A61P43/00;;G01N33/57492;;G01N2800/52;;G01N2333/71;;G01N2333/475;;G01N33/57492;;G01N2333/475;;G01N2800/52;;G01N2333/71,G01N33/574,,0,0,,,,DISCONTINUED
212,EP,A2,EP 1943521 A2,049-216-065-203-53X,2008-07-16,2008,EP 06827287 A,2006-11-01,US 2006/0042661 W;;US 73309805 P,2005-11-02,"METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY",,BAYER HEALTHCARE LLC,CARNEY WALTER P;;HAMER PETER J;;BIGWOOD DOUGLAS;;ELTING JAMES J,,https://lens.org/049-216-065-203-53X,Patent Application,yes,0,0,16,16,0,G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N2800/52;;G01N33/57492;;G01N2333/71;;G01N2333/475,G01N33/574,,0,0,,,,DISCONTINUED
213,AU,A1,AU 2006/312058 A1,107-541-520-517-399,2007-05-18,2007,AU 2006/312058 A,2006-11-01,US 73310005 P;;US 2006/0042660 W,2005-11-02,"Methods for prediction and prognosis of cancer, and monitoring cancer therapy",,BAYER HEALTHCARE LLC,ELTING JAMES J;;BIGWOOD DOUGLAS;;HAMER PETER J;;CARNEY WALTER P,,https://lens.org/107-541-520-517-399,Patent Application,no,0,0,14,14,0,G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N2800/52;;A61P35/00;;A61P43/00;;G01N33/57492;;G01N2800/52;;G01N2333/71;;G01N2333/475;;G01N33/57492;;G01N2333/475;;G01N2800/52;;G01N2333/71,G01N33/574,,0,0,,,,DISCONTINUED
214,WO,A1,WO 2007/002505 A1,118-044-912-507-183,2007-01-04,2007,US 2006/0024647 W,2006-06-23,US 69408205 P,2005-06-23,QUANTITATIVE ASSAYS FOR RAS P21 IN BODY FLUIDS,"The present invention is directed to the detection and quantification of total ras p21 in body fluids, particularly serial changes of total ras p21 levels in a subject's body fluids. Further, the invention is directed to detecting and quantitatiing total ras p21 in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for preneoplastic/neoplastic diseases, and useful to select therapies for patients with preneoplastic/neoplastic diseases. The disclosed methods are further useful to monitor the status of a patient's preneoplastic/neoplastic disease, and/or to monitor how a patient is responding to an anticancer therapy.",BAYER HEALTHCARE LLC;;CARNEY WALTER P;;HAMER PETER J;;PIERCE KAREN;;BROWN-SHIMER SHERYL,CARNEY WALTER P;;HAMER PETER J;;PIERCE KAREN;;BROWN-SHIMER SHERYL,,https://lens.org/118-044-912-507-183,Patent Application,yes,0,0,13,13,0,G01N33/5748;;G01N2333/82;;G01N2800/44;;G01N33/5748;;G01N2800/44;;G01N2333/82;;G01N33/574,G01N1/00;;G01N33/48;;G01N33/00,,2,2,009-045-673-374-880;;039-657-735-451-69X,10.1016/s0304-3835(02)00236-7;;12142081;;10.1158/0008-5472.can-04-1443;;15466206,"RUNDLE A. ET AL.: ""Association between the ras p21 oncoprotein in blood samples and breast cancer"", CANCER LETTERS, vol. 185, 2002, pages 71 - 78, XP002486942;;WILHELM ET AL., CANCER RESEARCH, vol. 64, 1 October 2004 (2004-10-01), pages 7099 - 7109",PENDING
215,US,S,US D0887295 S,167-593-098-576-561,2020-06-16,2020,US 201829671903 F,2018-11-30,GB 6036378 F,2018-05-31,Mass spectrometer,,MICROMASS LTD;;257 LTD,CARNEY PETER;;HENDERSON MATTHEW J;;MURRAY HAYDN;;BLAKE ARTHUR;;PAWSON ANDREW,MICROMASS UK LIMITED (2019-03-04);;257 LTD (2019-03-01),https://lens.org/167-593-098-576-561,Design Right,no,4,9,1,1,0,,,1004;;D10/81,0,0,,,,ACTIVE
216,CA,A1,CA 2612693 A1,034-446-732-716-216,2007-01-04,2007,CA 2612693 A,2006-06-23,US 69408205 P;;US 2006/0024647 W,2005-06-23,QUANTITATIVE ASSAYS FOR RAS P21 IN BODY FLUIDS,"The present invention is directed to the detection and quantification of total ras p21 in body fluids, particularly serial changes of total ras p21 levels in a subject's body fluids. Further, the invention is directed to detecting and quantitatiing total ras p21 in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for preneoplastic/neoplastic diseases, and useful to select therapies for patients with preneoplastic/neoplastic diseases. The disclosed methods are further useful to monitor the status of a patient's preneoplastic/neoplastic disease, and/or to monitor how a patient is responding to an anticancer therapy.",BAYER HEALTHCARE LLC,CARNEY WALTER P;;PIERCE KAREN;;BROWN-SHIMER SHERYL;;HAMER PETER J,,https://lens.org/034-446-732-716-216,Patent Application,no,0,0,13,13,0,G01N33/5748;;G01N2333/82;;G01N2800/44;;G01N33/5748;;G01N2800/44;;G01N2333/82;;G01N33/574,G01N33/48;;G01N1/00;;G01N33/00,,0,0,,,,INACTIVE
217,EP,A1,EP 3274631 A1,065-619-895-250-366,2018-01-31,2018,EP 16712207 A,2016-03-10,EP 15000860 A;;EP 2016000432 W,2015-03-24,A HEAT EXCHANGING SYSTEM FOR A FURNACE,,LINDE AG,MIETH RAINER;;GÖRISCH MATTHIAS;;CARNEY STEPHEN;;RICHARDSON ANDREW PETER;;KOEDER HORST,,https://lens.org/065-619-895-250-366,Patent Application,yes,0,0,3,3,0,C03B5/237;;F23L15/02;;F27B3/266;;F27D99/0033;;F27B3/263;;Y02E20/34;;Y02P40/50,F23L15/02;;C03B5/237,,0,0,,,,DISCONTINUED
218,DE,D1,DE 602006015957 D1,019-699-979-571-735,2010-09-16,2010,DE 602006015957 T,2006-06-23,US 69408205 P;;US 2006/0024647 W,2005-06-23,QUANTITATIVE ASSAYS FÜR RAS P21 IN KÖRPERFLÜSSIGKEITEN,"The present invention is directed to the detection and quantification of total ras p21 in body fluids, particularly serial changes of total ras p21 levels in a subject's body fluids. Further, the invention is directed to detecting and quantitating total ras p21 in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for preneoplastic/neoplastic diseases, and useful to select therapies for patients with preneoplastic/neoplastic diseases. The disclosed methods are further useful to monitor the status of a patient's preneoplastic/neoplastic disease, and/or to monitor how a patient is responding to an anticancer therapy.",SIEMENS HEALTHCARE DIAGNOSTICS,CARNEY WALTER P;;HAMER PETER J;;PIERCE KAREN;;BROWN-SHIMER SHERYL,,https://lens.org/019-699-979-571-735,Granted Patent,no,0,0,13,13,0,G01N33/5748;;G01N2333/82;;G01N2800/44;;G01N33/5748;;G01N2800/44;;G01N2333/82;;G01N33/574,G01N33/48;;G01N1/00;;G01N33/00,,0,0,,,,ACTIVE
219,BR,A2,BR PI0618092 A2,129-337-570-267-391,2011-08-16,2011,BR PI0618092 A,2006-11-01,US 73310005 P;;US 2006/0042660 W,2005-11-02,"métodos ""in vitro"" para monitorar o estado de uma doença, de seleção de terapia e de diagnóstico de cáncer","<b>MéTODOS IN VITRO PARA MONITORAR O ESTADO DE UMA DOENçA, DE SELEçãO DE TERAPIA E DE DIAGNóSTICO DE CáNCER<d>. A presente invenção refere-se a biomarcadores e ao uso de biomarcadores para a predição e prognóstico de câncer assim como o uso de biomarcadores para monitorar a eficácia de tratamento de câncer. Especificamente, essa invenção refere-se ao uso de VEGF como um biomarcador para inibidores de multiquinase.",BAYER HEALTHCARE LLC,ELTING JAMES J;;CARNEY WALTER P;;HAMER PETER J;;BIGWOOD DOUGLAS,,https://lens.org/129-337-570-267-391,Patent Application,no,0,0,14,14,0,G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N2800/52;;A61P35/00;;A61P43/00;;G01N33/57492;;G01N2800/52;;G01N2333/71;;G01N2333/475;;G01N33/57492;;G01N2333/475;;G01N2800/52;;G01N2333/71,G01N33/574,,0,0,,,,DISCONTINUED
220,WO,A1,WO 2016/150555 A1,137-546-176-781-131,2016-09-29,2016,EP 2016000432 W,2016-03-10,EP 15000860 A,2015-03-24,A HEAT EXCHANGING SYSTEM FOR A FURNACE,"The invention relates to a heat exchanging system for a furnace (300) with a supply pipe (120, 130) adapted to supply a medium to a burner (310a, 310b) of the furnace (300), an exhaust flue (100) adapted to exhaust combustion waste gases (101 ) from the furnace (300), the exhaust flue (100) comprising a refractory element (110), wherein the supply pipe (120, 130) is arranged at least partially inside or on the refractory element (110) of the exhaust flue (100).",LINDE AG,MIETH RAINER;;GÖRISCH MATTHIAS;;CARNEY STEPHEN;;RICHARDSON ANDREW PETER;;KOEDER HORST,,https://lens.org/137-546-176-781-131,Patent Application,yes,7,0,3,3,0,C03B5/237;;F23L15/02;;F27B3/266;;F27D99/0033;;F27B3/263;;Y02E20/34;;Y02P40/50,F23L15/02;;C03B5/237,,0,0,,,,PENDING
221,CA,A1,CA 2628091 A1,144-451-551-591-113,2007-05-18,2007,CA 2628091 A,2006-11-01,US 73309805 P;;US 2006/0042661 W,2005-11-02,"METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY",,BAYER HEALTHCARE LLC,CARNEY WALTER P;;HAMER PETER J;;BIGWOOD DOUGLAS;;ELTING JAMES J,,https://lens.org/144-451-551-591-113,Patent Application,no,0,0,16,16,0,G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N33/57492;;G01N2333/475;;G01N2333/71;;G01N2800/52;;G01N33/57492;;G01N2333/71;;G01N2333/475,G01N33/574;;G01N33/53;;G01N33/543;;G01N33/577;;G01N33/68,,0,0,,,,DISCONTINUED
222,EP,A1,EP 3803947 A1,087-420-152-774-695,2021-04-14,2021,EP 19730462 A,2019-05-31,GB 201808949 A;;GB 2019051499 W,2018-05-31,BENCH-TOP TIME OF FLIGHT MASS SPECTROMETER,,MICROMASS LTD,WAMSLEY RUTH;;WILSON MICHAEL;;TRIVETT IAN;;CARNEY PETER;;MURRAY HAYDN;;MCIVER PAUL,,https://lens.org/087-420-152-774-695,Patent Application,yes,0,0,9,9,0,H01J49/067;;H01J49/06;;H01J49/0027;;H01J49/0031;;H01J49/02;;H01J49/067;;H01J49/24;;H01J49/40;;H01J49/0031;;H01J49/0422;;H01J49/045;;H01J49/0486;;H01J49/0495;;H01J49/067;;H01J49/24;;H01J49/405,H01J49/06,,0,0,,,,PENDING
223,US,B2,US 11476103 B2,147-838-062-998-962,2022-10-18,2022,US 201917059872 A,2019-05-31,GB 201808936 A;;GB 2019051494 W,2018-05-31,Bench-top time of flight mass spectrometer,"A mass spectrometer includes a control system arranged to assess an operational state of the mass spectrometer. When a fault is detected, the control system assigns the fault to one of a plurality of categories, including a first category of faults which may be attempted to be rectified automatically by the mass spectrometer, a second category of faults which may be attempted to be rectified by the user, and a third category of faults which may only be attempted to be rectified by a service engineer. When a fault is assigned to the first category of faults, the control system initiates an attempt to automatically rectify the fault. When a fault is assigned to the second category of faults, the control system causes information relating to the fault to be displayed to the user, including data indicative of the fault and data one or more steps to be taken by the user to attempt to rectify the fault ( 2000 ). When a fault is assigned to the third category of faults, the control system causes information relating to the fault to be displayed to the user including data indicative of the fault, and an indication that the user should call a service engineer.",MICROMASS LTD,WAMSLEY RUTH;;WILSON MICHAEL;;CARNEY PETER;;THRELFALL RICHARD;;HENDERSON MATTHEW;;MCIVER PAUL,MICROMASS UK LIMITED (2021-10-25);;WATERS TECHNOLOGIES CORPORATION (2021-10-25),https://lens.org/147-838-062-998-962,Granted Patent,yes,264,0,10,10,0,H01J49/0027;;H01J49/0009;;H01J49/0027;;H01J49/02;;H01J49/022;;H01J49/24;;H01J49/0009;;H01J49/022;;H01J49/24;;H01J49/40,H01J49/00;;H01J49/02;;H01J49/24;;H01J49/40,,79,5,002-875-246-112-868;;004-471-982-018-484;;022-561-862-885-681;;119-779-971-342-191;;062-933-196-688-541,11523084;;10.1002/jms.207;;10.1002/rcm.1074;;12820206;;10.1021/ac0518811;;16579588;;10.1016/j.ijms.2013.02.010;;10.1063/1.4922913;;pmc4482810;;26133872,"Stanford Research Systems, “Operating Manual and Programming Reference: Models RGA100, RGA200 and RGA300 Residual Gas Analyzer”, Revision 1.May 8, 2009 (Year: 2009).;;Stanford Research Systems, “Operating Manual and Programming Reference: Models RGA100, RGA200 and RGA300 Residual Gas Analyzer”, Reivision 1.May 8, 2009 (Year: 2009).;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808932 6, dated Nov. 21, 2018, 4 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808890 6, dated Nov. 28, 2018, 7 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808912 8, dated Nov. 30, 2018, 10 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808942.5, dated Dec. 3, 2018, 7 pages.;;Chernushevich, I. V., et al., “An introduction to quadrupole-time-of-flight mass spectrometry”, Journal of Mass Spectrometry, 36(8):849-65 (2001) Abstract only.;;Chernushevich, I.V., et al., “Charge state separation for protein applications using a quadrupole time-of-flight mass spectrometer”, Rapid Communications in Mass Spectrometry 17(13):1416-1424 (2003). Abstract only.;;Makarov, A. et al., “Performance evaluation of a hybrid linear ion trap/orbitrap mass spectrometer,” Analytical Chemistry, 78(7):2113-20 (2006).;;Combined Search and Examination Report under Sections 117 and 18(3) for Application No. GB1808948.2 dated Nov. 21, 2018, 7 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808893.0 dated Nov. 27, 2018, 8 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808936.7 dated Nov. 20, 2018, 10 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808892.2, dated Dec. 3, 2018, 6 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Applicaton No. GB1808894.8 dated Dec. 3, 2018, 7 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808949.0 dated Oct. 31, 2018, 8 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1907722.1 dated Jun. 28, 2019, 8 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808889.8 dated Nov. 30, 2018, 7 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051504, dated Jul. 23, 2019, 11 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1818003.4, dated May 2, 2019, 6 pages.;;Invitation to pay additional fees and, where applicable, protest fee for PCT/GB2019/051508, dated Aug. 28, 2019.;;Author unknown, “Operating Manual and Programming Reference, Models RGA100, RGA200, and RGA300 Residual Gas Analyzer,” Stanford Research Systems Revision 1.8 (May 2009).;;Jungmann, J. H., et al., “An in-vacuum, pixelated detection system for mass spectrometric analysis and imaging of macromolecules,” International Journal of Mass Spectrometry, 341-342:34-44 (2013).;;Invitation to pay additional fees and, where applicable, protest fee for International application No. PCT/GB2019/051507, dated Aug. 20, 2019, 16 pages.;;Yang, C., and Hanley, L., “ChiMS: Open-source instrument control software platform on LabVIEW for imaging/depth profiling mass spectrometers,” Review of Scientific Instruments, 86:065106-1 through 065016-7 (2015).;;Invitation to pay additional fees and, where applicable, protest fee for International application No. PCT/GB2019/051506, dated Jul. 22, 2019, 13 pages.;;Invitation to pay additional fees and, where applicable, protest fee for PCT/GB2019/051503, dated Jul. 25, 2019, 17 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051500, dated Aug. 5, 2019, 9 pages.;;Kozlov, B., et al., “Time-of-flight mass spectrometer for investigations of laser ablation,” ASMS Conference paper, Dallas, TX (May 1999). [Retrieved from the Internet URL: https//www.researchgate.net/publication/330202298_Time-of-flight_mass_spectrometer_for_investigations_of_laser_ablation]. Abstract.;;Shion, H., et al., “Towards Overcoming the Challenges of Implementing Accurate Mass MS for Routine Biotherapeutic Analysis” 2018 ASMS Prototype oa-TOF Abstract HYS Final.;;Shion, S., et al., “Towards Overcoming the Challenges of Implementing Accurate Mass MS for Routine Biotherapeutic Analysis” 2018 ASMS Prototype oa-TOF WP699 HYS Final Poster.;;Shion, H., et al., “A Fit-for-purpose Accurate Mass MS for Routine Biotherapeutic Analysis”, 2018 CASSS Mass Spec HYS Final Poster.;;Shion, H., et al., “A Fit-for-purpose Accurate Mass MS for Routine Biotherapeutic Analysis”, 2018 CASSS Mass Spec BioTof HYS Final, Abstract.;;Shion, H., et al., “Progress Towards Implementing Simple Time-of-flight Accurate Mass MS for Routine Biotherapeutic Analysis”, XXII (IMSC) International Mass Spectrometry Conference Florence, Italy (2018) Abstract.;;Shion, H., et al., “Progress Towards Implementing Simple Time-of-flight Accurate Mass MS for Routine Biotherapeutic Analysis”, XXII International Mass Spectrometry Conference Florence, Italy (2018) poster.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 ASMS BioAccord Oral Session PowerPoint.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 ASMS BioAccord Abstract.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments” 2019 ATEurope BioAccord, Abstract.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments” 2019 ATEurope BioAccord, Poster.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 BioPharma Analytical Summit BioAccord, abstract.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 Bio Pharma Summit BioAccord, Poster.;;Shion, H., “Enabling Routine and Reproducible Biotherapeutic Analysis when Data Integrity Matters”, 2019 15th Annual PEGs Boston Waters BioAccord, PowerPoint 29 pages.;;Shion, H., “Enabling Routine and Reproducible Biotherapeutic Analysis when Data Integrity Matters”, 2019 15th Annual PEGs Boston Waters BioAccord, Abstract.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 Pitt Con Bio Accord, Poster.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 Pitt Con Bio Accord, Abstract.;;Combined Search and Exam Report from IPO for GB Application No. 1907739.5, dated Nov. 27, 2019, 8 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051510, dated Aug. 29, 2019, 13 pages.;;Combined Search and Exam Report from IPO for GB Application No. 1907735.3, dated Nov. 25, 2019, 7 pages.;;Combined S and E Report under Sections 17 and 18(3) for Application No. GB1907734.6, dated Oct. 31, 2019, 7 pages.;;International Search Report and Written Opinion for International Application No. PCT/GB2019/051498, dated Nov. 6, 2019, 21 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1907719.7, dated Nov. 15, 2019, 11 pages.;;Author unknown, “Waters Xevo G2-S QTof Operators Overview and Maintenance Guide”, Feb. 11, 2013 (Feb. 11, 2013), XP55606374, Retrieved from the Internet: URL:https://www.waters.eom/webassets/cms/support/docs/kevo_g2-s_qtof_715003596rb.pdf [retrieved on Jul. 17, 2019].;;International Search Report and Written Opinion for International application No. PCT/GB2019/051501, dated Sep. 25, 2019, 17 pages.;;Combined Search and Examination Report under Sections 17 and 18(3), for Application No. GB1907724 7, dated Sep. 25, 2019, 7 pages.;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fee for International application No. PCT/GB2019/051494, dated Sep. 19, 2019.;;Combined Search and Examination Report under Sections 17 and 18(3), dated Sep. 27, 2019, for Application No. GB1907736.1, 6 pages.;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fees, for International application No. PCT/GB2019/051499, dated Sep. 4, 2019.;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fee, for International Application No. PCT/GB2019/051496, dated Aug. 29, 2019.;;Anonymous, “Time-of-flight mass spectrometry”, Wikipedia, Apr. 28, 2018 (Apr. 28, 2018), XP055614063, Retrieved from the Internet:URL:https://en.wikipedia.org/w/index.phptitle=Time-of-flight_mass_spectrometry oldid=838663844 [retrieved on Aug. 20, 2019].;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fees for International application No. PCT/3B2019/051497, dated Sep. 2, 2019.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1907745 2, dated Aug. 13, 2019, 7 pages.;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fee, for International application No. PCT/GB2019/051501, dated Jul. 29, 2019, 14 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051497, dated Nov. 5, 2019, 19 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051503, dated Sep. 25, 2019, 17 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051496, dated Oct. 23, 2019, 29 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051506, dated Sep. 25, 2019, 14 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051494, dated Nov. 18, 2019, 20 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051507, dated Oct. 15, 2019, 17 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051508, dated Oct. 23, 2019, 16 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051499, dated Nov. 5, 2019, 19 pages.;;Examination Report under Section 18(3) for Application No. GB1907719.7, dated Jul. 28, 2021, 9 pages.;;Parkes, S. SpaceWire User Guide, STAR-Dundee [online] 2012 [retrieved on Aug. 13, 2021], Retrieved from Internet URL: https://www.star-dundee.com/wp-content/star_uploads/general/SpaceWire-Users-Guide.pdf, 117 pages.;;SCIEX, “3200 Series of Instruments System User Guide” [online], published Apr. 2018, available from: https://sciex.com/content/dam/SCIEX/pdf/customer-docs/user-guide/3200-system-user-guide-en.pdf, 241 pages.;;Combined Search and Examination Report under Sections 17 and 18(3), for Application No. GB2100898.2, dated Jun. 17, 2021, 7 pages.;;Combined Search and Examination Report under Sections 17 and 18(3), for Application No. GB2001530.1, dated Aug. 5, 2020, 7 pages.;;Thermo Fisher Scientific, Inc, Feb. 2015, Orbitrap Fusion Hardware Manual [online]. Retrieved from Internet URL: http://www.unitylabservices.eu/content/dam/tfs/ATG/CMD/cmddocuments/oper/oper/ms/lc-ms/sys/Man-80000-97016-Orbitrap-Fusion-Hardware-Man8000097016-A-EN.pdf, 122 pages.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 BioPharma Analytical Summit BioAccord Abstract. ASMS MS-in-QC, PowerPoint 24 pages.;;International Preliminary Report on Patentability for International application No. PCT/GB2019/051510, dated Dec. 1, 2020, 7 pages.;;Examination Report under Section 18(3) for Application No. GB1907739.5, dated Nov. 3, 2020, 5 pages.;;Examination Report under Section 18(3) for Application No. GB2020743.7, dated Jan. 28, 2022, 6 pages.",ACTIVE
224,DE,C2,DE 10024220 C2,167-716-961-025-275,2002-06-20,2002,DE 10024220 A,2000-05-17,US 31481999 A,1999-05-19,Verfahren und Vorrichtung zum Aktivieren eines Funktelefonempfängers mit Streuspektrum,"Ein Verfahren zum Aktivieren eines Funktelefons, welches in einem Mehrfachzugriff-Funktelefonsystem mit Streuspektrum betreibbar ist. Ein Suchempfänger (114) wird aktiviert, und der Suchempfänger (114) erfasst ein PN-Sequenz-Timing eines Pilotsignals. Wenigstens ein Demodulationszweig (122) wird nach der Aktivierung des Suchempfängers (114) aktiviert, und der Demodulationszweig wird zu dem PN-Sequenz-Timing des ausgewählten Pilotsignals synchronisiert, nachdem der Suchempfänger (114) das PN-Sequenz-Timing erfasst hat.",MOTOROLA INC,LAROSA CHRISTOPHER PETER;;STORM BRIAN DAVID;;CARNEY MICHAEL JOHN;;SCHIRTZINGER TRACIE ANN,"GOOGLE TECHNOLOGY HOLDINGS LLC, MOUNTAIN VIEW, US (2018-04-26)",https://lens.org/167-716-961-025-275,Granted Patent,no,4,2,14,30,0,H04B1/70752;;H04B1/70752;;H04B7/26;;H04B1/70751;;H04B1/70751;;H04B1/70753;;H04B1/70753;;H04B1/70756;;H04B1/70756;;H04B2201/70701;;H04B2201/70701;;H04B2201/70702;;H04B2201/70702;;H04B2201/70707;;H04B2201/70707;;H04B2201/70709;;H04B2201/70709,H04B1/16;;H04B1/7075;;H04B7/26;;H04M1/00;;H04M1/73,,0,0,,,,EXPIRED
225,WO,A3,WO 1992/008843 A3,048-817-673-506-961,1993-02-18,1993,US 9105462 W,1991-08-01,US 60726890 A,1990-10-31,FIBER TREATMENT APPARATUS,,WEYERHAEUSER CO,CARNEY ALLAN R;;GRAEF PETER A;;BOWNS MARK W;;BOLSTAD CLIFFORD R,,https://lens.org/048-817-673-506-961,Search Report,no,3,0,9,9,0,A61F2013/530007;;A61F2013/530474;;D21B1/066;;D21B1/066;;A61F2013/530007;;A61F2013/530474,A61F13/15;;D21B1/06;;D04H1/42,,0,0,,,,PENDING
226,GB,B,GB 2575726 B,167-647-744-526-843,2022-01-19,2022,GB 201907719 A,2019-05-31,GB 201808936 A,2018-05-31,Bench-top time of flight mass spectrometer,,MICROMASS LTD,MICHAEL WILSON;;RUTH WAMSLEY;;PETER CARNEY;;RICHARD THRELFALL;;MATTHEW HENDERSON;;PAUL MCIVER,,https://lens.org/167-647-744-526-843,Granted Patent,no,9,0,10,10,0,H01J49/0027;;H01J49/0009;;H01J49/0027;;H01J49/02;;H01J49/022;;H01J49/24;;H01J49/0009;;H01J49/022;;H01J49/24;;H01J49/40,H01J49/00;;H01J49/02;;H01J49/24,,1,0,,,"SCIEX, 3200 Series of Instruments System User Guide [online], published April 2018, available from:",ACTIVE
227,CN,A,CN 112243532 A,186-237-316-804-189,2021-01-19,2021,CN 201980036551 A,2019-05-31,GB 201808936 A;;GB 2019051494 W,2018-05-31,BENCH-TOP TIME OF FLIGHT MASS SPECTROMETER,"A mass spectrometer includes a control system arranged to assess an operational state of the mass spectrometer. When a fault is detected, the control system assigns the fault to one of a plurality ofcategories, including a first category of faults which may be attempted to be rectified automatically by the mass spectrometer, a second category of faults which may be attempted to be rectified by the user, and a third category of faults which may only be attempted to be rectified by a service engineer. When a fault is assigned to the first category of faults, the control system initiates an attempt to automatically rectify the fault. When a fault is assigned to the second category of faults, the control system causes information relating to the fault to be displayed to the user, including data indicative of the fault and data one or more steps to be taken by the user to attempt to rectify the fault (2000). When a fault is assigned to the third category of faults, the control system causes information relating to the fault to be displayed to the user including data indicative of the fault, and an indication that the user should call a service engineer.",MICROMASS LTD,WAMSLEY RUTH;;WILSON MICHAEL;;CARNEY PETER;;THRELFALL RICHARD;;HENDERSON MATTHEW;;MCIVER PAUL,,https://lens.org/186-237-316-804-189,Patent Application,no,6,4,10,10,0,H01J49/0027;;H01J49/0009;;H01J49/0027;;H01J49/02;;H01J49/022;;H01J49/24;;H01J49/0009;;H01J49/022;;H01J49/24;;H01J49/40,H01J49/00,,0,0,,,,ACTIVE
228,DE,D1,DE 60024814 D1,012-166-270-950-205,2006-01-19,2006,DE 60024814 T,2000-05-10,US 31481999 A;;US 55812100 A;;US 0012674 W,1999-05-19,VERFAHREN UND GERÄT ZUM ERFASSEN EINES SPREIZSPEKTRUMSIGNALS,,MOTOROLA INC,LAROSA PETER;;STORM DAVID;;CARNEY JOHN;;BECKER CHRISTOPHER;;SCHIRTZINGER ANN;;STECKL DAVE,"MOTOROLA MOBILITY, INC. ( N.D. GES. D. STAATES, US (2011-05-26)",https://lens.org/012-166-270-950-205,Granted Patent,no,0,1,16,30,0,H04B1/70752;;H04B1/70752;;H04B1/7077;;H04B1/70751;;H04B1/70751;;H04B1/70753;;H04B1/70753;;H04B1/70756;;H04B1/70756;;H04B1/709;;H04B1/709;;H04B2201/70701;;H04B2201/70701;;H04B2201/70702;;H04B2201/70702;;H04B2201/70707;;H04B2201/70707;;H04B2201/70709;;H04B2201/70709,H04B1/7075;;H04B1/709;;H04B7/216,,0,0,,,,EXPIRED
229,WO,A2,WO 1992/008843 A2,102-354-207-707-270,1992-05-29,1992,US 9105462 W,1991-08-01,US 60726890 A,1990-10-31,FIBER TREATMENT APPARATUS,"An apparatus is disclosed for preparing a quantity of individual treated fibers from one or more fiber mats. The apparatus comprises a fiber treatment zone, a conveyor for conveying each mat through the fiber treatment zone, wherein each mat is impregnated by an applicator with a treatment material, such as a crosslinking substance, and directly to an attrition device. The attrition device fiberizes the mats to form a fiber output having a low nit level, such as no more than about three, and a dryer for both drying the fiber output and curing the crosslinking substance. The fiberizer is configured to minimize the accumulation of fiber at locations therein. An optional component of the fiberizer is a novel fluff generator comprised of multiple rotors each having plural longitudinally extended rows of radially extending rotor pins that rotate past groups of shorter pins mounted on the inside surface of the fluff generator housing.",WEYERHAEUSER CO,CARNEY ALLAN R;;GRAEF PETER A;;BOWNS MARK W;;BOLSTAD CLIFFORD R,,https://lens.org/102-354-207-707-270,Patent Application,yes,0,3,9,9,0,A61F2013/530007;;A61F2013/530474;;D21B1/066;;D21B1/066;;A61F2013/530007;;A61F2013/530474,A61F13/15;;D21B1/06;;D04H1/42,,0,0,,,,PENDING
230,AU,A,AU 1991/083232 A,119-335-342-219-839,1992-06-11,1992,AU 1991/083232 A,1991-08-01,US 60726890 A,1990-10-31,FIBER TREATMENT APPARATUS,,WEYERHAEUSER CO,CARNEY ALLAN R;;GRAEF PETER A;;BOWNS MARK W;;BOLSTAD CLIFFORD R,,https://lens.org/119-335-342-219-839,Patent Application,no,0,0,9,9,0,A61F2013/530007;;A61F2013/530474;;D21B1/066;;D21B1/066;;A61F2013/530007;;A61F2013/530474,D04H1/42;;A61F13/15;;D21B1/06,,0,0,,,,PENDING
231,EP,A1,EP 0555226 A1,192-200-067-021-13X,1993-08-18,1993,EP 91914560 A,1991-08-01,US 60726890 A,1990-10-31,FIBER TREATMENT APPARATUS.,"L'invention concerne un appareil permettant de préparer une quantité de fibres traitées individuelles provenant d'une ou de plusieurs nappes de fibres. L'appareil comprend une zone de traitement des fibres, une transporteuse permettant d'acheminer chaque nappe dans la zone de traitement de fibres dans laquelle chaque nappe est imprégnée, à l'aide d'un applicateur, d'un matériau de traitement tel qu'une substance de réticulation, et l'acheminant directement vers un dispositif d'attrition. Ledit dispositif d'attrition sépare les fibres de la nappe pour produire une fibre de sortie ayant un faible taux de nit, de l'ordre de 3 environ au maximum, et une sécheuse sèche la fibre de sortie et durcit la substance de réticulation. Le système de séparation des fibres est conçu pour minimiser l'accumulation de fibre dans des endroits de ce dernier. Un élément optionnel du système de séparation des fibres est un nouveau générateur de bout de fil composé de plusieurs rotors comprenant chacun plusieurs rangées étendues dans le sens longitudinal de broches de rotor s'étendant radialement qui font tourner des groupes passés de broches plus petites montées sur la surface interne du boîtier du générateur de bout de fil.",WEYERHAEUSER CO,GRAEF PETER A;;CARNEY ALLAN R;;BOWNS MARK W;;BOLSTAD CLIFFORD R,,https://lens.org/192-200-067-021-13X,Patent Application,yes,0,0,9,9,0,A61F2013/530007;;A61F2013/530474;;D21B1/066;;D21B1/066;;A61F2013/530007;;A61F2013/530474,A61F13/15;;D04H1/42;;D21B1/06,,0,0,,,,DISCONTINUED
232,GB,A,GB 2575726 A,124-778-884-624-285,2020-01-22,2020,GB 201907719 A,2019-05-31,GB 201808936 A,2018-05-31,Bench-top time of flight mass spectrometer,"A control system assesses an operational state of a mass spectrometer and assign a fault to one of three categories when the fault is detected. When the fault is assigned to a first category of faults which may be attempted to be rectified automatically by the mass spectrometer, an attempt may be initiated to automatically rectify the fault. When the fault is assigned to a second category of faults which may be attempted to be rectified by the user, information relating to the fault may be displayed including steps to be taken by the user to attempt to rectify the fault. When the fault is assigned to a third category of faults which may only be attempted to be rectified by a service engineer, information relating to the fault may be displayed with an indication that the user should call a service engineer. A method of performing a start-up routine automatically upon switching on the mass spectrometer and a method of using a backing pressure measurement to determine the existence of a fault in relation to an atmospheric pressure interface are also disclosed.",MICROMASS LTD,RUTH WAMSLEY;;MICHAEL WILSON;;PETER CARNEY;;RICHARD THRELFALL;;MATTHEW HENDERSON;;PAUL MCIVER,,https://lens.org/124-778-884-624-285,Patent Application,no,6,0,10,10,0,H01J49/0027;;H01J49/0009;;H01J49/0027;;H01J49/02;;H01J49/022;;H01J49/24;;H01J49/0009;;H01J49/022;;H01J49/24;;H01J49/40,H01J49/00;;H01J49/02;;H01J49/24,,0,0,,,,ACTIVE
233,WO,A1,WO 2019/229453 A1,154-190-121-992-689,2019-12-05,2019,GB 2019051494 W,2019-05-31,GB 201808936 A,2018-05-31,BENCH-TOP TIME OF FLIGHT MASS SPECTROMETER,"A mass spectrometer includes a control system arranged to assess an operational state of the mass spectrometer. When a fault is detected, the control system assigns the fault to one of a plurality of categories, including a first category of faults which may be attempted to be rectified automatically by the mass spectrometer, a second category of faults which may be attempted to be rectified by the user, and a third category of faults which may only be attempted to be rectified by a service engineer. When a fault is assigned to the first category of faults, the control system initiates an attempt to automatically rectify the fault. When a fault is assigned to the second category of faults, the control system causes information relating to the fault to be displayed to the user, including data indicative of the fault and data one or more steps to be taken by the user to attempt to rectify the fault (2000). When a fault is assigned to the third category of faults, the control system causes information relating to the fault to be displayed to the user including data indicative of the fault, and an indication that the user should call a service engineer.",MICROMASS LTD,WAMSLEY RUTH;;WILSON MICHAEL;;CARNEY PETER;;THRELFALL RICHARD;;HENDERSON MATTHEW;;MCIVER PAUL,,https://lens.org/154-190-121-992-689,Patent Application,yes,7,3,10,10,0,H01J49/0027;;H01J49/0009;;H01J49/0027;;H01J49/02;;H01J49/022;;H01J49/24;;H01J49/0009;;H01J49/022;;H01J49/24;;H01J49/40,H01J49/00,,0,0,,,,PENDING
234,BR,A,BR 0002435 A,195-170-408-906-791,2001-01-02,2001,BR 0002435 A,2000-05-19,US 31481999 A,1999-05-19,Método e aparelho para ativar um receptor de radiotelefone de espectro de dispersão,"<B>MéTODO E APARELHO PARA ATIVAR UM RECEPTOR DE RADIOTELEFONE DE ESPECTRO DE DISPERSãO<D> Um método de ativar um radiotelefone operável em um sistema de radiotelefone de acesso múltiplo de espectro de dispersão. Um receptor buscador (114) é ativado e o receptor buscador (114) adquire uma sincronização de seq³ência PN de um sinal piloto. Pelo menos uma derivação de desmodulação (122) é ativada após ativação do receptor buscador (114), e a derivação de desmodulação sincroniza com a sincronização de seq³ência PN do sinal piloto selecionado após o receptor buscador (114) ter adquirido a sincronização de seq³ência PN.",MOTOROLA INC,LAROSA CHRISTOPHER PETER;;STORM BRIAN DAVID;;CARNEY MICHAEL JOHN;;SCHIRTZINGER TRACIE ANN,"MOTOROLA SOLUTIONS, INC. (US) (2012-12-18);;MOTOROLA MOBILITY, INC. (US) (2013-01-01)",https://lens.org/195-170-408-906-791,Patent Application,no,0,0,14,30,0,H04B1/70752;;H04B1/70752;;H04B7/26;;H04B1/70751;;H04B1/70751;;H04B1/70753;;H04B1/70753;;H04B1/70756;;H04B1/70756;;H04B2201/70701;;H04B2201/70701;;H04B2201/70702;;H04B2201/70702;;H04B2201/70707;;H04B2201/70707;;H04B2201/70709;;H04B2201/70709,H04B1/16;;H04B1/7075;;H04B7/26;;H04M1/00;;H04M1/73,,0,0,,,,EXPIRED
235,CN,A,CN 112204699 A,024-301-774-118-628,2021-01-08,2021,CN 201980036584 A,2019-05-31,GB 201808949 A;;GB 2019051499 W,2018-05-31,BENCH-TOP TIME OF FLIGHT MASS SPECTROMETER,A mass spectrometer comprising: a vacuum chamber; and an ion inlet assembly for transmitting analyte ions into the vacuum chamber; wherein the spectrometer is configured to operate in a cooling mode in which it selectively controls one or more gas flow to the ion inlet assembly for actively cooling the ion inlet assembly.,MICROMASS LTD,WAMSLEY RUTH;;WILSON MICHAEL;;TRIVETT IAN;;CARNEY PETER;;MURRAY HAYDN;;MCIVER PAUL,,https://lens.org/024-301-774-118-628,Patent Application,no,16,0,9,9,0,H01J49/067;;H01J49/06;;H01J49/0027;;H01J49/0031;;H01J49/02;;H01J49/067;;H01J49/24;;H01J49/40;;H01J49/0031;;H01J49/0422;;H01J49/045;;H01J49/0486;;H01J49/0495;;H01J49/067;;H01J49/24;;H01J49/405,H01J49/06,,0,0,,,,PENDING
236,GB,A,GB 2574327 A,026-521-431-155-627,2019-12-04,2019,GB 201907722 A,2019-05-31,GB 201808949 A,2018-05-31,Bench-top time of flight mass spectrometer,"A mass spectrometer comprising an ion inlet assembly, comprising ion block 802 and gas cones 517 and 513, for transmitting analyte ions into a vacuum chamber wherein the spectrometer is configured to operate in a cooling mode in which it selectively controls one or more gas flow to the ion inlet assembly 802, 513, 517 for actively cooling the ion inlet assembly. The gas flow can be an API gas flow, desolvation gas flow, nebuliser gas flow or cone gas flow. Other inventions relate to a solvent waste conduit (Fig. 17, 1720) for transmitting solvent waste away from the ion source and out of the spectrometer and a source pressure sensor for issuing a user alert when a pressure test (Fig. 7D) is carried out and the pressure is at or above a predetermined level.",MICROMASS LTD,RUTH WAMSLEY;;MICHAEL WILSON;;IAN TRIVETT;;PETER CARNEY;;HAYDN MURRAY;;PAUL MCIVER,,https://lens.org/026-521-431-155-627,Patent Application,no,5,2,9,9,0,H01J49/067;;H01J49/06;;H01J49/0027;;H01J49/0031;;H01J49/02;;H01J49/067;;H01J49/24;;H01J49/40;;H01J49/0031;;H01J49/0422;;H01J49/045;;H01J49/0486;;H01J49/0495;;H01J49/067;;H01J49/24;;H01J49/405,H01J49/06;;H01J49/02;;H01J49/24;;H01J49/40,,0,0,,,,ACTIVE
237,US,B2,US 11621154 B2,057-789-493-445-023,2023-04-04,2023,US 201917057004 A,2019-05-31,GB 201808949 A;;GB 2019051499 W,2018-05-31,Bench-top time of flight mass spectrometer,A mass spectrometer comprising: a vacuum chamber; and an ion inlet assembly for transmitting analyte ions into the vacuum chamber; wherein the spectrometer is configured to operate in a cooling mode in which it selectively controls one or more gas flow to the ion inlet assembly for actively cooling the ion inlet assembly.,MICROMASS LTD,WAMSLEY RUTH;;WILSON MICHAEL;;TRIVETT IAN;;CARNEY PETER;;MURRAY HAYDN;;MCIVER PAUL,MICROMASS UK LIMITED (2021-03-02),https://lens.org/057-789-493-445-023,Granted Patent,yes,302,1,9,9,0,H01J49/067;;H01J49/06;;H01J49/0027;;H01J49/0031;;H01J49/02;;H01J49/067;;H01J49/24;;H01J49/40;;H01J49/0031;;H01J49/0422;;H01J49/045;;H01J49/0486;;H01J49/0495;;H01J49/067;;H01J49/24;;H01J49/405,H01J49/04;;H01J49/00;;H01J49/06;;H01J49/24;;H01J49/40,,78,5,002-875-246-112-868;;004-471-982-018-484;;022-561-862-885-681;;119-779-971-342-191;;062-933-196-688-541,11523084;;10.1002/jms.207;;10.1002/rcm.1074;;12820206;;10.1021/ac0518811;;16579588;;10.1016/j.ijms.2013.02.010;;10.1063/1.4922913;;pmc4482810;;26133872,"Combined Search and Examination Report under Sections 17 and 18(3), for Application No. GB1907724.7, dated Sep. 25, 2019, 7 pages.;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fee for International application No. PCT/GB2019/051494, dated Sep. 19, 2019.;;Combined Search and Examination Report under Sections 17 and 18(3), dated Sep. 27, 2019, for Application No. GB1907736.1, 6 pages.;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fees, for International application No. PCT/GB2019/051499, dated Sep. 4, 2019.;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fee, for International Application No. PCT/GB2019/051496, dated Aug. 29, 2019.;;Anonymous, “Time-of-flight mass spectrometry”, Wikipedia, Apr. 28, 2018 (Apr. 28, 2018), XP055614063, Retrieved from the Internet:URL:https://en.wikipedia.org/w/index.php title=Time-of-flight_mass_spectrometry oldid=838663844 [retrieved on Aug. 20, 2019].;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fees for International application No. PCT/GB2019/051497, dated Sep. 2, 2019.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1907745.2, dated Aug. 13, 2019, 7 pages.;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fee, for International application No. PCT/GB2019/051501, dated Jul. 29, 2019, 14 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051497, dated Nov. 5, 2019, 19 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051503, dated Sep. 25, 2019, 17 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051496, dated Oct. 23, 2019, 29 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051506, dated Sep. 25, 2019, 14 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051494, dated Nov. 18, 2019, 20 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051507, dated Oct. 15, 2019, 17 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051508, dated Oct. 23, 2019, 16 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051499, dated Nov. 5, 2019, 19 pages.;;Examination Report under Section 18(3) for Application No. GB1907719.7, dated Jul. 28, 2021, 9 pages.;;Parkes, S. SpaceWire User Guide, STAR-Dundee [online] 2012 [retrieved on Aug. 13, 2021]. Retrieved from Internet URL: https://www.star-dundee.com/wp-content/star_uploads/general/SpaceWire-Users-Guide.pdf, 117 pages.;;SCIEX, “3200 Series of Instruments System User Guide” [online], published Apr. 2018, available from: https://sciex.com/content/dam/SCIEX/pdf/customer-docs/user-guide/3200-system-user-guide-en.pdf, 241 pages.;;Combined Search and Examination Report under Sections 17 and 18(3), for Application No. GB2100898.2, dated Jun. 21, 2021, 7 pages.;;Combined Search and Examination Report under Sections 17 and 18(3), for Application No. GB2001530.1, dated Aug. 5, 2020, 7 pages.;;Thermo Fisher Scientific, Inc, Feb. 2015, Orbitrap Fusion Hardware Manual [online]. Retrieved from Internet URL: http://www.unitylabservices.eu/content/dam/tfs/ATG/CMD/cmddocuments/oper/oper/ms/lc-ms/sys/Man-80000-97016-Orbitrap-Fusion-Hardware-Man8000097016-A-EN.pdf, 122 pages.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 BioPharma Analytical Summit BioAccord Abstract. ASMS MS-in-QC, PowerPoint 24 pages.;;International Preliminary Report on Patentability for International application No. PCT/GB2019/051510, dated Dec. 1, 2020, 7 pages.;;Examination Report under Section 18(3) for Application No. GB1907739.5, dated Nov. 3, 2020, 5 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808932.6, dated Nov. 21, 2018, 4 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808890.6, dated Nov. 28, 2018, 7 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808912.8, dated Nov. 30, 2018, 10 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808942.5, dated Dec. 3, 2018, 7 pages.;;Chernushevich, I. V., et al., “An introduction to quadrupole-time-of-flight mass spectrometry”, Journal of Mass Spectrometry, 36(8):849-65 (2001) Abstract only.;;Chernushevich, I.V., et al., “Charge state separation for protein applications using a quadrupole time-of-flight mass spectrometer”, Rapid Communications in Mass Spectrometry 17(13):1416-1424 (2003). Abstract only.;;Makarov, A. et al., “Performance evaluation of a hybrid linear ion trap/orbitrap mass spectrometer,” Analytical Chemistry, 78(7):2113-20 (2006).;;Combined Search and Examination Report under Sections 117 and 18(3) for Application No. GB1808948.2 dated Nov. 21, 2018, 7 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808893.0 dated Nov. 27, 2018, 8 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808936.7 dated Nov. 20, 2018, 10 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808892.2, dated Dec. 3, 2018, 6 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Applicaton No. GB1808894.8 dated Dec. 3, 2018, 7 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808949.0 dated Oct. 31, 2018, 8 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1907722.1 dated Jun. 28, 2019, 8 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808889.8 dated Nov. 30, 2018, 7 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051504, dated Jul. 23, 2019, 11 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1818003.4, dated May 2, 2019, 6 pages.;;Invitation to pay additional fees and, where applicable, protest fee for PCT/GB2019/051508, dated Aug. 28, 2019.;;Author unknown, “Operating Manual and Programming Reference, Models RGA100, RGA200, and RGA300 Residual Gas Analyzer,” Stanford Research Systems Revision 1.8 (May 2009).;;Jungmann, J. H., et al., “An in-vacuum, pixelated detection system for mass spectrometric analysis and imaging of macromolecules,” International Journal of Mass Spectrometry, 341-342:34-44 (2013).;;Invitation to pay additional fees and, where applicable, protest fee for International application No. PCT/GB2019/051507, dated Aug. 20, 2019, 16 pages.;;Yang, C., and Hanley, L., “ChiMS: Open-source instrument control software platform on LabVIEW for imaging/depth profiling mass spectrometers,” Review of Scientific Instruments, 86:065106-1 through 065016-7 (2015).;;Invitation to pay additional fees and, where applicable, protest fee for International application No. PCT/GB2019/051506, dated Jul. 22, 2019, 13 pages.;;Invitation to pay addition al fees and, where applicable, protest fee for PCT/GB2019/051503, dated Jul. 25, 2019, 17 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051500, dated Aug. 5, 2019, 9 pages.;;Kozlov, B., et al., “Time-of-flight mass spectrometer for investigations of laser ablation,” ASMS Conference paper, Dallas, TX (May 1999). [Retrieved from the Internet URL: https//www.researchgate.net/publication/330202298_Time-of-flight_mass_spectrometer_for_investigations_of_laser_ablation]. Abstract.;;Shion, H., et al., “Towards Overcoming the Challenges of Implementing Accurate Mass MS for Routine Biotherapeutic Analysis” 2018 ASMS Prototype oa-TOF Abstract HYS Final.;;Shion, S., et al., “Towards Overcoming the Challenges of Implementing Accurate Mass MS for Routine Biotherapeutic Analysis” 2018 ASMS Prototype oa-TOF WP699 HYS Final Poster.;;Shion, H., et al., “A Fit-for-purpose Accurate Mass MS for Routine Biotherapeutic Analysis”, 2018 CASSS Mass Spec HYS Final Poster.;;Shion, H., et al., “A Fit-for-purpose Accurate Mass MS for Routine Biotherapeutic Analysis”, 2018 CASSS Mass Spec BioTof HYS Final, Abstract.;;Shion, H., et al., “Progress Towards Implementing Simple Time-of-flight Accurate Mass MS for Routine Biotherapeutic Analysis”, XXII (IMSC) International Mass Spectrometry Conference Florence, Italy (2018) Abstract.;;Shion, H., et al., “Progress Towards Implementing Simple Time-of-flight Accurate Mass MS for Routine Biotherapeutic Analysis”, XXII International Mass Spectrometry Conference Florence, Italy (2018) poster.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 ASMS BioAccord Oral Session PowerPoint.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 ASMS BioAccord Abstract.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments” 2019 ATEurope BioAccord, Abstract.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments” 2019 ATEurope BioAccord, Poster.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 BioPharma Analytical Summit BioAccord, abstract.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 Bio Pharma Summit BioAccord, Poster.;;Shion, H., “Enabling Routine and Reproducible Biotherapeutic Analysis when Data Integrity Matters”, 2019 15th Annual PEGs Boston Waters BioAccord, PowerPoint 29 pages.;;Shion, H., “Enabling Routine and Reproducible Biotherapeutic Analysis when Data Integrity Matters”, 2019 15th Annual PEGs Boston Waters BioAccord, Abstract.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 Pitt Con Bio Accord, Poster.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 Pitt Con Bio Accord, Abstract.;;Combined Search and Exam Report from IPO for GB Application No. 1907739.5, dated Nov. 27, 2019, 8 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051510, dated Aug. 29, 2019, 13 pages.;;Combined Search and Exam Report from IPO for GB Application No. 1907735.3, dated Nov. 25, 2019, 7 pages.;;Combined S and E Report under Sections 17 and 18(3) for Application No. GB1907734.6, dated Oct. 31, 2019, 7 pages.;;International Search Report and Written Opinion for International Application No. PCT/GB2019/051498, dated Nov. 6, 2019, 21 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1907719.7, dated Nov. 15, 2019, 11 pages.;;Author unknown, “Waters Xevo G2-S QTof Operators Overview and Maintenance Guide”, Feb. 11, 2013 (Feb. 11, 2013), XP55606374, Retrieved from the Internet: URL:https://www.waters.eom/webassets/cms/support/docs/xevo_g2-s_qtof_715003596rb.pdf [retrieved on Jul. 17, 2019].;;International Search Report and Written Opinion for International application No. PCT/GB2019/051501, dated Sep. 25, 2019, 17 pages.;;Examination Report under Section 18(3) for Application No. GB1907722.1, dated Oct. 26, 2021, 4 pages.;;Examination Report under Section 18(3) for Application No. GB2020743.7, dated Jan. 28, 2022, 6 pages.",ACTIVE
238,US,A1,US 2021/0210322 A1,110-536-791-348-496,2021-07-08,2021,US 201917057004 A,2019-05-31,GB 201808949 A;;GB 2019051499 W,2018-05-31,BENCH-TOP TIME OF FLIGHT MASS SPECTROMETER,A mass spectrometer comprising: a vacuum chamber; and an ion inlet assembly for transmitting analyte ions into the vacuum chamber; wherein the spectrometer is configured to operate in a cooling mode in which it selectively controls one or more gas flow to the ion inlet assembly for actively cooling the ion inlet assembly.,MICROMASS LTD,WAMSLEY RUTH;;WILSON MICHAEL;;TRIVETT IAN;;CARNEY PETER;;MURRAY HAYDN;;MCIVER PAUL,MICROMASS UK LIMITED (2021-03-02),https://lens.org/110-536-791-348-496,Patent Application,yes,16,3,9,9,0,H01J49/067;;H01J49/06;;H01J49/0027;;H01J49/0031;;H01J49/02;;H01J49/067;;H01J49/24;;H01J49/40;;H01J49/0031;;H01J49/0422;;H01J49/045;;H01J49/0486;;H01J49/0495;;H01J49/067;;H01J49/24;;H01J49/405,H01J49/04;;H01J49/00;;H01J49/06;;H01J49/24;;H01J49/40,,0,0,,,,ACTIVE
239,WO,A1,WO 2019/229458 A1,002-549-847-164-82X,2019-12-05,2019,GB 2019051499 W,2019-05-31,GB 201808949 A,2018-05-31,BENCH-TOP TIME OF FLIGHT MASS SPECTROMETER,A mass spectrometer comprising: a vacuum chamber; and an ion inlet assembly for transmitting analyte ions into the vacuum chamber; wherein the spectrometer is configured to operate in a cooling mode in which it selectively controls one or more gas flow to the ion inlet assembly for actively cooling the ion inlet assembly.,MICROMASS LTD,WAMSLEY RUTH;;WILSON MICHAEL;;TRIVETT IAN;;CARNEY PETER;;MURRAY HAYDN;;MCIVER PAUL,,https://lens.org/002-549-847-164-82X,Patent Application,yes,7,0,9,9,0,H01J49/067;;H01J49/06;;H01J49/0027;;H01J49/0031;;H01J49/02;;H01J49/067;;H01J49/24;;H01J49/40;;H01J49/0031;;H01J49/0422;;H01J49/045;;H01J49/0486;;H01J49/0495;;H01J49/067;;H01J49/24;;H01J49/405,H01J49/06,,0,0,,,,PENDING
240,DE,A1,DE 10024220 A1,013-430-297-593-160,2001-01-25,2001,DE 10024220 A,2000-05-17,US 31481999 A,1999-05-19,"Pilot signal acquirement in code division multiple access radio telephone system, by comparing correlation energy with threshold energy until PN sequence timing which produces suitable correlation energy is found","A pseudo random noise (PN) offset for a PN sequence is selected from samples of received signal. A portion of samples is correlated with portion of PN sequence to produce correlation energy. Then, a new PN offset is chosen. Correlation energy is compared with threshold energy until PN sequence timing which produces correlation energy equivalent to threshold energy, is found. Independent claims are also included for the following: (a) method of activating radio telephone; (b) apparatus for acquiring pseudo random (PN) sequence timing; (c) CDMA cellular telephone system; (d) method of activating code division multiple access (CDMA) cellular telephone; (e) receiver circuit",MOTOROLA INC,LAROSA CHRISTOPHER PETER;;STORM BRIAN DAVID;;CARNEY MICHAEL JOHN;;SCHIRTZINGER TRACIE ANN,"GOOGLE TECHNOLOGY HOLDINGS LLC, MOUNTAIN VIEW, US (2018-04-26)",https://lens.org/013-430-297-593-160,Patent Application,no,0,0,14,30,0,H04B1/70752;;H04B1/70752;;H04B7/26;;H04B1/70751;;H04B1/70751;;H04B1/70753;;H04B1/70753;;H04B1/70756;;H04B1/70756;;H04B2201/70701;;H04B2201/70701;;H04B2201/70702;;H04B2201/70702;;H04B2201/70707;;H04B2201/70707;;H04B2201/70709;;H04B2201/70709,H04B1/16;;H04B1/7075;;H04B7/26;;H04M1/00;;H04M1/73,,0,0,,,,EXPIRED
241,US,A1,US 2021/0233755 A1,099-731-652-128-60X,2021-07-29,2021,US 201917059872 A,2019-05-31,GB 201808936 A;;GB 2019051494 W,2018-05-31,BENCH-TOP TIME OF FLIGHT MASS SPECTROMETER,"A mass spectrometer includes a control system arranged to assess an operational state of the mass spectrometer. When a fault is detected, the control system assigns the fault to one of a plurality of categories, including a first category of faults which may be attempted to be rectified automatically by the mass spectrometer, a second category of faults which may be attempted to be rectified by the user, and a third category of faults which may only be attempted to be rectified by a service engineer. When a fault is assigned to the first category of faults, the control system initiates an attempt to automatically rectify the fault. When a fault is assigned to the second category of faults, the control system causes information relating to the fault to be displayed to the user, including data indicative of the fault and data one or more steps to be taken by the user to attempt to rectify the fault ( 2000 ). When a fault is assigned to the third category of faults, the control system causes information relating to the fault to be displayed to the user including data indicative of the fault, and an indication that the user should call a service engineer.",MICROMASS LTD,WAMSLEY RUTH;;WILSON MICHAEL;;CARNEY PETER;;THRELFALL RICHARD;;HENDERSON MATTHEW;;MCIVER PAUL,MICROMASS UK LIMITED (2021-10-25);;WATERS TECHNOLOGIES CORPORATION (2021-10-25),https://lens.org/099-731-652-128-60X,Patent Application,yes,0,2,10,10,0,H01J49/0027;;H01J49/0009;;H01J49/0027;;H01J49/02;;H01J49/022;;H01J49/24;;H01J49/0009;;H01J49/022;;H01J49/24;;H01J49/40,H01J49/00;;H01J49/02;;H01J49/24;;H01J49/40,,0,0,,,,ACTIVE
242,EP,A1,EP 3803937 A1,079-421-370-675-868,2021-04-14,2021,EP 19730458 A,2019-05-31,GB 201808936 A;;GB 2019051494 W,2018-05-31,BENCH-TOP TIME OF FLIGHT MASS SPECTROMETER,,MICROMASS LTD,WAMSLEY RUTH;;WILSON MICHAEL;;CARNEY PETER;;THRELFALL RICHARD;;HENDERSON MATTHEW;;MCIVER PAUL,,https://lens.org/079-421-370-675-868,Patent Application,yes,0,0,10,10,0,H01J49/0027;;H01J49/0009;;H01J49/0027;;H01J49/02;;H01J49/022;;H01J49/24;;H01J49/0009;;H01J49/022;;H01J49/24;;H01J49/40,H01J49/00,,0,0,,,,PENDING
243,US,B1,US 7031271 B1,197-909-155-460-706,2006-04-18,2006,US 31481999 A,1999-05-19,US 31481999 A,1999-05-19,Method of and apparatus for activating a spread-spectrum radiotelephone,"A method of activating a radiotelephone operable in a spread-spectrum multiple access radiotelephone system. A searcher receiver ( 114 ) is activated, and the searcher receiver ( 114 ) acquires a PN sequence timing of a pilot signal. At least one demodulation branch ( 122 ) is activated after activation of the searcher receiver ( 114 ), and the demodulation branch synchronizes to the PN sequence timing of the selected pilot signal after the searcher receiver ( 114 ) has acquired the PN sequence timing.",MOTOROLA INC,LAROSA CHRISTOPHER PETER;;STORM BRIAN DAVID;;CARNEY MICHAEL JOHN;;SCHIRTZINGER TRACIE ANN,MOTOROLA MOBILITY LLC (2012-06-22);;GOOGLE TECHNOLOGY HOLDINGS LLC (2014-10-28);;MOTOROLA INC (1999-08-11),https://lens.org/197-909-155-460-706,Granted Patent,yes,37,25,14,30,0,H04B1/70752;;H04B1/70752;;H04B7/26;;H04B1/70751;;H04B1/70751;;H04B1/70753;;H04B1/70753;;H04B1/70756;;H04B1/70756;;H04B2201/70701;;H04B2201/70701;;H04B2201/70702;;H04B2201/70702;;H04B2201/70707;;H04B2201/70707;;H04B2201/70709;;H04B2201/70709,G08C17/00;;H04B1/16;;H04B1/7075;;H04B7/26;;H04M1/00;;H04M1/73,370/311;;370/342;;370/441;;375/136,0,0,,,,EXPIRED
244,JP,A,JP 2001007732 A,021-041-479-225-140,2001-01-12,2001,JP 2000146323 A,2000-05-18,US 31481999 A,1999-05-19,METHOD FOR STARTING SPREAD SPECTRUM RADIO TELEPHONE RECEIVER AND APPARATUS THEREOF,"PROBLEM TO BE SOLVED: To provide a method for starting a radio telephone operable in a spread spectrum multiple access radio telephone system. SOLUTION: A server receiver 114 is started, and the PN sequence timing of a pilot signal is captured by the server receiver 114. At least one demodulation branch 122 is started after the server receiver 114 is started, and the demodulation branch 122 is synchronized with the PN sequence timing of a selected pilot signal, after the PN sequence timing is captured by the searcher receiver 114.",MOTOROLA INC,LAROSA CHRISTOPHER PETER;;STORM BRIAN DAVID;;MICHAEL JOHN CARNEY;;SCHIRTZINGER TRACIE ANN,,https://lens.org/021-041-479-225-140,Patent Application,no,11,1,14,30,0,H04B1/70751;;H04B1/70752;;H04B1/70753;;H04B1/70756;;H04B2201/70701;;H04B2201/70702;;H04B2201/70707;;H04B2201/70709;;H04B7/26;;H04B1/70752;;H04B2201/70707;;H04B2201/70709;;H04B1/70756;;H04B1/70753;;H04B2201/70702;;H04B2201/70701;;H04B1/70751,H04B1/16;;H04B1/7075;;H04B7/26;;H04M1/00;;H04M1/73,,0,0,,,,PENDING
245,BR,B1,BR PI0002435 B1,039-844-482-283-790,2015-05-19,2015,BR 0002435 A,2000-05-19,US 31481999 A,1999-05-19,Método e aparelho para ativar um receptor de radiotelefone de espectro de dispersão,,MOTOROLA MOBILITY INC,LAROSA CHRISTOPHER PETER;;STORM BRIAN DAVID;;CARNEY MICHAEL JOHN;;SCHIRTZINGER TRACIE ANN,"MOTOROLA SOLUTIONS, INC. (US) (2012-12-18);;MOTOROLA MOBILITY, INC. (US) (2013-01-01)",https://lens.org/039-844-482-283-790,Granted Patent,no,0,0,14,30,0,H04B1/70752;;H04B1/70752;;H04B7/26;;H04B1/70751;;H04B1/70751;;H04B1/70753;;H04B1/70753;;H04B1/70756;;H04B1/70756;;H04B2201/70701;;H04B2201/70701;;H04B2201/70702;;H04B2201/70702;;H04B2201/70707;;H04B2201/70707;;H04B2201/70709;;H04B2201/70709,H04B7/216;;H04B1/16;;H04B1/7075;;H04B7/26;;H04M1/00;;H04M1/73,,0,0,,,,EXPIRED
246,GB,B,GB 2574327 B,075-632-020-647-845,2022-11-09,2022,GB 201907722 A,2019-05-31,GB 201808949 A,2018-05-31,Bench-top time of flight mass spectrometer,,MICROMASS LTD,RUTH WAMSLEY;;MICHAEL WILSON;;IAN TRIVETT;;PETER CARNEY;;HAYDN MURRAY;;PAUL MCIVER,,https://lens.org/075-632-020-647-845,Granted Patent,no,6,0,9,9,0,H01J49/067;;H01J49/06;;H01J49/0027;;H01J49/0031;;H01J49/02;;H01J49/067;;H01J49/24;;H01J49/40;;H01J49/0031;;H01J49/0422;;H01J49/045;;H01J49/0486;;H01J49/0495;;H01J49/067;;H01J49/24;;H01J49/405,H01J49/06;;H01J49/02;;H01J49/24;;H01J49/40,,0,0,,,,ACTIVE
247,DE,T2,DE 60024814 T2,072-391-588-982-669,2006-08-24,2006,DE 60024814 T,2000-05-10,US 31481999 A;;US 55812100 A;;US 0012674 W,1999-05-19,VERFAHREN UND GERÄT ZUM ERFASSEN EINES SPREIZSPEKTRUMSIGNALS,,MOTOROLA INC,LAROSA PETER;;STORM DAVID;;CARNEY JOHN;;BECKER CHRISTOPHER;;SCHIRTZINGER ANN;;STECKL DAVE,"MOTOROLA MOBILITY, INC. ( N.D. GES. D. STAATES, US (2011-05-26)",https://lens.org/072-391-588-982-669,Granted Patent,no,0,0,16,30,0,H04B1/70752;;H04B1/70752;;H04B1/7077;;H04B1/70751;;H04B1/70751;;H04B1/70753;;H04B1/70753;;H04B1/70756;;H04B1/70756;;H04B1/709;;H04B1/709;;H04B2201/70701;;H04B2201/70701;;H04B2201/70702;;H04B2201/70702;;H04B2201/70707;;H04B2201/70707;;H04B2201/70709;;H04B2201/70709,H04B7/216;;H04B1/7075;;H04B1/709,,0,0,,,,EXPIRED
248,EP,A1,EP 3803943 A1,051-118-649-527-24X,2021-04-14,2021,EP 19730469 A,2019-05-31,GB 201808894 A;;GB 2019051508 W,2018-05-31,MASS SPECTROMETER,,MICROMASS LTD,CARNEY PETER;;HARRISON JAMES;;HOUGH PAUL;;WORTHINGTON KENNETH R;;MCIVER PAUL;;SCHOFIELD ALISTAR,,https://lens.org/051-118-649-527-24X,Patent Application,yes,0,0,10,10,0,H01J49/02;;H01J49/022;;H01J49/068;;H01J49/0031;;H01J49/022;;H01J49/025;;H01J49/063;;H01J49/065;;H01J49/067;;H01J49/401;;H01J49/405;;H01J49/4295,H01J49/02;;H05K5/06,,0,0,,,,PENDING
249,EP,A2,EP 1573316 A2,141-365-413-338-304,2005-09-14,2005,EP 03709354 A,2003-02-27,US 0305831 W;;US 36067802 P;;US 42948702 P,2002-03-01,"ASSAYS FOR CANCER PATIENT MONITORING BASED ON LEVELS OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXTRACELLULAR DOMAIN (ECD) ANALYTE, ALONE OR IN COMBINATION WITH OTHER ANALYTES, IN BODY FLUID SAMPLES",,BAYER AG,CARNEY WALTER P;;HAMER PETER J;;LIPTON ALLAN;;LEITZEL KIM;;ALI SUHAIL M,SIEMENS HEALTHCARE DIAGNOSTICS INC. (2008-04-23),https://lens.org/141-365-413-338-304,Patent Application,yes,0,1,12,12,0,G01N33/57407;;G01N33/57415;;G01N33/57419;;G01N33/57423;;G01N33/57434;;G01N33/57449;;G01N33/57488;;G01N2333/485;;G01N2333/71;;G01N2800/52;;G01N33/57488;;G01N33/57434;;G01N2333/485;;G01N2800/52;;G01N33/57415;;G01N33/57423;;G01N33/57407;;G01N33/57419;;G01N33/57449;;G01N2333/71,G01N33/48;;A61B/;;G01N33/53;;G01N33/566;;G01N33/574,,0,0,,,,EXPIRED
250,WO,A2,WO 2003/073909 A2,190-860-237-816-770,2003-09-12,2003,US 0305831 W,2003-02-27,US 36067802 P;;US 42948702 P,2002-03-01,"ASSAYS FOR CANCER PATIENT MONITORING BASED ON LEVELS OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXTRACELLULAR DOMAIN (ECD) ANALYTE, ALONE OR IN COMBINATION WITH OTHER ANALYTES, IN BODY FLUID SAMPLES","The present invention describes clinically and medically important methods of monitoring outcome of a cancer patient who is suffering from disease or who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease or cancer treatment effectiveness in a cancer patient by measuring the level of the extracellular domain (ECD) of the epidermal growth factor receptor (EGFR) in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment, wherein a decrease in the level of the ECD of the EGFR in the cancer patient compared with the level of the ECD of the EGFR in normal control individuals serves as an indicator of cancer advancement or progression and/or a lack of treatment effectiveness for the patient. As another aspect of determining disease outcome and survival, the invention further provides assessing both EGFR and HER-2/neu levels, in combination, in a patient sample. A finding of decreased levels of EGFR concomitantly with elevated or increased levels of HER-2/neu relative to control levels indicates poor outcome and short time to progression.",BAYER AG,CARNEY WALTER P;;HAMER PETER J;;LIPTON ALLAN;;LEITZEL KIM;;ALI SUHAIL M,,https://lens.org/190-860-237-816-770,Patent Application,yes,1,0,12,12,0,G01N33/57407;;G01N33/57415;;G01N33/57419;;G01N33/57423;;G01N33/57434;;G01N33/57449;;G01N33/57488;;G01N2333/485;;G01N2333/71;;G01N2800/52;;G01N33/57488;;G01N33/57434;;G01N2333/485;;G01N2800/52;;G01N33/57415;;G01N33/57423;;G01N33/57407;;G01N33/57419;;G01N33/57449;;G01N2333/71,A61B/;;G01N33/48;;G01N33/53;;G01N33/566;;G01N33/574,,14,11,138-858-789-006-903;;165-919-681-781-612;;006-289-477-457-496;;049-860-577-336-835;;068-190-159-107-983;;029-722-926-651-446;;040-344-520-215-612;;045-751-499-875-041;;024-556-123-582-886;;024-118-704-687-15X;;039-787-167-745-336,2998607;;10.1016/s0021-9258(19)85573-4;;6246084;;6296087;;10.1016/s0021-9258(18)33127-2;;10.1002/(sici)1097-0142(19970515)79:10<1879::aid-cncr6>3.3.co;2-r;;9149012;;10.1002/(sici)1097-0142(19970515)79:10<1879::aid-cncr6>3.0.co;2-b;;10.1097/00043764-199412000-00013;;7884573;;10367244;;10.1177/172460089901400103;;11426640;;10.1038/sj.onc.1204082;;10.1038/307521a0;;6320011;;10.1128/mcb.6.1.257;;3023826;;pmc367506;;10.1128/mcb.6.1.257-264.1986;;pmc557382;;10.1002/j.1460-2075.1984.tb01842.x;;6325174;;10.1146/annurev.bi.48.070179.001205;;382984,"W.J. GULLICK ET AL., CANCER RES., vol. 46, 1986, pages 285 - 292;;S. COHEN ET AL., J. BIOL. CHEM., vol. 255, 1980, pages 4834 - 4842;;A.B. SCHREIBER ET AL., J. BIOL. CHEM., vol. 258, 1983, pages 846 - 853;;CHOI ET AL., CANCER, vol. 79, 1997, pages 1879 - 1883;;PATANEN ET AL., J. OCCUPATIONAL MEDICINE, vol. 36, 1994, pages 1324 - 1328;;ZHOU ET AL., FRONTIERS OF BIOTECHNOLOGY & PHARMACEUTICALS, vol. 3, 2002, pages 29 - 45;;L. HARRIS ET AL., INT. J. BIOL. MARKERS, vol. 14, 1999, pages 8 - 15;;J. MENDELSOHN; J. BASELGA, ONCOGENE, vol. 19, 2000, pages 6550 - 6565;;A.L. ULLRICH ET AL., NATURE, vol. 307, 1984, pages 418 - 425;;J. DOWNWARD ET AL., NATURE, vol. 307, 1984, pages 521 - 527;;C.R. CARLIN ET AL., MOL. CELL. BIOL., vol. 6, 1986, pages 257 - 264;;F.L.V. MAYES; M.D. WATERFIELD, THE EMBO J., vol. 3, 1984, pages 531 - 537;;G. CARPENTER; S. COHEN, ANN. REV. BIOCHEM., vol. 48, 1979, pages 193 - 216;;See also references of EP 1573316A4",PENDING
251,US,A1,US 2003/0219842 A1,016-597-083-327-813,2003-11-27,2003,US 37537103 A,2003-02-27,US 37537103 A;;US 36067802 P;;US 42948702 P,2002-03-01,"Assays for cancer patient monitoring based on levels of epidermal growth factor receptor (EGFR) extracellular domain (ECD) analyte, alone or in combination with other analytes, in body fluid samples","
   The present invention describes clinically and medically important methods of monitoring the outcome of a cancer patient who is suffering from disease or who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease or cancer treatment effectiveness in a cancer patient by measuring the level of the extracellular domain (ECD) of the epidermal growth factor receptor (EGFR) in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment, wherein a decrease in the level of the ECD of the EGFR in the cancer patient compared with the level of the ECD of the EGFR in normal control individuals serves as an indicator of cancer advancement or progression and/or a lack of treatment effectiveness for the patient. As another aspect of determining disease outcome and survival, the invention further provides assessing both EGFR and HER-2/neu levels, in combination, in a patient sample. A finding of decreased levels of EGFR concomitantly with elevated or increased levels of HER-2/neu relative to control levels indicates poor outcome and short time to progression. 
",CARNEY WALTER P.;;HAMER PETER J.;;LIPTON ALLAN;;LEITZEL KIM;;ALI SUHAIL M.,CARNEY WALTER P;;HAMER PETER J;;LIPTON ALLAN;;LEITZEL KIM;;ALI SUHAIL M,SIEMENS HEALTHCARE DIAGNOSTICS INC (2007-08-17);;BAYER CORPORATION (2003-04-30);;BAYER HEALTHCARE LLC (2002-12-26),https://lens.org/016-597-083-327-813,Patent Application,yes,11,17,12,12,0,G01N33/57407;;G01N33/57415;;G01N33/57419;;G01N33/57423;;G01N33/57434;;G01N33/57449;;G01N33/57488;;G01N2333/485;;G01N2333/71;;G01N2800/52;;G01N33/57488;;G01N33/57434;;G01N2333/485;;G01N2800/52;;G01N33/57415;;G01N33/57423;;G01N33/57407;;G01N33/57419;;G01N33/57449;;G01N2333/71,A61B/;;G01N33/48;;G01N33/53;;G01N33/566;;G01N33/574,435/7.23,0,0,,,,EXPIRED
252,US,B2,US 9678098 B2,024-903-934-407-321,2017-06-13,2017,US 201615203871 A,2016-07-07,US 201615203871 A;;US 201213607986 A,2012-09-10,Sensor and tooth arrangement for shaft speed detection,"A non-ferrous shaft includes multiple non-integral ferrous tooth components, thereby allowing a sensor to detect the shaft speed.",UNITED TECHNOLOGIES CORP,COSBY JAMES;;TOMEO PETER V;;SANTIAGO ANGEL L;;ANDERSON CARNEY R;;RODRIGUEZ HERIBERTO,RTX CORPORATION (2023-07-14),https://lens.org/024-903-934-407-321,Granted Patent,yes,30,0,8,8,0,F05D2270/80;;F01D21/003;;Y10T74/19949;;G01P3/488;;Y10T74/19949;;F05D2270/80;;F01D21/003;;G01P3/488;;F05D2220/30;;F05D2240/60;;F05D2300/11;;G01P3/44,G01B7/30;;F01D21/00;;F16H55/08;;G01P3/44;;G01P3/48;;G01P3/488,,4,0,,,"International Search Report and Written Opinion for International Application No. PCT/US2013/058656 completed on Dec. 23, 2013.;;International Preliminary Report on Patentability for International Application No. PCT/US2013/058656 mailed Mar. 19, 2015.;;Supplementary European Search Report for Application No. 13835799.1 dated Jul. 13, 2016.;;Supplementary European Search Report for Application No. 13835799.1 mailed Oct. 19, 2016.",ACTIVE
253,DE,A1,DE 2325854 A1,041-227-051-212-446,1973-12-13,1973,DE 2325854 A,1973-05-22,US 25682772 A,1972-05-25,VERFAHREN UND ANORDNUNG ZUM MULTIPLEXEN VON SIGNALEN IN EINER ENDSTELLE EINES ZEITMULTIPLEXSYSTEMS,,WESTERN ELECTRIC CO,CARNEY ADAM CAROLL;;CICHETTI JUN MICHAEL PETER;;KNEUER JOSEPH GEORGE;;RICE DONALD WESLEY,,https://lens.org/041-227-051-212-446,Patent Application,no,2,0,18,19,0,H04J3/1647;;H04L1/08;;H04L12/525;;H04L12/525;;H04L1/08;;H04J3/1647,H04J3/04;;H04J3/16;;H04L1/08;;H04L12/52,,0,0,,,,EXPIRED
254,US,B2,US 9417258 B2,061-164-302-448-200,2016-08-16,2016,US 201213607986 A,2012-09-10,US 201213607986 A,2012-09-10,Sensor and tooth arrangement for shaft speed detection,"A non-ferrous shaft includes multiple non-integral ferrous tooth components, thereby allowing a sensor to detect the shaft speed.",COSBY JAMES;;TOMEO PETER V;;SANTIAGO ANGEL L;;RODRIGUEZ HERIBERTO;;ANDERSON CARNEY R;;UNITED TECHNOLOGIES CORP,COSBY JAMES;;TOMEO PETER V;;SANTIAGO ANGEL L;;RODRIGUEZ HERIBERTO;;ANDERSON CARNEY R,RTX CORPORATION (2012-08-29),https://lens.org/061-164-302-448-200,Granted Patent,yes,27,0,8,8,0,F05D2270/80;;F01D21/003;;Y10T74/19949;;G01P3/488;;Y10T74/19949;;F05D2270/80;;F01D21/003;;G01P3/488;;F05D2220/30;;F05D2240/60;;F05D2300/11;;G01P3/44,G01B7/30;;F01D21/00;;G01P3/488,,2,0,,,"International Search Report and Written Opinion for International Application No. PCT/US2013/058656 completed on Dec. 23, 2013.;;International Preliminary Report on Patentability for International Application No. PCT/US2013/058656 mailed Mar. 19, 2015.",ACTIVE
255,US,E,US RE029215 E,155-249-832-729-043,1977-05-10,1977,US 68006576 A,1976-04-26,US 68006576 A;;US 25682772 A,1972-05-25,Cross-office connecting scheme for interconnecting multiplexers and central office terminals,"Interchange of data between two way loops and a data trunk is provided by way of channel units, submultiplexer/demultiplexers and a common multiplexer/demultiplexer. Submultiplexers have five, 10 or 20 ports, creating time frames with corresponding numbers of time slots, all of equal duration. The channel units, which terminate 9.6, 4.8 or 2.4 Kbs data subscribers, assemble the incoming data into bytes, repeat each byte five, 10 or 20 times, respectively, and align each successive one of the repeated bytes with successive time slots. Any port of a five port submultiplexer can be connected to any 9.6, 4.8 or 2.4 channel unit. Similarly, any port of a ten port submultiplexer can be connected to any 4.8 or 2.4 channel unit and any port of a twenty port submultiplexer can be connected to any 2.4 channel unit. The outputs of all submultiplexers are interleaved by the common multiplexer and applied to the trunk. Incoming data from the trunk is distributed to the several submultiplexers/demultiplexers which, in turn, distribute the data to the channel units.",,"Carney; Adam Carroll;;Cichetti, Jr.; Michael Peter;;Kneuer; Joseph George;;Rice; Donald Wesley",,https://lens.org/155-249-832-729-043,Amended Patent,yes,4,6,1,19,0,H04J3/1647;;H04L1/08;;H04L1/08;;H04J3/1647,H04J3/16;;H04L1/08,179 15BA;;179 15A;;179 15BV;;178 50,0,0,,,,DISCONTINUED
256,FI,B,FI 58416 B,180-733-808-472-912,1980-09-30,1980,FI 164273 A,1973-05-21,US 25682772 A,1972-05-25,FOERFARANDE OCH ANORDNING FOER MULTIPLEXERING AV SIGNALER I EN TERMINAL VID ETT TIDSMULTIPLEXSYSTEM,,WESTERN ELECTRIC CO,CICHETTI JR MICHAEL PETER;;KNEUER JOSEPH GEORGE;;CARNEY ADAM CARROLL;;RICE DONALD WESLEY,,https://lens.org/180-733-808-472-912,Patent Application,no,0,0,18,19,0,H04J3/1647;;H04L1/08;;H04L12/525;;H04L12/525;;H04L1/08;;H04J3/1647,H04J3/04;;H04J3/16;;H04L1/08;;H04L12/52,,0,0,,,,EXPIRED
257,AU,A8,AU 2003/212415 A8,068-061-860-064-861,2003-09-16,2003,AU 2003/212415 A,2003-02-27,US 36067802 P;;US 42948702 P;;US 0305831 W,2002-03-01,Assays to monitor levels of epidermal growth factor receptor (egfr) extracellular domain (ecd) in cancer patients,,BAYER AG,LIPTON ALLAN;;CARNEY WALTER P;;ALI SUHAIL M;;LEITZEL KIM;;HAMER PETER J,,https://lens.org/068-061-860-064-861,Patent Application,no,0,0,12,12,0,G01N33/57407;;G01N33/57415;;G01N33/57419;;G01N33/57423;;G01N33/57434;;G01N33/57449;;G01N33/57488;;G01N2333/485;;G01N2333/71;;G01N2800/52;;G01N33/57488;;G01N33/57434;;G01N2333/485;;G01N2800/52;;G01N33/57415;;G01N33/57423;;G01N33/57407;;G01N33/57419;;G01N33/57449;;G01N2333/71,A61B/;;G01N33/48;;G01N33/53;;G01N33/566;;G01N33/574,,0,0,,,,DISCONTINUED
258,CN,A,CN 112204698 A,167-245-102-182-426,2021-01-08,2021,CN 201980034180 A,2019-05-31,GB 201808894 A;;GB 2019051508 W,2018-05-31,MASS SPECTROMETER,"A mass spectrometer is disclosed comprising an ion optics device housing having one or more external electrical connectors (1719) provided thereon. An ion optics device (301) is arranged inside the ion optics device housing, the ion optics device (301) comprising one or more electrodes for manipulating ions, the one or more electrodes being electrically connected to the one or more external electrical connectors (1719) provided on the ion optics device housing. A voltage supply housing (1717) is provided having one or more external electrical connectors provided thereon. One or more voltage supplies are arranged inside the voltage supply housing (1717), the one or more voltage supplies being in electrical communication with the one or more external electrical connectors provided on the voltage supply housing. The one or more external electrical connectors provided on the voltage supply housing are directly physically and electrically connected to the one or more external electrical connectors (1719) provided on the ion optics device housing.",MICROMASS LTD,CARNEY PETER;;HARRISON JAMES;;HOUGH PAUL;;WORTHINGTON KENNETH R;;MCIVER PAUL;;SCHOFIELD ALISTAR,,https://lens.org/167-245-102-182-426,Patent Application,no,4,2,10,10,0,H01J49/02;;H01J49/022;;H01J49/068;;H01J49/0031;;H01J49/022;;H01J49/025;;H01J49/063;;H01J49/065;;H01J49/067;;H01J49/401;;H01J49/405;;H01J49/4295,H01J49/02;;H05K5/06,,1,0,,,"STANFORD RESEARCH SYSTEMS: ""Operating Manual and Programming Reference: Models RGA100, RGA200, and RGA300 Residual Gas Analyzer (Revision 1.8)"", pages 3",ACTIVE
259,AU,A1,AU 2003/212415 A1,000-329-191-772-285,2003-09-16,2003,AU 2003/212415 A,2003-02-27,US 36067802 P;;US 42948702 P;;US 0305831 W,2002-03-01,"ASSAYS FOR CANCER PATIENT MONITORING BASED ON LEVELS OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXTRACELLULAR DOMAIN (ECD) ANALYTE, ALONE OR IN COMBINATION WITH OTHER ANALYTES, IN BODY FLUID SAMPLES",,BAYER AG,HAMER PETER J;;LIPTON ALLAN;;LEITZEL KIM;;ALI SUHAIL M;;CARNEY WALTER P,,https://lens.org/000-329-191-772-285,Patent Application,no,0,0,12,12,0,G01N33/57407;;G01N33/57415;;G01N33/57419;;G01N33/57423;;G01N33/57434;;G01N33/57449;;G01N33/57488;;G01N2333/485;;G01N2333/71;;G01N2800/52;;G01N33/57488;;G01N33/57434;;G01N2333/485;;G01N2800/52;;G01N33/57415;;G01N33/57423;;G01N33/57407;;G01N33/57419;;G01N33/57449;;G01N2333/71,A61B/;;G01N33/48;;G01N33/53;;G01N33/566;;G01N33/574,,0,0,,,,DISCONTINUED
260,EP,B1,EP 2893168 B1,198-843-224-009-829,2018-08-08,2018,EP 13835799 A,2013-09-08,US 201213607986 A;;US 2013/0058656 W,2012-09-10,SENSOR AND TOOTH ARRANGEMENT FOR SHAFT SPEED DETECTION,,UNITED TECHNOLOGIES CORP,COSBY JAMES;;TOMEO PETER V;;SANTIAGO ANGEL L;;RODRIGUEZ HERIBERTO;;ANDERSON CARNEY R,"RAYTHEON TECHNOLOGIES CORPORATION (N.D.GES.D.S, US (2022-09-23);;UNITED TECHNOLOGIES CORPORATION (2016-10-26)",https://lens.org/198-843-224-009-829,Granted Patent,yes,9,1,8,8,0,F05D2270/80;;F01D21/003;;Y10T74/19949;;G01P3/488;;Y10T74/19949;;F05D2270/80;;F01D21/003;;G01P3/488;;F05D2220/30;;F05D2240/60;;F05D2300/11;;G01P3/44,G01P3/488;;F01D21/00;;F01D25/00;;F02C7/00;;F02C9/28;;F02K3/00,,0,0,,,,ACTIVE
261,FI,C,FI 58416 C,053-691-312-783-816,1981-01-12,1981,FI 164273 A,1973-05-21,US 25682772 A,1972-05-25,FOERFARANDE OCH ANORDNING FOER MULTIPLEXERING AV SIGNALER I EN TERMINAL VID ETT TIDSMULTIPLEXSYSTEM,,WESTERN ELECTRIC CO,CICHETTI JR MICHAEL PETER;;KNEUER JOSEPH GEORGE;;CARNEY ADAM CARROLL;;RICE DONALD WESLEY,,https://lens.org/053-691-312-783-816,Granted Patent,no,0,0,18,19,0,H04J3/1647;;H04L1/08;;H04L12/525;;H04L12/525;;H04L1/08;;H04J3/1647,H04J3/04;;H04J3/16;;H04L1/08;;H04L12/52,,0,0,,,,EXPIRED
262,US,A1,US 2021/0384024 A1,095-415-065-399-499,2021-12-09,2021,US 201917057201 A,2019-05-31,GB 201808894 A;;GB 2019051508 W,2018-05-31,MASS SPECTROMETER,"A mass spectrometer is disclosed comprising an ion optics device housing having one or more external electrical connectors ( 1719 ) provided thereon. An ion optics device ( 301 ) is arranged inside the ion optics device housing, the ion optics device ( 301 ) comprising one or more electrodes for manipulating ions, the one or more electrodes being electrically connected to the one or more external electrical connectors ( 1719 ) provided on the ion optics device housing. A voltage supply housing ( 1717 ) is provided having one or more external electrical connectors provided thereon. One or more voltage supplies are arranged inside the voltage supply housing ( 1717 ), the one or more voltage supplies being in electrical communication with the one or more external electrical connectors provided on the voltage supply housing. The one or more external electrical connectors provided on the voltage supply housing are directly physically and electrically connected to the one or more external electrical connectors ( 1719 ) provided on the ion optics device housing.",MICROMASS LTD,CARNEY PETER;;HARRISON JAMES;;HOUGH PAUL;;WORTHINGTON KENNETH R;;MCIVER PAUL;;SCHOFIELD ALISTAR,MICROMASS UK LIMITED (2021-09-01),https://lens.org/095-415-065-399-499,Patent Application,yes,3,2,10,10,0,H01J49/02;;H01J49/022;;H01J49/068;;H01J49/0031;;H01J49/022;;H01J49/025;;H01J49/063;;H01J49/065;;H01J49/067;;H01J49/401;;H01J49/405;;H01J49/4295,H01J49/06;;H01J49/00;;H01J49/02;;H01J49/40;;H01J49/42,,0,0,,,,ACTIVE
263,WO,A1,WO 2014/039934 A1,052-535-907-492-021,2014-03-13,2014,US 2013/0058656 W,2013-09-08,US 201213607986 A,2012-09-10,SENSOR AND TOOTH ARRANGEMENT FOR SHAFT SPEED DETECTION,"A non-ferrous shaft includes multiple non-integral ferrous tooth components, thereby allowing a sensor to detect the shaft speed.",UNITED TECHNOLOGIES CORP,COSBY JAMES;;TOMEO PETER V;;SANTIAGO ANGEL L;;RODRIGUEZ HERIBERTO;;ANDERSON CARNEY R,,https://lens.org/052-535-907-492-021,Patent Application,yes,9,0,8,8,0,F05D2270/80;;F01D21/003;;Y10T74/19949;;G01P3/488;;Y10T74/19949;;F05D2270/80;;F01D21/003;;G01P3/488;;F05D2220/30;;F05D2240/60;;F05D2300/11;;G01P3/44,F02C7/00;;F01D25/00;;F02C9/28;;F02K3/00,,1,0,,,See also references of EP 2893168A4,PENDING
264,US,A1,US 2016/0313363 A1,078-408-478-367-813,2016-10-27,2016,US 201615203871 A,2016-07-07,US 201615203871 A;;US 201213607986 A,2012-09-10,SENSOR AND TOOTH ARRANGEMENT FOR SHAFT SPEED DETECTION,"A non-ferrous shaft includes multiple non-integral ferrous tooth components, thereby allowing a sensor to detect the shaft speed.",UNITED TECHNOLOGIES CORP,COSBY JAMES;;TOMEO PETER V;;SANTIAGO ANGEL L;;ANDERSON CARNEY R;;RODRIGUEZ HERIBERTO,RTX CORPORATION (2023-07-14),https://lens.org/078-408-478-367-813,Patent Application,yes,0,0,8,8,0,F05D2270/80;;F01D21/003;;Y10T74/19949;;G01P3/488;;Y10T74/19949;;F05D2270/80;;F01D21/003;;G01P3/488;;F05D2220/30;;F05D2240/60;;F05D2300/11;;G01P3/44,G01P3/44;;F01D21/00,,0,0,,,,ACTIVE
265,EP,B1,EP 1573316 B1,180-387-716-537-476,2009-08-26,2009,EP 03709354 A,2003-02-27,US 0305831 W;;US 36067802 P;;US 42948702 P,2002-03-01,"ASSAYS FOR CANCER PATIENT MONITORING BASED ON LEVELS OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXTRACELLULAR DOMAIN (ECD) ANALYTE, ALONE OR IN COMBINATION WITH OTHER ANALYTES, IN BODY FLUID SAMPLES",,SIEMENS HEALTHCARE DIAGNOSTICS,CARNEY WALTER P;;HAMER PETER J;;LIPTON ALLAN;;LEITZEL KIM;;ALI SUHAIL M,SIEMENS HEALTHCARE DIAGNOSTICS INC. (2008-04-23),https://lens.org/180-387-716-537-476,Granted Patent,yes,1,2,12,12,0,G01N33/57407;;G01N33/57415;;G01N33/57419;;G01N33/57423;;G01N33/57434;;G01N33/57449;;G01N33/57488;;G01N2333/485;;G01N2333/71;;G01N2800/52;;G01N33/57488;;G01N33/57434;;G01N2333/485;;G01N2800/52;;G01N33/57415;;G01N33/57423;;G01N33/57407;;G01N33/57419;;G01N33/57449;;G01N2333/71,G01N33/48;;A61B/;;G01N33/53;;G01N33/566;;G01N33/574,,4,0,,,"CHOI J H ET AL: ""Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients."" CANCER. 15 MAY 1997, vol. 79, no. 10, 15 May 1997 (1997-05-15), pages 1879-1883, XP002371110 Bethesda MD USA ISSN: 0008-543X;;JACOT W. ET AL.: 'Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer' BRITISH JOURNAL OF CANCER vol. 91, 2004, pages 430 - 433, XP002986056;;PARTANEN R. ET AL.: 'The detection of increase amounts of the extracellular domain of the epidermal growth factor receptor in serum during carciogenesis in asbestosis patients' JOURNAL OF OCUPATIONAL MEDICINE vol. 36, no. 12, December 1994, pages 1324 - 1328, XP008047056;;ZHOU ET AL.: 'Clinical applications of oncogenes and oncoprotens: HER-2/neu and EGFR as new therapeutic targets' FRONTIERS OF BIOTECHNOLOGY & PHARMACEUTICALS vol. 3, 2002, pages 29 - 45, XP008047078",EXPIRED
266,EP,A4,EP 2893168 A4,011-102-606-580-449,2016-11-16,2016,EP 13835799 A,2013-09-08,US 201213607986 A;;US 2013/0058656 W,2012-09-10,SENSOR AND TOOTH ARRANGEMENT FOR SHAFT SPEED DETECTION,,UNITED TECHNOLOGIES CORP,COSBY JAMES;;TOMEO PETER V;;SANTIAGO ANGEL L;;RODRIGUEZ HERIBERTO;;ANDERSON CARNEY R,"RAYTHEON TECHNOLOGIES CORPORATION (N.D.GES.D.S, US (2022-09-23);;UNITED TECHNOLOGIES CORPORATION (2016-10-26)",https://lens.org/011-102-606-580-449,Search Report,no,4,0,8,8,0,F05D2270/80;;F01D21/003;;Y10T74/19949;;G01P3/488;;Y10T74/19949;;F05D2270/80;;F01D21/003;;G01P3/488;;F05D2220/30;;F05D2240/60;;F05D2300/11;;G01P3/44,G01P3/488;;F01D21/00;;F01D25/00;;F02C7/00;;F02C9/28;;F02K3/00,,1,0,,,See also references of WO 2014039934A1,ACTIVE
267,WO,A3,WO 2003/073909 A3,103-162-848-249-660,2005-06-02,2005,US 0305831 W,2003-02-27,US 36067802 P;;US 42948702 P,2002-03-01,ASSAYS TO MONITOR LEVELS OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXTRACELLULAR DOMAIN (ECD) IN CANCER PATIENTS,"The present invention describes clinically and medically important methods of monitoring outcome of a cancer patient who is suffering from disease or who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease or cancer treatment effectiveness in a cancer patient by measuring the level of the extracellular domain (ECD) of the epidermal growth factor receptor (EGFR) in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment, wherein a decrease in the level of the ECD of the EGFR in the cancer patient compared with the level of the ECD of the EGFR in normal control individuals serves as an indicator of cancer advancement or progression and/or a lack of treatment effectiveness for the patient. As another aspect of determining disease outcome and survival, the invention further provides assessing both EGFR and HER-2/neu levels, in combination, in a patient sample. A finding of decreased levels of EGFR concomitantly with elevated or increased levels of HER-2/neu relative to control levels indicates poor outcome and short time to progression.",BAYER AG,CARNEY WALTER P;;HAMER PETER J;;LIPTON ALLAN;;LEITZEL KIM;;ALI SUHAIL M,,https://lens.org/103-162-848-249-660,Search Report,yes,1,0,12,12,0,G01N33/57407;;G01N33/57415;;G01N33/57419;;G01N33/57423;;G01N33/57434;;G01N33/57449;;G01N33/57488;;G01N2333/485;;G01N2333/71;;G01N2800/52;;G01N33/57488;;G01N33/57434;;G01N2333/485;;G01N2800/52;;G01N33/57415;;G01N33/57423;;G01N33/57407;;G01N33/57419;;G01N33/57449;;G01N2333/71,A61B/;;G01N33/48;;G01N33/53;;G01N33/566;;G01N33/574,,3,2,103-057-593-048-837;;068-190-159-107-983,10.1038/sj.bjc.6601987;;15226769;;pmc2409859;;10.1097/00043764-199412000-00013;;7884573,"JACOT W. ET AL.: ""Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer"", BRITISH JOURNAL OF CANCER, vol. 91, 2004, pages 430 - 433, XP002986056;;PARTANEN R. ET AL.: ""The detection of increase amounts of the extracellular domain of the epidermal growth factor receptor in serum during carciogenesis in asbestosis patients"", JOURNAL OF OCUPATIONAL MEDICINE, vol. 36, no. 12, December 1994 (1994-12-01), pages 1324 - 1328, XP008047056;;ZHOU ET AL.: ""Clinical applications of oncogenes and oncoprotens: HER-2/neu and EGFR as new therapeutic targets"", FRONTIERS OF BIOTECHNOLOGY & PHARMACEUTICALS, vol. 3, 2002, pages 29 - 45, XP008047078",PENDING
268,US,A1,US 2014/0070794 A1,135-609-369-182-701,2014-03-13,2014,US 201213607986 A,2012-09-10,US 201213607986 A,2012-09-10,SENSOR AND TOOTH ARRANGEMENT FOR SHAFT SPEED DETECTION,"A non-ferrous shaft includes multiple non-integral ferrous tooth components, thereby allowing a sensor to detect the shaft speed.",COSBY JAMES;;TOMEO PETER V;;SANTIAGO ANGEL L;;RODRIGUEZ HERIBERTO;;ANDERSON CARNEY R,COSBY JAMES;;TOMEO PETER V;;SANTIAGO ANGEL L;;RODRIGUEZ HERIBERTO;;ANDERSON CARNEY R,RTX CORPORATION (2012-08-29),https://lens.org/135-609-369-182-701,Patent Application,yes,15,6,8,8,0,F05D2270/80;;F01D21/003;;Y10T74/19949;;G01P3/488;;Y10T74/19949;;F05D2270/80;;F01D21/003;;G01P3/488;;F05D2220/30;;F05D2240/60;;F05D2300/11;;G01P3/44,G01P3/481;;F16H55/08,324/173;;74/457,0,0,,,,ACTIVE
269,WO,A1,WO 2019/229467 A1,159-563-476-279-592,2019-12-05,2019,GB 2019051508 W,2019-05-31,GB 201808894 A,2018-05-31,MASS SPECTROMETER,"A mass spectrometer is disclosed comprising an ion optics device housing having one or more external electrical connectors (1719) provided thereon. An ion optics device (301) is arranged inside the ion optics device housing, the ion optics device (301) comprising one or more electrodes for manipulating ions, the one or more electrodes being electrically connected to the one or more external electrical connectors (1719) provided on the ion optics device housing. A voltage supply housing (1717) is provided having one or more external electrical connectors provided thereon. One or more voltage supplies are arranged inside the voltage supply housing (1717), the one or more voltage supplies being in electrical communication with the one or more external electrical connectors provided on the voltage supply housing. The one or more external electrical connectors provided on the voltage supply housing are directly physically and electrically connected to the one or more external electrical connectors (1719) provided on the ion optics device housing.",MICROMASS LTD,CARNEY PETER;;HARRISON JAMES;;HOUGH PAUL;;WORTHINGTON KENNETH R;;MCIVER PAUL;;SCHOFIELD ALISTAR,,https://lens.org/159-563-476-279-592,Patent Application,yes,4,0,10,10,0,H01J49/02;;H01J49/022;;H01J49/068;;H01J49/0031;;H01J49/022;;H01J49/025;;H01J49/063;;H01J49/065;;H01J49/067;;H01J49/401;;H01J49/405;;H01J49/4295,H05K5/06;;H01J49/02,,2,1,119-779-971-342-191,10.1016/j.ijms.2013.02.010,"ANONYMOUS: ""Operating Manual and Programming Reference, Models RGA100, RGA200, and RGA300 Residual Gas Analyzer"", 1 May 2009 (2009-05-01), XP055613161, Retrieved from the Internet <URL:https://www.thinksrs.com/downloads/pdfs/manuals/RGAm.pdf> [retrieved on 20190815];;JULIA H. JUNGMANN ET AL: ""An in-vacuum, pixelated detection system for mass spectrometric analysis and imaging of macromolecules"", INTERNATIONAL JOURNAL OF MASS SPECTROMETRY, vol. 341-342, 4 March 2013 (2013-03-04), pages 34 - 44, XP055089714, ISSN: 1387-3806, DOI: 10.1016/j.ijms.2013.02.010",PENDING
270,DE,D1,DE 60329020 D1,189-707-953-569-188,2009-10-08,2009,DE 60329020 T,2003-02-27,US 36067802 P;;US 42948702 P;;US 0305831 W,2002-03-01,"ASSAYS ZUR ÜBERWACHUNG VON KREBSPATIENTEN AUF GRUNDLAGE DER SPIEGEL DES ANALYTEN FÜR DIE EXTRAZELLULÄRE DOMÄNE (ECD) DES EPIDERMALEN WACHSTUMSFAKTOR-REZEPTORS (EGFR), ALLEIN ODER IN KOMBINATION MIT ANDEREN ANALYTEN, IN PROBEN VON KÖRPERFLÜSSIGKEITEN",,SIEMENS HEALTHCARE DIAGNOSTICS,CARNEY WALTER P;;HAMER PETER J;;LIPTON ALLAN;;LEITZEL KIM;;ALI SUHAIL M,,https://lens.org/189-707-953-569-188,Granted Patent,no,0,0,12,12,0,G01N33/57407;;G01N33/57415;;G01N33/57419;;G01N33/57423;;G01N33/57434;;G01N33/57449;;G01N33/57488;;G01N2333/485;;G01N2333/71;;G01N2800/52;;G01N33/57488;;G01N33/57434;;G01N2333/485;;G01N2800/52;;G01N33/57415;;G01N33/57423;;G01N33/57407;;G01N33/57419;;G01N33/57449;;G01N2333/71,G01N33/48;;A61B/;;G01N33/53;;G01N33/566;;G01N33/574,,0,0,,,,EXPIRED
271,US,B2,US 11538676 B2,078-475-062-830-843,2022-12-27,2022,US 201917057201 A,2019-05-31,GB 201808894 A;;GB 2019051508 W,2018-05-31,Mass spectrometer,"A mass spectrometer is disclosed comprising an ion optics device housing having one or more external electrical connectors ( 1719 ) provided thereon. An ion optics device ( 301 ) is arranged inside the ion optics device housing, the ion optics device ( 301 ) comprising one or more electrodes for manipulating ions, the one or more electrodes being electrically connected to the one or more external electrical connectors ( 1719 ) provided on the ion optics device housing. A voltage supply housing ( 1717 ) is provided having one or more external electrical connectors provided thereon. One or more voltage supplies are arranged inside the voltage supply housing ( 1717 ), the one or more voltage supplies being in electrical communication with the one or more external electrical connectors provided on the voltage supply housing. The one or more external electrical connectors provided on the voltage supply housing are directly physically and electrically connected to the one or more external electrical connectors ( 1719 ) provided on the ion optics device housing.",MICROMASS LTD,CARNEY PETER;;HARRISON JAMES;;HOUGH PAUL;;WORTHINGTON KENNETH R;;MCIVER PAUL;;SCHOFIELD ALISTAR,MICROMASS UK LIMITED (2021-09-01),https://lens.org/078-475-062-830-843,Granted Patent,yes,278,0,10,10,0,H01J49/02;;H01J49/022;;H01J49/068;;H01J49/0031;;H01J49/022;;H01J49/025;;H01J49/063;;H01J49/065;;H01J49/067;;H01J49/401;;H01J49/405;;H01J49/4295,H01J49/00;;H01J49/06;;H01J49/02;;H01J49/40;;H01J49/42,,79,5,002-875-246-112-868;;004-471-982-018-484;;022-561-862-885-681;;119-779-971-342-191;;062-933-196-688-541,11523084;;10.1002/jms.207;;10.1002/rcm.1074;;12820206;;10.1021/ac0518811;;16579588;;10.1016/j.ijms.2013.02.010;;10.1063/1.4922913;;pmc4482810;;26133872,"Stanford Research Systems, “Operating Manual and Programing Reference: Models RGA100, RGA200 and RGA300 Residual Gas Analyzer”, Revision 1.8, May 2009 (Year: 2009).;;Stanford Research Systems, “Operating Manual and Programming Reference: Models RGA 100, RGA 200 and RGA 300 Residual Gas Analyzer”, Revision 1.8, May 2009. (Year: 2009) (Year: 2009).;;Combined Search and Examination Report under Sections 17 and 18(3), for Application No. GB1907724 7, dated Sep. 25, 2019, 7 pages.;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fee for International application No. PCT/GB2019/051494, dated Sep. 19, 2019.;;Combined Search and Examination Report under Sections 17 and 18(3), dated Sep. 27, 2019, for Application No. GB1907736.1, 6 pages.;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fees, for International application No. PCT/GB2019/051499, dated Sep. 4, 2019.;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fee, for International Application No. PCT/GB2019/051496, dated Aug. 29, 2019.;;Anonymous, “Time-of-flight mass spectrometry”, Wikipedia, Apr. 28, 2018 (Apr. 28, 2018), XP055614063, Retrieved from the Internet:URL:https://en.wikipedia.org/w/index.php title=Time-of-flight_mass_spectrometry oldid=838663844 [retrieved on Aug. 20, 2019].;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fees for International application No. PCT/GB2019/051497, dated Sep. 2, 2019.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1907745 2, dated Aug. 13, 2019, 7 pages.;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fee, for International application No. PCT/GB2019/051501, dated Jul. 29, 2019, 14 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051497, dated Nov. 5, 2019, 19 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051503, dated Sep. 25, 2019, 17 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051496, dated Oct. 23, 2019, 29 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051506, dated Sep. 25, 2019, 14 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051494, dated Nov. 18, 2019, 20 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051507, dated Oct. 15, 2019, 17 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051508, dated Oct. 23, 2019, 16 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051499, dated Nov. 5, 2019, 19 pages.;;Examination Report under Section 18(3) for Application No. GB1907719.7, dated Jul. 28, 2021, 9 pages.;;Parkes, S. SpaceWire User Guide, STAR-Dundee [online] 2012 [retrieved on Aug. 13, 2021]. Retrieved from Internet URL: https://www.star-dundee.com/wp-content/star_uploads/general/SpaceWire-Users-Guide.pdf, 117 pages.;;SCIEX, “3200 Series of Instruments System User Guide” [online], published Apr. 2018, available from: https://sciex.com/content/dam/SCIEX/pdf/customer-docs/user-guide/3200-system-user-guide-en.pdf, 241 pages.;;Combined Search and Examination Report under Sections 17 and 18(3), for Application No. GB2100898.2, dated Jun. 21, 2021, 7 pages.;;Combined Search and Examination Report under Sections 17 and 18(3), for Application No. GB2001530.1, dated Aug. 5, 2020, 7 pages.;;Thermo Fisher Scientific, Inc, Feb. 2015, Orbitrap Fusion Hardware Manual [online]. Retrieved from Internet URL: http://www.unitylabservices.eu/content/dam/tfs/ATG/CMD/cmddocuments/oper/oper/ms/lc-ms/sys/Man-80000-97016-Orbitrap-Fusion-Hardware-Man8000097016-A-EN.pdf, 122 pages.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 BioPharma Analytical Summit BioAccord Abstract. ASMS MS-in-QC, PowerPoint 24 pages.;;International Preliminary Report on Patentability for International application No. PCT/GB2019/051510, dated Dec. 1, 2020, 7 pages.;;Examination Report under Section 18(3) for Application No. GB1907739.5, dated Nov. 3, 2020, 5 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808932.6, dated Nov. 21, 2018, 4 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808890.6, dated Nov. 28, 2018, 7 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808912.8, dated Nov. 30, 2018, 10 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808942.5, dated Dec. 3, 2018, 7 pages.;;Chernushevich, I. V., et al., “An introduction to quadrupole-time-of-flight mass spectrometry”, Journal of Mass Spectrometry, 36(8):849-65 (2001) Abstract only.;;Chernushevich, I.V., et al., “Charge state separation for protein applications using a quadrupole time-of-flight mass spectrometer”, Rapid Communications in Mass Spectrometry 17(13):1416-1424 (2003). Abstract only.;;Makarov, A. et al., “Performance evaluation of a hybrid linear ion trap/orbitrap mass spectrometer,” Analytical Chemistry, 78(7):2113-20 (2006). Abstract only.;;Combined Search and Examination Report under Sections 117 and 18(3) for Application No. GB1808948.2 dated Nov. 21, 2018, 7 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808893.0 dated Nov. 27, 2018, 8 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808936.7 dated Nov. 20, 2018, 10 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808892.2, dated Dec. 3, 2018, 6 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Applicaton No. GB1808894.8 dated Dec. 3, 2018, 7 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808949.0 dated Oct. 31, 2018, 8 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1907722.1 dated Jun. 28, 2019, 8 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808889.8 dated Nov. 30, 2018, 7 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051504, dated Jul. 23, 2019, 11 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1818003.4, dated May 2, 2019, 6 pages.;;Invitation to pay additional fees and, where applicable, protest fee for PCT/GB2019/051508, dated Aug. 28, 2019.;;Author unknown, “Operating Manual and Programming Reference, Models RGA100, RGA200, and RGA300 Residual Gas Analyzer,” Stanford Research Systems Revision 1.8 (May 2009).;;Jungmann, J. H., et al., “An in-vacuum, pixelated detection system for mass spectrometric analysis and imaging of macromolecules,” International Journal of Mass Spectrometry, 341-342:34-44 (2013).;;Invitation to pay additional fees and, where applicable, protest fee for International application No. PCT/GB2019/051507, dated Aug. 20, 2019, 16 pages.;;Yang, C., and Hanley, L., “ChiMS: Open-source instrument control software platform on LabVIEW for imaging/depth profiling mass spectrometers,” Review of Scientific Instruments, 86:065106-1 through 065016-7 (2015).;;Invitation to pay additional fees and, where applicable, protest fee for International application No. PCT/GB2019/051506, dated Jul. 22, 2019, 13 pages.;;Invitation to pay addition al fees and, where applicable, protest fee for PCT/GB2019/051503, dated Jul. 25, 2019, 17 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051500, dated Aug. 5, 2019, 9 pages.;;Kozlov, B., et al., “Time-of-flight mass spectrometer for investigations of laser ablation,” ASMS Conference paper, Dallas, TX (May 1999). [Retrieved from the Internet URL: https//www.researchgate.net/publication/330202298_Time-of-flight_mass_spectrometer_for_investigations_of_laser_ablation]. Abstract.;;Shion, H., et al., “Towards Overcoming the Challenges of Implementing Accurate Mass MS for Routine Biotherapeutic Analysis” 2018 ASMS Prototype oa-TOF Abstract HYS Final.;;Shion, S., et al., “Towards Overcoming the Challenges of Implementing Accurate Mass MS for Routine Biotherapeutic Analysis” 2018 ASMS Prototype oa-TOF WP699 HYS Final Poster.;;Shion, H., et al., “A Fit-for-purpose Accurate Mass MS for Routine Biotherapeutic Analysis”, 2018 CASSS Mass Spec HYS Final Poster.;;Shion, H., et al., “A Fit-for-purpose Accurate Mass MS for Routine Biotherapeutic Analysis”, 2018 CASSS Mass Spec BioTof HYS Final, Abstract.;;Shion, H., et al., “Progress Towards Implementing Simple Time-of-flight Accurate Mass MS for Routine Biotherapeutic Analysis”, XXII (IMSC) International Mass Spectrometry Conference Florence, Italy (2018) Abstract.;;Shion, H., et al., “Progress Towards Implementing Simple Time-of-flight Accurate Mass MS for Routine Biotherapeutic Analysis”, XXII International Mass Spectrometry Conference Florence, Italy (2018) poster.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 ASMS BioAccord Oral Session PowerPoint.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 ASMS BioAccord Abstract.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments” 2019 ATEurope BioAccord, Abstract.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments” 2019 ATEurope BioAccord, Poster.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 BioPharma Analytical Summit BioAccord, abstract.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 Bio Pharma Summit BioAccord, Poster.;;Shion, H., “Enabling Routine and Reproducible Biotherapeutic Analysis when Data Integrity Matters”, 2019 15th Annual PEGs Boston Waters BioAccord, PowerPoint 29 pages.;;Shion, H., “Enabling Routine and Reproducible Biotherapeutic Analysis when Data Integrity Matters”, 2019 15th Annual PEGs Boston Waters BioAccord, Abstract.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 Pitt Con Bio Accord, Poster.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 Pitt Con Bio Accord, Abstract.;;Combined Search and Exam Report from IPO for GB Application No. 1907739.5, dated Nov. 27, 2019, 8 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051510, dated Aug. 29, 2019, 13 pages.;;Combined Search and Exam Report from IPO for GB Application No. 1907735.3, dated Nov. 25, 2019, 7 pages.;;Combined S and E Report under Sections 17 and 18(3) for Application No. GB1907734.6, dated Oct. 31, 2019, 7 pages.;;International Search Report and Written Opinion for International Application No. PCT/GB2019/051498, dated Nov. 6, 2019, 21 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1907719.7, dated Nov. 15, 2019, 11 pages.;;Author unknown, “Waters Xevo G2-S QTof Operators Overview and Maintenance Guide”, Feb. 11, 2013 (Feb. 11, 2013), XP55606374, Retrieved from the Internet: URL:https://www.waters.eom/webassets/cms/support/docs/xevo_g2-s_qtof_715003596rb.pdf [retrieved on Jul. 17, 2019].;;International Search Report and Written Opinion for International application No. PCT/GB2019/051501, dated Sep. 25, 2019, 17 pages.;;Examination Report under Section 18(3) for Application No. GB2020743.7, dated Jan. 28, 2022, 6 pages.",ACTIVE
272,US,B2,US 7473534 B2,189-342-697-980-533,2009-01-06,2009,US 37537103 A,2003-02-27,US 37537103 A;;US 36067802 P;;US 42948702 P,2002-03-01,"Assays for cancer patient monitoring based on levels of epidermal growth factor receptor (EGFR) extracellular domain (ECD) analyte, alone or in combination with other analytes, in body fluid samples","The present invention describes clinically and medically important methods of monitoring the outcome of a cancer patient who is suffering from disease or who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease or cancer treatment effectiveness in a cancer patient by measuring the level of the extracellular domain (ECD) of the epidermal growth factor receptor (EGFR) in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment, wherein a decrease in the level of the ECD of the EGFR in the cancer patient compared with the level of the ECD of the EGFR in normal control individuals serves as an indicator of cancer advancement or progression and/or a lack of treatment effectiveness for the patient. As another aspect of determining disease outcome and survival, the invention further provides assessing both EGFR and HER-2/neu levels, in combination, in a patient sample. A finding of decreased levels of EGFR concomitantly with elevated or increased levels of HER-2/neu relative to control levels indicates poor outcome and short time to progression.",SIEMENS HEALTHCARE DIAGNOSTICS,CARNEY WALTER P;;HAMER PETER J;;LIPTON ALLAN;;LEITZEL KIM;;ALI SUHAIL M,SIEMENS HEALTHCARE DIAGNOSTICS INC (2007-08-17);;BAYER CORPORATION (2003-04-30);;BAYER HEALTHCARE LLC (2002-12-26),https://lens.org/189-342-697-980-533,Granted Patent,yes,24,3,12,12,0,G01N33/57407;;G01N33/57415;;G01N33/57419;;G01N33/57423;;G01N33/57434;;G01N33/57449;;G01N33/57488;;G01N2333/485;;G01N2333/71;;G01N2800/52;;G01N33/57488;;G01N33/57434;;G01N2333/485;;G01N2800/52;;G01N33/57415;;G01N33/57423;;G01N33/57407;;G01N33/57419;;G01N33/57449;;G01N2333/71,G01N33/574;;A61B/;;G01N33/48;;G01N33/53;;G01N33/566,435/7.23;;435/4,74,52,021-743-178-291-503;;068-190-159-107-983;;003-837-314-245-689;;060-549-544-933-98X;;097-492-678-630-245;;061-007-512-959-237;;103-057-593-048-837;;036-638-350-462-598;;093-940-707-835-938;;103-057-593-048-837;;068-190-159-107-983;;138-858-789-006-903;;165-919-681-781-612;;006-289-477-457-496;;017-077-300-427-35X;;101-395-260-712-954;;011-699-709-349-99X;;094-495-688-845-199;;039-771-118-673-253;;000-675-563-545-617;;001-075-703-287-400;;001-807-171-352-291;;055-326-310-965-736;;050-320-015-840-544;;008-580-880-858-886;;110-658-042-198-502;;073-659-966-706-479;;049-953-305-917-444;;021-743-178-291-503;;041-863-374-864-841;;181-448-152-035-827;;055-542-669-483-094;;064-741-687-897-846;;035-081-115-342-527;;106-753-778-592-300;;020-026-345-586-213;;077-903-001-903-019;;029-722-926-651-446;;040-344-520-215-612;;045-751-499-875-041;;024-556-123-582-886;;024-118-704-687-15X;;039-787-167-745-336;;144-350-917-845-93X;;061-879-284-371-703;;024-296-083-451-508;;101-840-783-050-294;;047-042-958-819-614;;048-112-887-077-517;;004-290-724-724-172;;063-250-505-461-994;;053-205-123-738-104,10067810;;10.1097/00043764-199412000-00013;;7884573;;7612898;;10.1007/bf00694752;;9066616;;7906254;;10.1002/ijc.2910560316;;16326100;;10.1016/j.ejca.2005.08.036;;10.1038/sj.bjc.6601987;;15226769;;pmc2409859;;10.1159/000227606;;9394844;;10657373;;10.1093/clinchem/46.2.175;;10.1038/sj.bjc.6601987;;15226769;;pmc2409859;;10.1097/00043764-199412000-00013;;7884573;;2998607;;10.1016/s0021-9258(19)85573-4;;6246084;;6296087;;10.1016/s0021-9258(18)33127-2;;6204768;;10.1016/0092-8674(84)90412-4;;2997370;;10.1099/0022-1317-66-11-2347;;10.1016/0378-1119(86)90137-x;;3023199;;10.1038/nbt0790-662;;1369995;;pmc392331;;10.1073/pnas.74.2.565;;265522;;313928;;10.1016/s0021-9258(19)86851-5;;2566965;;3843705;;10.1016/0003-2697(85)90442-7;;10.1006/abio.1976.9999;;942051;;10.1016/0003-2697(76)90527-3;;14907713;;10.1016/s0021-9258(19)52451-6;;2158859;;10.1016/0092-8674(90)90801-k;;10.1023/a:1006127527107;;10206071;;10096554;;10690556;;10067810;;10.1016/0022-1759(95)00016-4;;7769243;;7658022;;10.1016/0022-1759(95)00086-p;;10.1002/eji.1830240426;;8149964;;10.1016/s0378-1119(96)00627-0;;10.1016/s0065-2776(08)60674-4;;7872158;;1172191;;10.1038/256495a0;;25291284;;10.1016/0167-5699(83)90123-8;;6186024;;10.1126/science.6186024;;10367244;;10.1177/172460089901400103;;11426640;;10.1038/sj.onc.1204082;;10.1038/307521a0;;6320011;;10.1128/mcb.6.1.257;;3023826;;pmc367506;;10.1128/mcb.6.1.257-264.1986;;pmc557382;;10.1002/j.1460-2075.1984.tb01842.x;;6325174;;10.1146/annurev.bi.48.070179.001205;;382984;;11156231;;2425067;;10.1002/path.1711490104;;1684291;;10.1016/0304-419x(91)90014-c;;pmc1977338;;10.1038/bjc.1992.22;;1346366;;10.1016/0165-1110(92)90016-3;;1374522;;10.1210/edrv-13-1-3;;10.1210/er.13.1.3;;1313356;;10.1038/bjc.1991.211;;1712624;;pmc1972558;;2884496;;3258739,"Serum sErbB1 and Epidermal Growth Factor Levels As TumorBiomarkers in Women with Stage III or IV Epithelial Ovarian cancer Andre T. Baron, Jacqueline M. Lafky, et al vol. 8, 129-137, Feb. 1999.;;The detection of increased amounts of the extracellular domain of the epidermal growth factor receptor in serum during carcinogenesis in asbestosis patients. J Occup Med. Dec. 1994;36(12):1324-8. Partanen R, Hemminki K, Koskinen H, Luo JC, Carney WP, Brand.;;Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Earp HS, Dawson, et Breast Cancer Res Treat. Jul. 1995;35(1):115-32.;;Prognostic significance of p105 (c-erbB-2 HER2/neu) serum levels in patients with ovarian cancer. Anticancer Res. Jan.-Feb. 1997;17(1B):757-60. Meden H, Marx D, Schauer A, Wuttke W, Kuhn W.;;Her-2/neu and EGFR oncoprotein expression in breast, ovarian and cervical cancers. Carney, WP, Williams Julie, Advance for adinstrators of the laboratory, vol. 10, p. 34, 2001.;;expression of herstatin, an alternative Her-2/NEU product, in cells that express either p185HER-2 or the EGF receptor inhibits receptor activity and cell growth WO02/14470 A2, International Publication date, Feb. 21, 2002.;;Detection of increased amounts of the extracellular domain of the c-erbB-2 oncoprotein in serum during pulmonary carcinogenesis in humans. Int J Cancer. Feb. 1, 1994;56(3):383-6. Brandt-Rauf PW, Luo JC, Carney WP, Smith S, De Vivo I, Milling C, Hemminki K.;;Hudelist et al., Eur J Cancer, vol. 42, p. 186-92, 2005.;;Jacot et al., Br J Cancer, vol. 91, p. 430-3, 2004.;;Carney et al., Abstract #240, American Association of Cancer Research, Annual Meeting , Apr. 2002.;;Krainer et al., Oncology, vol. 54, p. 475-81, 1997, abstract.;;Payne et al., Clinical Chemistry, vol. 46, p. 175-182, 2000.;;Marx III et al., Abstract #1743, American Society of Clinical oncology, May, 2002.;;Int'l. Search Report, dated Apr. 14, 2005, corresponding to PCT/US03/05831.;;Jacot et al. Serum EGF-receptor and HER-2 extracellular and prognosis of non-small-cell lung cancer. British Journal of Cancer. 2004, vol. 91, pp. 430-433.;;Partanen et al. The Detection of Increased Amounts of the Extracellular Domain of the Epidermal Growth Factor Receptor in Serum During Carcinogenesis in Asbestosis Patients. Journal of Occupational Medicine. Dec. 1994, vol. 36, No. 12, pp. 1324-1328.;;Zhou et al. Clinical Applications of Oncogenes and Oncoproteins: HER-2/neu and EGFR as New Therapeutic Targets. Frontiers of Biotechnology & Pharmaceuticals. 2002, vol. 3, pp. 29-45.;;W. J. Gullick et al., Cancer Res., 1986, 46:285-292.;;S. Cohen et al, J. Biol. Chem., 1980, 255: 4834-4842.;;A.B. Schreiber et al., J. Biol. Chem., 1983, 258:846-853.;;Wilson et al., Cell, 1984, 37: 767-778.;;Francis et al., J. Gen. Virol., 1985, 66: 2347-2354.;;Foecking et al., Gene, 1986, 45: 101-105.;;Cockett et al., Bio/Technology, July 1990, 8:662-667.;;R.N. Fabricant et al., Proc. Natl. Acad. Sci. USA, 1977, 74: 565-569.;;M.M. Wrann et al., J. Biol. Chem., 1979, 254: 8083-8086.;;S.J. McKenzie et al., Oncogene, 1989, 4: 543-548.;;P.K. Smith et al., Analyt. Biochem., 1985, 150: 76-85.;;M.M. Bradford, Analyt. Biochem., 1976, 72: 248-254.;;O.H. Lowry et al., J. Biol. Chem., 1951, 193: 265-275.;;A. Ullrich et al., Cell, 1990, 61: 203-212.;;R. Nicolson et al., British Journal Cancer, 1991, 63: 146-150.;;R.G. Dullea, Proc. 91st Ann. Meeting of the American Association for Cancer Research (AACR), 2000, 41 (Abstract #2550): 401.;;J.M. Nelson et al, Proc. 91st Ann. Meeting of the American Association for Cancer Research (AACR), 2000, 41 (Abstract #1533): 241.;;T. O'Reilly et al., Proc. 91st Ann. Meeting of the American Association for Cancer Research (AACR), 2000, 41 (Abstract #3069): 481.;;H.C. Kelly et al., Proc. 91st Ann. Meeting of the American Association for Cancer Research (AACR), 2000, 41 (Abstract #3896): 612.;;L. Witters et al., Breast Cancer Research and Treatment, 1999, 53: 41-50.;;X.-D. Yang et al., Proc. 91st Ann. Meeting of the American Association for Cancer Research (AACR), 2000, 41 (Abstract #3380): 530.;;X.-D. Yang et al., Cancer Research, 1999, 59: 1236-1243.;;L. Milas et al., Clinical Cancer Research, 2000, 6: 701-708.;;T. Ohmori et al., Proc. 91st Ann. Meeting of the American Association for Cancer Research (AACR), 2000, 41 (Abstract #3072): 482.;;A. Budillon et al., Proc. 91st Ann. Meeting of the American Association for Cancer Research (AACR), 2000, 41 (Abstract #4910): 773.;;W.P. Carney et al., J. Tumor Marker Oncol., 1991, 6(2): 53-72.;;A.J. Baron et al., Cancer Epidemiology, Biomarkers and Prevention, 1999, 8: 129-137.;;Brinkman et al., J. Immunol. Methods, 1995, 182: 41-50.;;Ames et al., J. Immunol. Methods, 1995, 184: 177-186.;;Kettleborough et al., Eur. J. Immunol., 1994, 24: 952-958.;;Persic et al., Gene, 1997, 187: 9-18.;;Burton et al., Advances in Immunology, Dixon et al. (eds.), 1994, 57: 191-280.;;Kohler et al., Nature, 1975, 256: 495-497.;;Harlow et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 2nd Ed., 1988, p. 1-10.;;Hammerling et al., Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., 1981, pp. 563-587.;;Kozbor et al., Immunol. Today, 1983, 4: 72-79.;;Cole et al., Monoclonal Antibodies and Cancer Therapy, Reisfield et al. (eds.), Alan R. Liss, Inc., 1985, pp. 77-96.;;Sutcliffe et al., Science, 1983, 219: 660-666.;;L. Harris et al., Int. J. Biol. Markers, 1999, 14: 8-15.;;J. Mendelsohn et al, Oncogene, 2000, 19: 6550-6565.;;A. L. Ulrich et al., Nature, 1984, 307: 418-425.;;J. Downward et al., Nature, 1984, 307: 521-527.;;C.R. Carlin et al., Mol. Cell. Biol., 1986, 6: 257-264.;;F.L.V. Mayes et al., The EMBO J., 1984, 3: 531-537.;;G. Carpenter et al., Ann. Rev. Biochem., 1979, 48: 193-216.;;M.-J. Oh et al., Clin. Cancer Res., 2000, 6: 4760-4763.;;W.P. Carney et al, Advance Newsmagazines for Medical Laboratory Professionals, Jun. 2001, 13 (13) : 18.;;B. Ozanne et al, J. Pathol., 1986, 149: 9-14.;;S.J. McKenzie, Biochim. et Biophys. Acta, 1991, 1072: 193-214.;;C. Wright et al., Br. J. Cancer, 1992, 65: 118-121.;;G.N. Fuller et al., Mutation Res., 1992, 276: 299-306.;;J.G.M. Klijn et al., Endocrine Rev., 1992, 13: 3-17.;;S. Nicolson et al., Diagnostic Oncology, 1991, 1: 43-52.;;C. Wright et al., Br. J. Cancer, 1991, 63: 967-970.;;J.-H. Choi et al., Proc. 87th Ann. Meeting of the American Association for Cancer Research (AACR), 1996, 37 (Abstract #1413): p. 207.;;J.R.C. Sainsbury et al., Lancet, 1987, 1: 1398-1402.;;M.A. Rios et al., Anticancer Research, 1988, 8: 173-176.",EXPIRED
273,JP,B2,JP S5812775 B2,064-471-099-469-493,1983-03-10,1983,JP 5787873 A,1973-05-25,US 25682772 A,1972-05-25,JP S5812775 B2,,WESTERN ELECTRIC CO,MICHAEL PETER CICHETTI JR.;;JOSEPH GEORGE KNEUER;;ADAM CAROLL CARNEY;;DONALD WESLEY RICE,,https://lens.org/064-471-099-469-493,Unknown,no,0,0,18,19,0,H04J3/1647;;H04L1/08;;H04L12/525;;H04L12/525;;H04L1/08;;H04J3/1647,H04J3/04;;H04J3/16;;H04L1/08;;H04L12/52,,0,0,,,,DISCONTINUED
274,ES,T3,ES 2329565 T3,169-163-415-955-083,2009-11-27,2009,ES 03709354 T,2003-02-27,US 36067802 P;;US 42948702 P,2002-03-01,"PRUEBAS PARA MONITOREAR PACIENTES CON CANCER, BASADAS EN LOS NIVELES DE ANALITO DE DOMINIO EXTRACELULAR (ECD) DEL FACTOR RECEPTOR DEL CRECIMIENTO EPIDERMICO (EGFR),SOLO O EN COMBINACION CON OTROS ANALITOS,EN MUESTRAS DE FLUIDOS CORPORALES.","Un método para monitorear el tratamiento de cáncer de mama, cáncer de próstata, cáncer de pulmón, cáncer de ovarios y cáncer de colon, o la eficacia de este, en un paciente con cáncer sometido a dicho tratamiento, que comprende: (a) medición del nivel del dominio extracelular dividido activamente o descartado (ECD) del receptor del factor de crecimiento epidérmico (EGFR) en una muestra de fluido corporal del paciente con cáncer, siendo dicho fluido corporal seleccionado de sangre, suero o plasma; y (b) determinar si dicho nivel del ECD del EGFR se disminuye durante el curso del tratamiento del cáncer en comparación con el nivel en controles normales; en donde el rango normal del nivel en controles normales es 45 a 78 ng/ml; y además en donde una disminución en el nivel del ECD descartado o dividido activamente de EGFR en comparación con el nivel del ECD descartado o dividido activamente de EGFR en controles normales durante el periodo de seguimiento indica uno o más de los siguientes: (i) evolución del cáncer, (ii) una etapa más avanzada del cáncer, o (iii) falta de respuesta por el paciente al tratamiento del cáncer.",SIEMENS HEALTHCARE DIAGNOSTICS,CARNEY WALTER P;;HAMER PETER J;;LIPTON ALLAN;;LEITZEL KIM;;ALI SUHAIL M,,https://lens.org/169-163-415-955-083,Granted Patent,no,0,0,12,12,0,G01N33/57407;;G01N33/57415;;G01N33/57419;;G01N33/57423;;G01N33/57434;;G01N33/57449;;G01N33/57488;;G01N2333/485;;G01N2333/71;;G01N2800/52;;G01N33/57488;;G01N33/57434;;G01N2333/485;;G01N2800/52;;G01N33/57415;;G01N33/57423;;G01N33/57407;;G01N33/57419;;G01N33/57449;;G01N2333/71,G01N33/48;;A61B/;;G01N33/53;;G01N33/566;;G01N33/574,,0,0,,,,EXPIRED
275,EP,A4,EP 1573316 A4,161-799-628-862-641,2006-05-03,2006,EP 03709354 A,2003-02-27,US 0305831 W;;US 36067802 P;;US 42948702 P,2002-03-01,"ASSAYS FOR CANCER PATIENT MONITORING BASED ON LEVELS OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXTRACELLULAR DOMAIN (ECD) ANALYTE, ALONE OR IN COMBINATION WITH OTHER ANALYTES, IN BODY FLUID SAMPLES",,BAYER AG,CARNEY WALTER P;;HAMER PETER J;;LIPTON ALLAN;;LEITZEL KIM;;ALI SUHAIL M,SIEMENS HEALTHCARE DIAGNOSTICS INC. (2008-04-23),https://lens.org/161-799-628-862-641,Search Report,no,0,0,12,12,0,G01N33/57407;;G01N33/57415;;G01N33/57419;;G01N33/57423;;G01N33/57434;;G01N33/57449;;G01N33/57488;;G01N2333/485;;G01N2333/71;;G01N2800/52;;G01N33/57488;;G01N33/57434;;G01N2333/485;;G01N2800/52;;G01N33/57415;;G01N33/57423;;G01N33/57407;;G01N33/57419;;G01N33/57449;;G01N2333/71,G01N33/48;;A61B/;;G01N33/53;;G01N33/566;;G01N33/574,,1,1,049-860-577-336-835,10.1002/(sici)1097-0142(19970515)79:10<1879::aid-cncr6>3.3.co;2-r;;9149012;;10.1002/(sici)1097-0142(19970515)79:10<1879::aid-cncr6>3.0.co;2-b,"CHOI J H ET AL: ""Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients."", CANCER. 15 MAY 1997, vol. 79, no. 10, 15 May 1997 (1997-05-15), Bethesda MD USA, pages 1879 - 1883, XP002371110, ISSN: 0008-543X",EXPIRED
276,EP,A1,EP 2893168 A1,170-151-196-831-888,2015-07-15,2015,EP 13835799 A,2013-09-08,US 201213607986 A;;US 2013/0058656 W,2012-09-10,SENSOR AND TOOTH ARRANGEMENT FOR SHAFT SPEED DETECTION,,UNITED TECHNOLOGIES CORP,COSBY JAMES;;TOMEO PETER V;;SANTIAGO ANGEL L;;RODRIGUEZ HERIBERTO;;ANDERSON CARNEY R,"RAYTHEON TECHNOLOGIES CORPORATION (N.D.GES.D.S, US (2022-09-23);;UNITED TECHNOLOGIES CORPORATION (2016-10-26)",https://lens.org/170-151-196-831-888,Patent Application,yes,0,0,8,8,0,F05D2270/80;;F01D21/003;;Y10T74/19949;;G01P3/488;;Y10T74/19949;;F05D2270/80;;F01D21/003;;G01P3/488;;F05D2220/30;;F05D2240/60;;F05D2300/11;;G01P3/44,G01P3/488;;F01D21/00;;F01D25/00;;F02C7/00;;F02C9/28;;F02K3/00,,0,0,,,,ACTIVE
277,US,A1,US 2021/0290545 A1,080-101-816-000-762,2021-09-23,2021,US 202117337306 A,2021-06-02,US 202117337306 A;;US 201615383201 A;;US 201514858539 A;;US 201462052689 P,2014-09-19,FORMULATIONS AND METHODS FOR CONTEMPORANEOUS STABILIZATION OF ACTIVE PROTEINS DURING SPRAY DRYING AND STORAGE,"A method of treatment of plasma with a physiologically compatible spray dry stable acidic substance (SDSAS) prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compositions related to plasma dried by the methods of the present invention.",VELICO MEDICAL INC,LIU QIYONG PETER;;CUI JUNQING;;LUCIEN RUD KARLY;;CARNEY RYAN;;SOHN JIHAE;;ARYA MICHELLE,VELICO MEDICAL INC (2015-03-10),https://lens.org/080-101-816-000-762,Patent Application,yes,0,4,10,10,0,A61K9/1688;;F26B3/12;;F26B3/06;;F26B5/065;;B65D81/266;;B65D51/30;;A61K9/1688;;F26B3/12;;A61K9/16;;A61K9/1682;;F26B5/04;;A61K9/1617;;A61K35/16;;B01J19/06;;B01J2219/00177;;F26B3/04,A61K9/16;;A61K35/16;;B01J19/06;;F26B3/04;;F26B3/06;;F26B3/12;;F26B5/04,,4,2,001-760-864-299-790;;148-449-159-462-862,21825929;;10.1097/ta.0b013e31821f4234;;10.1097/ta.0b013e3182214f44;;21818011,"Hamilton GJ, Van PY, Differding JA, Kremenevskiy IV, Spoerke NJ, Sambasivan C, Watters JM, Schreiber MA. ""Lyophilized plasma with ascorbic acid decreases inflammation in hemorrhagic shock."" J Trauma,Aug 2011,71(2),pp.292-7; PMID:21825929; doi:10.1097/TA.0b013e31821f4234. (Year: 2011);;Van PY, Hamilton GJ, Kremenevskiy IV, Sambasivan C, Spoerke NJ, Differding JA, Watters JM, Schreiber MA ""Lyophilized plasma reconstituted with ascorbic acid suppresses inflammation and oxidative DNA damage"", J Trauma, Jul 2011,71(1),pp.20-4; PMID:21818011; doi:10.1097/TA.0b013e3182214f44. (Year: 2011);;CardianBCT, INC ""Mirasol Pathogen Reduction Technology"", PN 306690-148, retrieved online 4/4/2023 <URL: http://eurolambda.sk/shared/files/mirasol_plasma.pdf>, 2 pages. (Year: 2009);;Terumo BCT, INC ""Mirasol Pathogen Reduction Technology System"", PN 306690232, retrieved online 4/4/2023 <URL: https://www.terumopenpol.com/wp-content/uploads/2019/12/306690232-1.pdf>, 7 pages. (Year: 2012)",ACTIVE
278,GB,B,GB 2441483 B,181-723-950-353-41X,2009-09-16,2009,GB 0725350 A,2006-06-21,US 2006/0024087 W;;US 69241505 P;;US 69447205 P,2005-06-21,Method and apparatus for telecommunications equipment transfer,,PORTA SYSTEMS CORP,SQUILLANTE ALAN J;;CARNEY WILLIAM V;;STRANGE CLIFFORD D LE;;KOBSA PETER;;SEEMAN JOSEPH,,https://lens.org/181-723-950-353-41X,Granted Patent,no,6,0,5,5,0,H01R9/2433;;H01R9/2441;;H01R31/06;;H01R31/08;;H01R31/06;;H01R9/2433;;H01R9/2441;;H01R31/08,H01R31/06;;H01R9/24;;H01R31/08,,0,0,,,,INACTIVE
279,WO,A2,WO 2007/002159 A2,105-455-723-072-808,2007-01-04,2007,US 2006/0024087 W,2006-06-21,US 69241505 P;;US 69447205 P,2005-06-21,METHOD AND APPARATUS FOR TELECOMMUNICATIONS EQUIPMENT TRANSFER,"A device for electrically connecting new equipment to an existing connector block in a telecommunications system, where the connector block is connected to old equipment to be replaced, includes an adapter which is mountable on the existing connector block and electrically coupleable thereto. The adapter includes a plurality of electrical wires provided for connection to the new equipment, and has a surface on which is mountable at least one protector module. The adapter has a first set of contacts mateable with electrical contacts of the at least one protector module, and has second contacts mateable with electrical contacts of the existing connector block. The adapter is mounted on the connector block, and at least one specially designed first protector module is installed on the adapter to provide a connection between customer wires and the old equipment and the new equipment. Then, the at least one first protector module is removed from the adapter and replaced with at least one specially designed second protector module which effects a connection through the adapter between the customer wires and the new equipment and breaks the connection between the customer wires and the old equipment.",PORTA SYSTEMS CORP;;SQUILLANTE ALAN J;;CARNEY WILLIAM V;;LE STRANGE CLIFFORD D;;KOBSA PETER;;SEEMAN JOSEPH,SQUILLANTE ALAN J;;CARNEY WILLIAM V;;LE STRANGE CLIFFORD D;;KOBSA PETER;;SEEMAN JOSEPH,,https://lens.org/105-455-723-072-808,Patent Application,yes,0,2,5,5,0,H01R9/2433;;H01R9/2441;;H01R31/06;;H01R31/08;;H01R31/06;;H01R9/2433;;H01R9/2441;;H01R31/08,H04J7/00,,0,0,,,,PENDING
280,US,A1,US 2016/0082044 A1,021-637-344-767-839,2016-03-24,2016,US 201514858539 A,2015-09-18,US 201514858539 A;;US 201462052689 P,2014-09-19,FORMULATIONS AND METHODS FOR CONTEMPORANEOUS STABILIZATION OF ACTIVE PROTEINS DURING SPRAY DRYING AND STORAGE,"A method of treatment of plasma with a physiologically compatible spray dry stable acidic substance (SDSAS) prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compositions related to plasma dried by the methods of the present invention.",VELICO MEDICAL INC,LIU QIYONG PETER;;CUI JUNQING;;LUCIEN RUD KARLY;;CARNEY RYAN;;SOHN JIHAE;;ARYA MICHELLE,VELICO MEDICAL INC (2015-03-10),https://lens.org/021-637-344-767-839,Patent Application,yes,13,14,10,10,0,A61K9/1688;;F26B3/12;;F26B3/06;;F26B5/065;;B65D81/266;;B65D51/30;;A61K9/1688;;F26B3/12;;A61K9/16;;A61K9/1682;;F26B5/04;;A61K9/1617;;A61K35/16;;B01J19/06;;B01J2219/00177;;F26B3/04,A61K35/16;;A61K9/16,,0,0,,,,ACTIVE
281,MX,A,MX 9101901 A,022-932-709-978-240,1993-01-01,1993,MX 9101901 A,1991-10-31,US 60726890 A,1990-10-31,APARATO DE TRATAMIENTO DE FIBRAS,,WEYERHAEUSER CO,CARNEY ALLAN R;;GRAEF PETER A;;BOWNS MARK W;;BOLSTAD CLIFFORD R;;FRED E,,https://lens.org/022-932-709-978-240,Patent Application,no,0,0,9,9,0,A61F2013/530007;;A61F2013/530474;;D21B1/066;;D21B1/066;;A61F2013/530007;;A61F2013/530474,A61F13/15;;D04H1/42;;D21B1/06,,0,0,,,,PENDING
282,GB,B,GB 2574330 B,128-746-179-635-703,2022-11-30,2022,GB 201907745 A,2019-05-31,GB 201808894 A,2018-05-31,Mass spectrometer,,MICROMASS LTD,PETER CARNEY;;JAMES PAUL HARRISON;;PAUL HOUGH;;KENNETH RUSSELL WORTHINGTON;;PAUL MCIVER;;ALISTAIR SCHOFIELD,,https://lens.org/128-746-179-635-703,Granted Patent,no,6,0,10,10,0,H01J49/02;;H01J49/022;;H01J49/068;;H01J49/0031;;H01J49/022;;H01J49/025;;H01J49/063;;H01J49/065;;H01J49/067;;H01J49/401;;H01J49/405;;H01J49/4295,H01J49/02;;H01J49/06,,0,0,,,,ACTIVE
283,US,A1,US 2017/0100339 A1,114-807-961-029-672,2017-04-13,2017,US 201615383201 A,2016-12-19,US 201615383201 A;;US 201514858539 A;;US 201462052689 P,2014-09-19,FORMULATIONS AND METHODS FOR CONTEMPORANEOUS STABILIZATION OF ACTIVE PROTEINS DURING SPRAY DRYING AND STORAGE,"A method of treatment of plasma with a physiologically compatible spray dry stable acidic substance (SDSAS) prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compositions related to plasma dried by the methods of the present invention.",VELICO MEDICAL INC,LIU QIYONG PETER;;CUI JUNQING;;LUCIEN RUD KARLY;;CARNEY RYAN;;SOHN JIHAE;;ARYA MICHELLE,VELICO MEDICAL INC (2015-03-10),https://lens.org/114-807-961-029-672,Patent Application,yes,1,11,10,10,0,A61K9/1688;;F26B3/12;;F26B3/06;;F26B5/065;;B65D81/266;;B65D51/30;;A61K9/1688;;F26B3/12;;A61K9/16;;A61K9/1682;;F26B5/04;;A61K9/1617;;A61K35/16;;B01J19/06;;B01J2219/00177;;F26B3/04,A61K9/16;;A61K35/16;;B01J19/06;;F26B3/04;;F26B3/12,,0,0,,,,ACTIVE
284,US,B2,US 11052045 B2,034-356-296-047-204,2021-07-06,2021,US 201615383201 A,2016-12-19,US 201615383201 A;;US 201514858539 A;;US 201462052689 P,2014-09-19,Formulations and methods for contemporaneous stabilization of active proteins during spray drying and storage,"A method of treatment of plasma with a physiologically compatible spray dry stable acidic substance (SDSAS) prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compositions related to plasma dried by the methods of the present invention.",VELICO MEDICAL INC,LIU QIYONG PETER;;CUI JUNQING;;LUCIEN RUD KARLY;;CARNEY RYAN;;SOHN JIHAE;;ARYA MICHELLE,VELICO MEDICAL INC (2015-03-10),https://lens.org/034-356-296-047-204,Granted Patent,yes,201,11,10,10,0,A61K9/1688;;F26B3/12;;F26B3/06;;F26B5/065;;B65D81/266;;B65D51/30;;A61K9/1688;;F26B3/12;;A61K9/16;;A61K9/1682;;F26B5/04;;A61K9/1617;;A61K35/16;;B01J19/06;;B01J2219/00177;;F26B3/04,A61K9/16;;A61K35/16;;B01J19/06;;B65D51/30;;B65D81/26;;F26B3/04;;F26B3/06;;F26B3/12;;F26B5/04;;F26B5/06,,23,5,013-429-438-959-472;;108-944-047-417-001;;058-152-224-378-14X;;015-630-703-147-043;;142-922-446-901-189,10.1042/bj0470626;;pmc1275276;;14800979;;10.1007/978-1-4615-0557-0;;10.1007/978-1-4615-0557-0_5;;11987749;;21610357;;10.1097/ta.0b013e31820e83be;;10.1016/j.thromres.2006.07.005;;16962645;;10.1136/bmj.1.4131.377;;20782987;;pmc2176676,"Lea, et al. “The Reaction between Proteins and Reducing Sugars in the “Dry” State” Department of Pathology, University of Cambridge; Jun. 5, 1950; pp. 626-629.;;Carpenter, et al. “Rational Design of Stable Lyophilized Protein Formulations: Theory and Practice” Kluwer Academic/Plenum Publishers; 2002; pp. 109-133.;;Schmid “Spray drying of protein precipitates and Evaluation of the Nano Spray Dryer B-90” PhD Thesis; 2011; 125 pages.;;Shuja, et al. “Development and Testing of Low-Volume Hyperoncotic, Hyperosmotic Spray-Dried Plasma for the Treatment of Trauma-Associated Coagulopathy” The Journal of Trauma; Mar. 2011; vol. 70; No. 3; pp. 664-671.;;Bakaltcheva; et al. “Freeze-dried whole plasma: Evaluating sucrose, trehalose, sorbitol, mannitol and glycine as stabilizers” Thrombosis Research; 2007; vol. 120; pp. 105-116.;;European Search Report, EP Application No. 14154366, dated Aug. 29, 2014.;;European Search Opinion, EP Application No. 14154366, dated Aug. 29, 2014.;;Answer, Affirmative Defenses, Counterclaims, Cross-Claims and Jury Demand, Entegrion, Inc. vs Velico Medical, Inc., dated Dec. 3, 2012.;;Civil Action Cover Sheet; Entegrion, Inc. vs Velico Medical, Inc., dated Oct. 19, 2012.;;Complaint including Exhibit A, B, and C; Entegrion, Inc. vs Velico Medical, Inc., dated Oct. 19, 2012.;;Mini Spray Dryer B-290-Application Note; www.buchi.com; Mar. 30, 2008.;;Nano Spray Dryer B-90; www.buchi.com; Jul. 18, 2011.;;Mini Spray Dryer System Configuration; www.buchi.com; Jan. 8, 2007.;;Quick Operation Guide; Mini Spray Dryer B-290; www.buchi.com; Sep. 16, 2004.;;Process Parameters; www.buchi.com; Nov. 21, 2008.;;Training Papers Spray Drying; Version B; www.buchi.com; 19 pages; Oct. 29, 2002.;;Mini Spray Dryer B-290; www.buchi.com; May 10, 2007.;;Operation Manual; Mini Spray Dryer B-290; Version G; www.buchi.com; Feb. 8, 2007.;;International Preliminary Report on Patentability, PCT/US2011/058358, dated Apr. 30, 2013.;;Edwards et al., The Preparation and Use of Dried Plasma for Transfusion; British Medical journal; vol. 1, No. 4131;Mar. 9, 1940; pp. 377-381.;;Entegrion's Reply to Counterclaims; Entegrion, Inc. vs Velico Medical, Inc; Dated: Jan. 14, 2013.;;Entegrion's Motion to Dismiss Counts I, II, V, VI and XI of Velico Medical, Inc's Counterclaims and Memorandum in Support of Entegrion's Motion to Dismiss Counts I, II, V, VI, and XI of Velico Medical, Inc.'s Counterclaims; Entegrion, Inc. vs Velico Medical, Inc; Dated: Jan. 14, 2013.;;International Preliminary Report on Patentability, PCT/US2010/049176, dated Feb. 18, 2014.",ACTIVE
285,US,A1,US 2022/0040110 A1,113-182-790-520-737,2022-02-10,2022,US 202117508904 A,2021-10-22,US 202117508904 A;;US 202117337306 A;;US 201615383201 A;;US 201514858539 A;;US 201462052689 P,2014-09-19,Formulations and Methods for Contemporaneous Stabilization of Active Proteins During Spray Drying and Storage,"A method of treatment of plasma with a physiologically compatible spray dry stable acidic substance (SDSAS) prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compostions related to plasma dried by the methods of the present invention.",VELICO MEDICAL INC,LIU QIYONG PETER;;CUI JUNQING;;LUCIEN RUD KARLY;;CARNEY RYAN;;SOHN JIHAE;;ARYA MICHELLE,VELICO MEDICAL INC (2015-03-10),https://lens.org/113-182-790-520-737,Patent Application,yes,1,4,10,10,0,A61K9/1688;;F26B3/12;;F26B3/06;;F26B5/065;;B65D81/266;;B65D51/30;;A61K9/1688;;F26B3/12;;A61K9/16;;A61K9/1682;;F26B5/04;;A61K9/1617;;A61K35/16;;B01J19/06;;B01J2219/00177;;F26B3/04,A61K9/16;;A61K35/16;;B01J19/06;;F26B3/04;;F26B3/06;;F26B3/12;;F26B5/04,,0,0,,,,PENDING
286,GB,A,GB 2574330 A,197-828-105-536-00X,2019-12-04,2019,GB 201907745 A,2019-05-31,GB 201808894 A,2018-05-31,Mass spectrometer,"A mass spectrometer is disclosed comprising: an ion optics device 301 arranged within an ion optics device housing, the one or more electrodes of the device being electrically connected at least one external electrical connector 1719 provided on the housing; and one or more voltage supplies arranged within a voltage supply housing 1717, said supplies being in electrical communication with at least one external electrical connector provided on the voltage supply housing; wherein the electrical connectors on the voltage supply housing are directly physically and electrically connected to the electrical connectors 1719 on the ion optics housing. The electrical connectors on the ion optics device housing may be provided on at least one interface printed circuit board (PCB) arranged to cover and seal one or more apertures leading to at least one vacuum chamber in the ion optics device housing. Also disclosed is an analogue interface for a module operable to perform a predetermined function of a mass spectrometer.",MICROMASS LTD,PETER CARNEY;;JAMES PAUL HARRISON;;PAUL HOUGH;;KENNETH RUSSELL WORTHINGTON;;PAUL MCIVER;;ALISTAIR SCHOFIELD,,https://lens.org/197-828-105-536-00X,Patent Application,no,3,0,10,10,0,H01J49/02;;H01J49/022;;H01J49/068;;H01J49/0031;;H01J49/022;;H01J49/025;;H01J49/063;;H01J49/065;;H01J49/067;;H01J49/401;;H01J49/405;;H01J49/4295,H01J49/02;;H01J49/06,,0,0,,,,ACTIVE
287,US,B2,US 9545379 B2,030-370-261-011-637,2017-01-17,2017,US 201514858539 A,2015-09-18,US 201514858539 A;;US 201462052689 P,2014-09-19,Formulations and methods for contemporaneous stabilization of active proteins during spray drying and storage,"A method of treatment of plasma with a physiologically compatible spray dry stable acidic substance (SDSAS) prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compositions related to plasma dried by the methods of the present invention.",VELICO MEDICAL INC,LIU QIYONG PETER;;CUI JUNQING;;LUCIEN RUD KARLY;;CARNEY RYAN;;SOHN JIHAE;;ARYA MICHELLE,VELICO MEDICAL INC (2015-03-10),https://lens.org/030-370-261-011-637,Granted Patent,yes,31,21,10,10,0,A61K9/1688;;F26B3/12;;F26B3/06;;F26B5/065;;B65D81/266;;B65D51/30;;A61K9/1688;;F26B3/12;;A61K9/16;;A61K9/1682;;F26B5/04;;A61K9/1617;;A61K35/16;;B01J19/06;;B01J2219/00177;;F26B3/04,A61K35/16;;A61K9/16;;A61K35/14;;A61K35/15;;F26B3/06;;F26B3/12;;F26B5/04,,5,4,013-429-438-959-472;;108-944-047-417-001;;058-152-224-378-14X;;015-630-703-147-043,10.1042/bj0470626;;pmc1275276;;14800979;;10.1007/978-1-4615-0557-0;;10.1007/978-1-4615-0557-0_5;;11987749;;21610357;;10.1097/ta.0b013e31820e83be;;10.1016/j.thromres.2006.07.005;;16962645,"Lea, et al. ""The Reaction between Proteins and Reducing Sugars in the ""Dry"" State"" Department of Pathology, University of Cambridge; Jun. 5, 1950; pp. 626-629.;;Carpenter, et al. ""Rational Design of Stable Lyophilized Protein Formulations: Theory and Practice"" Kluwer Academic/Plenum Publishers; 2002; pp. 109-133.;;Schmid ""Spray drying of protein precipitates and Evaluation of the Nano Spray Dryer B-90"" PhD Thesis; 2011; 125 pages.;;Shuja, et al. ""Development and Testing of Low-Volume Hyperoncotic, Hyperosmotic Spray-Dried Plasma for the Treatment of Trauma-Associated Coagulopathy"" The Journal of Trauma; Mar. 2011; vol. 70; No. 3; pp. 664-671.;;Bakaltcheva; et al. ""Freeze-dried whole plasma: Evaluating sucrose, trehalose, sorbitol, mannitol and glycine as stabilizers"" Thrombosis Research; 2007; vol. 120; pp. 105-116.",ACTIVE
288,GB,A,GB 2441483 A,012-052-012-209-152,2008-03-05,2008,GB 0725350 A,2006-06-21,US 2006/0024087 W;;US 69241505 P;;US 69447205 P,2005-06-21,Method and apparatus for telecommunications equipment transfer,"A device for electrically connecting new equipment to an existing connector block in a telecommunications system, where the connector block is connected to old equipment to be replaced, includes an adapter which is mountable on the existing connector block and electrically coupleable thereto. The adapter includes a plurality of electrical Wes provided for connection to the new equipment, and has a surface on which is mountable at least one protector module. The adapter has a first set of contacts mateable with electrical contacts of the at least one protector module, and has second contacts mateable with electrical contacts of the existing connector block.",PORTA SYSTEMS CORP,SQUILLANTE ALAN J;;CARNEY WILLIAM V;;STRANGE CLIFFORD D LE;;KOBSA PETER;;SEEMAN JOSEPH,,https://lens.org/012-052-012-209-152,Patent Application,no,6,0,5,5,0,H01R9/2433;;H01R9/2441;;H01R31/06;;H01R31/08;;H01R31/06;;H01R9/2433;;H01R9/2441;;H01R31/08,H01R31/06;;H01R9/24;;H01R31/08,,0,0,,,,INACTIVE
289,WO,A3,WO 2007/002159 A3,091-168-090-370-54X,2007-04-12,2007,US 2006/0024087 W,2006-06-21,US 69241505 P;;US 69447205 P,2005-06-21,METHOD AND APPARATUS FOR TELECOMMUNICATIONS EQUIPMENT TRANSFER,"A device for electrically connecting new equipment to an existing connector block in a telecommunications system, where the connector block is connected to old equipment to be replaced, includes an adapter which is mountable on the existing connector block and electrically coupleable thereto. The adapter includes a plurality of electrical Wes provided for connection to the new equipment, and has a surface on which is mountable at least one protector module. The adapter has a first set of contacts mateable with electrical contacts of the at least one protector module, and has second contacts mateable with electrical contacts of the existing connector block.",PORTA SYSTEMS CORP;;SQUILLANTE ALAN J;;CARNEY WILLIAM V;;LE STRANGE CLIFFORD D;;KOBSA PETER;;SEEMAN JOSEPH,SQUILLANTE ALAN J;;CARNEY WILLIAM V;;LE STRANGE CLIFFORD D;;KOBSA PETER;;SEEMAN JOSEPH,,https://lens.org/091-168-090-370-54X,Search Report,yes,6,0,5,5,0,H01R9/2433;;H01R9/2441;;H01R31/06;;H01R31/08;;H01R31/06;;H01R9/2433;;H01R9/2441;;H01R31/08,H01R11/20,,0,0,,,,PENDING
290,NZ,A,NZ 239636 A,055-392-363-516-542,1993-06-25,1993,NZ 23963691 A,1991-09-02,US 60726890 A,1990-10-31,BREAKING UP CELLULOSE FIBRE MATS BY PASSING THROUGH DISK REFINER IN PRESENCE OF CROSSLINKING AGENT,,WEYERHAEUSER CO,CARNEY ALLAN R;;GRAEF PETER A;;BOWNS MARK W;;BOLSTAD CLIFFORD R;;OLMSTEAD FRED E,,https://lens.org/055-392-363-516-542,Patent Application,no,0,0,9,9,0,A61F2013/530007;;A61F2013/530474;;D21B1/066;;D21B1/066;;A61F2013/530007;;A61F2013/530474,A61F13/15;;D21B1/06;;D04H1/42,,0,0,,,,PENDING
291,TW,B,TW 491819 B,192-865-139-017-030,2002-06-21,2002,TW 89116531 A,2000-08-16,US 37492199 A,1999-08-16,Method of boosting a glass melting furnace using a roof mounted oxygen-fuel burner,"In an industrial glass furnace which contains recuperators, regenerators, electric boost or other devices for providing heat to glass batch material an oxy-fuel burner mounted in the roof of the furnace provides additional heat to melt the batch material. A method of mounting and using such a roof-mounted oxy-fuel burner including the operating parameters to maximize heat transfer while minimizing the disturbance of the batch material is disclosed.",BOC GROUP INC,SIMPSON NEIL G;;PRUSIA GREGORY F;;CARNEY STEPHEN MCDONALD;;CLAYTON THOMAS G;;RICHARDSON ANDREW PETER,,https://lens.org/192-865-139-017-030,Granted Patent,no,0,0,29,71,0,C03B5/193;;C03B5/2353;;C03B2211/30;;C03B2211/40;;C03B2211/60;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/002;;F23L7/00;;F23L2900/07005;;Y02P40/57;;Y02E20/34;;Y02P40/50;;C03B5/16;;C03B5/193;;C03B2211/30;;C03B2211/40;;C03B5/2353;;F23D14/32;;F23D14/02;;C03B2211/60;;F23L2900/07005;;F23D17/002;;F23C5/00;;F23L7/00;;Y02P40/57;;Y02E20/34;;Y02P40/50,F23C5/08;;C03B5/16;;C03B5/235;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/00;;F23L7/00;;F27D7/02,,0,0,,,,EXPIRED
292,WO,A1,WO 2019/229455 A1,036-160-324-034-100,2019-12-05,2019,GB 2019051496 W,2019-05-31,GB 201808942 A,2018-05-31,BENCH-TOP TIME OF FLIGHT MASS SPECTROMETER,"A mass spectrometer comprising: an ion guide (301) comprising a first portion (1811) configured to guide ions along a first axial path, a second portion (1812) configured to guide ions along a second different axial path, and a transition portion (1813) configured to urge ions from the first axial path onto the second axial path; a downstream electrode (1713) arranged downstream of the ion guide (301); and a voltage supply arranged and configured to apply a potential difference between the ion guide (301) and the downstream electrode (1713) so as to accelerate ions to collide with gas and fragment.",MICROMASS LTD,WILDGOOSE JASON LEE;;CARNEY PETER;;WAMSLEY RUTH;;JOHNSON WILLIAM;;MCIVER PAUL;;WALLIS DAVID;;HARRISON JAMES,,https://lens.org/036-160-324-034-100,Patent Application,yes,6,0,7,7,0,H01J49/005;;H01J49/062;;H01J49/005;;H01J49/0013;;H01J49/065;;H01J49/24;;H01J49/40;;H01J49/062,H01J49/00;;H01J49/06,,1,0,,,"ANONYMOUS: ""Time-of-flight mass spectrometry"", WIKIPEDIA, 28 April 2018 (2018-04-28), XP055614063, Retrieved from the Internet <URL:https://en.wikipedia.org/w/index.php?title=Time-of-flight_mass_spectrometry&oldid=838663844> [retrieved on 20190820]",PENDING
293,CA,A1,CA 2095047 A1,186-479-359-701-720,1992-05-01,1992,CA 2095047 A,1991-08-01,US 60726890 A,1990-10-31,FIBER TREATMENT APPARATUS,"2095047 9208843 PCTABS00013 An apparatus is disclosed for preparing a quantity of individual treated fibers from one or more fiber mats. The apparatus comprises a fiber treatment zone, a conveyor for conveying each mat through the fiber treatment zone, wherein each mat is impregnated by an applicator with a treatment material, such as a crosslinking substance, and directly to an attrition device. The attrition device fiberizes the mats to form a fiber output having a low nit level, such as no more than about three, and a dryer for both drying the fiber output and curing the crosslinking substance. The fiberizer is configured to minimize the accumulation of fiber at locations therein. An optional component of the fiberizer is a novel fluff generator comprised of multiple rotors each having plural longitudinally extended rows of radially extending rotor pins that rotate past groups of shorter pins mounted on the inside surface of the fluff generator housing.",WEYERHAEUSER CO,CARNEY ALLAN R;;GRAEF PETER A;;BOWNS MARK W;;BOLSTAD CLIFFORD R;;OLMSTEAD FRED E,,https://lens.org/186-479-359-701-720,Patent Application,no,0,0,9,9,0,A61F2013/530007;;A61F2013/530474;;D21B1/066;;D21B1/066;;A61F2013/530007;;A61F2013/530474,D04H1/42;;A61F13/15;;D21B1/06,,0,0,,,,DISCONTINUED
294,US,B1,US 8617309 B1,099-073-773-658-63X,2013-12-31,2013,US 201313763276 A,2013-02-08,US 201313763276 A,2013-02-08,Cement compositions including resilient graphitic carbon fraction,"A method for improving the thermal characteristics of cement compositions is provided in which fine resilient graphitic carbon particles (“RGC”) are substituted for a portion of the fine aggregate (typically sand) in the cement formulation. For the purposes of the present disclosure, “fine” is intended to describe particulates having a mesh size of less than about 8 mesh, or a particle size of less than about 2.38 mm, or, more preferably when referring to RGC, a mesh size of less than about 16 mesh and a particle size of less than about 1.19 mm. “Resilient” is intended to describe graphitic carbon particles that exhibit a rebound of at least about 20% after compression to 10,000 psi.",SUPERIOR GRAPHITE CO,CARNEY PETER ROY;;BAER CRAIG ALLEN;;DERWIN DAVID J;;ZHOU CHANGJUN;;WAWRZOS FRANK A;;TLUSTOCHOWICZ MARCIN,SUPERIOR GRAPHITE CO (2013-02-14),https://lens.org/099-073-773-658-63X,Granted Patent,yes,22,12,1,1,0,C04B28/02;;C04B28/02;;C04B2111/00465;;C04B2111/00465;;C04B2111/92;;C04B2111/92;;Y02W30/91;;Y02W30/91,C04B14/36;;C04B14/00;;C04B22/00;;C04B28/00;;C04B103/00;;C04B111/90,106/814;;106/668;;106/716;;106/717,0,0,,,,ACTIVE
295,EP,B1,EP 1183795 B1,112-631-980-185-153,2005-12-14,2005,EP 00935889 A,2000-05-10,US 0012674 W;;US 31481999 A;;US 55812100 A,1999-05-19,METHOD AND APPARATUS FOR ACQUISITION OF A SPREAD-SPECTRUM SIGNAL,,MOTOROLA INC,LAROSA CHRISTOPHER PETER;;STORM BRIAN DAVID;;CARNEY MICHAEL JOHN;;BECKER CHRISTOPHER;;SCHIRTZINGER TRACIE ANN;;STECKL DAVE,"MOTOROLA MOBILITY, INC. (2012-03-05);;GOOGLE TECHNOLOGY HOLDINGS LLC, US (2017-12-14);;GOOGLE TECHNOLOGY HOLDINGS LLC, MOUNTAIN VIEW, US (2018-04-26);;GOOGLE TECHNOLOGY HOLDING LLC (2017-11-21);;MOTOROLA MOBILITY, INC. ( N.D. GES. D. STAATES, US (2011-03-24);;MOTOROLA MOBILITY, INC., US (2011-09-12)",https://lens.org/112-631-980-185-153,Granted Patent,yes,8,1,16,30,0,H04B1/70752;;H04B1/70752;;H04B1/7077;;H04B1/70751;;H04B1/70751;;H04B1/70753;;H04B1/70753;;H04B1/70756;;H04B1/70756;;H04B1/709;;H04B1/709;;H04B2201/70701;;H04B2201/70701;;H04B2201/70702;;H04B2201/70702;;H04B2201/70707;;H04B2201/70707;;H04B2201/70709;;H04B2201/70709,H04B1/7075;;H04B1/709,,0,0,,,,EXPIRED
296,DK,U1,DK 201700002 U1,110-734-330-110-140,2017-01-27,2017,DK BA201700002 U,2017-01-11,DK BA201700002 U,2017-01-11,CEMENTSAMMENSÆTNINGER INDEHOLDENDE EN ELASTISK GRAFITFORMET KULSTOFANDEL,"Der angives en cementsammensætning indeholdende et finkornet tilslagsmateriale hvori finkornede elastiske grafitformede kulstofpartikler ('RGC') erstatter en andel af det finkornede tilslagsmateriale (typisk sand) i cementformuleringen. I den foreliggende beskrivelse angiver ""finkornet"" partikler med en maskestørrelse på mindre end ca. 8 mesh eller en partikelstørrelse på mindre end ca. 2,38 mm, eller mere foretrukket, når der henvises til RGC, en maskestørrelse på mindre end ca. 16 mesh og en partikelstørrelse på mindre end ca. 1,19 mm. ""Elastisk"" beskriver grafitformede kulstofpartikler, der udviser et tilbagespring på mindst ca. 20% efter sammentrykning til 10.000 psi.",SUPERIOR GRAPHITE CO,ZHOU CHANGJUN;;DERWIN DAVID J;;WAWRZOS FRANK A;;CARNEY PETER ROY;;BAER CRAIG ALLEN;;TLUSTOCHOWICZ MARCIN,,https://lens.org/110-734-330-110-140,Patent Application,no,0,0,2,2,0,,C04B28/04,,0,0,,,,INACTIVE
297,GB,A,GB 2574328 A,113-526-145-143-664,2019-12-04,2019,GB 201907724 A,2019-05-31,GB 201808942 A,2018-05-31,Bench-top time of flight mass spectrometer,"A mass spectrometer comprising: an ion guide (301, Fig. 3) comprising a first portion 1811 for guiding ions along a first axial path, a second portion 1812 for guiding ions along a second different axial path, and a transition portion 1813 in which ions are urged from the first axial path onto the second axial path; and a voltage supply for applying a potential difference between the ion guide and a downstream electrode 1713 so as to accelerate ions to collide with gas and fragment.",MICROMASS LTD,JASON LEE WILDGOOSE;;PETER CARNEY;;RUTH WAMSLEY;;WILLIAM JOHNSON;;PAUL MCIVER;;DAVID WALLIS;;JAMES PAUL HARRISON,,https://lens.org/113-526-145-143-664,Patent Application,no,3,1,7,7,0,H01J49/005;;H01J49/062;;H01J49/005;;H01J49/0013;;H01J49/065;;H01J49/24;;H01J49/40;;H01J49/062,H01J49/00;;H01J49/06;;H01J49/24;;H01J49/40,,0,0,,,,DISCONTINUED
298,AU,A,AU 2000/051284 A,001-575-770-228-954,2000-12-05,2000,AU 2000/051284 A,2000-05-10,US 31481999 A;;US 55812100 A;;US 0012674 W,1999-05-19,Method and apparatus for acquisition of a spread-spectrum signal,,MOTOROLA INC,LAROSA CHRISTOPHER PETER;;STORM BRIAN DAVID;;CARNEY MICHAEL JOHN;;BECKER CHRISTOPHER;;SCHIRTZINGER TRACIE ANN;;STECKL DAVE,,https://lens.org/001-575-770-228-954,Patent Application,no,0,0,16,30,0,H04B1/70752;;H04B1/70752;;H04B1/7077;;H04B1/70751;;H04B1/70751;;H04B1/70753;;H04B1/70753;;H04B1/70756;;H04B1/70756;;H04B1/709;;H04B1/709;;H04B2201/70701;;H04B2201/70701;;H04B2201/70702;;H04B2201/70702;;H04B2201/70707;;H04B2201/70707;;H04B2201/70709;;H04B2201/70709,H04B1/7075;;H04B1/709,,0,0,,,,DISCONTINUED
299,EP,A4,EP 1183795 A4,178-880-706-684-664,2003-05-14,2003,EP 00935889 A,2000-05-10,US 0012674 W;;US 31481999 A;;US 55812100 A,1999-05-19,METHOD AND APPARATUS FOR ACQUISITION OF A SPREAD-SPECTRUM SIGNAL,,MOTOROLA INC,LAROSA CHRISTOPHER PETER;;STORM BRIAN DAVID;;CARNEY MICHAEL JOHN;;BECKER CHRISTOPHER;;SCHIRTZINGER TRACIE ANN;;STECKL DAVE,"MOTOROLA MOBILITY, INC. (2012-03-05);;GOOGLE TECHNOLOGY HOLDINGS LLC, US (2017-12-14);;GOOGLE TECHNOLOGY HOLDINGS LLC, MOUNTAIN VIEW, US (2018-04-26);;GOOGLE TECHNOLOGY HOLDING LLC (2017-11-21);;MOTOROLA MOBILITY, INC. ( N.D. GES. D. STAATES, US (2011-03-24);;MOTOROLA MOBILITY, INC., US (2011-09-12)",https://lens.org/178-880-706-684-664,Search Report,no,4,0,16,30,0,H04B1/70752;;H04B1/70752;;H04B1/7077;;H04B1/70751;;H04B1/70751;;H04B1/70753;;H04B1/70753;;H04B1/70756;;H04B1/70756;;H04B1/709;;H04B1/709;;H04B2201/70701;;H04B2201/70701;;H04B2201/70702;;H04B2201/70702;;H04B2201/70707;;H04B2201/70707;;H04B2201/70709;;H04B2201/70709,H04B1/7075;;H04B1/709,,1,0,,,See also references of WO 0070792A1,EXPIRED
300,US,B1,US 7085246 B1,160-617-896-407-753,2006-08-01,2006,US 55812100 A,2000-04-25,US 55812100 A;;US 31481999 A,1999-05-19,Method and apparatus for acquisition of a spread-spectrum signal,An apparatus for acquiring a pseudo-random (PN) sequence timing for a code division multiple access (CDMA) radiotelephone. A buffer stores samples of representations of at least one pilot signal. A correlator coupled to the buffer is operable to correlate at least a portion of the samples with a PN sequence at each of a plurality of different PN offsets to produce corresponding correlation energies. A controller coupled to the correlator interrupts the correlator as soon as the PN sequence at a particular PN offset produces a correlation energy at least equal to an energy threshold.,MOTOROLA INC,LAROSA CHRISTOPHER PETER;;STORM BRIAN DAVID;;CARNEY MICHAEL JOHN;;BECKER CHRISTOPHER;;SCHIRTZINGER TRACIE ANN;;STECKL DAVE,MOTOROLA MOBILITY LLC (2012-06-22);;GOOGLE TECHNOLOGY HOLDINGS LLC (2014-10-28);;MOTOROLA INC (2000-08-21),https://lens.org/160-617-896-407-753,Granted Patent,yes,49,63,16,30,0,H04B1/70752;;H04B1/70752;;H04B1/7077;;H04B1/70751;;H04B1/70751;;H04B1/70753;;H04B1/70753;;H04B1/70756;;H04B1/70756;;H04B1/709;;H04B1/709;;H04B2201/70701;;H04B2201/70701;;H04B2201/70702;;H04B2201/70702;;H04B2201/70707;;H04B2201/70707;;H04B2201/70709;;H04B2201/70709,H04B1/7075;;H04B1/709,370/311;;370/335;;370/441,0,0,,,,EXPIRED
301,DK,Y3,DK 201700002 Y3,097-056-461-333-943,2017-02-24,2017,DK BA201700002 U,2017-01-11,DK BA201700002 U,2017-01-11,CEMENTSAMMENSÆTNINGER INDEHOLDENDE EN ELASTISK GRAFITFORMET KULSTOFANDEL,"Der angives en cementsammensætning indeholdende et finkornet tilslagsmateriale hvori finkornede elastiske grafitformede kulstofpartikler ('RGC') erstatter en andel af det finkornede tilslagsmateriale (typisk sand) i cementformuleringen. I den foreliggende beskrivelse angiver ""finkornet"" partikler med en maskestørrelse på mindre end ca. 8 mesh eller en partikelstørrelse på mindre end ca. 2,38 mm, eller mere foretrukket, når der henvises til RGC, en maskestørrelse på mindre end ca. 16 mesh og en partikelstørrelse på mindre end ca. 1,19 mm. ""Elastisk"" beskriver grafitformede kulstofpartikler, der udviser et tilbagespring på mindst ca. 20% efter sammentrykning til 10.000 psi.",SUPERIOR GRAPHITE CO,ZHOU CHANGJUN;;DERWIN DAVID J;;WAWRZOS FRANK A;;CARNEY PETER ROY;;BAER CRAIG ALLEN;;TLUSTOCHOWICZ MARCIN,,https://lens.org/097-056-461-333-943,Limited Patent,no,0,0,2,2,0,,C04B28/04,,0,0,,,,INACTIVE
302,GB,A,GB 2606328 A,166-191-779-473-690,2022-11-02,2022,GB 202211823 A,2019-05-31,GB 201808942 A;;GB 201907724 A,2018-05-31,Bench-top time of flight mass spectrometer,"A mass spectrometer is configured to operate an AC or RF voltage supply in: a low-attenuation mode in which a relatively high peak-to-peak amplitude AC/RF voltage is supplied to the electrodes of an ion guide 301 to provide relatively strong radial confinement of ions therein; and a high-attenuation mode in which a lower amplitude AC/RF voltage is supplied to the electrodes to provide weaker radial confinement of ions. The spectrometer may preferably switch between the low- and high- attenuation modes based on whether an ion signal detected by a downstream ion detector is above or below a threshold intensity or threshold ion impact rate. The ion guide may also comprise first and second axial paths, the second axial path 1802 being parallel to and displaced from the first 1801. Ions are urged from the first to the second axial path in a transition portion 1813 of the ion guide.",MICROMASS LTD,JASON LEE WILDGOOSE;;PETER CARNEY;;RUTH WAMSLEY;;WILLIAM JOHNSON;;DAVID WALLIS;;PAUL JAMES MCLVER;;JAMES HARRISON,,https://lens.org/166-191-779-473-690,Patent Application,no,2,0,7,7,0,H01J49/005;;H01J49/062;;H01J49/005;;H01J49/0013;;H01J49/065;;H01J49/24;;H01J49/40;;H01J49/062,H01J49/06;;H01J49/00;;H01J49/24;;H01J49/40,,0,0,,,,ACTIVE
303,EP,A1,EP 3074362 A1,000-904-519-320-513,2016-10-05,2016,EP 13814679 A,2013-11-25,US 2013/0071675 W,2013-11-25,CEMENT COMPOSITIONS INCLUDING RESILIENT GRAPHITIC CARBON FRACTION,,SUPERIOR GRAPHITE CO,CARNEY PETER ROY;;BAER CRAIG ALLEN;;DERWIN DAVID J;;ZHOU CHANGJUN;;WAWRZOS FRANK A;;TLUSTOCHOWICZ MARCIN,,https://lens.org/000-904-519-320-513,Patent Application,yes,0,0,6,6,0,C04B28/04;;C04B28/14;;C04B14/024;;C04B2111/00465;;C04B2111/94;;C04B2111/00663;;C04B2111/00706;;Y02W30/91,C04B28/04;;C04B14/02;;C04B28/14;;C04B111/00;;C04B111/94,,0,0,,,,DISCONTINUED
304,CA,C,CA 2926081 C,025-698-420-988-380,2019-07-09,2019,CA 2926081 A,2013-11-25,US 2013/0071675 W,2013-11-25,CEMENT COMPOSITIONS INCLUDING RESILIENT GRAPHITIC CARBON FRACTION,"A method for improving the thermal characteristics of cement compositions is provided in which fine resilient graphitic carbon particles (""RGC"") are substituted for a portion of the fine aggregate (typically send) in the cement formulation. For the purposes of the present disclosure, ""fine"" is intended to describe particulates having a mesh size of less than about 8 mesh, or a particle size of less than about 2.38 mm, or, more preferably when referring to RGC, a mesh size of less than about 16 mesh and a particle size of less than about 1.19 mm. ""Resilient"" is intended to describe graphitic carbon particles that exhibit a rebound of at least about 20% after compression to 10,000 psi.",SUPERIOR GRAPHITE CO,CARNEY PETER ROY;;BAER CRAIG ALLEN;;DERWIN DAVID J;;ZHOU CHANGJUN;;WAWRZOS FRANK A;;TLUSTOCHOWICZ MARCIN,,https://lens.org/025-698-420-988-380,Granted Patent,no,0,0,6,6,0,C04B28/04;;C04B28/14;;C04B14/024;;C04B2111/00465;;C04B2111/94;;C04B2111/00663;;C04B2111/00706;;Y02W30/91,C04B28/04;;C04B14/02;;C04B28/14,,0,0,,,,ACTIVE
305,ES,T3,ES 2254181 T3,054-077-078-321-846,2006-06-16,2006,ES 00935889 T,2000-05-10,US 31481999 A;;US 55812100 A,1999-05-19,METODO Y APARATO PARA LA ADQUISION DE SEÑALES DE ESPECTRO EXPANDIDO.,"Un método de adquisición de una señal piloto, en un radioteléfono (104) operable en sistemas de acceso múltiple por división de código (CDMA), comprendiendo el método: almacenamiento de muestras de las señales recibidas; generación, durante el paso de almacenamiento, de una secuencia PN; selección de una desviación del ruido seudo- aleatorio (PN) para la secuencia PN; correlación de al menos una porción de las muestras con al menos una porción de la secuencia PN para producir una energía de correlación; elección de una nueva desviación PN; comparación de la energía de correlación con un umbral de energía; y repetición de los pasos de correlación, selección, y comparación hasta que se dé cualquiera de los casos: se encuentra una temporización de secuencia PN que produce una energía de correlación al menos igual al umbral de energía, o el paso de comparación se realiza un predeterminado número de veces; y caracterizado en que, durante el paso de correlación, la secuencia PN se regenera con referencia a la desviación PN a una velocidad más rápida que el paso de generación.",MOTOROLA INC,LAROSA CHRISTOPHER PETER;;STORM BRIAN DAVID;;CARNEY MICHAEL JOHN;;BECKER CHRISTOPHER;;SCHIRTZINGER TRACIE ANN;;STECKL DAVE,,https://lens.org/054-077-078-321-846,Granted Patent,no,0,0,16,30,0,H04B1/70752;;H04B1/70752;;H04B1/7077;;H04B1/70751;;H04B1/70751;;H04B1/70753;;H04B1/70753;;H04B1/70756;;H04B1/70756;;H04B1/709;;H04B1/709;;H04B2201/70701;;H04B2201/70701;;H04B2201/70702;;H04B2201/70702;;H04B2201/70707;;H04B2201/70707;;H04B2201/70709;;H04B2201/70709,H04B1/7075;;H04B1/709,,0,0,,,,EXPIRED
306,CA,A1,CA 2926081 A1,088-750-635-643-460,2015-05-28,2015,CA 2926081 A,2013-11-25,US 2013/0071675 W,2013-11-25,CEMENT COMPOSITIONS INCLUDING RESILIENT GRAPHITIC CARBON FRACTION,"A method for improving the thermal characteristics of cement compositions is provided in which fine resilient graphitic carbon particles (""RGC"") are substituted for a portion of the fine aggregate (typically send) in the cement formulation. For the purposes of the present disclosure, ""fine"" is intended to describe particulates having a mesh size of less than about 8 mesh, or a particle size of less than about 2.38 mm, or, more preferably when referring to RGC, a mesh size of less than about 16 mesh and a particle size of less than about 1.19 mm. ""Resilient"" is intended to describe graphitic carbon particles that exhibit a rebound of at least about 20% after compression to 10,000 psi.",SUPERIOR GRAPHITE CO,CARNEY PETER ROY;;BAER CRAIG ALLEN;;DERWIN DAVID J;;ZHOU CHANGJUN;;WAWRZOS FRANK A;;TLUSTOCHOWICZ MARCIN,,https://lens.org/088-750-635-643-460,Patent Application,no,0,0,6,6,0,C04B28/04;;C04B28/14;;C04B14/024;;C04B2111/00465;;C04B2111/94;;C04B2111/00663;;C04B2111/00706;;Y02W30/91,C04B28/04;;C04B14/02;;C04B28/14,,0,0,,,,ACTIVE
307,MX,A,MX 2016006524 A,186-370-105-659-252,2016-09-06,2016,MX 2016006524 A,2013-11-25,US 2013/0071675 W,2013-11-25,CEMENT COMPOSITIONS INCLUDING RESILIENT GRAPHITIC CARBON FRACTION.,"A method for improving the thermal characteristics of cement compositions is provided in which fine resilient graphitic carbon particles (""RGC"") are substituted for a portion of the fine aggregate (typically send) in the cement formulation. For the purposes of the present disclosure, ""fine"" is intended to describe particulates having a mesh size of less than about 8 mesh, or a particle size of less than about 2.38 mm, or, more preferably when referring to RGC, a mesh size of less than about 16 mesh and a particle size of less than about 1.19 mm. ""Resilient"" is intended to describe graphitic carbon particles that exhibit a rebound of at least about 20% after compression to 10,000 psi.",SUPERIOR GRAPHITE CO,CHANGJUN ZHOU;;FRANK A WAWRZOS;;PETER ROY CARNEY;;CRAIG ALLEN BAER;;DAVID J DERWIN;;MARCIN TLUSTOCHOWICZ,,https://lens.org/186-370-105-659-252,Patent Application,no,0,0,6,6,0,C04B28/04;;C04B28/14;;C04B14/024;;C04B2111/00465;;C04B2111/94;;C04B2111/00663;;C04B2111/00706;;Y02W30/91,C04B28/04;;C04B14/02;;C04B28/14;;C04B111/00;;C04B111/94,,0,0,,,,PENDING
308,WO,A1,WO 2015/076841 A1,172-346-925-795-358,2015-05-28,2015,US 2013/0071675 W,2013-11-25,US 2013/0071675 W,2013-11-25,CEMENT COMPOSITIONS INCLUDING RESILIENT GRAPHITIC CARBON FRACTION,"A method for improving the thermal characteristics of cement compositions is provided in which fine resilient graphitic carbon particles (""RGC"") are substituted for a portion of the fine aggregate (typically send) in the cement formulation. For the purposes of the present disclosure, ""fine"" is intended to describe particulates having a mesh size of less than about 8 mesh, or a particle size of less than about 2.38 mm, or, more preferably when referring to RGC, a mesh size of less than about 16 mesh and a particle size of less than about 1.19 mm. ""Resilient"" is intended to describe graphitic carbon particles that exhibit a rebound of at least about 20% after compression to 10,000 psi.",SUPERIOR GRAPHITE CO,CARNEY PETER ROY;;BAER CRAIG ALLEN;;DERWIN DAVID J;;ZHOU CHANGJUN;;WAWIZOS FRANK A;;TLUSTOCHOWICZ MARCIN,,https://lens.org/172-346-925-795-358,Patent Application,yes,6,1,6,6,0,C04B28/04;;C04B28/14;;C04B14/024;;C04B2111/00465;;C04B2111/94;;C04B2111/00663;;C04B2111/00706;;Y02W30/91,C04B28/04;;C04B14/02;;C04B28/14;;C04B111/00;;C04B111/94,,1,1,053-916-624-910-698,10.12989/cac.2013.12.3.337,"WU T ET AL: ""A study on electrical and thermal properties of conductive concrete"", COMPUTERS & CONCRETE : AN INTERNATIONAL JOURNAL, TECHNO-PRESS, TAEJON, KOREA, vol. 12, no. 3, 1 January 2013 (2013-01-01), pages 337 - 349, XP008170651, ISSN: 1598-8198, DOI: 10.12989/CAC.2013.12.3.337",PENDING
309,EP,A1,EP 1183795 A1,111-213-599-662-186,2002-03-06,2002,EP 00935889 A,2000-05-10,US 0012674 W;;US 31481999 A;;US 55812100 A,1999-05-19,METHOD AND APPARATUS FOR ACQUISITION OF A SPREAD-SPECTRUM SIGNAL,,MOTOROLA INC,LAROSA CHRISTOPHER PETER;;STORM BRIAN DAVID;;CARNEY MICHAEL JOHN;;BECKER CHRISTOPHER;;SCHIRTZINGER TRACIE ANN;;STECKL DAVE,"MOTOROLA MOBILITY, INC. (2012-03-05);;GOOGLE TECHNOLOGY HOLDINGS LLC, US (2017-12-14);;GOOGLE TECHNOLOGY HOLDINGS LLC, MOUNTAIN VIEW, US (2018-04-26);;GOOGLE TECHNOLOGY HOLDING LLC (2017-11-21);;MOTOROLA MOBILITY, INC. ( N.D. GES. D. STAATES, US (2011-03-24);;MOTOROLA MOBILITY, INC., US (2011-09-12)",https://lens.org/111-213-599-662-186,Patent Application,yes,0,0,16,30,0,H04B1/70752;;H04B1/70752;;H04B1/7077;;H04B1/70751;;H04B1/70751;;H04B1/70753;;H04B1/70753;;H04B1/70756;;H04B1/70756;;H04B1/709;;H04B1/709;;H04B2201/70701;;H04B2201/70701;;H04B2201/70702;;H04B2201/70702;;H04B2201/70707;;H04B2201/70707;;H04B2201/70709;;H04B2201/70709,H04B1/7075;;H04B1/709,,0,0,,,,EXPIRED
310,GB,B,GB 2606328 B,021-595-867-648-852,2023-01-18,2023,GB 202211823 A,2019-05-31,GB 201808942 A;;GB 201907724 A,2018-05-31,Bench-top time of flight mass spectrometer,,MICROMASS LTD,JASON LEE WILDGOOSE;;PETER CARNEY;;RUTH WAMSLEY;;WILLIAM JOHNSON;;DAVID WALLIS;;PAUL JAMES MCLVER;;JAMES HARRISON,,https://lens.org/021-595-867-648-852,Granted Patent,no,2,0,7,7,0,H01J49/005;;H01J49/062;;H01J49/005;;H01J49/0013;;H01J49/065;;H01J49/24;;H01J49/40;;H01J49/062,H01J49/06;;H01J49/00;;H01J49/24;;H01J49/40,,0,0,,,,ACTIVE
311,WO,A8,WO 2015/076841 A8,072-937-257-634-792,2016-05-19,2016,US 2013/0071675 W,2013-11-25,US 2013/0071675 W,2013-11-25,CEMENT COMPOSITIONS INCLUDING RESILIENT GRAPHITIC CARBON FRACTION,"A method for improving the thermal characteristics of cement compositions is provided in which fine resilient graphitic carbon particles (""RGC"") are substituted for a portion of the fine aggregate (typically send) in the cement formulation. For the purposes of the present disclosure, ""fine"" is intended to describe particulates having a mesh size of less than about 8 mesh, or a particle size of less than about 2.38 mm, or, more preferably when referring to RGC, a mesh size of less than about 16 mesh and a particle size of less than about 1.19 mm. ""Resilient"" is intended to describe graphitic carbon particles that exhibit a rebound of at least about 20% after compression to 10,000 psi.",SUPERIOR GRAPHITE CO,CARNEY PETER ROY;;BAER CRAIG ALLEN;;DERWIN DAVID J;;ZHOU CHANGJUN;;WAWRZOS FRANK A;;TLUSTOCHOWICZ MARCIN,,https://lens.org/072-937-257-634-792,Amended Application,yes,0,0,6,6,0,C04B28/04;;C04B28/14;;C04B14/024;;C04B2111/00465;;C04B2111/94;;C04B2111/00663;;C04B2111/00706;;Y02W30/91,C04B28/04;;C04B14/02;;C04B28/14;;C04B111/00;;C04B111/94,,0,0,,,,PENDING
312,WO,A1,WO 2000/070792 A1,073-772-103-776-652,2000-11-23,2000,US 0012674 W,2000-05-10,US 31481999 A;;US 55812100 A,1999-05-19,METHOD AND APPARATUS FOR ACQUISITION OF A SPREAD-SPECTRUM SIGNAL,An apparatus (114) for acquiring a pseudo-random (PN) sequence timing for a code division multiple access (CDMA) radiotelephone (104). A buffer (230) stores samples of representations of at least one pilot signal. A correlator (202) coupled to the buffer (230) is operable to correlate at least a portion of the samples with a PN sequence at each of a plurality of different PN offsets to produce corresponding correlation energies. A controller (116) coupled to the correlator (202) interrupts the correlator (202) as soon as the PN sequence at a particular PN offset produces a correlation energy at least equal to an energy threshold.,MOTOROLA INC,LAROSA CHRISTOPHER PETER;;STORM BRIAN DAVID;;CARNEY MICHAEL JOHN;;BECKER CHRISTOPHER;;SCHIRTZINGER TRACIE ANN;;STECKL DAVE,,https://lens.org/073-772-103-776-652,Patent Application,yes,5,21,16,30,0,H04B1/70752;;H04B1/70752;;H04B1/7077;;H04B1/70751;;H04B1/70751;;H04B1/70753;;H04B1/70753;;H04B1/70756;;H04B1/70756;;H04B1/709;;H04B1/709;;H04B2201/70701;;H04B2201/70701;;H04B2201/70702;;H04B2201/70702;;H04B2201/70707;;H04B2201/70707;;H04B2201/70709;;H04B2201/70709,H04B1/7075;;H04B1/709,,1,0,,,See also references of EP 1183795A4,PATENTED
313,EP,B1,EP 0863919 B1,045-003-890-219-174,2000-11-15,2000,EP 96936975 A,1996-10-25,US 9617140 W;;US 760995 P,1995-11-27,SUPPORTED CATALYST CONTAINING TETHERED CATION FORMING ACTIVATOR,,DOW CHEMICAL CO;;GRACE W R & CO,CARNAHAN EDMUND M;;CARNEY MICHAEL J;;NEITHAMER DAVID R;;NICKIAS PETER N;;SHIH KENG-YU;;SPENCER LEE,,https://lens.org/045-003-890-219-174,Granted Patent,yes,4,0,27,27,0,C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F10/00;;C08F4/65925;;C08F4/6592;;C08F4/025;;C08F4/6192;;C08F4/61908;;C08F4/61916;;C08F4/61912;;C08F10/02;;C08F4/65912;;C08F210/16;;C08F110/02;;Y10S526/943,C08F4/02;;C08F4/603;;C08F4/619;;C08F4/6192;;C08F4/643;;C08F4/645;;C08F4/646;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16,,1,0,,,"MAKROMOLEKULARE CHEMIE: MACROMOLECULAR SYMPOSIA, vol. 66, no. 1297b, February 1993, BASEL, pages 215-224, XP000360504 SIEDLE: ""The role of non-coordinating anions in homogeneous olefin polymerization""",EXPIRED
314,MY,A,MY 113931 A,114-385-564-547-348,2002-06-29,2002,MY PI19964942 A,1996-11-26,US 760995 P,1995-11-27,SUPPORTED CATALYST CONTAINING TETHERED CATION FORMING ACTIVATOR,"A SUPPORT FOR USE IN PREPARING SUPPORTED CATALYSTS FOR ADDITION POLYMERIZATIONS COMPRISING THE REACTION PRODUCT OF:(A) AN INORGANIC OXIDE MATERIAL COMPRISING REACTIVE SURFACE HYDROXYL GROUPS, AT LEAST SOME OF SAID HYDROXYL GROUPS OPTIONALLY HAVING BEEN FUNCTIONALIZED AND CONVERTED TO A REACTIVE SILANE MOIETY CORRESPONDING TO THE FORMULA:-OSIR2H,WHEREIN R, INDEPENDENTLY EACH OCCURRENCE, IS HYDROGEN, C1-20HYDROCARBYL, OR C1-20 HYDROCARBYLOXY,SAID INORGANIC OXIDE OR FUNCTIONALIZED DERIVATIVE THEREOF COMPRISING LESS THAN 1.0 MMOL OF REACTIVE SURFACE HYDROXYL FUNCTIONALITY PER GRAM, AND(B) AN ACTIVATOR COMPOUND COMPRISING:B1) A CATION WHICH IS CAPABLE OF REACTING WITH A TRANSITION METAL COMPOUND TO FORM A CATALYTICALLY ACTIVE TRANSITION METAL COMPLEX, ANDB2) A COMPATIBLE ANION CONTAINING AT LEAST ONE SUBSTITUENT ABLE TO REACT WITH THE INORGANIC OXIDE, WITH RESIDUAL HYDROXYL FUNCTIONALITY OF THE INORGANIC OXIDE, OR WITH THE REACTIVE SILANE MOIETY , THEREBY COVALENTLY BONDING THE COMPATIBLE ANION TO THE SUPPORT; CATALYSTS FORMED THEREFROM, PROCESS OF MANUFACTURE AND THE METHOD OF USE.",DOW CHEMICAL CO;;GRACE W R & CO,DAVID R NEITHSMER;;PETER N NICKIAS;;KENG-YU SHIH;;EDMUND M CARNAHAN;;MICHALE J CARNEY;;LEE SPENCER,,https://lens.org/114-385-564-547-348,Granted Patent,no,0,0,27,27,0,C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F10/00;;C08F4/65925;;C08F4/6592;;C08F4/025;;C08F4/6192;;C08F4/61908;;C08F4/61916;;C08F4/61912;;C08F10/02;;C08F4/65912;;C08F210/16;;C08F110/02;;Y10S526/943,C08F4/603;;C08F4/02;;C08F4/619;;C08F4/6192;;C08F4/643;;C08F4/645;;C08F4/646;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16,,0,0,,,,EXPIRED
315,DK,T3,DK 0863919 T3,037-011-569-462-768,2000-12-11,2000,DK 96936975 T,1996-10-25,US 760995 P;;US 9617140 W,1995-11-27,"Understøttet katalysator indeholdende en tøjret, kationdannende aktivator",,GRACE W R & CO;;DOW CHEMICAL CO,SHIH KENG-YU;;CARNAHAN EDMUND M;;CARNEY MICHAEL J;;NEITHAMER DAVID R;;NICKIAS PETER N;;SPENCER LEE,,https://lens.org/037-011-569-462-768,Granted Patent,no,0,0,27,27,0,C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F10/00;;C08F4/65925;;C08F4/6592;;C08F4/025;;C08F4/6192;;C08F4/61908;;C08F4/61916;;C08F4/61912;;C08F10/02;;C08F4/65912;;C08F210/16;;C08F110/02;;Y10S526/943,C08F4/02;;C08F4/603;;C08F4/619;;C08F4/6192;;C08F4/643;;C08F4/645;;C08F4/646;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16,,0,0,,,,EXPIRED
316,NO,D0,NO 982370 D0,093-857-717-486-084,1998-05-26,1998,NO 982370 A,1998-05-26,US 760995 P;;US 9617140 W,1995-11-27,"Katalysatorbµrer, hvor kationdannende aktivator er bundet til bµrer",,DOW CHEMICAL CO;;GRACE W R & CO,CARNAHAN EDMUND M;;CARNEY MICHAEL J;;NEITHAMER DAVID R;;NICKIAS PETER N;;SHIH KENG-YU;;SPENCER LEE,,https://lens.org/093-857-717-486-084,Patent Application,no,0,0,27,27,0,C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F10/00;;C08F4/65925;;C08F4/6592;;C08F4/025;;C08F4/6192;;C08F4/61908;;C08F4/61916;;C08F4/61912;;C08F10/02;;C08F4/65912;;C08F210/16;;C08F110/02;;Y10S526/943,C08F4/02;;C08F4/603;;C08F4/619;;C08F4/6192;;C08F4/643;;C08F4/645;;C08F4/646;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16,,0,0,,,,DISCONTINUED
317,EP,A1,EP 0863919 A1,147-617-812-076-897,1998-09-16,1998,EP 96936975 A,1996-10-25,US 9617140 W;;US 760995 P,1995-11-27,SUPPORTED CATALYST CONTAINING TETHERED CATION FORMING ACTIVATOR,,DOW CHEMICAL CO;;GRACE W R & CO,CARNAHAN EDMUND M;;CARNEY MICHAEL J;;NEITHAMER DAVID R;;NICKIAS PETER N;;SHIH KENG-YU;;SPENCER LEE,,https://lens.org/147-617-812-076-897,Patent Application,yes,0,1,27,27,0,C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F10/00;;C08F4/65925;;C08F4/6592;;C08F4/025;;C08F4/6192;;C08F4/61908;;C08F4/61916;;C08F4/61912;;C08F10/02;;C08F4/65912;;C08F210/16;;C08F110/02;;Y10S526/943,C08F4/02;;C08F4/603;;C08F4/619;;C08F4/6192;;C08F4/643;;C08F4/645;;C08F4/646;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16,,0,0,,,,EXPIRED
318,CA,A1,CA 2233655 A1,009-689-757-003-984,1997-06-05,1997,CA 2233655 A,1996-10-25,US 760995 P;;US 9617140 W,1995-11-27,SUPPORTED CATALYST CONTAINING TETHERED CATION FORMING ACTIVATOR,"A support for use in preparing supported catalysts for addition polymerizations comprising the reaction product of: (A) an inorganic oxide material comprising reactive surface hydroxyl groups, at least some of said hydroxyl groups optionally having been functionalized and converted to a reactive silane moiety corresponding to the formula: -OSiR2H, wherein R, independently each occurrence, is hydrogen, C1-20 hydrocarbyl, or C1-20 hydrocarbyloxy, said inorganic oxide or functionalized derivative thereof comprising less than 1.0 mmol of reactive surface hydroxyl functionality per gram; and (B) an activator compound comprising: b1) a cation which is capable of reacting with a transition metal compound to form a catalytically active transition metal complex, and b2) a compatible anion containing at least one substituent able to react with the inorganic oxide, with residual hydroxyl functionality of the inorganic oxide, or with the reactive silane moiety, thereby covalently bonding the compatible anion to the support; catalysts formed therefrom, process of manufacture and the method of use.",DOW CHEMICAL CO;;GRACE W R & CO,NICKIAS PETER N;;NEITHAMER DAVID R;;CARNAHAN EDMUND M;;CARNEY MICHAEL J;;SHIH KENG-YU;;SPENCER LEE,,https://lens.org/009-689-757-003-984,Patent Application,no,0,0,27,27,0,C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F10/00;;C08F4/65925;;C08F4/6592;;C08F4/025;;C08F4/6192;;C08F4/61908;;C08F4/61916;;C08F4/61912;;C08F10/02;;C08F4/65912;;C08F210/16;;C08F110/02;;Y10S526/943,C08F4/02;;C08F4/603;;C08F4/619;;C08F4/6192;;C08F4/643;;C08F4/645;;C08F4/646;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16,,0,0,,,,EXPIRED
319,ES,T3,ES 2152567 T3,021-425-673-689-742,2001-02-01,2001,ES 96936975 T,1996-10-25,US 760995 P,1995-11-27,CATALIZADOR SOPORTADO QUE CONTIENE UN ACTIVADOR DE FORMACION DE CATIONES ENLAZADOS.,"UN SOPORTE PARA SU USO EN LA PREPARACION DE CATALIZADORES SOPORTADOS PARA POLIMERIZACIONES POR ADICION QUE INCLUYE EL PRODUCTO DE REACCION DE: (A) UN MATERIAL OXIDO INORGANICO QUE INCLUYE GRUPOS HIDROXILO SUPERFICIALES REACTIVOS, AL MENOS ALGUNOS DE LOS CUALES HAN SIDO OPCIONALMENTE FUNCIONALIZADOS Y CONVERTIDOS A UNA FRACCION SILANO REACTIVA CORRESPONDIENTE A LA FORMULA: - OSIR 2 H, DONDE R, DE FORMA INDEPENDIENTE EN CADA APARICION, ES HIDROGENO, HIDROCARBILO C 1-20 , O HIDROCARBILOXI C 1-20 , CON UN LIMITE SUPERIOR PARA DICHO OXIDO INO RGANICO O SU DERIVADO FUNCIONALIZADO DE 1.0 MMOL DE FUNCIONALIDAD HIDROXILO REACTIVA SUPERFICIAL POR GRAMO; Y (B) UN COMPUESTO ACTIVADOR QUE INCLUYE: B 1 ) UN CATION CAPAZ DE REACCIO NAR CON UN COMPUESTO DE METAL DE TRANSICION PARA FORMAR UN COMPLEJO DE METAL DE TRANSICION CATALITICAMENTE ACTIVO, Y B 2 ) UN ANION COMPATIBLE QUE CONTIENE AL MENOS UN SUSTITUYENTE CAPAZ DE REACCIONAR CON EL OXIDO INORGANICO, CON FUNCIONALIDAD HIDROXILO RESIDUAL DEL OXIDO INORGANICO, O CON LA FRACCION SILANO REACTIVA, ENLAZANDO ASI COVALENTEMENTE EL ANION COMPATIBLE AL SOPORTE; CATALIZADORES FORMADOS A PARTIR DEL MISMO, PROCESO DE FABRICACION Y METODOS DE UTILIZACION.",DOW CHEMICAL CO;;GRACE W R & CO,CARNAHAN EDMUND M;;CARNEY MICHAEL J;;NEITHAMER DAVID R;;NICKIAS PETER N;;SHIH KENG-YU;;SPENCER LEE,,https://lens.org/021-425-673-689-742,Granted Patent,no,0,0,27,27,0,C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F10/00;;C08F4/65925;;C08F4/6592;;C08F4/025;;C08F4/6192;;C08F4/61908;;C08F4/61916;;C08F4/61912;;C08F10/02;;C08F4/65912;;C08F210/16;;C08F110/02;;Y10S526/943,C08F4/02;;C08F4/603;;C08F4/619;;C08F4/6192;;C08F4/643;;C08F4/645;;C08F4/646;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16,,0,0,,,,EXPIRED
320,AU,B2,AU 710813 B2,074-106-325-386-061,1999-09-30,1999,AU 1996/074757 A,1996-10-25,US 760995 P;;US 9617140 W,1995-11-27,Supported catalyst containing tethered cation forming activator,,DOW CHEMICAL CO;;GRACE W R & CO,CARNAHAN EDMUND M;;CARNEY MICHAEL J;;NEITHAMER DAVID R;;NICKIAS PETER N;;SHIH KENG-YU;;SPENCER LEE,,https://lens.org/074-106-325-386-061,Granted Patent,no,1,0,27,27,0,C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F10/00;;C08F4/65925;;C08F4/6592;;C08F4/025;;C08F4/6192;;C08F4/61908;;C08F4/61916;;C08F4/61912;;C08F10/02;;C08F4/65912;;C08F210/16;;C08F110/02;;Y10S526/943,C08F4/02;;C08F4/603;;C08F4/619;;C08F4/6192;;C08F4/643;;C08F4/645;;C08F4/646;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16,,0,0,,,,EXPIRED
321,WO,A1,WO 1997/019959 A1,045-244-571-315-588,1997-06-05,1997,US 9617140 W,1996-10-25,US 760995 P,1995-11-27,SUPPORTED CATALYST CONTAINING TETHERED CATION FORMING ACTIVATOR,"A support for use in preparing supported catalysts for addition polymerizations comprising the reaction product of: (A) an inorganic oxide material comprising reactive surface hydroxyl groups, at least some of said hydroxyl groups optionally having been functionalized and converted to a reactive silane moiety corresponding to the formula: -OSiR2H, wherein R, independently each occurrence, is hydrogen, C1-20 hydrocarbyl, or C1-20 hydrocarbyloxy, said inorganic oxide or functionalized derivative thereof comprising less than 1.0 mmol of reactive surface hydroxyl functionality per gram; and (B) an activator compound comprising: b1) a cation which is capable of reacting with a transition metal compound to form a catalytically active transition metal complex, and b2) a compatible anion containing at least one substituent able to react with the inorganic oxide, with residual hydroxyl functionality of the inorganic oxide, or with the reactive silane moiety, thereby covalently bonding the compatible anion to the support; catalysts formed therefrom, process of manufacture and the method of use.",DOW CHEMICAL CO;;GRACE W R & CO;;CARNAHAN EDMUND M;;CARNEY MICHAEL J;;NEITHAMER DAVID R;;NICKIAS PETER N;;SHIH KENG YU;;SPENCER LEE,CARNAHAN EDMUND M;;CARNEY MICHAEL J;;NEITHAMER DAVID R;;NICKIAS PETER N;;SHIH KENG-YU;;SPENCER LEE,,https://lens.org/045-244-571-315-588,Patent Application,yes,4,90,27,27,0,C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F10/00;;C08F4/65925;;C08F4/6592;;C08F4/025;;C08F4/6192;;C08F4/61908;;C08F4/61916;;C08F4/61912;;C08F10/02;;C08F4/65912;;C08F210/16;;C08F110/02;;Y10S526/943,C08F4/02;;C08F4/603;;C08F4/619;;C08F4/6192;;C08F4/643;;C08F4/645;;C08F4/646;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16,,1,1,062-031-934-715-474,10.1002/masy.19930660119,"SIEDLE: ""The role of non-coordinating anions in homogeneous olefin polymerization"", MAKROMOLEKULARE CHEMIE: MACROMOLECULAR SYMPOSIA, vol. 66, no. 1297b, February 1993 (1993-02-01), BASEL, pages 215 - 224, XP000360504",PATENTED
322,CA,C,CA 2233655 C,148-011-293-772-734,2005-05-17,2005,CA 2233655 A,1996-10-25,US 760995 P;;US 9617140 W,1995-11-27,SUPPORTED CATALYST CONTAINING TETHERED CATION FORMING ACTIVATOR,"A support for use in preparing supported catalysts for addition polymerizations comprising the reaction product of: (A) an inorganic oxide material comprising reactive surface hydroxyl groups, at least some of said hydroxyl groups optionally having been functionalized and converted to a reactive silane moiety corresponding to the formula: - OSiR2H, wherein R, independently each occurrence, is hydrogen, C1-20 hydrocarbyl, or C1-20 hydrocarbyloxy, said inorganic oxide or functionalized derivative thereof comprising less than 1.0 mmol of reactive surface hydroxyl functionality per gram; and (B) an activator compound comprising: b1) a cation which is capable of reacting with a transition metal compound to form a catalytically active transition metal complex, and b2) a compatible anion containing at least one substituent able to react with the inorganic oxide, with residual hydroxyl functionality of the inorganic oxide, or with the reactive silane moiety, thereby covalently bonding the compatible anion to the support; catalysts formed therefrom, process of manufacture and the method of use.",DOW CHEMICAL CO;;GRACE W R & CO,CARNAHAN EDMUND M;;NEITHAMER DAVID R;;SPENCER LEE;;CARNEY MICHAEL J;;SHIH KENG-YU;;NICKIAS PETER N,,https://lens.org/148-011-293-772-734,Granted Patent,no,0,0,27,27,0,C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F10/00;;C08F4/65925;;C08F4/6592;;C08F4/025;;C08F4/6192;;C08F4/61908;;C08F4/61916;;C08F4/61912;;C08F10/02;;C08F4/65912;;C08F210/16;;C08F110/02;;Y10S526/943,C08F4/02;;C08F4/603;;C08F4/619;;C08F4/6192;;C08F4/643;;C08F4/645;;C08F4/646;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16,,0,0,,,,EXPIRED
323,HU,A2,HU P9902066 A2,103-636-289-072-919,1999-10-28,1999,HU P9902066 A,1996-10-25,US 760995 P,1995-11-27,SUPPORTED CATALYST CONTAINING TETHERED CATION FORMING ACTIVATOR,"A találmány tárgya hőrdőzó addíciós pőlimerizáláshőz szőlgáló hőrdőzóskatalizátőrők előállításában való felhasználásra, amely hőrdőzó azalábbi összetevők reakciótermékét tartalmazza: (A) egy reaktívfelületi hidrőxilcsőpőrtőkat tartalmazó szervetlen őxid anyag,amelynek hidrőxilcsőpőrtjai közül legalább néhány fűnkciőnalizálva vanés át van alakítva -OSiR2H általánős képletnek megfelelő reaktívszilán egységgé, ahől az R helyettesítők jelentése egymástólfüggetlenül hidrőgénatőm, 1-20 szénatőmős hidrőkarbil- vagy 1-20szénatőmős hidrőkarbil-őxi-csőpőrt, és ahől az említett szervetlenőxid vagy fűnkciőnalizált származéka kevesebb, mint 1,0 mmól reaktívfelületi hidrőxil fűnkciőnalitást tartalmaz grammőnként, és (B) egyaktivátőr vegyület, amelynek összetevői: b1) egy őlyan katiőn, amelyegy átmenetifém vegyülettel reagálni képes egy katalitikűsan aktívátmenetifém kőmplex kialakítására, és b2) egy kőmpatíbilis aniőn,amely legalább egy, a szervetlen őxid anyag felületén levőhidrőxilcsőpőrt szilánnal fűnkciőnalizált származékaival reagálniképes szűbsztitűenst tartalmaz, ezáltal kővalensen kötve akőmpatíbilis aniőnt a hőrdőzóhőz. A találmány tárgyát képezik még afenti hőrdőzóból kialakítőtt katalizátőrők, valamint ezek gyártásieljárásai és felhasználási eljárásai. ŕ",DOW CHEMICAL CO;;GRACE W R & CO,CARNAHAN EDMUND M;;CARNEY MICHAEL J;;NEITHAMER DAVID R;;NICKIAS PETER N;;SHIH KENG-YU;;SPENCER LEE,,https://lens.org/103-636-289-072-919,Patent Application,no,0,0,27,27,0,C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F10/00;;C08F4/65925;;C08F4/6592;;C08F4/025;;C08F4/6192;;C08F4/61908;;C08F4/61916;;C08F4/61912;;C08F10/02;;C08F4/65912;;C08F210/16;;C08F110/02;;Y10S526/943,C08F4/02;;C08F4/603;;C08F4/619;;C08F4/6192;;C08F4/643;;C08F4/645;;C08F4/646;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16,,0,0,,,,PENDING
324,US,B2,US 11806431 B2,137-317-388-444-98X,2023-11-07,2023,US 202117337306 A,2021-06-02,US 202117337306 A;;US 201615383201 A;;US 201514858539 A;;US 201462052689 P,2014-09-19,Formulations and methods for contemporaneous stabilization of active proteins during spray drying and storage,"A method of treatment of plasma with a physiologically compatible spray dry stable acidic substance (SDSAS) prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compositions related to plasma dried by the methods of the present invention.",VELICO MEDICAL INC,LIU QIYONG PETER;;CUI JUNQING;;LUCIEN RUD KARLY;;CARNEY RYAN;;SOHN JIHAE;;ARYA MICHELLE;;KHAN ABDUL W,VELICO MEDICAL INC (2015-03-10),https://lens.org/137-317-388-444-98X,Granted Patent,yes,284,0,10,10,0,A61K9/1688;;F26B3/12;;F26B3/06;;F26B5/065;;B65D81/266;;B65D51/30;;A61K9/1688;;F26B3/12;;A61K9/16;;A61K9/1682;;F26B5/04;;A61K9/1617;;A61K35/16;;B01J19/06;;B01J2219/00177;;F26B3/04,A61K9/16;;A61K35/16;;B01J19/06;;B65D51/30;;B65D81/26;;F26B3/04;;F26B3/06;;F26B3/12;;F26B5/04;;F26B5/06,,204,150,001-760-864-299-790;;148-449-159-462-862;;013-429-438-959-472;;108-944-047-417-001;;058-152-224-378-14X;;015-630-703-147-043;;142-922-446-901-189;;014-305-382-767-763;;023-933-608-439-724;;031-416-400-878-511;;074-219-078-981-015;;040-815-778-853-679;;003-725-117-099-794;;075-060-622-151-977;;040-121-558-353-713;;024-551-595-166-765;;031-824-562-363-53X;;000-404-162-795-725;;014-684-489-304-307;;066-406-885-575-471;;069-267-972-682-322;;029-713-953-444-077;;124-661-931-235-137;;003-241-966-746-297;;040-837-156-634-911;;104-698-204-192-111;;009-912-774-120-196;;063-376-067-849-561;;038-967-593-003-302;;128-527-176-996-757;;032-764-440-921-630;;043-965-000-026-296;;010-560-775-503-577;;130-180-842-023-095;;016-476-815-094-269;;132-106-932-008-478;;044-186-220-953-204;;033-939-379-879-354;;000-140-877-042-966;;014-641-779-961-997;;091-032-083-464-369;;003-189-354-552-605;;020-988-515-668-72X;;017-836-573-988-923;;133-002-043-825-443;;084-577-241-289-903;;159-970-130-576-686;;068-326-932-149-196;;070-571-950-673-232;;027-443-136-829-807;;024-664-661-542-142;;034-166-181-048-293;;042-470-195-098-378;;090-969-017-869-444;;115-013-431-326-663;;009-181-444-666-763;;111-256-994-039-95X;;173-575-083-305-927;;155-087-044-271-095;;050-201-843-525-900;;086-786-348-497-984;;050-702-492-727-628;;000-480-904-446-319;;006-915-491-126-007;;074-417-764-299-785;;020-637-581-229-034;;011-126-181-965-103;;004-628-213-172-391;;030-411-943-938-315;;078-545-779-309-060;;148-449-159-462-862;;102-644-087-210-213;;098-013-389-597-413;;025-064-764-752-836;;019-939-939-498-369;;026-584-991-805-155;;004-159-873-948-408;;014-864-233-581-931;;021-645-305-718-030;;039-070-105-266-059;;028-837-064-629-547;;124-961-148-169-03X;;010-165-361-584-290;;066-611-306-452-673;;033-325-473-521-918;;070-140-337-722-732;;026-854-701-991-429;;111-614-207-906-91X;;084-577-241-289-903;;019-072-286-292-849;;031-733-553-268-596;;081-732-872-576-763;;071-443-882-375-435;;015-036-102-542-88X;;062-959-712-642-781;;049-263-983-812-299;;052-641-817-989-148;;021-659-371-026-144;;072-177-735-669-596;;003-860-396-993-415;;080-456-385-204-968;;048-218-829-606-877;;058-281-456-635-126;;151-816-236-769-295;;020-031-985-432-534;;049-552-207-799-31X;;088-400-103-557-326;;070-740-578-639-672;;126-596-341-391-695;;004-687-366-771-897;;076-286-482-960-243;;005-279-280-538-49X;;004-140-484-558-094;;154-824-268-653-309;;064-045-702-160-844;;042-636-759-093-853;;003-715-322-640-034;;123-964-712-037-888;;025-193-951-609-323;;073-290-947-046-367;;063-342-394-592-868;;097-765-500-933-16X;;001-974-585-005-984;;094-738-592-589-016;;012-067-234-611-819;;025-107-719-398-636;;085-431-986-444-976;;024-710-276-435-978;;131-209-922-956-605;;023-974-704-918-216;;110-712-589-796-359;;043-997-340-466-948;;018-199-711-091-178;;004-731-084-647-113;;154-191-980-905-808;;074-219-078-981-015;;127-450-737-386-686;;049-204-756-216-665;;079-632-389-520-364;;032-020-384-648-104;;012-401-616-732-879;;145-191-014-857-121;;001-760-864-299-790;;078-762-913-567-556;;000-520-804-302-370;;034-022-075-769-414;;031-956-676-157-472;;028-966-246-911-149;;016-762-137-402-45X;;182-471-809-952-518,21825929;;10.1097/ta.0b013e31821f4234;;10.1097/ta.0b013e3182214f44;;21818011;;10.1042/bj0470626;;pmc1275276;;14800979;;10.1007/978-1-4615-0557-0;;10.1007/978-1-4615-0557-0_5;;11987749;;21610357;;10.1097/ta.0b013e31820e83be;;10.1016/j.thromres.2006.07.005;;16962645;;10.1136/bmj.1.4131.377;;20782987;;pmc2176676;;34171166;;10.1111/tbed.14192;;pmc7363457;;10.1186/s40813-020-00155-1;;32690994;;10.1371/journal.pone.0249935;;33909651;;pmc8081231;;10.1111/trf.13580;;27100749;;10.1111/trf.13331;;27001356;;pmc7169678;;34269448;;10.1111/trf.16536;;33499449;;10.1093/milmed/usaa347;;34269465;;10.1111/trf.16502;;25233805;;10.1111/trf.12864;;pmc7165965;;10.1111/lam.13017;;29889981;;23478819;;10.2527/jas.2012-5705;;pmc7130610;;10.1016/j.vetmic.2019.108450;;31753544;;pmc6383881;;10.1371/journal.pone.0212332;;30789926;;10.2527/jas.2010-3502;;21278103;;pmc7117516;;25465663;;10.1016/j.vetmic.2014.10.021;;30152866;;pmc7165488;;10.1111/lam.13068;;25539662;;10.1186/s12985-014-0232-x;;pmc4304624;;10.1186/s40813-015-0010-1;;pmc5382482;;28405424;;10.1016/j.vetmic.2014.09.008;;pmc7117534;;25281254;;10.2527/jas.2009-2696;;20675601;;10.1016/j.tvjl.2011.02.021;;21458335;;pmc5388490;;28399166;;10.1371/journal.pone.0175289;;pmc4501813;;26171968;;10.1371/journal.pone.0133008;;18978366;;10.1136/vr.163.18.536;;25116479;;10.1371/journal.pone.0104766;;pmc4130536;;16024714;;10.2527/2005.8381933x;;28405442;;pmc5382520;;10.1186/s40813-016-0034-1;;pmc7031359;;32076042;;10.1038/s41598-020-59756-z;;30803120;;10.1111/jam.14235;;pmc6849764;;pmc4282400;;25098383;;10.1111/tbed.12269;;32289108;;pmc7107225;;10.1093/tas/txy088;;10.2527/jas.2017.1486;;10.2527/jas2017.1486;;pmc7109998;;28727088;;32289110;;10.1093/tas/txy100;;pmc7107256;;10.1139/cjm-2014-0130;;24773334;;10.3390/nu8100657;;pmc5084043;;27782068;;32860645;;10.1111/jpn.13435;;10.5772/intechopen.72247;;10.1111/trf.12191;;23581390;;10.1111/trf.12038;;23301975;;10.1007/978-3-030-20820-2_8;;23301978;;10.1111/trf.12040;;pmc2830894;;19836465;;10.1016/j.bbalip.2009.10.003;;10.1016/j.jcin.2011.02.010;;21596325;;22192678;;10.1016/j.jacc.2011.08.065;;pmc3711809;;pmc3516197;;22245910;;10.1039/c2cc17852d;;10.1007/bf02708643;;2758600;;10.1093/clinchem/35.7.1523;;10.1586/erc.11.120;;pmc3243497;;21985544;;10.1159/000095358;;16940712;;12151573;;10.1136/pmj.78.919.288;;pmc1742351;;20453403;;10.2169/internalmedicine.49.3045;;4758378;;pmc2072557;;1191516;;pmc2072690;;pmc2041183;;1268041;;10.1161/01.str.11.2.184;;7368248;;pmc2921919;;20225282;;10.1002/ana.21871;;10.1038/nature08938;;pmc2946640;;20428172;;24554772;;pmc3985066;;10.4049/jimmunol.1302484;;10.1007/s11926-012-0313-z;;pmc3623938;;23412688;;pmc3720827;;23812099;;10.1038/ni.2639;;23897251;;10.1309/ajcpgkojv15avznt;;10.1111/trf.16772;;34907536;;29274254;;10.1111/jth.13929;;10.1097/ta.0b013e3182214f44;;21818011;;10.1002/jca.20019;;15493055;;10.1111/j.1348-0421.2011.00309.x;;21244468;;10.1007/978-3-030-53606-0_42;;10.1155/2016/4860284;;pmc5192317;;28070448;;pmc9306459;;10.1111/trf.16756;;34951486;;10.1097/ta.0000000000001425;;28333835;;10.1097/ta.0000000000000292;;25058244;;pmc5818807;;10.1001/jama.2017.15097;;29067429;;10.1097/aco.0000000000000574;;29470190;;24317352;;pmc4004607;;10.1097/shk.0000000000000110;;18557827;;10.1111/j.1423-0410.2008.01074.x;;10.3109/10903127.2014.923077;;24932734;;23560283;;pmc3740072;;10.1001/2013.jamasurg.387;;10.1097/ta.0b013e3180324124;;17297317;;25647203;;pmc4374744;;10.1001/jama.2015.12;;10.1056/nejmoa1802345;;30044935;;10.1016/j.amjsurg.2008.12.014;;19393349;;10.1111/trf.12038;;23301975;;29334571;;10.1097/ta.0000000000001801;;10.1097/ta.0000000000001569;;28930960;;10.1097/ta.0000000000002094;;30358770;;27100755;;10.1111/trf.13500;;10.1097/ta.0000000000001436;;pmc5488798;;28328671;;10.5482/hamo-14-11-0075;;25666572;;16673266;;10.1055/s-2006-939554;;27082315;;10.1097/shk.0000000000000635;;pmc4841450;;26002270;;10.1097/ta.0000000000000631;;10.1186/s12967-015-0481-5;;25889764;;pmc4397670;;pmc5300027;;10.1097/sla.0000000000001751;;27144442;;pmc7519668;;32978505;;10.1038/s41598-020-73021-3;;10.1186/s13054-017-1605-5;;28705251;;pmc5299749;;28179016;;pmc5513393;;10.1186/s13054-017-1756-4;;24026641;;10.1007/s11883-013-0363-3;;10.1111/j.1537-2995.2009.02335.x;;19682336;;20551272;;10.1309/ajcp3wpoyskk6bfe;;10.1097/ta.0000000000000348;;25099452;;10.1111/j.1538-7836.2012.04752.x;;22519961;;10.1111/jth.12078;;23176206;;20655560;;10.1016/j.surg.2010.06.010;;20580091;;10.1016/j.molimm.2010.05.010;;2954962;;10.1055/s-0038-1643883;;10.1016/s0021-9258(18)47998-7;;10.1182/blood-2016-03-705384;;27531677;;10.1097/ta.0000000000000885;;pmc4688194;;26491796;;10.1097/shk.0000000000000360;;26920989;;pmc4834914;;10.1016/j.jamcollsurg.2016.01.006;;10.1016/s0140-6736(10)60835-5;;20554319;;10.1097/shk.0b013e31829f91fc;;23807246;;pmc3764452;;29287059;;10.1097/ta.0000000000001791;;pmc6933102;;10.1097/shk.0000000000001399;;31454826;;29905671;;pmc6292777;;10.1097/shk.0000000000001207;;pmc8211399;;10.1097/shk.0000000000001564;;32433215;;10.1097/shk.0000000000001432;;31389906;;pmc4684456;;26263440;;10.1097/shk.0000000000000458;;10.1097/ta.0b013e318232e5ab;;pmc3241929;;22071999;;10.1371/journal.pone.0192363;;pmc5796727;;29394283;;10.1021/bk-1988-0370.ch007;;30443975;;10.1111/trf.15035;;10.1111/trf.15038;;30450617;;30737823;;10.1111/trf.14985;;10.1111/vox.13027;;33277925;;26002258;;10.1097/ta.0000000000000629;;10.1046/j.1537-2995.2001.41040570.x;;11316912;;25371048;;10.1111/trf.12914;;10.1111/j.1423-0410.2009.01190.x;;19392784;;34919639;;10.1097/aln.0000000000004089;;10.1111/trf.13580;;27100749;;22739764;;10.1097/aln.0b013e3182608cdd;;10.1016/j.annemergmed.2017.07.327;;10.1111/trf.12039;;23301977;;10.1097/sla.0b013e318185a9ad;;18791365;;10.31274/rtd-180813-7504;;20345563;;10.1111/j.1537-2995.2010.02630.x;;21825929;;10.1097/ta.0b013e31821f4234;;10.1111/j.1538-7836.2009.03562.x;;19656278;;12941351;;10.1016/s1473-0502(03)00117-4;;7559492;;10.1074/jbc.270.40.23352;;18699575;;10.1063/1.1135868;;10.1172/jci112736;;3491092;;pmc423893;;19001961;;10.1097/ta.0b013e3181801cd9;;10.1111/trf.17139;;pmc10092463;;36181447,"Hamilton GJ, Van PY, Differding JA, Kremenevskiy IV, Spoerke NJ, Sambasivan C, Watters JM, Schreiber MA. “Lyophilized plasma with ascorbic acid decreases inflammation in hemorrhagic shock.” J Trauma,Aug. 2011,71(2),pp. 292-297; PMID:21825929; doi: 10.1097/TA.0b013e31821f4234. (Year: 2011).;;Van PY, Hamilton GJ, Kremenevskiy IV, Sambasivan C, Spoerke NJ, Differding JA, Watters JM, Schreiber MA “Lyophilized plasma reconstituted with ascorbic acid suppresses inflammation and oxidative DNA damage”, J Trauma, Jul. 2011,71(1),pp. 20-24; PMID: 21818011; doi:10.1097/TA.0b013e3182214f44. (Year: 2011).;;Cardianbct, Inc “Mirasol Pathogen Reduction Technology”, PN 306690-148, retrieved online Apr. 4, 2023 <URL: http://eurolambda.sk/shared/files/mirasol_plasma.pdf>, 2 pages. (Year: 2009).;;Terumo BCT, Inc “Mirasol Pathogen Reduction Technology System”, PN 306690232, retrieved online Apr. 4, 2023 <URL: https://www.terumopenpol.com/wp-content/uploads/2019/12/306690232-1.pdf>, 7 pages. (Year: 2012).;;Lea, et al. “The Reaction between Proteins and Reducing Sugars in the “Dry” State” Department of Pathology, University of Cambridge; Jun. 5, 1950; pp. 626-629.;;Carpenter, et al. “Rational Design of Stable Lyophilized Protein Formulations: Theory and Practice” Kluwer Academic/Plenum Publishers; 2002; pp. 109-133.;;Schmid “Spray drying of protein precipitates and Evaluation of the Nano Spray Dryer B-90” PhD Thesis; 2011; 125 pages.;;Shuja, et al. “Development and Testing of Low-Volume Hyperoncotic, Hyperosmotic Spray-Dried Plasma for the treatment of Trauma-Associated Coagulopathy” The Journal of Trauma; Mar. 2011; vol. 70; No. 3; pp. 664-671.;;Bakaltcheva; et al. “Freeze-dried whole plasma: Evaluating sucrose, trehalose, sorbitol, mannitol and glycine as stabilizers” Thrombosis Research; 2007; vol. 120; pp. 105-116.;;Training Papers Spray Drying; Version B; www.buchi.com; 19 pages; Oct. 29, 2002.;;Edwards et al., The Preparation and Use of Dried Plasma for Transfusion; British Medical journal; vol. 1, No. 4131;Mar. 9, 1940; pp. 377-381.;;European Search Report, EP Application No. 14154366, dated Aug. 29, 2014, pp. 1-3.;;European Search Opinion, EP Application No. 14154366, dated Aug. 29, 2014, pp. 1-3.;;International Search Report and Written Opinion, PCT/US2010/049176, dated Nov. 4, 2010, pp. 1-10.;;International Search Report and Written Opinion, PCT/US2011/058358, dated Jul. 4, 2012, pp. 1-9.;;Answer, Affirmative Defenses, Counterclaims, Cross-Claims and Jury Demand, Entegrion, Inc. vs Velico Medical, Inc., dated Dec. 3, 2012, pp. 1-47.;;Civil Action Cover Sheet; Entegrion, Inc. vs Velico Medical, Inc., dated Oct. 19, 2012, pp. 1-2.;;Complaint including Exhibit A, B, and C; Entegrion, Inc. vs Velico Medical, Inc., dated Oct. 19, 2012, pp. 1-29.;;Mini Spray Dryer B-290- Application Note; www.buchi.com; Mar. 30, 2008, entire document , 1 Page.;;Nano Spray Dryer B-90; www.buchi.com; Jul. 18, 2011, entire document , 12 Pages.;;Mini Spray Dryer System Configuration; www.buchi.com; Jan. 8, 2007, entire document , 1 Page.;;Quick Operation Guide; Mini Spray Dryer B-290; www.buchi.com; Sep. 16, 2004 pp. 15-53.;;Process Parameters; www.buchi.com; Nov. 21, 2008, pp. 1-2.;;Mini Spray Dryer B-290; www.buchi.com; May 10, 2007, pp. 1-8.;;Fischer M., et al., “Stability of African swine fever virus on spiked spray-dried porcine plasma,” Transboundary and Emerging Diseases, 68(5): 2806-2811 (2021).;;International Preliminary Report on Patentability, PCT/US2011/058358, dated Apr. 30, 2013, pp. 1-7.;;Blazquez, E., et al., “Biosafety steps in the manufacturing process of spray-dried plasma: a review with emphasis on the use of ultraviolet irradiation as a redundant biosafety procedure,” Porcine Health Management, 6(16): p., 78 refs. (2020). 9 Pages.;;Blazquez, E., et al., “Effect of spray-drying and ultraviolet C radiation as biosafety steps for CSFV and ASFV inactivation in porcine plasma,” PLOS One, 16(4) (2021) , entire document, 11 Pages.;;Entegrion's Reply To Counterclaims; Entegrion, Inc. vs Velico Medical, Inc; Dated: Jan. 14, 2013, entire document, 22 pages.;;Entegrion's Motion To Dismiss Counts I, II, V, VI and XI of Velico Medical, Inc's Counterclaims and Memorandum in Support of Entegrion's Motion To Dismiss Counts I, II, V, VI, and XI of Velico Medical, Inc.'S Counterclaims; Entegrion, Inc. vs Velico Medical, Inc; Dated: Jan. 14, 2013, entire document, 3 Pages.;;International Preliminary Report on Patentability, PCT/US2010/049176, dated Feb. 18, 2014, pp. 1-9.;;Pusateri, Anthony E.“ Dried plasma: state of the science and recent developments” Transfusion 56: S128-S139 (Apr. 2016).;;Pusateri, Anthony E.“ Comprehensive US government program for dried plasma development” Transfusion 56: S16-S23 (2016).;;Popovsky, Mark A. “Spray-dried plasma: A post-traumatic blood ”bridge“ for life-saving resuscitation” Transfusion. 2021;61:S294-S300 (2021).;;Flaumenhaft, Elissa J. et al., “Retention of Coagulation Factors and Storage of Freeze- Dried Plasma,” Military Med. 186 (S1):400-407 (2021).;;Parr, Ashely, “Coagulation Activity of Freeze-Dried Plasma is similar to that of Fresh Frozen Plasma” (May 16, 2018), entire document, 14 Pages.;;Peng, Henry T. “Ex vivo hemostatic and immune-inflammatory profiles of freeze-dried plasma” Transfusion 61: S119-S130 (2021).;;Larry J. Dumont, et al., “The bioequivalence of frozen plasma prepared from whole blood held overnight at room temperature compared to fresh-frozen plasma prepared within eight hours of collection,” Transfusion 55: 480 (2015) , entire document, 9 Pages.;;Blazquez, E., et al., “Combined effects of spray-drying conditions and postdrying storage time and temperature on Salmonella choleraesuis and Salmonella typhimurium survival when inoculated in liquid porcine plasma,” Letters in Applied Microbiology, 67(2): 205-211 (2018).;;S. Suessner, et al., “Comparison of several complement and coagulation factor concentrations in different plasma products.” Transfusion Medicine and Hemotherapy, 41 (supplement 1) Abstract No. PBK-V02: p. 36 (2014), 3 Pages.;;Cancelas, J. A., “A Phase 1, Single-Center, Partial Double-blind, Randomized, Controlled (Versus Fresh Frozen Plasma [FFP] In Cohort 3 Only) Clinical Study Of The Safety Of Ascending Doses Of Autologous Freeze Dried Plasma (FDP) In Healthy Volunteers,” Falls Church, VA: The Surgeon General, Department of the Army (2018), p. 1-128.;;Polo, J., et al., “Neutralizing antibodies against porcine circovirus type 2 in liquid pooled plasma contribute to the biosafety of commercially manufactured spray-dried porcine plasma,” Journal of Animal Science, 91(5): 2192-2198 (2013).;;Blazquez, E., et al., “UV-C irradiation is able to inactivate pathogens found in commercially collected porcine plasma as demonstrated by swine bioassay,” Veterinary Microbiology, 239 (2019) , entire document, 2 Pages.;;Blazquez, E., et al., “Evaluation of the effectiveness of the SurePure Turbulator ultraviolet-C irradiation equipment on inactivation of different enveloped and non-enveloped viruses inoculated in commercially collected liquid animal plasma,” PLOS One, 14(2) (2019), entire document, 17 Pages.;;Shen, E., et al., “Commercially produced spray-dried porcine plasma contains increased concentrations of porcine circovirus type 2 DNA but does not transmit porcine circovirus type 2 when fed to naïve pigs,” Journal of Animal Science, 89(6): 1930-1938 (2011).;;Pujols, J., and Segales, J., “Survivability of porcine epidemic diarrhea virus (PEDV) in bovine plasma submitted to spray drying processing and held at different time by temperature storage conditions,” Veterinary Microbiology, 174(3/4): 427-432 (2014).;;Blazquez, E., et al., “Evaluation of ultraviolet-C and spray-drying processes as two independent inactivation steps on enterotoxigenic Escherichia coli K88 and K99 strains inoculated in fresh unconcentrated porcine plasma,” Letters in Applied Microbiology, 67(5): 442-448 (2018).;;Pujols, J., et al., “No transmission of hepatitis E virus in pigs fed diets containing commercial spray-dried porcine plasma: a retrospective study of samples from several swine trials,” Virology Journal, 11: p. 232 (2014), 8 Pages.;;Foddai, A., et al., “Probability of introducing porcine epidemic diarrhea virus into Danish pig herds by imported spray-dried porcine plasma,” Porcine Health Management, 1: p. 18 (2015), 11 Pages.;;Gerber, P. F., et al., “The spray-drying process is sufficient to inactivate infectious porcine epidemic diarrhea virus in plasma,” Veterinary Microbiology, 174(1/2): 86-92 (2014).;;Patterson, A. R., et al., “Efficacy of experimentally produced spray-dried plasma on infectivity of porcine circovirus type 2,” Journal of Animal Science, 88(12: 4078-4085 (2010).;;Pujols, J., et al., “Commercial spray-dried porcine plasma does not transmit porcine circovirus type 2 in weaned pigs challenged with porcine reproductive and respiratory syndrome virus,” Veterinary Journal, 190(2): 16-20 (2011).;;Blazquez, E., et al., “Ultraviolet (UV-C) inactivation of Enterococcus faecium, Salmonella choleraesuis and Salmonella typhimurium in porcine plasma,” PLoS One, 12(4) (2017), 11 Pages.;;Polo, J., et al., “Ultraviolet Light (UV) Inactivation of Porcine Parvovirus in Liquid Plasma and Effect of UV Irradiated Spray Dried Porcine Plasma on Performance of Weaned Pigs,” PLOS One, 10(7) (2015), 12 Pages.;;Pujols, J., et al., “Lack of transmission of porcine circovirus type 2 to weanling pigs by feeding them spray-dried porcine plasma,” Veterinary Record, 163(18): 536-538 (2008).;;Opriessnig, T., et al., “Porcine Epidemic Diarrhea Virus RNA Present in Commercial Spray-Dried Porcine Plasma Is Not Infectious to Naïve Pigs,” PLOS One, 9(8) (2014), 10 Pages.;;Polo, J., et al., “Efficacy of spray-drying to reduce infectivity of pseudorabies and porcine reproductive and respiratory syndrome (PRRS) viruses and seroconversion in pigs fed diets containing spray-dried animal plasma,” Journal of Animal Science, 83(8): 1933-1938 (2005).;;Perez-Bosque, A., et al., “Spray dried plasma as an alternative to antibiotics in piglet feeds, mode of action and biosafety,” Porcine Health Management, 2: p. 16 (2016), 10 Pages.;;Moreto, M., et al., “Dietary supplementation with spray-dried porcine plasma has prebiotic effects on gut microbiota in mice,” Scientific Reports, 10(1): p. 2926 (2020), 13 Pages.;;Hulst, M. M., et al., “Study on inactivation of porcine epidemic diarrhoea virus, porcine sapelovirus 1 and adenovirus in the production and storage of laboratory spray-dried porcine plasma,” Journal of Applied Microbiology, 126(6): 1931-1943 (2019).;;Pasick, J., et al., “Investigation into the Role of Potentially Contaminated Feed as a Source of the First-Detected Outbreaks of Porcine Epidemic Diarrhea in Canada,” Transboundary and Emerging Diseases, 61(5): 397-410 (2014).;;Duffy, M. A., et al., “Impact of dietary spray-dried bovine plasma addition on pigs infected with porcine epidemic diarrhea virus,” Translational Animal Science, 2(4): 349-357 (2018).;;Cottingim, K. M., et al., “Ultraviolet irradiation of spray-dried porcine plasma does not affect the growth performance of nursery pigs when compared with nonirradiated bovine plasma,” Journal of Animal Science, 95(7): 3120-3128 (2017).;;Gebhardt, J. T., et al., “Determining the impact of commercial feed additives as potential porcine epidemic diarrhea virus mitigation strategies as determined by polymerase chain reaction analysis and bioassay,” Translational Animal Science, 3(1): 28-37 (2019).;;Champagne C. P., et al., “Effect of bovine colostrum, cheese whey, and spray- dried porcine plasma on the in vitro growth of probiotic bacteria and Escherichia coli,” Canadian Journal of Microbiology, 60(5): 287-295 (2014).;;Perez-Bosque, A., et al., “The Anti-Inflammatory Effect of Spray-Dried Plasma Is Mediated by a Reduction in Mucosal Lymphocyte Activation and Infiltration in a Mouse Model of Intestinal Inflammation,” Nutrients, 8(10) (2016), p. 1-13.;;Prabhu, B., et al., “Effects of spray-dried animal plasma on the growth performance of weaned piglets—A review,” Journal of Animal Physiology and Animal Nutrition, 105(4): 699-714 (2021).;;Santos, D., et al., “Spray Drying: An Overview,” Biomaterials, (2017), p. 1-29.;;USAMRMC military plasma article “Advanced Development Products,” (Second Edition). U.S. Army Medical Research and Materiel Command (2017), p. 521-529.;;Govtribe, “Definitive Contract H9222216C0081”, [online], [retrieved on Mar. 20, 2020], Retrieved from https://govtribe.com/award/federal-contract-award/definitive-contract-h9222216c0081, entire document, 3 Pages.;;Noorman, F. et al. “Lyophilized Plasma, an Alternative to 4 degrees C Stored Thawed Plasma for the Early Treatment of Trauma Patients with (Massive) Blood Loss in Military Theatre,” Transfusion 55A (2012), p. 1-2.;;Bux, J., et al., “Quality of freeze-dried (lyophilized) quarantined single-donor plasma,” Transfusion, 53: 3203-3209 (2013).;;Noorman, F., “Comparison of a single Spray dried plasma product with standard Sanquin and MBB frozen, thawed (coldstored) plasma,” (Final Report). Utrecht, Netherlands: Military Blood Bank (2021), p. 1-7.;;Sailliol, A., et al., “The evolving role of lyophilized plasma in remote damage control resuscitation in the French Armed Forces Health Service,” Transfusion, 53: 65S-71S (2013).;;Zaza, M., et al. “Dried Plasma,” Damage Control Resuscitation: Identification and Treatment of Life-Threatening Hemorrhage, 145-162 (2019).;;Wataha, K., et al., “Spray-dried plasma and fresh frozen plasma modulate permeability and inflammation in vitro in vascular endothelial cells,” Transfusion, 53: 80S-90S (2013).;;Wang, H.H., et al., “Effect of gallbladder hypomotility on cholesterol crystallization and growth in CCK-deficient mice,” Biochim Biophys Acta, 1801(2): 138-146 (2010).;;Gadeela, N., et al., “The Impact of Circulating Cholesterol Crystals on Vasomotor Function. Implications for No-Reflow Phenomenon,” J Am Coll Cardiol Int, 4: 521-529 (2011).;;Abela, G.S., et al., “The Effect of Ethanol on Cholesterol Crystals During Tissue Preparation for Scanning Electron Microscopy, ” J Am Coll Cardiol 1: 93 (2012), 1 Page.;;Li, H., et al., “Synthesis of ß-cyclodextrin conjugated superparamagnetic iron oxide nanoparticles for selective binding and detection of cholesterol crystals,” Chem Commun, 48(28): 3385-3387 (2012).;;Elizabeth, A., et al., “Growth and micro-topographical studies of gel grown cholesterol crystals,” Bull Mater Sci, 24(4): 431-434 (2001).;;Kroll, M.H., et al., “Effect of Lyophilization on Results of Five Enzymatic Methods for Cholesterol,” Clin Chem, 35(7): 1523-1526 (1989).;;Mughal, M.M., et al., “Symptomatic and asymptomatic carotid artery plaque,” Expert Rev Cardiovasc Ther, 9(10): 1315-1330 (2011).;;Morales, J., and Gonzalez, E., “Cholesterol Crystal Embolization,” Blood Purif, 24: 431-432 (2006).;;Walton, T.J., et al., “Systemic cholesterol crystal embolisation with pulmonary involvement: a fatal combination after coronary angiography,” Postgrad Med J, 78: 288-289 (2002).;;Oe, K., et al., “Late Onset of Cholesterol Crystal Embolism after Thrombolysis for Cerebral Infarction,” Inter Med, 49: 833-836 (2010).;;Warren, B. A., and Vales, O., “The ultrastructure of the stages of atheroembolic occlusion of renal arteries,” Br J Exp Pathol, 54(5): 469-478 (1973).;;Warren B. A., Vales, O., “Electron microscopy of the sequence of events in the atheroembolic occlusion of cerebral arteries in an animal model,” Br J Exp Pathol, 56(3):205-215 (1975).;;Warren, B. A., and Vales, O., “The ultrastructure of the reaction of arterial walls to cholesterol crystals in atheroembolism,” Br J Exp Pathol, 57(1), 67-77 (1976).;;Steiner, T.J., et al., “Cholesterol crystal embolization in rat brain: a model for atheroembolic cerebral infarction,” Stroke, 11: 184-189 (1980).;;Nozari A., et al., “Microemboli may link spreading depression, migraine aura, and patent foramen ovale,” Ann Neurol, 67(2):221-229 (2010).;;Duewell, P., et al., “NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals,” Nature, 464,7293: 1357-1361 (2010).;;Samstadt, E. O., et al., “Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release,” J Immunol, 192(67): 2837-2845 (2014).;;Grebe, A., and Latz, E., “Cholesterol Crystals and Inflammation,” Curr Rheumatol Rep, 15: 313 (2013), 7 Pages.;;Sheedy, F., et al., “CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation,” Nat Immunol, 14: 812-820 (2013).;;Ness, M. V., et al., “Neutrophils Contain Cholesterol Crystals in Transfusion-Related Acute Lung Injury (TRALI),” Am J Clin Pathol, 140(2): 170-176 (2013).;;Sheffield, W. P., et al., “Retention of hemostatic and immunological properties of frozen plasma and COVID-19 convalescent apheresis fresh-frozen plasma produced and freeze-dried in Canada,” Transfusion, 62: 418-428 (2021).;;Garrigue, D., et al., “French lyophilized plasma versus fresh frozen plasma for the initial management of trauma-induced coagulopathy: a randomized open-label trial,” J Thrombosis and Haemostasis, 16:481-489 (2017).;;Van, P. Y., et al., “Lyophilized Plasma Reconstituted With Ascorbic Acid Suppresses Inflammation and Oxidative DNA Damage,” J Trauma, 71(1) :20-24 (2011).;;Medical Countermeasures, “BARDA continues partnership with Velico Medical for development of their FrontlineODP spray-dry plasma system to prepare for a radiological or nuclear emergency,” [online], [retrieved on Sep. 20, 2021], Retrieved from https://www.medicalcountermeasures.gov/newsroom/2021/velico-medical/ entire document, 20 Pages.;;Burnouf, T., et al., “Assessment of complement activation during membrane- based plasmapheresis procedures,” J Clin Apheresis, 19: 142-147 (2004).;;Ohta, R., et al., “Serum concentrations of complement anaphylatoxins and proinflammatory mediators in patients with 2009 H1N1 influenza,” Microbiology and Immunology, 55: 191-198 (2011).;;“French Lyophilised Plasma (FLYP),” Ministry of Defence, Armed Forces Health Service, Jean Julliard Armed Forces Blood Transfusion Service (Technical Notice and Summary of Product Characteristics) (2013), 2 Pages.;;Arun, R., “Freeze Dried Plasma Role in Emergency Resuscitation”, Tirupati, India: Sri Venkateswara Institute of Medical Sciences, https://www.istm.net.in/transmedcon2016-presentations/99.9%20Freeze %20Dried %20Plasma-Role%20in%20Emergency %20Resuscitation.pdf, downloaded on Jan. 16, 2021, entire document, 51 Pages.;;Pusateri, A.E., and Weiskopf, R.B. “Dried Plasma for Trauma Resuscitation,” Trauma Induced Coagulopathy, 705-718 (2021).;;Sunde, G.A., “Prehospital Plasma / TXA experience—FDP in Norwegian HEMS,” Norway: Norsk Luftambulanse (2014), p. 1-24.;;Acker, J. P., et al., “Quality Assessment of Established and Emerging Blood Components for Transfusion,” Journal of Blood Transfusion, (2016), p. 1-29.;;Warr, M., “Lyoplas reconstitution English,” Deutsches Rotes Kreuz, [Youtube], [retrieved on Jan. 9, 2022], Retrieved from https://www.youtube.com/watch?v=PdydStBygtk. Entire document.;;Mew, I., “Reconstituting Lyoplas (Freeze dried FFP)”, [Youtube], [retrieved on Jan. 9, 2022], Retrieved from https://www.youtube.com/watch?v=RxpQDMwVK8Y. ), entire document, 9 Pages.;;Cancelas, J. A., et al., “Characterization and first-in-human clinical dose- escalation safety evaluation of a next-gen human freeze-dried plasma,” Transfusion, 62: 406-417 (2021).;;Terumo BCT, “Terumo BCT Awarded $1.9 Million from the United States Government to Support Development of Freeze-Dried Plasma,” [online], [retrieved on Mar. 20, 2020], Retrieved from https://www.terumobct.com/Pages/News/Press%20Releases/Terumo_BCT_Awarded_$1-9_Million_from_the_United_States_Government_to_Support_Development_of_Freeze-Dried_Plasma_aspx. , entire document, 2 pages.;;Spinella, P. C., “Zero preventable deaths after traumatic injury: an achievable goal,” J Trauma Acute Care Surg, 82:S2-S8 (2017).;;Davis, J. S., et al., “An analysis of prehospital deaths: who can we save?,” J Trauma Acute Care Surg, 77:213-218 (2014).;;Shackelford, S. A., et al., “Association of prehospital blood product transfusion during medical evacuation of combat casualties in Afghanistan with acute and 30-day survival,” JAMA, 318:1581-1591 (2017).;;Gurney, J. M., and Spinella, P. C., “Blood transfusion management in the severely bleeding military patient,” Curr Opin Anesthesiol, 31:207-214 (2018).;;Moore, E. E., et al., “Plasma first in the field for postinjury hemorrhagic shock,” Shock, 41(Suppl 1):35-38 (2014).;;Maegele, M., et al., “Red-blood-cell to plasma ratios transfused during massive transfusion are associated with mortality in severe multiple injury: a retrospective analysis from the trauma registry of the deutsche Gesellshaft fur Unfallchirugerie,” Vox Sang, 95:112-119 (2008).;;Holcomb, J. B., et al., “Prehospital transfusion of plasma and red blood cells in trauma patients,” Prehosp Emerg Care, 19:1-9 (2015).;;Holcomb, J. B., et al., “The prospective, observational, multicenter major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks,” JAMA Surg, 148:127-136 (2013).;;Holcomb, J. B., et al., “Damage control resuscitation: directly addressing the early coagulopathy of trauma,” J Trauma Acute Care Surg, 62:307-310 (2007).;;Holcomb, J. B., et al., “Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial,” JAMA, 313:471-482 (2015).;;Sperry, J. L., et al., “Prehospital plasma during air medical transport in trauma patients at risk for hemorrhagic shock,” N Engl J Med, 379:315-326 (2018).;;Zink, K. A., et al., “A high ratio of plasma and platelets to packed red blood cells in the first 6 hours of massive transfusion improves outcomes in a large multicenter study,” Am J Surg, 197:565-570 (2009).;;Saillol, A., et al., “The evolving role of lyophilized plasma in remote damage control resuscitation in the French armed forces health service,” Transfusion, 53(Suppl 1): S129-S39 (2013).;;Nuguyen, C., et al., “Use of French lyophilized plasma transfusion in severe trauma patients is associated with an early plasma transfusion and early transfusion ratio improvement,” J Trauma Acute Care Surg, 84:780-785 (2018).;;Shlaifer, A., et al., “Prehospital administration of freeze-dried plasma, is it the solution for trauma casualties?,” J Trauma Acute Care Surg, 83:675-682 (2017).;;Shlaifer, A., et al., “The impact of prehospital administration of freeze-dried plasma on casualty outcome,” J Trauma Acute Care Surg, 86:108-115 (2019).;;Bjerkvig, C.K., et al., “”Blood failure“ time to view blood as an organ: how oxygen debt contributes to blood failure and its implications for remote damage control resuscitation,” Transfusion, 56(Suppl 2):S182-S189 (2016).;;White, N. J., et al., “Hemorrhagic blood failure: oxygen debt, coagulopathy, and endothelial damage,” J Trauma Acute Care Surg, 82(6S Suppl 1): S41-S49 (2017).;;Aird, W. C., “Endothelium and haemostasis,” Hamostaseologie, 35:11-16 (2015).;;Esmon, C. T., “Inflammation and the activated protein C anticoagulant pathway,” Semin Thromb Hemost, 32(Suppl 1):49-60 (2006).;;Tuma, M., et al., “Trauma and endothelial glycocalyx: the microcirculation helmet?,” Shock, 46:352-357 (2016).;;Kozar, R. A., and Pati, S., “Syndecan-1 restitution by plasma after hemorrhagic shock,” J Trauma Acute Care Surg, 78(6 Suppl 1):S83-S86 (2015).;;Rahbar, E., et al., “Endothelial glycocalyx shedding and vascular permeability in severely injured trauma patients,” J Transl Med, 13:117 (2015), entire document, 7 Pages.;;Johansson, P. I., et al., “Traumatic Endotheliopathy: a prospective observational Study of 424 severely injured patients,” Ann Surg, 265:597-603 (2017).;;Wu, F., et al., “miR-19b targets pulmonary endothelial syndecan-1 following hemorrhagic shock,” Sci Rep, 10:15811 (2020), 10 Pages.;;Johansson, P. I., et al., “Shock induced endotheliopathy (SHINE) in acute critical illness-a unifying pathophysiologic mechanism,” Crit Care, 21:25 (2017), 7 Pages.;;Spronk, H. M., et al., “New insights into modulation of thrombin formation,” Curr Atheroscler Rep, 15:363 (2013), 9 Pages.;;Dunbar, N. M., and Chandler, W. L., “Thrombin generation in trauma patients,” Transfusion, 49:2652-2660 (2009).;;Chandler, W. L., “Procoagulant activity in trauma patients,” Am J Clin Pathol, 134:90-96 (2010).;;Cardenas, J. C., et al., “Measuring thrombin generation as a tool for predicting hemostatic potential and transfusion requirements following trauma,” J Trauma Acute Care Surg, 77:839-845 (2014).;;Rourke, C., et al., “Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes,” J Thromb Haemost, 10:1342-1351 (2012).;;Raza, I., et al., “The incidence and magnitude of fibrinolytic activation in trauma patients,” J Thromb Haemost, 11:307-314 (2013).;;Hayakawa, M., et al., “Disseminated intravascular coagulation at an early phase of trauma is associated with consumption coagulopathy and excessive fibrinolysis both by plasmin and neutrophil elastase,” Surgery, 149:221-230 (2011).;;Kaplan, A. P., and Ghebrehiwet, B., “The plasma bradykinin-forming pathways and its interrelationships with complement,” Mol Immunol, 47:2161-2169 (2010).;;Omar, M. N., Mann, K. G., “Inactivation of factor Va by plasmin,” J Biol Chem, 262:9750-9755 (1987).;;Marcos-Contreras, O. A., et al., “Hyperfibrinolysis increases blood-brain barrier permeability by a plasmin- and bradykinin-dependent mechanism,” Blood, 128:2423-2434 (2016).;;Chapman, M. P., et al., “Overwhelming tPA release, not PAI-1 degradation, is responsible for hyperfibrinolysis in severely injured trauma patients,” J Trauma Acute Care Surg, 80:16-25 (2016).;;Cardenas, J. C., et al., “Elevated tissue plasminogen activator and reduced plasminogen activator inhibitor promote hyperfibrinolysis in trauma patients,” Shock, 41:514-521 (2014).;;Moore, H. B., et al., “Acute fibrinolysis shutdown after injury occurs frequently and increases mortality: a multicenter evaluation of 2,540 severely injured patients,” J Am Coll Surg, 222:347-355 (2016).;;Shakur, H., et al., “Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial,” Lancet, 376:23-32 (2010).;;Peng, Z., et al., “Fresh frozen plasma lessens pulmonary endothelial inflammation and hyperpermeability after hemorrhagic shock and is associated with loss of syndecan 1,” Shock, 40:195-202 (2013).;;Diebel, L. N., “Microfluidics: a high-throughput system for the assessment of the endotheliopathy of trauma and the effect of timing of plasma administration on ameliorating shock-associated endothelial dysfunction,” J Trauma Acute Care Surg, 84:575-582 (2018).;;Yu, Q., et al., “Identification of fibrinogen as a key anti-apoptotic factor in human fresh frozen plasma for protecting endothelial cells in vitro,” Shock, 53:646-652 (2020).;;Wu, F., and Kozar, R. A., “Fibrinogen protects against barrier dysfunction through maintaining cell surface syndecan-1 in vitro,” Shock, 51:740-744 (2019).;;Wu, F., et al., “Fibrinogen activates PAK1/Cofilin signaling pathway to protect endothelial barrier integrity,” Shock, 55:660-665 (2020).;;Lopez, E., et al., “Antithrombin III contributes to the protective effects of fresh frozen plasma following hemorrhagic shock by preventing syndecan-1 shedding and endothelial barrier disruption,” Shock, 53:156-163 (2020).;;Deng, X., et al., “Adiponectin in fresh frozen plasma contributes to restoration of vascular barrier function after hemorrhagic shock,” Shock, 45:50-54 (2016).;;Rizoli, S. B., et al., “Clotting factor deficiency in early trauma-associated coagulopathy,” J Trauma, 71(5 Suppl 1):S427-S434 (2011).;;Pati, S., et al., “Lyophilized plasma attenuates vascular permeability, inflammation and lung injury in hemorrhagic shock,” PLOS One, 13:e0192363 (2018) , entire document, 13 Pages.;;Reineccius, G., “Flavor encapsulation, Chapter 7. Spray-drying of food flavors,” United Kingdom: Taylor and Francis, 55-66 (1989).;;“Considerations for the Development of Dried Plasma Products Intended for Transfusion”, (Final Report). Food and Drug Administration (2019), entire document, 9 Pages.;;Liu, Q. P., et al., “Single-donor spray-dried plasma,” Transfusion, 59:707-719 (2019).;;Meledeo, M. A., et al., “Spray-dried plasma deficient in high-molecular weight multimers of von Willebrand factor retains hemostatic properties,” Transfusion, 59:714-722 (2019).;;Buckley, L., and Gonzales, R., “Challenges to producing novel therapies-dried plasma for use in trauma and critical care,” Transfusion, 59:837-845 (2019).;;Bercovitz, R., et al., “Microfluidic analysis of thrombus formation in reconstituted whole blood samples comparing spray-dried plasma versus fresh- frozen plasma,” Vox Sang, 116:540-546 (2020).;;Spinella, P. C., et al., “All plasma products are not created equal: characterizing differences between plasma products,” J Trauma Acute Care Surg, 78:S18-S25 (2015).;;Bomey, N., “Hurricane Maria halts crucial drug manufacturing in Puerto Rico, may cause shortages,” USA Today, [online], [retrieved on Oct. 20, 2017] Retrieved from https://www.usatoday.com/story/money/2017/09/22/hurricane-maria-pharmaceutical industry-puerto-rico/692752001/ (2017), entire document, 9 Pages.;;Robinson, R. A., “Barda Strategic Plan 2011-2016”, Washington, D.C.: Biomedical Advanced Research and Development Authority. (2016), entire document, 20 Pages.;;Pusateri A.E., “Dried Plasma Development Update,” Defense Health Agency (2015), entire document, 58 Pages.;;Downes, K. A., et al., “Serial measurement of clotting factors in thawed plasma stored for 5 days,” Transfusion, 41: 570-570 (2001).;;Runkel, S., et al., “The impact of whole blood processing and freezing conditions on the quality of therapeutic plasma prepared from whole blood,” Transfusion, 55: 796-804 (2015).;;Kelley, D., “Update on Plasma and Cryoprecipitate Transfusion,” (Issue 1). Institute for Transfusion Medicine (2004), Entire Document, 2 Pages.;;ARUP Consult, “Von Willebrand Disease Testing,” [online], [retrieved on May 12, 2015], Retrieved from https://arupconsult.com/sites/default/files/von_Willebrand_Disease_Testing_Algorithm.pdf , entire document, 1 Page.;;Heger, A., et al., “Biochemical quality of the pharmaceutically licensed plasma OctaplasLG® after implementation of a novel prion protein (PrPSc) removal technology and reduction of the solvent/detergent (S/D) process time,” Vox Sanguinis, 97: 219-225 (2009).;;Pusateri, A. E., et al., “Use of Dried Plasma in Prehospital and Austere Environments,” Anesthesiology, 136: 327-335 (2022).;;Pusateri, A. E., “Dried plasma: state of the science and recent developments,” Transfusion, 56: S128-S139 (2016).;;Chaffin, J., “Liquid Plasma,” [online], [retrieved on Nov. 2, 2021], Retrieved from https://www.bbguy.org/education/glossary/gl104/, entire document, 2 Pages.;;Chaffin, J., “Thawed Plasma,” [online], [retrieved on Nov. 2, 2021], Retrieved from https://www.bbguy.org/education/glossary/elt04/, entire document, 2 Pages.;;Barrows, E., “Freeze-dried Plasma The Trail Back to the Battlefield,” Defense AT&L Technology Transition, pp. 16-19 (Sep.-Oct. 2006).;;Martinaud, C., et al., “In Vitro Hemostatic Properties of French Lyophilized Plasma,” Anesthesiology, 117: 339-346 (2012).;;Sicard, B., et al., “Lyophilized Plasma in Out-of-Hospital Resuscitation: Risk Benefit Balance,” Ann Emerg Med, S141:357 (2017).;;Jost, D., et al., “Pre-hospital Administration of Lyophilized Plasma for Post-traumatic Coagulopathy Treatment (PREHO-PLYO),” [online], [retrieved on Apr. 25, 2022], Retrieved from https://clinicaltrials.gov/ct2/show/study/NCT02736812 , entire document, 9 Pages. et al.",ACTIVE
325,CZ,A3,CZ 162698 A3,026-926-080-235-080,1998-08-12,1998,CZ 162698 A,1996-10-25,US 760995 P,1995-11-27,"CARRIER MATERIAL, CATALYST APPLIED THERETO AND CONTAINING FREELY ATTACHED ACTIVATOR FORMING A CATION AS WELL AS ADDITION POLYMERIZATION PROCESS EMPLOYING SUCH CATALYST",,DOW CHEMICAL CO;;GRACE W R & CO,CARNAHAN EDMUND M;;CARNEY MICHAEL J;;NEITHAMER DAVID R;;NICKIAS PETER N;;SHIH KENG-YU;;SPENCER LEE,,https://lens.org/026-926-080-235-080,Patent Application,no,0,0,27,27,0,C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F10/00;;C08F4/65925;;C08F4/6592;;C08F4/025;;C08F4/6192;;C08F4/61908;;C08F4/61916;;C08F4/61912;;C08F10/02;;C08F4/65912;;C08F210/16;;C08F110/02;;Y10S526/943,C08F4/02;;C08F4/603;;C08F4/619;;C08F4/6192;;C08F4/643;;C08F4/645;;C08F4/646;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16,,0,0,,,,PENDING
326,NO,L,NO 982370 L,004-101-627-052-348,1998-05-27,1998,NO 982370 A,1998-05-26,US 760995 P;;US 9617140 W,1995-11-27,"Katalysatorbµrer, hvor kationdannende aktivator er bundet til bµrer","En bærer for anvendelse ved fremstilling av katalysatorer på bærer, for addisjonspolymeriseringer, omfattende produktet fra reaksjonen mellom (A) et uor- ganisk oksidmateriale omfattende reaktive overflate-hydroksylgrupper, idet i det minste en del av hydroksylgruppene eventuelt er blitt funksjonalisert og omdannet til en reaktiv sildandel, svarende til formelen -OSiR2H, hvor R uavhengig ved hver forekomst er hydrogen, C,.20-hydrokarbyl eller C1.20-hydrokarbyloksy, idet det uor- ganiske oksid eller det funksjonaliserte derivat derav omfatter mindre enn 1,0 mmol reaktiv overflatehydroksyl-funksjonalitet pr. gram; og (B) en aktivatorforbin- delse som omfatter: b,) et kation som kan reagere med en overgangsmetall- forbindelse under dannelse av et katalytisk aktivt overgangsmetall-kompleks, og b2) et forenlig anion inneholdende minst en substituent som kan reagere med det uorganiske oksid, med rest-hydroksylfunksjonaliteten på det uorganiske oksid eller med den reaktive silan-del, hvorved det forenlige anion bindes kovalent til bære- ren; katalysatorer dannet derav, en fremgangsmåte for fremstilling samt en frem- gangsmåte for anvendelse.",DOW CHEMICAL CO;;GRACE W R & CO,CARNAHAN EDMUND M;;CARNEY MICHAEL J;;NEITHAMER DAVID R;;NICKIAS PETER N;;SHIH KENG-YU;;SPENCER LEE,,https://lens.org/004-101-627-052-348,Abstract,no,0,0,27,27,0,C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F10/00;;C08F4/65925;;C08F4/6592;;C08F4/025;;C08F4/6192;;C08F4/61908;;C08F4/61916;;C08F4/61912;;C08F10/02;;C08F4/65912;;C08F210/16;;C08F110/02;;Y10S526/943,C08F4/02;;C08F4/603;;C08F4/619;;C08F4/6192;;C08F4/643;;C08F4/645;;C08F4/646;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16,,0,0,,,,DISCONTINUED
327,PT,E,PT 863919 E,151-699-504-678-155,2001-04-30,2001,PT 96936975 T,1996-10-25,US 760995 P,1995-11-27,CATALISADOR SOBRE SUPORTE CONTENDO UM ACTIVADOR IMOBILIZADO QUE FORMA CATIOES,,GRACE W R & CO;;DOW CHEMICAL CO,NEITHAMER DAVID R;;NICKIAS PETER N;;CARNAHAN EDMUND M;;CARNEY MICHAEL J;;SHIH KENG-YU;;SPENCER LEE,,https://lens.org/151-699-504-678-155,Granted Patent,no,0,0,27,27,0,C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F10/00;;C08F4/65925;;C08F4/6592;;C08F4/025;;C08F4/6192;;C08F4/61908;;C08F4/61916;;C08F4/61912;;C08F10/02;;C08F4/65912;;C08F210/16;;C08F110/02;;Y10S526/943,C08F4/02;;C08F4/603;;C08F4/619;;C08F4/6192;;C08F4/643;;C08F4/645;;C08F4/646;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16,,0,0,,,,EXPIRED
328,US,A,US 6087293 A,034-498-674-061-788,2000-07-11,2000,US 11747098 A,1998-03-02,US 11747098 A;;US 9617140 W;;US 760995 P,1995-11-27,Supported catalyst containing tethered cation forming activator,"A support for use in preparing supported catalysts for addition polymerizations comprising the reaction product of: (A) an inorganic oxide material comprising reactive surface hydroxyl groups, at least some of said hydroxyl groups optionally having been functionalized an converted to a reactive silano moiety corresponding to the formula: --OSiR.sub.2 H, wherein R, independently each occurrence, is hydrogen C.sub.1-20 hydrocarbyl, or C.sub.1-20 hydrocarbyloxy, said inorganic oxide or functionalized derivative thereof comprising less than 1.0 mmol of reactive surface hydroxyl functionality per gram, and (B) an activator compound comprising: b.sub.1) a cation which is capable of reacting with a transition metal compound to form a catalytically active transition metal complex, and b.sub.2) a compatible anion containing at least one substituent able to react with the inorgnaic oxide, with residual hydroxyl functionality of the inorganic oxide, or with the reactive silane moiety, hereby covalently bonding the compatible anion to the support, catalysts formed therefrom, process of manufacture and the method to use.",DOW CHEMICAL CO;;GRACE W R & CO,CARNAHAN EDMUND M;;CARNEY MICHAEL J;;NEITHAMER DAVID R;;NICKIAS PETER N;;SHIH KENG-YU;;SPENCER LEE,W.R. GRACE & CO.-CONN (1997-11-19);;DOW CHEMICAL COMPANY THE (1997-11-26),https://lens.org/034-498-674-061-788,Granted Patent,yes,16,54,27,27,0,C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F10/00;;C08F4/65925;;C08F4/6592;;C08F4/025;;C08F4/6192;;C08F4/61908;;C08F4/61916;;C08F4/61912;;C08F10/02;;C08F4/65912;;C08F210/16;;C08F110/02;;Y10S526/943,C08F4/02;;C08F4/603;;C08F4/619;;C08F4/6192;;C08F4/643;;C08F4/645;;C08F4/646;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16,502/158;;502/150;;502/152;;502/155;;502/202;;526/128;;526/130;;526/134;;526/160;;526/943,3,2,106-346-169-319-853;;136-161-840-649-857,10.1021/ma00032a025;;10.1021/ja00093a054,"A.R. Siedel et al., Makromol.Chem., Macromol. Symp., vol. 66, pp. 215 224, Feb. 1993.;;S. Collins et al., Macromolecules, vol. 25, No. 6, pp. 1780 1785, 1992.;;R. Quyoum et al., J. Am. Chem. Soc., vol. 116, No. 14, pp. 6435 6436, 1994.",EXPIRED
329,BR,A,BR 9611772 A,030-018-548-172-726,1999-02-23,1999,BR 9611772 A,1996-10-25,US 760995 P;;US 9617140 W,1995-11-27,Suporte para uso na preparação de catalisadores para polimerizações por adição catalisador suportado e processo de polimerização por adição,,DOW CHEMICAL CO,NEITHAMER DAVID R;;NICKIAS PETER N;;SHIH KENG YU;;CARNAHAN EDMUND M;;SPENCER LEE;;CARNEY MICHAEL J,,https://lens.org/030-018-548-172-726,Patent Application,no,0,0,27,27,0,C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F10/00;;C08F4/65925;;C08F4/6592;;C08F4/025;;C08F4/6192;;C08F4/61908;;C08F4/61916;;C08F4/61912;;C08F10/02;;C08F4/65912;;C08F210/16;;C08F110/02;;Y10S526/943,C08F4/02;;C08F4/603;;C08F4/619;;C08F4/6192;;C08F4/643;;C08F4/645;;C08F4/646;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16,,0,0,,,,DISCONTINUED
330,ZA,B,ZA 969874 B,086-042-718-333-572,1998-05-25,1998,ZA 969874 A,1996-11-25,US 760995 P,1995-11-27,Supported catalyst containing tethered cation forming activator.,,DOW CHEMICAL CO;;GRACE W R & CO,CARNEY MICHAEL J;;CARNAHAN EDMUND M;;NEITHAMER DAVID R;;NICKIAS PETER N;;SHIH KENG-YU;;SPENCER LEE,,https://lens.org/086-042-718-333-572,Granted Patent,no,0,0,27,27,0,C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F10/00;;C08F4/65925;;C08F4/6592;;C08F4/025;;C08F4/6192;;C08F4/61908;;C08F4/61916;;C08F4/61912;;C08F10/02;;C08F4/65912;;C08F210/16;;C08F110/02;;Y10S526/943,C08F4/02;;C08F4/603;;C08F4/619;;C08F4/6192;;C08F4/643;;C08F4/645;;C08F4/646;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16,,0,0,,,,EXPIRED
331,AU,A,AU 1996/074757 A,169-722-345-483-92X,1997-06-19,1997,AU 1996/074757 A,1996-10-25,US 760995 P;;US 9617140 W,1995-11-27,Supported catalyst containing tethered cation forming activator,,DOW CHEMICAL CO;;GRACE W R & CO,CARNAHAN EDMUND M;;CARNEY MICHAEL J;;NEITHAMER DAVID R;;NICKIAS PETER N;;SHIH KENG-YU;;SPENCER LEE,,https://lens.org/169-722-345-483-92X,Patent Application,no,0,0,27,27,0,C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F10/00;;C08F4/65925;;C08F4/6592;;C08F4/025;;C08F4/6192;;C08F4/61908;;C08F4/61916;;C08F4/61912;;C08F10/02;;C08F4/65912;;C08F210/16;;C08F110/02;;Y10S526/943,C08F4/02;;C08F4/603;;C08F4/619;;C08F4/6192;;C08F4/643;;C08F4/645;;C08F4/646;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16,,0,0,,,,EXPIRED
332,TW,B,TW 357161 B,063-951-985-215-929,1999-05-01,1999,TW 85114585 A,1996-11-26,US 760995 P,1995-11-27,"A support for use in preparing supported catalyst for addition polymerizations, supported catalyst comprising the same and polymerization procses using the supported catalyst","A support for use in preparing supported catalyst for addition polymerizations comprising the reaction product of: (A) an inorganic oxide material comprising reactive surface hydroxyl groups, at least some of said hydroxyl groups optionally having been functionalized and converted to a reaction silane moiety corresponding to the formula: -OSiR2H, wherein R, independently each occurrence, is hydrogen, C1-20 hydrocarbyl or C1-20 hydrocarbyloxy, said inorganic oxide or functionalized derivative thereof comprising less than 1.0 mmol of reactive surface hydroxyl functinality per gram, and (B) an activator compound having the followign formula: where G+e is the cationic residue of Bronster hydrochloric acid, oxidized cation; [DM^Q3] is non-coordinated compatible anion, D is bonded group, containing funtionality of silane, siloxane, hydrocarbyloxysilane, halogenated silane, hydroxyl, thioester, amino, carboxyl, carboxylate, aldehyde ketone or epoxy oxide that can react with the inorganic oxide, residual hydroxyl functionality or reactive silane functionality, M is boron or aluminum with oxidation state of 3, Q is hydrocarbyl, hydrocarbyloxy, fluorinated hydrocarbyl, fluorinated hydrocarbyloxy or fluorinated methylsilylhydroxy having at most non-hydrogen atoms, and e is an integer from 1 to 3.",DOW CHEMICAL CO;;GRACE W R & CO,CARNAHAN EDMUND M;;CARNEY MICHAEL J;;NEITHAMER DAVID R;;NICKIAS PETER N;;SHIH KENG-YU;;LEE SPENCER,,https://lens.org/063-951-985-215-929,Granted Patent,no,0,0,27,27,0,C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F10/00;;C08F4/65925;;C08F4/6592;;C08F4/025;;C08F4/6192;;C08F4/61908;;C08F4/61916;;C08F4/61912;;C08F10/02;;C08F4/65912;;C08F210/16;;C08F110/02;;Y10S526/943,C08F4/603;;C08F4/619;;C08F4/6192;;C08F4/643;;C08F4/645;;C08F4/646;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16,,0,0,,,,EXPIRED
333,PL,A1,PL 326932 A1,155-464-564-008-742,1998-11-09,1998,PL 32693296 A,1996-10-25,US 760995 P,1995-11-27,"SUPPORTED CATALYST CONTAINING AN ACTIVATOR CAPABLE TO FORM ""CAPTURED"" CATIONS",,DOW CHEMICAL CO;;GRACE W R & CO,CARNAHAN EDMUND M;;CARNEY MICHAEL J;;NEITHAMER DAVID R;;NICKIAS PETER N;;SHIH KENG-YU;;SPENCER LEE,,https://lens.org/155-464-564-008-742,Patent Application,no,0,0,27,27,0,C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F4/025;;C08F4/61908;;C08F4/61912;;C08F4/61916;;C08F4/6192;;C08F4/65912;;C08F4/6592;;C08F4/65925;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16;;Y10S526/943;;C08F10/00;;C08F4/65925;;C08F4/6592;;C08F4/025;;C08F4/6192;;C08F4/61908;;C08F4/61916;;C08F4/61912;;C08F10/02;;C08F4/65912;;C08F210/16;;C08F110/02;;Y10S526/943,C08F4/02;;C08F4/603;;C08F4/619;;C08F4/6192;;C08F4/643;;C08F4/645;;C08F4/646;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F10/02;;C08F110/02;;C08F210/16,,0,0,,,,PENDING
334,EP,A1,EP 3803133 A1,088-588-596-541-134,2021-04-14,2021,EP 19730465 A,2019-05-31,GB 201808912 A;;GB 2019051503 W,2018-05-31,BENCH-TOP TIME OF FLIGHT MASS SPECTROMETER,,MICROMASS LTD,MARSH CEDRIC;;CARNEY PETER;;WILDGOOSE JASON LEE;;WALLIS DAVID;;MCIVER PAUL;;CHUMMAR SOJI;;ANTONIADES GEORGE ANDREAS;;MISTRY DIPESH,,https://lens.org/088-588-596-541-134,Patent Application,yes,0,0,16,16,0,H01J49/24;;F04D19/042;;F04D29/701;;H01J49/24;;H01J49/40;;F04D29/12;;F04D19/042;;F04D29/122;;F04D29/701;;H01J49/24;;H01J49/405,F04D29/70;;H01J49/24,,0,0,,,,PENDING
335,US,A1,US 2021/0207608 A1,199-962-648-973-951,2021-07-08,2021,US 201917057357 A,2019-05-31,GB 201808912 A;;GB 2019051503 W,2018-05-31,BENCH-TOP TIME OF FLIGHT MASS SPECTROMETER,"A mass spectrometer comprising: a vacuum housing comprising a first vacuum chamber having a first gas exhaust port; a gas pump ( 1700 ) having a first gas inlet port connected to the first gas exhaust port (H 1 ) by a first gas conduit for evacuating the first vacuum chamber; and a first apertured cover ( 2010 ) arranged over the first gas exhaust port (H 1 ) or first gas inlet port, or in the first gas conduit therebetween.",MICROMASS LTD,MARSH CEDRIC;;CARNEY PETER;;WOLDGOOSE JASON LEE;;WALLIS DAVID;;MCIVER PAUL;;CHUMMAR SOJI;;ANTONIADES GEORGE ANDREAS;;MISTRY DIPESH,MICROMASS UK LIMITED (2021-04-28),https://lens.org/199-962-648-973-951,Patent Application,yes,2,0,16,16,0,H01J49/24;;F04D19/042;;F04D29/701;;H01J49/24;;H01J49/40;;F04D29/12;;F04D19/042;;F04D29/122;;F04D29/701;;H01J49/24;;H01J49/405,F04D19/04;;F04D29/12;;F04D29/70;;H01J49/24;;H01J49/40,,0,0,,,,ACTIVE
336,JP,A,JP 2007099620 A,094-264-035-368-18X,2007-04-19,2007,JP 2006311006 A,2006-11-17,US 37492199 A,1999-08-16,METHOD OF IMPROVING CAPABILITY OF GLASS MELTING FURNACE USING CEILING-MOUNTED OXYGEN-FUEL BURNER,"<P>PROBLEM TO BE SOLVED: To improve melting speed of a glass forming batch raw material, glass quality and/or glass yield. <P>SOLUTION: In a glass melting furnace 10 comprising: an air fuel burner; an upstream melting zone 27; and a downstream clarification zone 28 wherein the burner is mounted to a ceiling 22 in an upper part than a glass forming batch material in the melting zone 27, the glass forming batch material 30 is melted. A fuel and a combustion air stream to an air fuel burner are reduced, a gaseous oxidizing agent is passed into a burner 34 mounted at a ceiling, a gaseous fuel is poured to the burner 34, flames 36 are generated from the burner 34, reduced energy from the air fuel burner is substituted to give additional energy, the glass forming batch material 30 is made not to generate substantial disturbance, and flames 36 are controlled to have sufficient velocity in order to make heat transfer from the flames 36 to the glass forming batch material 30 into the maximum. <P>COPYRIGHT: (C)2007,JPO&INPIT",BOC GROUP INC,SIMPSON NEIL G;;CLAYTON THOMAS G;;PRUSIA GREGORY F;;RICHARDSON ANDREW PETER;;CARNEY STEPHEN MCDONALD;;LEBLANC JOHN R,,https://lens.org/094-264-035-368-18X,Patent Application,no,2,1,29,71,0,C03B5/193;;C03B5/2353;;C03B2211/30;;C03B2211/40;;C03B2211/60;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/002;;F23L7/00;;F23L2900/07005;;Y02P40/57;;Y02E20/34;;Y02P40/50;;C03B5/16;;C03B5/193;;C03B2211/30;;C03B2211/40;;C03B5/2353;;F23D14/32;;F23D14/02;;C03B2211/60;;F23L2900/07005;;F23D17/002;;F23C5/00;;F23L7/00;;Y02P40/57;;Y02E20/34;;Y02P40/50,C03B5/235;;F23C5/08;;C03B5/16;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/00;;F23L7/00;;F27D7/02,,0,0,,,,INACTIVE
337,US,A,US 5324391 A,094-807-625-544-102,1994-06-28,1994,US 97436592 A,1992-11-09,US 97436592 A;;US 60726890 A,1990-10-31,Method for crosslinking cellulose fibers,"A method is disclosed for preparing a quantity of individual treated fibers from one or more fiber mats in a treatment apparatus. The apparatus comprises a fiber treatment zone, a conveyor for conveying each mat through the fiber treatment zone, wherein each mat is impregnated by an applicator with a crosslinking substance, and directly to an attrition device. The attrition device fiberizes the mats to form a fiber output having a low nit level, such as no more than about three, and a dryer for both drying the fiber output and curing the crosslinking substance. The fiberizer is configured to have minimize the accumulation of fiber at locations therein. An optional component of the fiberizer is a novel fluff generator comprised of multiple rotors each having plural longitudinally extended rows of radially extending rotor pins that rotate past groups of shorter pins mounted on the inside surface of the fluff generator housing.",WEYERHAEUSER CO,CARNEY ALLAN R;;GRAEF PETER A;;BOWNS MARK W;;BOLSTAD CLIFFORD R;;OLMSTEAD FRED E;;HUNTER FRANK R,WEYERHAEUSER NR COMPANY (2009-04-21),https://lens.org/094-807-625-544-102,Granted Patent,yes,52,7,9,9,0,A61F2013/530007;;A61F2013/530474;;D21B1/066;;D21B1/066;;A61F2013/530007;;A61F2013/530474,A61F13/15;;D04H1/42;;D21B1/06,162/9;;162/100;;162/157.6;;162/182;;162/201,0,0,,,,EXPIRED
338,US,A1,US 2002/0144518 A1,153-817-946-853-843,2002-10-10,2002,US 11789802 A,2002-04-08,US 11789802 A;;US 37492199 A,1999-08-16,Method of boosting a glass melting furnace using a roof mounted oxygen-fuel burner,"
   In an industrial glass furnace which contains recuperators, regenerators, electric boost or other devices for providing heat to glass batch material an oxy-fuel burner mounted in the roof of the furnace provides additional heat to melt the batch material. A method of mounting and using such a roof-mounted oxy-fuel burner including the operating parameters to maximize heat transfer while minimizing the disturbance of the batch material is disclosed. 
",BOC GROUP INC,SIMPSON NEIL GEORGE;;PRUSIA GREG FLOYD;;CARNEY STEPHEN MCDONALD;;CLAYTON THOMAS G;;RICHARDSON ANDREW PETER;;LEBLANC JOHN R,LINDE INC (2007-12-19);;MESSER INDUSTRIES USA INC (2019-07-19);;MESSER LLC (2019-02-13),https://lens.org/153-817-946-853-843,Patent Application,yes,0,3,29,71,0,C03B5/193;;C03B5/2353;;C03B2211/30;;C03B2211/40;;C03B2211/60;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/002;;F23L7/00;;F23L2900/07005;;Y02P40/57;;Y02E20/34;;Y02P40/50;;C03B5/16;;C03B5/193;;C03B2211/30;;C03B2211/40;;C03B5/2353;;F23D14/32;;F23D14/02;;C03B2211/60;;F23L2900/07005;;F23D17/002;;F23C5/00;;F23L7/00;;Y02P40/57;;Y02E20/34;;Y02P40/50,F23C5/08;;C03B5/16;;C03B5/235;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/00;;F23L7/00;;F27D7/02,65/134.4;;65/157,0,0,,,,EXPIRED
339,CN,A,CN 112166255 A,166-306-891-592-400,2021-01-01,2021,CN 201980035096 A,2019-05-31,GB 201808912 A;;GB 2019051503 W,2018-05-31,BENCH-TOP TIME OF FLIGHT MASS SPECTROMETER,"A mass spectrometer comprising: a vacuum housing comprising a first vacuum chamber having a first gas exhaust port; a gas pump (1700) having a first gas inlet port connected to the first gas exhaust port (H1) by a first gas conduit for evacuating the first vacuum chamber; and a first apertured cover (2010) arranged over the first gas exhaust port (H1) or first gas inlet port, or in the first gas conduit therebetween.",MICROMASS LTD,MARSH CEDRIC;;CARNEY PETER;;WILDGOOSE JASON LEE;;WALLIS DAVID;;MCIVER PAUL;;CHUMMAR SOJI;;ANTONIADES GEORGE ANDREAS;;MISTRY DIPESH,,https://lens.org/166-306-891-592-400,Patent Application,no,10,0,16,16,0,H01J49/24;;F04D19/042;;F04D29/701;;H01J49/24;;H01J49/40;;F04D29/12;;F04D19/042;;F04D29/122;;F04D29/701;;H01J49/24;;H01J49/405,F04D29/70;;H01J49/24,,0,0,,,,ACTIVE
340,ZA,B,ZA 200004135 B,083-623-899-280-356,2001-02-20,2001,ZA 200004135 A,2000-08-14,US 37492199 A,1999-08-16,A method of boosting a glass melting furnace using a roof mounted oxygen-fuel burner.,,BOC GROUP INC,SIMPSON NEL G;;PRUSIA GREGORY F;;CARNEY STEPHEN MCDONALD;;CLAYTON THOMAS G;;RICHARDSON ANDREW PETER;;LEBLANC JOHN R,,https://lens.org/083-623-899-280-356,Granted Patent,no,0,0,29,71,0,C03B5/193;;C03B5/2353;;C03B2211/30;;C03B2211/40;;C03B2211/60;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/002;;F23L7/00;;F23L2900/07005;;Y02P40/57;;Y02E20/34;;Y02P40/50;;C03B5/16;;C03B5/193;;C03B2211/30;;C03B2211/40;;C03B5/2353;;F23D14/32;;F23D14/02;;C03B2211/60;;F23L2900/07005;;F23D17/002;;F23C5/00;;F23L7/00;;Y02P40/57;;Y02E20/34;;Y02P40/50,F23C5/08;;C03B5/16;;C03B5/235;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/00;;F23L7/00;;F27D7/02,,0,0,,,,EXPIRED
341,EP,B1,EP 1077201 B1,083-950-439-324-707,2005-11-30,2005,EP 00306970 A,2000-08-15,US 37492199 A,1999-08-16,Method of boosting the heating in a glass melting furnace using a roof-mounted oxygen-fuel burner,,BOC GROUP INC,SIMPSON NEIL GEORGE;;PRUSIA GREGORY FLOYD;;CARNEY STEPHEN MCDONALD;;CLAYTON THOMAS G;;RICHARDSON ANDREW PETER;;LEBLANC JOHN R,"LINDE GAS NORTH AMERICA LLC, BRIDGEWATER, US (2020-04-16);;LINDE GAS NORTH AMERICA LLC (2019-11-07)",https://lens.org/083-950-439-324-707,Granted Patent,yes,5,2,29,71,0,C03B5/193;;C03B5/2353;;C03B2211/30;;C03B2211/40;;C03B2211/60;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/002;;F23L7/00;;F23L2900/07005;;Y02P40/57;;Y02E20/34;;Y02P40/50;;C03B5/16;;C03B5/193;;C03B2211/30;;C03B2211/40;;C03B5/2353;;F23D14/32;;F23D14/02;;C03B2211/60;;F23L2900/07005;;F23D17/002;;F23C5/00;;F23L7/00;;Y02P40/57;;Y02E20/34;;Y02P40/50,F23C5/08;;C03B5/16;;C03B5/235;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/00;;F23L7/00;;F27D7/02,,0,0,,,,EXPIRED
342,EP,A3,EP 1077201 A3,104-330-131-269-329,2003-02-05,2003,EP 00306970 A,2000-08-15,US 37492199 A,1999-08-16,Method of boosting the heating in a glass melting furnace using a roof-mounted oxygen-fuel burner,"In an industrial glass furnace 10 which contains recuperators, regenerators, electric boost or other devices for providing heat to glass batch material at least one oxy-fuel burner (34) mounted in the roof of the furnace provides additional heat to melt the batch material. By using such a roof-mounted oxy-fuel burner 34 heat transfer can be maximised while minimising the disturbance of the batch material. The velocity of the flame 36 produced by operation of the oxy-fuel burner 34 is kept to 30 metres per second of less near the surface.",BOC GROUP INC,SIMPSON NEIL GEORGE;;PRUSIA GREGORY FLOYD;;CARNEY STEPHEN MCDONALD;;CLAYTON THOMAS G;;RICHARDSON ANDREW PETER;;LEBLANC JOHN R,"LINDE GAS NORTH AMERICA LLC, BRIDGEWATER, US (2020-04-16);;LINDE GAS NORTH AMERICA LLC (2019-11-07)",https://lens.org/104-330-131-269-329,Search Report,yes,5,0,29,71,0,C03B5/193;;C03B5/2353;;C03B2211/30;;C03B2211/40;;C03B2211/60;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/002;;F23L7/00;;F23L2900/07005;;Y02P40/57;;Y02E20/34;;Y02P40/50;;C03B5/16;;C03B5/193;;C03B2211/30;;C03B2211/40;;C03B5/2353;;F23D14/32;;F23D14/02;;C03B2211/60;;F23L2900/07005;;F23D17/002;;F23C5/00;;F23L7/00;;Y02P40/57;;Y02E20/34;;Y02P40/50,F23C5/08;;C03B5/16;;C03B5/235;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/00;;F23L7/00;;F27D7/02,,0,0,,,,EXPIRED
343,AT,T1,AT E311351 T1,031-605-905-264-075,2005-12-15,2005,AT 00306970 T,2000-08-15,US 37492199 A,1999-08-16,VERFAHREN ZUM ZUSATZERHITZEN EINES GLASSCHMELZOFENS MIT EINEM IM GEWÖLBE MONTIERTEN SAUERSTOFF-BRENNSTOFF-BRENNER,,BOC GROUP INC,SIMPSON NEIL GEORGE;;PRUSIA GREGORY FLOYD;;CARNEY STEPHEN MCDONALD;;CLAYTON THOMAS G;;RICHARDSON ANDREW PETER;;LEBLANC JOHN R,,https://lens.org/031-605-905-264-075,Granted Patent,no,0,0,29,71,0,C03B5/193;;C03B5/2353;;C03B2211/30;;C03B2211/40;;C03B2211/60;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/002;;F23L7/00;;F23L2900/07005;;Y02P40/57;;Y02E20/34;;Y02P40/50;;C03B5/16;;C03B5/193;;C03B2211/30;;C03B2211/40;;C03B5/2353;;F23D14/32;;F23D14/02;;C03B2211/60;;F23L2900/07005;;F23D17/002;;F23C5/00;;F23L7/00;;Y02P40/57;;Y02E20/34;;Y02P40/50,F23C5/08;;C03B5/16;;C03B5/235;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/00;;F23L7/00;;F27D7/02,,0,0,,,,EXPIRED
344,ES,T3,ES 2253186 T3,089-231-881-810-051,2006-06-01,2006,ES 00306970 T,2000-08-15,US 37492199 A,1999-08-16,METODO PARA AUMENTAR EL CALENTAMIENTO EN UN HORNO DE FUSION DE VIDRIO QUE UTILIZA UN QUEMADOR DE COMBUSTIBLE Y OXIGENO MONTADO EN EL TECHO.,"Un método para fundir una carga de materia prima en un horno de vidrio que tiene regeneradores, recuperadores y/o sobrealimentación eléctrica, teniendo dicho horno paredes laterales, una pared posterior, una pared anterior y un techo, que comprende generar una llama a partir de al menos un quemador de combustible y oxígeno montado en el techo del horno sobre dicha carga de materia prima, siendo gaseoso el combustible proporcionado al quemador, teniendo dicha llama una velocidad suficiente para maximizar la transferencia de calor desde dicha llama a dicha carga de materia prima sin alterar sustancialmente dicha carga de materia prima.",BOC GROUP INC,SIMPSON NEIL GEORGE;;PRUSIA GREGORY FLOYD;;CARNEY STEPHEN MCDONALD;;CLAYTON THOMAS G;;RICHARDSON ANDREW PETER;;LEBLANC JOHN R,,https://lens.org/089-231-881-810-051,Granted Patent,no,0,0,29,71,0,C03B5/193;;C03B5/2353;;C03B2211/30;;C03B2211/40;;C03B2211/60;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/002;;F23L7/00;;F23L2900/07005;;Y02P40/57;;Y02E20/34;;Y02P40/50;;C03B5/16;;C03B5/193;;C03B2211/30;;C03B2211/40;;C03B5/2353;;F23D14/32;;F23D14/02;;C03B2211/60;;F23L2900/07005;;F23D17/002;;F23C5/00;;F23L7/00;;Y02P40/57;;Y02E20/34;;Y02P40/50,F23C5/08;;C03B5/16;;C03B5/235;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/00;;F23L7/00;;F27D7/02,,0,0,,,,EXPIRED
345,DE,T3,DE 60024370 T3,092-170-602-530-076,2013-04-11,2013,DE 60024370 T,2000-08-15,US 37492199 A;;EP 00306970 A,1999-08-16,Verfahren zum Zusatzerhitzen eines Glasschmelzofens mit einem im Gewölbe montierten Sauerstoff-Brennstoff-Brenner,,BOC GROUP INC,SIMPSON NEIL GEORGE;;PRUSIA GREGORY FLOYD;;CARNEY STEPHEN MCDONALD;;CLAYTON THOMAS G;;RICHARDSON ANDREW PETER;;LEBLANC JOHN R,,https://lens.org/092-170-602-530-076,Amended Patent,no,0,0,29,71,0,C03B5/193;;C03B5/2353;;C03B2211/30;;C03B2211/40;;C03B2211/60;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/002;;F23L7/00;;F23L2900/07005;;Y02P40/57;;Y02E20/34;;Y02P40/50;;C03B5/16;;C03B5/193;;C03B2211/30;;C03B2211/40;;C03B5/2353;;F23D14/32;;F23D14/02;;C03B2211/60;;F23L2900/07005;;F23D17/002;;F23C5/00;;F23L7/00;;Y02P40/57;;Y02E20/34;;Y02P40/50,C03B5/235;;F23C5/08;;C03B5/16;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/00;;F23L7/00;;F23M5/02;;F27D7/02,,0,0,,,,EXPIRED
346,CA,C,CA 2315486 C,142-526-453-581-174,2006-11-21,2006,CA 2315486 A,2000-08-11,US 37492199 A,1999-08-16,METHOD OF BOOSTING A GLASS MELTING FURNACE USING A ROOF-MOUNTED OXYGEN-FUEL BURNER,"In an industrial glass furnace which contains recuperators, regenerators, electric boost or other devices for providing heat to glass batch material an oxy-fue l burner mounted in the roof of the furnace provides additional heat to melt the batc h material. A method of mounting and using such a roof mounted oxy-fuel burner including the operating parameters to maximize heat transfer while minimizing the disturbance of the batch material is disclosed.",BOC GROUP INC,LEBLANC JOHN R;;RICHARDSON ANDREW PETER;;CARNEY STEPHEN MCDONALD;;SIMPSON NEIL GEORGE;;CLAYTON THOMAS G;;PRUSIA GREGORY FLOYD,,https://lens.org/142-526-453-581-174,Granted Patent,no,0,0,29,71,0,C03B5/193;;C03B5/2353;;C03B2211/30;;C03B2211/40;;C03B2211/60;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/002;;F23L7/00;;F23L2900/07005;;Y02P40/57;;Y02E20/34;;Y02P40/50;;C03B5/16;;C03B5/193;;C03B2211/30;;C03B2211/40;;C03B5/2353;;F23D14/32;;F23D14/02;;C03B2211/60;;F23L2900/07005;;F23D17/002;;F23C5/00;;F23L7/00;;Y02P40/57;;Y02E20/34;;Y02P40/50,C03B5/237;;F23C5/08;;C03B5/16;;C03B5/235;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/00;;F23L7/00;;F27D7/02,,0,0,,,,EXPIRED
347,DE,D1,DE 60024370 D1,150-728-481-768-222,2006-01-05,2006,DE 60024370 T,2000-08-15,US 37492199 A;;EP 00306970 A,1999-08-16,Verfahren zum Zusatzerhitzen eines Glasschmelzofens mit einem im Gewölbe montierten Sauerstoff-Brennstoff-Brenner,,BOC GROUP INC,SIMPSON NEIL GEORGE;;PRUSIA GREGORY FLOYD;;CARNEY STEPHEN MCDONALD;;CLAYTON THOMAS G;;RICHARDSON ANDREW PETER;;LEBLANC JOHN R,,https://lens.org/150-728-481-768-222,Granted Patent,no,0,0,29,71,0,C03B5/193;;C03B5/2353;;C03B2211/30;;C03B2211/40;;C03B2211/60;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/002;;F23L7/00;;F23L2900/07005;;Y02P40/57;;Y02E20/34;;Y02P40/50;;C03B5/16;;C03B5/193;;C03B2211/30;;C03B2211/40;;C03B5/2353;;F23D14/32;;F23D14/02;;C03B2211/60;;F23L2900/07005;;F23D17/002;;F23C5/00;;F23L7/00;;Y02P40/57;;Y02E20/34;;Y02P40/50,F23C5/08;;C03B5/16;;C03B5/235;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/00;;F23L7/00;;F23M5/02;;F27D7/02,,0,0,,,,EXPIRED
348,US,B1,US 6422041 B1,182-635-317-000-949,2002-07-23,2002,US 37492199 A,1999-08-16,US 37492199 A,1999-08-16,Method of boosting a glass melting furnace using a roof mounted oxygen-fuel burner,"
    In an industrial glass furnace which contains recuperators, regenerators, electric boost or other devices for providing heat to glass batch material an oxy-fuel burner mounted in the roof of the furnace provides additional heat to melt the batch material. A method of mounting and using such a roof-mounted oxy-fuel burner including the operating parameters to maximize heat transfer while minimizing the disturbance of the batch material is disclosed. 
",BOC GROUP INC,SIMPSON NEIL GEORGE;;PRUSIA GREG FLOYD;;CARNEY STEPHEN MCDONALD;;CLAYTON THOMAS G;;RICHARDSON ANDREW PETER;;LEBLANC JOHN R,LINDE INC (2007-12-19);;BOC GROUP INC THE (1999-11-03);;MESSER INDUSTRIES USA INC (2019-07-19);;MESSER LLC (2019-02-13),https://lens.org/182-635-317-000-949,Granted Patent,yes,7,108,29,71,0,C03B5/193;;C03B5/2353;;C03B2211/30;;C03B2211/40;;C03B2211/60;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/002;;F23L7/00;;F23L2900/07005;;Y02P40/57;;Y02E20/34;;Y02P40/50;;C03B5/16;;C03B5/193;;C03B2211/30;;C03B2211/40;;C03B5/2353;;F23D14/32;;F23D14/02;;C03B2211/60;;F23L2900/07005;;F23D17/002;;F23C5/00;;F23L7/00;;Y02P40/57;;Y02E20/34;;Y02P40/50,F23C5/08;;C03B5/16;;C03B5/235;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/00;;F23L7/00;;F27D7/02,65/134.4;;65/134.6;;65/135.6;;65/135.8;;65/136.3;;65/356,0,0,,,,EXPIRED
349,JP,A,JP 2001220150 A,072-900-668-326-162,2001-08-14,2001,JP 2000246273 A,2000-08-15,US 37492199 A,1999-08-16,METHOD OF IMPROVING PERFORMANCE OF GLASS MELTING FURNACE USING CEILING MOUNTING TYPE OXYGEN BURNER,"PROBLEM TO BE SOLVED: To increase the volume of a glass furnace and to improve the quality of glass. SOLUTION: In an industrial glass furnace having a recuperator, a heat storage unit, an electrical boost or an other device for giving heat to a glass batch material, an oxygen burner 34 attached to the ceiling of the furnace gives an additional amount of heat for melting the batch material 30. The method for improving the performance of the glass melting furnace comprises thus attaching the oxygen burner 34 to the ceiling of the furnace and includes operation parameters with which heat transfer is made maximum while making the disorder of the batch material minimum. The oxygen burner 34 is directed so as to cross orthogonally with the surface of the batch material. The range of angle is about 30 degrees, preferably less than 10 degrees.",BOC GROUP INC,SIMPSON NEIL G;;CLAYTON THOMAS G;;PRUSIA GREGORY F;;RICHARDSON ANDREW PETER;;CARNEY STEPHEN MCDONALD;;LEBLANC JOHN R,,https://lens.org/072-900-668-326-162,Patent Application,no,3,4,29,71,0,C03B5/193;;C03B5/2353;;C03B2211/30;;C03B2211/40;;C03B2211/60;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/002;;F23L7/00;;F23L2900/07005;;Y02P40/57;;Y02E20/34;;Y02P40/50;;C03B5/16;;C03B5/193;;C03B2211/30;;C03B2211/40;;C03B5/2353;;F23D14/32;;F23D14/02;;C03B2211/60;;F23L2900/07005;;F23D17/002;;F23C5/00;;F23L7/00;;Y02P40/57;;Y02E20/34;;Y02P40/50,F23C5/08;;C03B5/16;;C03B5/235;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/00;;F23L7/00;;F27D7/02,,0,0,,,,EXPIRED
350,CN,A,CN 115763216 A,086-569-425-725-936,2023-03-07,2023,CN 202211515781 A,2019-05-31,GB 201808912 A;;CN 201980035096 A;;GB 2019051503 W,2018-05-31,Table type time-of-flight mass spectrometer,"A mass spectrometer includes: a vacuum housing including a first vacuum chamber having a first gas vent; the gas pump (1700) is provided with a first gas inlet, and the first gas inlet is connected to the first gas exhaust port (H1) through a first gas pipeline so as to be used for emptying the first vacuum chamber; and a first perforated cover (2010) arranged in the first gas conduit above or between the first gas outlet (H1) or the first gas inlet.",MICROMASS LTD,MARSH CEDRIC;;CARNEY PETER;;WILDGOSER JASON LEE;;WALLIS DAVID;;MCIVER PAUL;;CUMA SUJIT;;ANTONIAS GEORGE ANDREAS;;MISTRY DIPI,,https://lens.org/086-569-425-725-936,Patent Application,no,0,0,16,16,0,H01J49/24;;F04D19/042;;F04D29/701;;H01J49/24;;H01J49/40;;F04D29/12;;F04D19/042;;F04D29/122;;F04D29/701;;H01J49/24;;H01J49/405,H01J49/24;;G01N27/62;;G01N27/64;;G01N27/68;;H01J49/40,,0,0,,,,PENDING
351,WO,A1,WO 2019/229462 A1,112-897-232-721-49X,2019-12-05,2019,GB 2019051503 W,2019-05-31,GB 201808912 A,2018-05-31,BENCH-TOP TIME OF FLIGHT MASS SPECTROMETER,"A mass spectrometer comprising: a vacuum housing comprising a first vacuum chamber having a first gas exhaust port; a gas pump (1700) having a first gas inlet port connected to the first gas exhaust port (H1) by a first gas conduit for evacuating the first vacuum chamber; and a first apertured cover (2010) arranged over the first gas exhaust port (H1) or first gas inlet port, or in the first gas conduit therebetween.",MICROMASS LTD,MARSH CEDRIC;;CARNEY PETER;;WILDGOOSE JASON LEE;;WALLIS DAVID;;MCIVER PAUL;;CHUMMAR SOJI;;ANTONIADES GEORGE ANDREAS;;MISTRY DIPESH,,https://lens.org/112-897-232-721-49X,Patent Application,yes,6,1,16,16,0,H01J49/24;;F04D19/042;;F04D29/701;;H01J49/24;;H01J49/40;;F04D29/12;;F04D19/042;;F04D29/122;;F04D29/701;;H01J49/24;;H01J49/405,F04D29/70;;H01J49/24,,0,0,,,,PENDING
352,US,B2,US 11879470 B2,024-228-332-201-16X,2024-01-23,2024,US 201917057357 A,2019-05-31,GB 201808912 A;;GB 2019051503 W,2018-05-31,Bench-top time of flight mass spectrometer,"A mass spectrometer comprising: a vacuum housing comprising a first vacuum chamber having a first gas exhaust port; a gas pump ( 1700 ) having a first gas inlet port connected to the first gas exhaust port (H 1 ) by a first gas conduit for evacuating the first vacuum chamber; and a first apertured cover ( 2010 ) arranged over the first gas exhaust port (H 1 ) or first gas inlet port, or in the first gas conduit therebetween.",MICROMASS LTD,MARSH CEDRIC;;CARNEY PETER;;WILDGOOSE JASON LEE;;WALLIS DAVID;;MCIVER PAUL;;CHUMMAR SOJI;;ANTONIADES GEORGE ANDREAS;;MISTRY DIPESH,MICROMASS UK LIMITED (2021-04-28),https://lens.org/024-228-332-201-16X,Granted Patent,yes,316,0,16,16,0,H01J49/24;;F04D19/042;;F04D29/701;;H01J49/24;;H01J49/40;;F04D29/12;;F04D19/042;;F04D29/122;;F04D29/701;;H01J49/24;;H01J49/405,H01J49/24;;F04D19/04;;F04D29/12;;F04D29/70;;H01J49/40,,80,6,002-875-246-112-868;;004-471-982-018-484;;022-561-862-885-681;;119-779-971-342-191;;062-933-196-688-541;;026-406-361-689-178,11523084;;10.1002/jms.207;;10.1002/rcm.1074;;12820206;;10.1021/ac0518811;;16579588;;10.1016/j.ijms.2013.02.010;;10.1063/1.4922913;;pmc4482810;;26133872;;10.1116/1.574781,"Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808932.6, dated Nov. 21, 2018, 4 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808890.6, dated Nov. 28, 2018, 7 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808912.8, dated Nov. 30, 2018, 10 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808942.5, dated Dec. 3, 2018, 7 pages.;;Chernushevich, I. V., et al., “An introduction to quadrupole-time-of-flight mass spectrometry”, Journal of Mass Spectrometry, 36(8):849-65 (2001) Abstract only.;;Chernushevich, I.V., et al., “Charge state separation for protein applications using a quadrupole time-of-flight mass spectrometer”, Rapid Communications in Mass Spectrometry 17(13):1416-1424 (2003). Abstract only.;;Makarov, A. et al., “Performance evaluation of a hybrid linear ion trap/orbitrap mass spectrometer,” Analytical Chemistry, 78(7):2113-20 (2006). Abstract only.;;Combined Search and Examination Report under Sections 117 and 18(3) for Application No. GB1808948.2 dated Nov. 21, 2018, 7 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808893.0 dated Nov. 27, 2018, 8 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808936.7 dated Nov. 20, 2018, 10 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808892.2, dated Dec. 3, 2018, 6 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Applicaton No. GB1808894.8 dated Dec. 3, 2018, 7 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808949.0 dated Oct. 31, 2018, 8 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1907722.1 dated Jun. 28, 2019, 8 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1808889.8 dated Nov. 30, 2018, 7 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051504, dated Jul. 23, 2019, 11 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1818003.4, dated May 2, 2019, 6 pages.;;Invitation to pay additional fees and, where applicable, protest fee for PCT/GB2019/051508, dated Aug. 28, 2019.;;Author unknown, “Operating Manual and Programming Reference, Models RGA100, RGA200, and RGA300 Residual Gas Analyzer,” Stanford Research Systems Revision 1.8 (May 2009).;;Jungmann, J. H., et al., “An in-vacuum, pixelated detection system for mass spectrometric analysis and imaging of macromolecules,” International Journal of Mass Spectrometry, 341-342:34-44 (2013).;;Invitation to pay additional fees and, where applicable, protest fee for International application No. PCT/GB2019/051507, dated Aug. 20, 2019, 16 pages.;;Yang, C., and Hanley, L., “ChiMS: Open-source instrument control software platform on LabView for imaging/depth profiling mass spectrometers,” Review of Scientific Instruments, 86:065106-1 through 065016-7 (2015).;;Invitation to pay additional fees and, where applicable, protest fee for International application No. PCT/GB2019/051506, dated Jul. 22, 2019, 13 pages.;;Invitation to pay addition al fees and, where applicable, protest fee for PCT/GB2019/051503, dated Jul. 25, 2019, 17 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051500, dated Aug. 5, 2019, 9 pages.;;Kozlov, B., et al., “Time-of-flight mass spectrometer for investigations of laser ablation,” ASMS Conference paper, Dallas, TX (May 1999). [Retrieved from the Internet URL: https//www.researchgate.net/publication/330202298_Time-of-flight_mass_spectrometer_for_investigations_of_laser_ablation]. Abstract.;;Shion, H., et al., “Towards Overcoming the Challenges of Implementing Accurate Mass MS for Routine Biotherapeutic Analysis” 2018 ASMS Prototype oa-TOF Abstract HYS Final.;;Shion, S., et al., “Towards Overcoming the Challenges of Implementing Accurate Mass MS for Routine Biotherapeutic Analysis” 2018 ASMS Prototype oa-TOF WP699 HYS Final Poster.;;Shion, H., et al., “A Fit-for-purpose Accurate Mass MS for Routine Biotherapeutic Analysis”, 2018 CASSS Mass Spec HYS Final Poster.;;Shion, H., et al., “A Fit-for-purpose Accurate Mass MS for Routine Biotherapeutic Analysis”, 2018 CASSS Mass Spec BioTof HYS Final, Abstract.;;Shion, H., et al., “Progress Towards Implementing Simple Time-of-flight Accurate Mass MS for Routine Biotherapeutic Analysis”, XXII (IMSC) International Mass Spectrometry Conference Florence, Italy (2018) Abstract.;;Shion, H., et al., “Progress Towards Implementing Simple Time-of-flight Accurate Mass MS for Routine Biotherapeutic Analysis”, XXII International Mass Spectrometry Conference Florence, Italy (2018) poster.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 ASMS BioAccord Oral Session PowerPoint.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 ASMS BioAccord Abstract.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments” 2019 ATEurope BioAccord, Abstract.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments” 2019 ATEurope BioAccord, Poster.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 BioPharma Analytical Summit BioAccord, abstract.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 Bio Pharma Summit BioAccord, Poster.;;Shion, H., “Enabling Routine and Reproducible Biotherapeutic Analysis when Data Integrity Matters”, 2019 15th Annual PEGs Boston Waters BioAccord, PowerPoint 29 pages.;;Shion, H., “Enabling Routine and Reproducible Biotherapeutic Analysis when Data Integrity Matters”, 2019 15th Annual PEGs Boston Waters BioAccord, Abstract.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 Pitt Con Bio Accord, Poster.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 Pitt Con Bio Accord, Abstract.;;Combined Search and Exam Report from IPO for GB Application No. 1907739.5, dated Nov. 27, 2019, 8 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051510, dated Aug. 29, 2019, 13 pages.;;Combined Search and Exam Report from IPO for GB Application No. 1907735.3, dated Nov. 25, 2019, 7 pages.;;Combined S and E Report under Sections 17 and 18(3) for Application No. GB1907734.6, dated Oct. 31, 2019, 7 pages.;;International Search Report and Written Opinion for International Application No. PCT/GB2019/051498, dated Nov. 6, 2019, 21 pages.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1907719.7, dated Nov. 15, 2019, 11 pages.;;Author unknown, “Waters Xevo G2-S QTof Operators Overview and Maintenance Guide”, Feb. 11, 2013 (Feb. 11, 2013), XP55606374, Retrieved from the Internet: URL:https://www.waters.eom/webassets/cms/support/docs/xevo_g2-s_qtof_715003596rb.pdf [retrieved on Jul. 17, 2019].;;International Search Report and Written Opinion for International application No. PCT/GB2019/051501, dated Sep. 25, 2019, 17 pages.;;Combined Search and Examination Report under Sections 17 and 18(3), for Application No. GB1907724.7, dated Sep. 25, 2019, 7 pages.;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fee for International application No. PCT/GB2019/051494, dated Sep. 19, 2019.;;Combined Search and Examination Report under Sections 17 and 18(3), dated Sep. 27, 2019, for Application No. GB1907736.1, 6 pages.;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fees, for International application No. PCT/GB2019/051499, dated Sep. 4, 2019.;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fee, for International Application No. PCT/GB2019/051496, dated Aug. 29, 2019.;;Anonymous, “Time-of-flight mass spectrometry”, Wikipedia, Apr. 28, 2018 (Apr. 28, 2018), XP055614063, Retrieved from the Internet:URL:https://en.wikipedia.org/w/index.php title=Time-of-flight_mass_spectrometry oldid=838663844 [retrieved on Aug. 20, 2019].;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fees for International application No. PCT/GB2019/051497, dated Sep. 2, 2019.;;Combined Search and Examination Report under Sections 17 and 18(3) for Application No. GB1907745.2, dated Aug. 13, 2019, 7 pages.;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fee, for International application No. PCT/GB2019/051501, dated Jul. 29, 2019, 14 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051497, dated Nov. 5, 2019, 19 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051503, dated Sep. 25, 2019, 17 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051496, dated Oct. 23, 2019, 29 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051506, dated Sep. 25, 2019, 14 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051494, dated Nov. 18, 2019, 20 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051507, dated Oct. 15, 2019, 17 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051508, dated Oct. 23, 2019, 16 pages.;;International Search Report and Written Opinion for International application No. PCT/GB2019/051499, dated Nov. 5, 2019, 19 pages.;;Examination Report under Section 18(3) for Application No. GB1907719.7, dated Jul. 28, 2021, 9 pages.;;Parkes, S. SpaceWire User Guide, STAR-Dundee [online] 2012 [retrieved on Aug. 13, 2021]. Retrieved from Internet URL: https://www.star-dundee.com/wp-content/star_uploads/general/SpaceWire-Users-Guide.pdf, 117 pages.;;SCIEX, “3200 Series of Instruments System User Guide” [online], published Apr. 2018, available from: https://sciex.com/content/dam/SCIEX/pdf/customer-docs/user-guide/3200-system-user-guide-en.pdf, 241 pages.;;Combined Search and Examination Report under Sections 17 and 18(3), for Application No. GB2100898.2, dated Jun. 21, 2021, 7 pages.;;Combined Search and Examination Report under Sections 17 and 18(3), for Application No. GB2001530.1, dated Aug. 5, 2020, 7 pages.;;Thermo Fisher Scientific, Inc, Feb. 2015, Orbitrap Fusion Hardware Manual [online]. Retrieved from Internet URL: http://www.unitylabservices.eu/content/dam/tfs/ATG/CMD/cmddocuments/oper/oper/ms/lc-ms/sys/Man-80000-97016-Orbitrap-Fusion-Hardware-Man8000097016-A-EN.pdf, 122 pages.;;Shion, H., et al., “Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/non-Regulated Environments”, 2019 BioPharma Analytical Summit BioAccord Abstract. ASMS MS-in-QC, PowerPoint 24 pages.;;International Preliminary Report on Patentability for International application No. PCT/GB2019/051510, dated Dec. 1, 2020, 7 pages.;;Examination Report under Section 18(3) for Application No. GB1907739.5, dated Nov. 3, 2020, 5 pages.;;Examination Report under Section 18(3) for Application No. GB2020743.7, dated Jan. 28, 2022, 6 pages.;;Communication Pursuant to Article 94(3) EPC for EP Patent Application No. 19730465.2, dated Nov. 22, 2023.;;Communication Pursuant to Article 94(3) EPC for EP Patent Application No. 19730470.2, dated Nov. 23, 2023.;;Niehuis, E., et al., “Design and performance of a reflectron based time-of-flight secondary ion mass spectrometer with electrodynamic primary ion mass separation”, Journal of Vacuum Science and Technology A, 5(4): 1243-1246, Jul. 31, 1987.",ACTIVE
353,KR,A,KR 20010050066 A,104-163-024-498-374,2001-06-15,2001,KR 20000046760 A,2000-08-12,US 37492199 A,1999-08-16,METHOD OF BOOSTING A GLASS MELTING FURNACE USING A ROOF MOUNTED OXYGEN-FUEL BURNER,"PURPOSE: A method for melting a batch material in a glass melting furnace is provided, to increase the volume of a glass furnace and the melting velocity and to improve the quality and production yield of the prepared glass. CONSTITUTION: The method comprises the steps of attaching the oxygen burner(34) on the batch material(30) in the ceiling of the furnace(10); providing a flow of gaseous oxidizing agent into at least one burner(34); providing a flow of gaseous fuel into at least one burner(34); and generating flame from at least one burner(34). The flame(36) has a sufficient velocity enough to make the heat transfer be maximum while making the disorder of the batch material be minimum. The oxygen burner(34) is directed to cross perpendicularly with the surface of the batch material, and the range of angle is about 30 degree or less.",BOC GROUP INC,CARNEY STEPHEN MCDONALD;;CLAYTON THOMAS G;;LEBLANC JOHN R;;PRUSIA GREGORY F;;RICHARDSON ANDREW PETER;;SIMPSON NEIL G,,https://lens.org/104-163-024-498-374,Patent Application,no,0,0,29,71,0,C03B5/193;;C03B5/2353;;C03B2211/30;;C03B2211/40;;C03B2211/60;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/002;;F23L7/00;;F23L2900/07005;;Y02P40/57;;Y02E20/34;;Y02P40/50;;C03B5/16;;C03B5/193;;C03B2211/30;;C03B2211/40;;C03B5/2353;;F23D14/32;;F23D14/02;;C03B2211/60;;F23L2900/07005;;F23D17/002;;F23C5/00;;F23L7/00;;Y02P40/57;;Y02E20/34;;Y02P40/50,F23C5/08;;C03B5/16;;C03B5/235;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/00;;F23L7/00;;F27D7/02,,0,0,,,,EXPIRED
354,AU,A,AU 2000/051952 A,147-758-507-233-226,2001-02-22,2001,AU 2000/051952 A,2000-08-11,US 37492199 A,1999-08-16,Method of boosting a glass-melting furnace using a roof- mounted oxygen-fuel burner,,BOC GROUP INC,SIMPSON NEIL G;;PRUSIA GREGORY F;;CARNEY STEPHEN MCDONALD;;CLAYTON THOMAS G;;RICHARDSON ANDREW PETER;;LEBLANC JOHN R,,https://lens.org/147-758-507-233-226,Patent Application,no,0,0,29,71,0,C03B5/193;;C03B5/2353;;C03B2211/30;;C03B2211/40;;C03B2211/60;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/002;;F23L7/00;;F23L2900/07005;;Y02P40/57;;Y02E20/34;;Y02P40/50;;C03B5/16;;C03B5/193;;C03B2211/30;;C03B2211/40;;C03B5/2353;;F23D14/32;;F23D14/02;;C03B2211/60;;F23L2900/07005;;F23D17/002;;F23C5/00;;F23L7/00;;Y02P40/57;;Y02E20/34;;Y02P40/50,F23C5/08;;C03B5/16;;C03B5/235;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/00;;F23L7/00;;F27D7/02,,0,0,,,,EXPIRED
355,ES,T5,ES 2253186 T5,107-627-666-365-305,2013-02-18,2013,ES 00306970 T,2000-08-15,US 37492199 A,1999-08-16,Método de calentamiento asistido en un horno de fundición de vidrio utilizando un quemador de combustible y oxígeno montado en el techo,"Un método para fundir una carga de materia prima en un horno de vidrio que tiene regeneradores, recuperadores y/o sobrealimentación eléctrica, teniendo dicho horno paredes laterales, una pared posterior, una pared anterior y un techo, que comprende generar una llama a partir de al menos un quemador de combustible y oxígeno montado en el techo del horno sobre dicha carga de materia prima, siendo gaseoso el combustible proporcionado al quemador, teniendo dicha llama una velocidad suficiente para maximizar la transferencia de calor desde dicha llama a dicha carga de materia prima sin alterar sustancialmente dicha carga de materia prima.",BOC GROUP INC,SIMPSON NEIL GEORGE;;PRUSIA GREGORY FLOYD;;CARNEY STEPHEN MCDONALD;;CLAYTON THOMAS G;;RICHARDSON ANDREW PETER;;LEBLANC JOHN R,,https://lens.org/107-627-666-365-305,Amended Patent,no,0,0,29,71,0,C03B5/193;;C03B5/2353;;C03B2211/30;;C03B2211/40;;C03B2211/60;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/002;;F23L7/00;;F23L2900/07005;;Y02P40/57;;Y02E20/34;;Y02P40/50;;C03B5/16;;C03B5/193;;C03B2211/30;;C03B2211/40;;C03B5/2353;;F23D14/32;;F23D14/02;;C03B2211/60;;F23L2900/07005;;F23D17/002;;F23C5/00;;F23L7/00;;Y02P40/57;;Y02E20/34;;Y02P40/50,C03B5/235;;F23C5/08;;C03B5/16;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/00;;F23L7/00;;F23M5/02;;F27D7/02,,0,0,,,,EXPIRED
356,DE,T2,DE 60024370 T2,163-112-028-169-770,2006-07-06,2006,DE 60024370 T,2000-08-15,US 37492199 A;;EP 00306970 A,1999-08-16,Verfahren zum Zusatzerhitzen eines Glasschmelzofens mit einem im Gewölbe montierten Sauerstoff-Brennstoff-Brenner,,BOC GROUP INC,SIMPSON NEIL GEORGE;;PRUSIA GREGORY FLOYD;;CARNEY STEPHEN MCDONALD;;CLAYTON THOMAS G;;RICHARDSON ANDREW PETER;;LEBLANC JOHN R,,https://lens.org/163-112-028-169-770,Granted Patent,no,0,0,29,71,0,C03B5/193;;C03B5/2353;;C03B2211/30;;C03B2211/40;;C03B2211/60;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/002;;F23L7/00;;F23L2900/07005;;Y02P40/57;;Y02E20/34;;Y02P40/50;;C03B5/16;;C03B5/193;;C03B2211/30;;C03B2211/40;;C03B5/2353;;F23D14/32;;F23D14/02;;C03B2211/60;;F23L2900/07005;;F23D17/002;;F23C5/00;;F23L7/00;;Y02P40/57;;Y02E20/34;;Y02P40/50,C03B5/235;;F23C5/08;;C03B5/16;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/00;;F23L7/00;;F23M5/02;;F27D7/02,,0,0,,,,EXPIRED
357,US,B2,US 6705118 B2,078-209-185-811-616,2004-03-16,2004,US 11789802 A,2002-04-08,US 11789802 A;;US 37492199 A,1999-08-16,Method of boosting a glass melting furnace using a roof mounted oxygen-fuel burner,"
    In an industrial glass furnace which contains recuperators, regenerators, electric boost or other devices for providing heat to glass batch material an oxy-fuel burner mounted in the roof of the furnace provides additional heat to melt the batch material. A method of mounting and using such a roof-mounted oxy-fuel burner including the operating parameters to maximize heat transfer while minimizing the disturbance of the batch material is disclosed. 
",BOC GROUP INC,SIMPSON NEIL GEORGE;;PRUSIA GREG FLOYD;;CARNEY STEPHEN MCDONALD;;CLAYTON THOMAS G;;RICHARDSON ANDREW PETER;;LEBLANC JOHN R,LINDE INC (2007-12-19);;MESSER INDUSTRIES USA INC (2019-07-19);;MESSER LLC (2019-02-13),https://lens.org/078-209-185-811-616,Granted Patent,yes,28,73,29,71,0,C03B5/193;;C03B5/2353;;C03B2211/30;;C03B2211/40;;C03B2211/60;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/002;;F23L7/00;;F23L2900/07005;;Y02P40/57;;Y02E20/34;;Y02P40/50;;C03B5/16;;C03B5/193;;C03B2211/30;;C03B2211/40;;C03B5/2353;;F23D14/32;;F23D14/02;;C03B2211/60;;F23L2900/07005;;F23D17/002;;F23C5/00;;F23L7/00;;Y02P40/57;;Y02E20/34;;Y02P40/50,F23C5/08;;C03B5/16;;C03B5/235;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/00;;F23L7/00;;F27D7/02,65/134.4;;65/134.6;;65/136.3;;65/356;;432/10;;432/20;;432/94,1,0,,,"McMahon et al, Can Partial Conversion to Oxy-Fuel Combustion Be a Solution to Furnace Problems? In Glass Industry pp 23-24, Dec. 1994.",EXPIRED
358,CA,A1,CA 2315486 A1,131-571-286-314-637,2001-02-16,2001,CA 2315486 A,2000-08-11,US 37492199 A,1999-08-16,METHOD OF BOOSTING A GLASS MELTING FURNACE USING A ROOF-MOUNTED OXYGEN-FUEL BURNER,"In an industrial glass furnace which contains recuperators, regenerators, electric boost or other devices for providing heat to glass batch material an oxy-fue l burner mounted in the roof of the furnace provides additional heat to melt the batc h material. A method of mounting and using such a roof mounted oxy-fuel burner including the operating parameters to maximize heat transfer while minimizing the disturbance of the batch material is disclosed.",BOC GROUP INC,SIMPSON NEIL GEORGE;;PRUSIA GREGORY FLOYD;;LEBLANC JOHN R;;RICHARDSON ANDREW PETER;;CARNEY STEPHEN MCDONALD;;CLAYTON THOMAS G,,https://lens.org/131-571-286-314-637,Patent Application,no,0,0,29,71,0,C03B5/193;;C03B5/2353;;C03B2211/30;;C03B2211/40;;C03B2211/60;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/002;;F23L7/00;;F23L2900/07005;;Y02P40/57;;Y02E20/34;;Y02P40/50;;C03B5/16;;C03B5/193;;C03B2211/30;;C03B2211/40;;C03B5/2353;;F23D14/32;;F23D14/02;;C03B2211/60;;F23L2900/07005;;F23D17/002;;F23C5/00;;F23L7/00;;Y02P40/57;;Y02E20/34;;Y02P40/50,F23C5/08;;C03B5/16;;C03B5/235;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/00;;F23L7/00;;F27D7/02,,0,0,,,,EXPIRED
359,AU,B2,AU 780088 B2,160-310-123-424-811,2005-03-03,2005,AU 2000/051952 A,2000-08-11,US 37492199 A,1999-08-16,Method of boosting a glass-melting furnace using a roof- mounted oxygen-fuel burner,,BOC GROUP INC,SIMPSON NEIL G;;PRUSIA GREGORY F;;CARNEY STEPHEN MCDONALD;;CLAYTON THOMAS G;;RICHARDSON ANDREW PETER;;LEBLANC JOHN R,,https://lens.org/160-310-123-424-811,Granted Patent,no,2,0,29,71,0,C03B5/193;;C03B5/2353;;C03B2211/30;;C03B2211/40;;C03B2211/60;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/002;;F23L7/00;;F23L2900/07005;;Y02P40/57;;Y02E20/34;;Y02P40/50;;C03B5/16;;C03B5/193;;C03B2211/30;;C03B2211/40;;C03B5/2353;;F23D14/32;;F23D14/02;;C03B2211/60;;F23L2900/07005;;F23D17/002;;F23C5/00;;F23L7/00;;Y02P40/57;;Y02E20/34;;Y02P40/50,F23C5/08;;C03B5/16;;C03B5/235;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/00;;F23L7/00;;F27D7/02,,0,0,,,,EXPIRED
360,EP,A2,EP 1077201 A2,167-695-059-007-70X,2001-02-21,2001,EP 00306970 A,2000-08-15,US 37492199 A,1999-08-16,Method of boosting the heating in a glass melting furnace using a roof-mounted oxygen-fuel burner,"In an industrial glass furnace 10 which contains recuperators, regenerators, electric boost or other devices for providing heat to glass batch material at least one oxy-fuel burner (34) mounted in the roof of the furnace provides additional heat to melt the batch material. By using such a roof-mounted oxy-fuel burner 34 heat transfer can be maximised while minimising the disturbance of the batch material. The velocity of the flame 36 produced by operation of the oxy-fuel burner 34 is kept to 30 metres per second of less near the surface.",BOC GROUP INC,SIMPSON NEIL GEORGE;;PRUSIA GREGORY FLOYD;;CARNEY STEPHEN MCDONALD;;CLAYTON THOMAS G;;RICHARDSON ANDREW PETER;;LEBLANC JOHN R,"LINDE GAS NORTH AMERICA LLC, BRIDGEWATER, US (2020-04-16);;LINDE GAS NORTH AMERICA LLC (2019-11-07)",https://lens.org/167-695-059-007-70X,Patent Application,yes,0,11,29,71,0,C03B5/193;;C03B5/2353;;C03B2211/30;;C03B2211/40;;C03B2211/60;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/002;;F23L7/00;;F23L2900/07005;;Y02P40/57;;Y02E20/34;;Y02P40/50;;C03B5/16;;C03B5/193;;C03B2211/30;;C03B2211/40;;C03B5/2353;;F23D14/32;;F23D14/02;;C03B2211/60;;F23L2900/07005;;F23D17/002;;F23C5/00;;F23L7/00;;Y02P40/57;;Y02E20/34;;Y02P40/50,F23C5/08;;C03B5/16;;C03B5/235;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/00;;F23L7/00;;F27D7/02,,0,0,,,,EXPIRED
361,TR,A3,TR 200002370 A3,096-176-796-325-451,2002-02-21,2002,TR 200002370 A,2000-08-15,US 37492199 A,1999-08-16,Firinin üstüne monte edilen bir oksijen-yakit brulörü kullanilarak cam eritme firininin kuvvetlendirilmesi yöntemi,,"THE BOC GROUP, INC.",NEIL G. SIMPSON;;THOMAS G. CLAYTON;;GREGORY F. PRUSIA;;ANDREW PETER RICHARDSON;;STEPHEN MCDONALD CARNEY;;JOHN R. LEBLANC,,https://lens.org/096-176-796-325-451,Search Report,no,0,0,29,71,0,C03B5/193;;C03B5/2353;;C03B2211/30;;C03B2211/40;;C03B2211/60;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/002;;F23L7/00;;F23L2900/07005;;Y02P40/57;;Y02E20/34;;Y02P40/50;;C03B5/16;;C03B5/193;;C03B2211/30;;C03B2211/40;;C03B5/2353;;F23D14/32;;F23D14/02;;C03B2211/60;;F23L2900/07005;;F23D17/002;;F23C5/00;;F23L7/00;;Y02P40/57;;Y02E20/34;;Y02P40/50,F23C5/08;;C03B5/16;;C03B5/235;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/00;;F23L7/00;;F27D7/02,,0,0,,,,PENDING
362,TR,A2,TR 200002370 A2,190-669-061-539-427,2002-02-21,2002,TR 200002370 A,2000-08-15,US 37492199 A,1999-08-16,Fırının üstüne monte edilen bir oksijen-yakıt brulörü kullanılarak cam eritme fırınının kuvvetlendirilmesi yöntemi,"Cam yigin malzemesine isi vermek için ilk isiticilar, rejenatörler, elektrikli kuvvetlendirme veya baska tertibatlar içeren sinai bir cam firininda, firinin üstüne monte edilen bir oksi-yakitli brulör, yigin malzemeyi eritmek için ek isi temin eder. yigin malzemenin bozulmasini en aza indirirken isi aktarimini azamiye çikarmak için isletme parametreleri de dahil olmak üzere firinin üstüne monte edilen böyle bir oksi-yakitli brülorü monte etme ve kullanma yöntemi açiklanmaktadir.",BOC GROUP INC,SIMPSON NEIL G;;CLAYTON THOMAS G;;PRUSIA GREGORY F;;RICHARDSON ANDREW PETER;;CARNEY STEPHEN MCDONALD;;LEBLANC JOHN R,,https://lens.org/190-669-061-539-427,Patent Application,no,0,0,29,71,0,C03B5/193;;C03B5/2353;;C03B2211/30;;C03B2211/40;;C03B2211/60;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/002;;F23L7/00;;F23L2900/07005;;Y02P40/57;;Y02E20/34;;Y02P40/50;;C03B5/16;;C03B5/193;;C03B2211/30;;C03B2211/40;;C03B5/2353;;F23D14/32;;F23D14/02;;C03B2211/60;;F23L2900/07005;;F23D17/002;;F23C5/00;;F23L7/00;;Y02P40/57;;Y02E20/34;;Y02P40/50,F23C5/08;;C03B5/16;;C03B5/235;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/00;;F23L7/00;;F27D7/02,,0,0,,,,PENDING
363,EP,B2,EP 1077201 B2,196-614-171-823-533,2012-09-19,2012,EP 00306970 A,2000-08-15,US 37492199 A,1999-08-16,Method of boosting the heating in a glass melting furnace using a roof-mounted oxygen-fuel burner,,BOC GROUP INC,SIMPSON NEIL GEORGE;;PRUSIA GREGORY FLOYD;;CARNEY STEPHEN MCDONALD;;CLAYTON THOMAS G;;RICHARDSON ANDREW PETER;;LEBLANC JOHN R,"LINDE GAS NORTH AMERICA LLC, BRIDGEWATER, US (2020-04-16);;LINDE GAS NORTH AMERICA LLC (2019-11-07)",https://lens.org/196-614-171-823-533,Granted Patent,yes,4,0,29,71,0,C03B5/193;;C03B5/2353;;C03B2211/30;;C03B2211/40;;C03B2211/60;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/002;;F23L7/00;;F23L2900/07005;;Y02P40/57;;Y02E20/34;;Y02P40/50;;C03B5/16;;C03B5/193;;C03B2211/30;;C03B2211/40;;C03B5/2353;;F23D14/32;;F23D14/02;;C03B2211/60;;F23L2900/07005;;F23D17/002;;F23C5/00;;F23L7/00;;Y02P40/57;;Y02E20/34;;Y02P40/50,C03B5/235;;F23C5/08;;C03B5/16;;F23C5/00;;F23D14/02;;F23D14/32;;F23D17/00;;F23L7/00;;F23M5/02;;F27D7/02,,1,1,001-471-291-336-02X,10.1201/9781420050257,"CH.E.BAUKAL: ""Oxygen-enhanced combustion"", 1998, CRC PRESS, pages: 215 - 236",EXPIRED
364,GB,A,GB 2583811 A,061-761-738-204-43X,2020-11-11,2020,GB 202001530 A,2019-05-31,GB 201808912 A;;GB 201907731 A,2018-05-31,Bench-top time of flight mass spectrometer,"A mass spectrometer comprising: a vacuum housing; a gas pump 1700 for evacuating first vacuum chamber; and an electrically conductive, compressible gasket 2043 arranged between the vacuum housing and the gas pump. The gasket may have a conductive fabric or wire mesh formed over a compressible foam core. A vacuum gasket seal 2064, 2099 may also be located between the gas pump and the vacuum housing, near the gasket. An adapter may be between the gas pump and vacuum housing, preferably: having vacuum seals 2064, 2099 connecting the adapter to the pump and vacuum housings; and, engaging with a tubular flange 2063 of the gas pump housing. Alternative arrangements are disclosed, including the use of: a cover with a hook for attachment to a slot in a chassis; and, voltage or electronics modules for mounting adjacent to apertures in a main housing of a mass analyser.",MICROMASS LTD,CEDRIC ROLAND MARSH;;PETER CARNEY;;JASON LEE WILDGOOSE;;DAVID WALLIS;;PAUL MCIVER;;SOJI CHUMMAR;;GEORGE ANDREAS ANTONIADES;;DIPESH MISTRY,,https://lens.org/061-761-738-204-43X,Patent Application,no,3,0,16,16,0,H01J49/24;;F04D19/042;;F04D29/701;;H01J49/24;;H01J49/40;;F04D29/12;;F04D19/042;;F04D29/122;;F04D29/701;;H01J49/24;;H01J49/405,H01J49/24;;F04D29/12,,0,0,,,,ACTIVE
365,GB,B,GB 2583811 B,055-519-055-059-592,2021-05-19,2021,GB 202001530 A,2019-05-31,GB 201808912 A;;GB 201907731 A,2018-05-31,Bench-top time of flight mass spectrometer,,MICROMASS LTD,CEDRIC ROLAND MARSH;;PETER CARNEY;;JASON LEE WILDGOOSE;;DAVID WALLIS;;PAUL MCIVER;;SOJI CHUMMAR;;GEORGE ANDREAS ANTONIADES;;DIPESH MISTRY,,https://lens.org/055-519-055-059-592,Granted Patent,no,3,0,16,16,0,H01J49/24;;F04D19/042;;F04D29/701;;H01J49/24;;H01J49/40;;F04D29/12;;F04D19/042;;F04D29/122;;F04D29/701;;H01J49/24;;H01J49/405,H01J49/24;;F04D29/12,,0,0,,,,ACTIVE
366,GB,B,GB 2574724 B,083-845-936-760-02X,2020-07-29,2020,GB 201907731 A,2019-05-31,GB 201808912 A,2018-05-31,Bench-top time of flight mass spectrometer,,MICROMASS LTD,CEDRIC ROLAND MARSH;;PETER CARNEY;;JASON LEE WILDGOOSE;;DAVID WALLIS;;PAUL MCIVER;;SOJI CHUMMAR;;GEORGE ANDREAS ANTONIADES;;DIPESH MISTRY,,https://lens.org/083-845-936-760-02X,Granted Patent,no,5,0,16,16,0,H01J49/24;;F04D19/042;;F04D29/701;;H01J49/24;;H01J49/40;;F04D29/12;;F04D19/042;;F04D29/122;;F04D29/701;;H01J49/24;;H01J49/405,H01J49/24;;H01J49/40,,0,0,,,,ACTIVE
367,GB,A,GB 2574724 A,186-426-075-968-192,2019-12-18,2019,GB 201907731 A,2019-05-31,GB 201808912 A,2018-05-31,Bench-top time of flight mass spectrometer,"A mass spectrometer comprising: a first vacuum chamber, with gas exhaust port (H1); a gas pump, with gas inlet port coupled to the exhaust by a conduit; and, an apertured cover 2010 over the exhaust or inlet port, or in the conduit. The cover may be electrically conductive to block electric fields and/or may have elongated fingers extending away from an apertured main body. There may be a second vacuum chamber with associated gas inlet and apertured cover. The chambers may be separated by a differential pumping aperture. A time-of-flight mass analyser may be in a vacuum port. Alternative arrangements are disclosed, including: the use of a compressible electrically conductive gasket; a cover with a hook for attachment to a slot in a chassis; and, voltage or electronics modules for mounting adjacent to apertures in a main housing of a mass analyser.",MICROMASS LTD,CEDRIC ROLAND MARSH;;PETER CARNEY;;JASON LEE WILDGOOSE;;DAVID WALLIS;;PAUL MCIVER;;SOJI CHUMMAR;;GEORGE ANDREAS ANTONIADES;;DIPESH MISTRY,,https://lens.org/186-426-075-968-192,Patent Application,no,5,0,16,16,0,H01J49/24;;F04D19/042;;F04D29/701;;H01J49/24;;H01J49/40;;F04D29/12;;F04D19/042;;F04D29/122;;F04D29/701;;H01J49/24;;H01J49/405,H01J49/24;;H01J49/40,,0,0,,,,ACTIVE
368,US,A,US 5774729 A,049-713-512-490-591,1998-06-30,1998,US 15906393 A,1993-11-29,US 15906393 A;;US 81061991 A,1991-12-19,Event handling in a high level programming language environment,"A method and means for handling events in a computer system which occur during the execution of programs including routines prepared in a plurality of computer programming languages is described. The number and identity of each unique computer programming language used in the preparation of the program is determined using a language list contained in the application program. A unique event handling means (event handler) is initialized for each unique computer programming language used in the program. As the program executes selected events of interest to the event handlers are detected. The parameters associated with the selected event are determined. Optionally the detected events may be divided into two types: broadcast or targeted. Broadcast events are sent to all event handlers (except the debug event handler), whereas, the targeted events are sent to a single event handler. An event code and the relevant parameters are passed to the event handlers so that each event handler may perform whatever actions are appropriate for that event in the context of the programming language being supported. The event handlers generate an appropriate return code indicating the success, failure, or non-processing of the event and, for selected events, return request information. The invention provides for a separate specialized debug event handler.",IBM,CARNEY WILLIAM PETER;;ENGLAND LAURENCE EDWARD;;HOCHMUTH GARY JOHN;;OWINGS BRIAN;;PORTER ERIC LYNN;;SHANNON ALFRED WILLIAM;;WILSON ROBERT AARON,,https://lens.org/049-713-512-490-591,Granted Patent,yes,14,73,4,4,0,G06F9/542;;G06F9/542,G06F9/46,395/707;;395/708,5,4,026-140-852-454-407;;022-276-724-393-512;;027-084-849-076-786;;042-130-086-396-72X,10.1109/52.35586;;10.1109/tse.1987.232879;;10.1109/32.42737;;10.1145/42392.42396,"Zave, A Compositional Approach to Multiparadigm Programming, IEEE Software, Sep. 1989, V6 Issue 5, pp. 15 25.;;Hayes et al, Facilitating Mixed Language Programming in Distributed Systems, IEEE Transactions of Software Engineering, vol. SE 13, No. 12, Dec. 1987, pp. 1254 1264.;;Demurjian et al, Towards a Better Understanding of Data Models through the Multilingual Database System, IEEE Trans. on Soft. Engr., V14, No. 7, Jul. 1988, pp. 946 958.;;Notkin et al, Interconnecting Heterogeneous Computer Systems, Communications of the ACM, Mar. 1988 V31 N3 p. 258(16).;;Hansen, Angie, New Compiler Technology Boosts Microsoft Quickbasic H.O Productivity, Microsoft Systems Journal May 1988 V3 N3 p. 49(14).",EXPIRED
369,CA,A1,CA 2128015 A1,180-756-413-237-813,1993-07-22,1993,CA 2128015 A,1993-01-13,US 82032392 A,1992-01-13,METHOD AND APPARATUS FOR CROSSLINKING INDIVIDUALIZED CELLULOSE FIBERS,"2128015 9314264 PCTABS00024 An apparatus is disclosed for preparing a quantity of individual treated fibers from one or more fiber mats. The apparatus comprises a fiber treatment zone, and a conveyor for conveying each mat through the fiber treatment zone. In the treatment zone each mat is impregnated by an applicator with a treatment material, such as a crosslinking substance, and conveyed directly to an attrition device. The attrition device fiberizes the mats to form a fiber output having a low nit level, such as no more than about three, and a dryer both dries the fiber output and cures the crosslinking substance. The fiberizer is configured to minimize the accumulation of fiber at locations therein. Fiber is transported from the attrition device to the dryer at a high velocity under reduced pressure to promote drying. A heated retention bin is provided after drying to increase curing time in the system. A thermobonding agent may be added to the dried and cured fibers to enhance the wet strength of webs made from the fiber.",WEYERHAEUSER CO,HUNTER FRANK R;;CARNEY ALLAN R;;GRAEF PETER A;;ELSTON COLIN;;OLMSTEAD FRED E;;BOLSTAD CLIFFORD R;;BOWNS MARK W,,https://lens.org/180-756-413-237-813,Patent Application,no,0,0,8,8,0,A61F13/15707;;A61F13/53;;A61F2013/530007;;A61F2013/530474;;A61L15/28;;D04H1/54;;D06M11/30;;D06M13/137;;D06M13/1845;;D06M13/192;;D06M13/262;;D06M13/418;;D06M13/419;;D06M13/432;;D06M13/438;;D06M13/44;;D06M13/52;;D21B1/066;;D21C9/005;;D21H11/20;;D21H15/10;;D21H17/05;;D21H17/06;;D21H17/07;;D21H17/10;;D21H21/06;;D21H21/24;;D21H23/04;;D21H23/18;;D21H23/20;;D21H23/28;;D21H25/005;;D21H25/02;;D04H1/655;;A61F13/15707;;D21C9/005;;D06M13/137;;D21H17/06;;D06M13/262;;A61F2013/530474;;D21H17/07;;D21H23/20;;A61F13/53;;D06M13/44;;D21H15/10;;D21H23/18;;D06M13/1845;;D06M13/432;;D06M13/438;;D06M13/52;;D21H11/20;;D06M11/30;;A61L15/28;;D21H23/04;;D06M13/419;;D21H21/24;;D04H1/54;;D21H25/005;;D06M13/418;;D21B1/066;;D21H17/05;;D21H21/06;;A61F2013/530007;;D21H17/10;;D21H23/28;;D06M13/192;;D21H25/02;;D04H1/655,A61F13/15;;A61L15/28;;D04H1/58;;D04H1/64;;D06M11/30;;D06M13/137;;D06M13/184;;D06M13/192;;D06M13/262;;D06M13/418;;D06M13/419;;D06M13/432;;D06M13/438;;D06M13/44;;D06M13/52;;D21B1/06;;D21C9/00;;D21H11/20;;D21H15/10;;D21H17/05;;D21H17/06;;D21H17/07;;D21H17/10;;D21H21/06;;D21H21/24;;D21H23/04;;D21H23/18;;D21H23/20;;D21H23/28;;D21H25/00;;D21H25/02,,0,0,,,,DISCONTINUED
370,US,B1,US 6436231 B1,121-426-577-523-208,2002-08-20,2002,US 50940195 A,1995-07-31,US 50940195 A;;US 82032392 A;;US 66576191 A;;US 60726890 A;;US 39520889 A;;US 28488588 A;;US 14092287 A;;US 472987 A,1987-01-20,Method and apparatus for crosslinking individualized cellulose fibers,"
    An apparatus is disclosed for preparing a quantity of individual treated fibers from one or more fiber mats. The apparatus comprises a fiber treatment zone, and a conveyor for conveying each mat through the fiber treatment zone. In the treatment zone each mat is impregnated by an applicator with a treatment material, such as a crosslinking substance, and conveyed directly to an attrition device. The attrition device fiberizes the mats to form a fiber output having a low nit level, such as no more than about three, and a dryer both dries the fiber output and cures the crosslinking substance. The fiberizer is configured to minimize the accumulation of fiber at locations therein. Fiber is transported from the attrition device to the dryer at a high velocity under reduced pressure to promote drying. A heated retention bin is provided after drying to increase curing time in the system. A thermobonding agent may be added to the dried and cured fibers to enhance the wet strength of webs made from the fiber. 
",WEYERHAEUSER CO,GRAEF PETER A;;ELSTON COLIN;;OLMSTEAD FRED E;;BOLSTAD CLIFFORD R;;BOWNS MARK W;;HUNTER FRANK R;;CARNEY ALLAN R,WEYERHAEUSER NR COMPANY (2009-04-21),https://lens.org/121-426-577-523-208,Granted Patent,yes,68,45,8,8,0,A61F13/15707;;A61F13/15707;;A61F13/53;;A61F13/53;;A61F2013/530007;;A61F2013/530007;;A61F2013/530474;;A61F2013/530474;;A61L15/28;;A61L15/28;;D04H1/54;;D04H1/54;;D04H1/655;;D04H1/655;;D06M11/30;;D06M11/30;;D06M13/137;;D06M13/137;;D06M13/1845;;D06M13/1845;;D06M13/192;;D06M13/192;;D06M13/262;;D06M13/262;;D06M13/418;;D06M13/418;;D06M13/419;;D06M13/419;;D06M13/432;;D06M13/432;;D06M13/438;;D06M13/438;;D06M13/44;;D06M13/44;;D06M13/52;;D06M13/52;;D21B1/066;;D21B1/066;;D21C9/005;;D21C9/005;;D21H11/20;;D21H11/20;;D21H15/10;;D21H15/10;;D21H17/05;;D21H17/05;;D21H17/06;;D21H17/06;;D21H17/07;;D21H17/07;;D21H17/10;;D21H17/10;;D21H21/06;;D21H21/06;;D21H21/24;;D21H21/24;;D21H23/04;;D21H23/04;;D21H23/18;;D21H23/18;;D21H23/20;;D21H23/20;;D21H23/28;;D21H23/28;;D21H25/005;;D21H25/005;;D21H25/02;;D21H25/02,A61F13/15;;A61L15/28;;D04H1/58;;D04H1/64;;D06M11/30;;D06M13/137;;D06M13/184;;D06M13/192;;D06M13/262;;D06M13/418;;D06M13/419;;D06M13/432;;D06M13/438;;D06M13/44;;D06M13/52;;D21B1/06;;D21C9/00;;D21H11/20;;D21H15/10;;D21H17/05;;D21H17/06;;D21H17/07;;D21H17/10;;D21H21/06;;D21H21/24;;D21H23/04;;D21H23/18;;D21H23/20;;D21H23/28;;D21H25/00;;D21H25/02,162/9;;162/146,7,0,,,"Van Verst, et al., Amine-Induced Lossen Rearrangements of 3-Hydroxy-5, 6-dihydrodouracil and N-Hydroxysuccinimide Benzenesulfonates, Journal of Heterocyclic Chemistry, vol. 16, (1979) p. 1329.;;American Society of Agricultural Engineers, ASAE publication 10-81, Forest Regeneration , 108-117, (Mar. 1981).;;HBA, Weyerhaeuser Paper Company, 1990.;;Textile Fibers, Hoechst Celanese Corporation Catalog, Mar. 1991.;;Marcher, Tailor-made Polyproplene and Bicomponent Fibers for the Nonwovens Industry, TAPPI Journal, Dec. 1991.;;Barker, Polyester Fiber for Thermal Bonding Nonwovens, Eastman Chemical Products, Inc.;;Thermal Bonding of Nonwovens by Means of Copolyester Melt Adhesive Fibers.",EXPIRED
371,FI,A0,FI 943323 A0,089-601-411-426-704,1994-07-12,1994,FI 943323 A,1994-07-12,US 9300280 W;;US 82032392 A,1992-01-13,Menetelmä ja laite yksittäisten selluloosakuitujen verkkouttamiseksi,,WEYERHAEUSER CO,HUNTER FRANK R;;CARNEY ALLAN R;;GRAEF PETER A;;ELSTON COLIN;;OLMSTEAD FRED E;;BOLSTEAD CLIFFORD R;;BOWNS MARK W,,https://lens.org/089-601-411-426-704,Patent Application,no,0,0,8,8,0,A61F13/15707;;A61F13/15707;;A61F13/53;;A61F13/53;;A61F2013/530007;;A61F2013/530007;;A61F2013/530474;;A61F2013/530474;;A61L15/28;;A61L15/28;;D04H1/54;;D04H1/54;;D04H1/655;;D04H1/655;;D06M11/30;;D06M11/30;;D06M13/137;;D06M13/137;;D06M13/1845;;D06M13/1845;;D06M13/192;;D06M13/192;;D06M13/262;;D06M13/262;;D06M13/418;;D06M13/418;;D06M13/419;;D06M13/419;;D06M13/432;;D06M13/432;;D06M13/438;;D06M13/438;;D06M13/44;;D06M13/44;;D06M13/52;;D06M13/52;;D21B1/066;;D21B1/066;;D21C9/005;;D21C9/005;;D21H11/20;;D21H11/20;;D21H15/10;;D21H15/10;;D21H17/05;;D21H17/05;;D21H17/06;;D21H17/06;;D21H17/07;;D21H17/07;;D21H17/10;;D21H17/10;;D21H21/06;;D21H21/06;;D21H21/24;;D21H21/24;;D21H23/04;;D21H23/04;;D21H23/18;;D21H23/18;;D21H23/20;;D21H23/20;;D21H23/28;;D21H23/28;;D21H25/005;;D21H25/005;;D21H25/02;;D21H25/02,A61F13/15;;A61L15/28;;D04H1/58;;D04H1/64;;D06M11/30;;D06M13/137;;D06M13/184;;D06M13/192;;D06M13/262;;D06M13/418;;D06M13/419;;D06M13/432;;D06M13/438;;D06M13/44;;D06M13/52;;D21B1/06;;D21C9/00;;D21H11/20;;D21H15/10;;D21H17/05;;D21H17/06;;D21H17/07;;D21H17/10;;D21H21/06;;D21H21/24;;D21H23/04;;D21H23/18;;D21H23/20;;D21H23/28;;D21H25/00;;D21H25/02,,0,0,,,,DISCONTINUED
372,FI,A,FI 943323 A,179-413-238-491-258,1994-09-05,1994,FI 943323 A,1994-07-12,US 9300280 W;;US 82032392 A,1992-01-13,Menetelmä ja laite yksittäisten selluloosakuitujen verkkouttamiseksi,,WEYERHAEUSER CO,HUNTER FRANK R;;CARNEY ALLAN R;;GRAEF PETER A;;ELSTON COLIN;;OLMSTEAD FRED E;;BOLSTEAD CLIFFORD R;;BOWNS MARK W,,https://lens.org/179-413-238-491-258,Patent Application,no,0,0,8,8,0,A61F13/15707;;A61F13/15707;;A61F13/53;;A61F13/53;;A61F2013/530007;;A61F2013/530007;;A61F2013/530474;;A61F2013/530474;;A61L15/28;;A61L15/28;;D04H1/54;;D04H1/54;;D04H1/655;;D04H1/655;;D06M11/30;;D06M11/30;;D06M13/137;;D06M13/137;;D06M13/1845;;D06M13/1845;;D06M13/192;;D06M13/192;;D06M13/262;;D06M13/262;;D06M13/418;;D06M13/418;;D06M13/419;;D06M13/419;;D06M13/432;;D06M13/432;;D06M13/438;;D06M13/438;;D06M13/44;;D06M13/44;;D06M13/52;;D06M13/52;;D21B1/066;;D21B1/066;;D21C9/005;;D21C9/005;;D21H11/20;;D21H11/20;;D21H15/10;;D21H15/10;;D21H17/05;;D21H17/05;;D21H17/06;;D21H17/06;;D21H17/07;;D21H17/07;;D21H17/10;;D21H17/10;;D21H21/06;;D21H21/06;;D21H21/24;;D21H21/24;;D21H23/04;;D21H23/04;;D21H23/18;;D21H23/18;;D21H23/20;;D21H23/20;;D21H23/28;;D21H23/28;;D21H25/005;;D21H25/005;;D21H25/02;;D21H25/02,A61F13/15;;A61L15/28;;D04H1/58;;D04H1/64;;D06M11/30;;D06M13/137;;D06M13/184;;D06M13/192;;D06M13/262;;D06M13/418;;D06M13/419;;D06M13/432;;D06M13/438;;D06M13/44;;D06M13/52;;D21B1/06;;D21C9/00;;D21H11/20;;D21H15/10;;D21H17/05;;D21H17/06;;D21H17/07;;D21H17/10;;D21H21/06;;D21H21/24;;D21H23/04;;D21H23/18;;D21H23/20;;D21H23/28;;D21H25/00;;D21H25/02,,0,0,,,,DISCONTINUED
373,EP,A2,EP 0547840 A2,145-127-759-150-888,1993-06-23,1993,EP 92311302 A,1992-12-10,US 81061991 A,1991-12-19,Event handling in a high level programming language environment.,"Events occurring in a computer system during the execution of programs 12 including routines 17, 18 prepared in a plurality of computer programming languages is as described are handled by a number of event handling means. The number and identity of each unique computer programming language used in the preparation of the program is determined using a language list contained in the application program. A unique event handling means (event handler) 13, 14 is initialized for each unique computer programming language used in the program. As the program executes selected events of interest to the event handlers are detected. The parameters associated with the selected event are determined. Optionally the detected events may be divided into two types : broadcast or targeted. Broadcast events are sent to all event handlers (except the debug event handler), whereas, the targeted events are sent to a single event handler. An event code and the relevant parameters are passed to the event handlers so that each event handler may perform whatever actions are appropriate for that event in the context of the programming language being supported. The event handlers generate an appropriate return code indicating the success, failure, or non-processing of the event and, for selected events, return requested information. The invention provides for a separate specialized debug event handler 15.",IBM,CARNEY WILLIAM PETER;;ENGLAND LAURENCE EDWARD;;HOCHMUTH GARY JOHN;;OWINGS BRIAN;;PORTER ERIC LYNN;;SHANNON ALFRED WILLIAM;;WILSON ROBERT AARON,,https://lens.org/145-127-759-150-888,Patent Application,yes,0,4,4,4,0,G06F9/542;;G06F9/542,G06F9/46,,0,0,,,,DISCONTINUED
374,US,A,US 5437418 A,168-338-493-977-531,1995-08-01,1995,US 82032392 A,1992-01-13,US 82032392 A;;CA 2145198 A;;US 9306124 W;;US 66576191 A;;US 60726890 A;;US 39520889 A;;US 28488588 A;;US 14092287 A;;US 472987 A,1987-01-20,Apparatus for crosslinking individualized cellulose fibers,"An apparatus is disclosed for preparing a quantity of individual treated fibers from one or more fiber mats. The apparatus comprises a fiber treatment zone, and a conveyor for conveying each mat through the fiber treatment zone. In the treatment zone each mat is impregnated by an applicator with a treatment material, such as a crosslinking substance, and conveyed directly to an attrition device. The attrition device fiberizes the mats to form a fiber output having a low nit level, such as no more than about three, and a dryer both dries the fiber output and cures the crosslinking substance. The fiberizer is configured to minimize the accumulation of fiber at locations therein. Fiber is transported from the attrition device to the dryer at a high velocity under reduced pressure to promote drying. A heated retention bin is provided after drying to increase curing time in the system. A thermobonding agent may be added to the dried and cured fibers to enhance the wet strength of webs made from the fiber.",WEYERHAEUSER CO,GRAEF PETER A;;ELSTON COLIN;;OLMSTEAD FRED E;;BOLSTAD CLIFFORD R;;BOWNS MARK W;;HUNTER FRANK R;;CARNEY ALLAN R,WEYERHAEUSER COMPANY (1992-06-22);;WEYERHAEUSER NR COMPANY (2009-04-21),https://lens.org/168-338-493-977-531,Granted Patent,yes,57,78,8,8,0,A61F13/15707;;A61F13/15707;;A61F13/53;;A61F13/53;;A61F2013/530007;;A61F2013/530007;;A61F2013/530474;;A61F2013/530474;;A61L15/28;;A61L15/28;;D04H1/54;;D04H1/54;;D04H1/655;;D04H1/655;;D06M11/30;;D06M11/30;;D06M13/137;;D06M13/137;;D06M13/1845;;D06M13/1845;;D06M13/192;;D06M13/192;;D06M13/262;;D06M13/262;;D06M13/418;;D06M13/418;;D06M13/419;;D06M13/419;;D06M13/432;;D06M13/432;;D06M13/438;;D06M13/438;;D06M13/44;;D06M13/44;;D06M13/52;;D06M13/52;;D21B1/066;;D21B1/066;;D21C9/005;;D21C9/005;;D21H11/20;;D21H11/20;;D21H15/10;;D21H15/10;;D21H17/05;;D21H17/05;;D21H17/06;;D21H17/06;;D21H17/07;;D21H17/07;;D21H17/10;;D21H17/10;;D21H21/06;;D21H21/06;;D21H21/24;;D21H21/24;;D21H23/04;;D21H23/04;;D21H23/18;;D21H23/18;;D21H23/20;;D21H23/20;;D21H23/28;;D21H23/28;;D21H25/005;;D21H25/005;;D21H25/02;;D21H25/02,A61F13/15;;A61L15/28;;D04H1/58;;D04H1/64;;D06M11/30;;D06M13/137;;D06M13/184;;D06M13/192;;D06M13/262;;D06M13/418;;D06M13/419;;D06M13/432;;D06M13/438;;D06M13/44;;D06M13/52;;D21B1/06;;D21C9/00;;D21H11/20;;D21H15/10;;D21H17/05;;D21H17/06;;D21H17/07;;D21H17/10;;D21H21/06;;D21H21/24;;D21H23/04;;D21H23/18;;D21H23/20;;D21H23/28;;D21H25/00;;D21H25/02,241/65;;241/152.2,9,1,088-913-604-496-297,10.1002/jhet.5570160708,"VanVerst, et al., Amine Induced Lossen Rearrangments of 3 Hydroxy 5,6 dihydrodouracil and N Hydroxysuccinimide Benzenesulfonates, Journal of Heterocyclic Chemistry, vol. 16, (1979) p. 1329.;;American Society of Agricultural Engineers, ASAE publication 10 81, Forest Regeneration, 108 117, (Mar. 1981).;;HBA, Weyerhauser Paper Company, 1990.;;Texile Fibers, Hoechst Celanese Corporation Catalog, Mar. 1991.;;Marcher, Tailor made Polypropylene and Bicomponent Fibers For the Nonwovens Industry, TAPPI Journal, Dec. 1991.;;Barker, Polyester Fiber For Thermal Bonding Nonwovens, Eastman Chemical Products, Inc.;;Thermal Bonding of Nonwovens by Means of Copolyester Melt Adhesive Fibers.;;International Search Report, PCT/US93/00280, filed Jan. 1, 1993 (2 Pages).;;International Search Report, PCT/US 91/07229 (3pp).",EXPIRED
375,EP,A3,EP 0547840 A3,115-529-101-281-906,1993-12-15,1993,EP 92311302 A,1992-12-10,US 81061991 A,1991-12-19,EVENT HANDLING IN A HIGH LEVEL PROGRAMMING LANGUAGE ENVIRONMENT,"Events occurring in a computer system during the execution of programs 12 including routines 17, 18 prepared in a plurality of computer programming languages is as described are handled by a number of event handling means. The number and identity of each unique computer programming language used in the preparation of the program is determined using a language list contained in the application program. A unique event handling means (event handler) 13, 14 is initialized for each unique computer programming language used in the program. As the program executes selected events of interest to the event handlers are detected. The parameters associated with the selected event are determined. Optionally the detected events may be divided into two types : broadcast or targeted. Broadcast events are sent to all event handlers (except the debug event handler), whereas, the targeted events are sent to a single event handler. An event code and the relevant parameters are passed to the event handlers so that each event handler may perform whatever actions are appropriate for that event in the context of the programming language being supported. The event handlers generate an appropriate return code indicating the success, failure, or non-processing of the event and, for selected events, return requested information. The invention provides for a separate specialized debug event handler 15.",IBM,"CARNEY, WILLIAM PETER;;ENGLAND, LAURENCE EDWARD;;HOCHMUTH, GARY JOHN;;OWINGS, BRIAN;;PORTER, ERIC LYNN;;SHANNON, ALFRED WILLIAM;;WILSON, ROBERT AARON",,https://lens.org/115-529-101-281-906,Search Report,yes,2,0,4,4,0,G06F9/542;;G06F9/542,G06F9/46,,2,0,,,"PATENT ABSTRACTS OF JAPAN vol. 13, no. 332 (P-905)26 July 1989 & JP-A-10 96 741 ( FUJITSU ) 14 April 1989;;SOFTWARE PRACTICE & EXPERIENCE. vol. 21, no. 4, April 1991, CHICHESTER, GB pages 375 - 390 W. W HO ET AL. 'AN APPROACH TO GENUINE DYNAMIC LINKING'",DISCONTINUED
376,US,A1,US 2008/0126168 A1,179-869-940-930-404,2008-05-29,2008,US 94022207 A,2007-11-14,US 94022207 A;;US 85939806 P,2006-11-15,OILFIELD MANAGEMENT SYSTEM,"Systems and methods of managing a workflow of an oilfield activity are provided. A problem in the oilfield activity is identified, where the oilfield activity includes a number of tasks necessary to complete a project of a number of projects in the workflow, and where the number of tasks are arranged within a number of workflow states associated with the oilfield activity. A sequence for the number of tasks is selectively updated based on an analysis of the oilfield activity performed by a user. The project is analyzed by examining a progress of the project within one of the number of workflow states to obtain a decision, where the project is associated with the problem. The problem is resolved in the oilfield activity based on the decision.",SCHLUMBERGER TECHNOLOGY CORP,CARNEY MICHAEL;;LUNDY PAUL S;;MCKEE RANDALL G;;PAO PHALYN;;ROSSI DAVID J;;SCHIPPERIJN PETER A;;SHIPLEY DAVID N;;TRABOULAY IAN H,SCHLUMBERGER TECHNOLOGY CORPORATION (2007-11-13),https://lens.org/179-869-940-930-404,Patent Application,yes,13,41,2,2,0,E21B41/00;;G06Q10/06316;;G06Q10/0633;;G06Q10/0639;;E21B41/00;;G06Q10/0639;;G06Q10/0633;;G06Q10/06316,G05B19/418,705/8,0,0,,,,DISCONTINUED
377,WO,A1,WO 2008/061200 A1,129-978-969-928-550,2008-05-22,2008,US 2007/0084852 W,2007-11-15,US 85939806 P;;US 94022207 A,2006-11-15,OILFIELD MANAGEMENT SYSTEM,"Systems and methods of managing a workflow of an oilfield activity are provided. A problem in the oilfield activity is identified, where the oilfield activity includes a number of tasks necessary to complete a project of a number of projects in the workflow, and where the number of tasks are arranged within a number of workflow states associated with the oilfield activity. A sequence for the number of tasks is selectively updated based on an analysis of the oilfield activity performed by a user. The project is analyzed by examining a progress of the project within one of the number of workflow states to obtain a decision, where the project is associated with the problem. The problem is resolved in the oilfield activity based on the decision.",CHEVRON USA INC;;SCHLUMBERGER CA LTD;;SCHLUMBERGER SERVICES PETROL;;LOGINED BV;;PRAD RES & DEV LTD;;CARNEY MICHAEL;;LUNDY PAUL S;;MCKEE RANDALL G;;PAO PHALYN;;ROSSI DAVID J;;SCHIPPERIJN PETER A;;SHIPLEY DAVID N;;TRABOULAY IAN H,CARNEY MICHAEL;;LUNDY PAUL S;;MCKEE RANDALL G;;PAO PHALYN;;ROSSI DAVID J;;SCHIPPERIJN PETER A;;SHIPLEY DAVID N;;TRABOULAY IAN H,,https://lens.org/129-978-969-928-550,Patent Application,yes,4,4,2,2,0,E21B41/00;;G06Q10/06316;;G06Q10/0633;;G06Q10/0639;;E21B41/00;;G06Q10/0639;;G06Q10/0633;;G06Q10/06316,E21B43/12;;G06F19/00,,0,0,,,,PENDING
378,US,B2,US 8764220 B2,135-994-048-094-106,2014-07-01,2014,US 201113095349 A,2011-04-27,US 201113095349 A;;US 32887510 P;;US 41020410 P,2010-04-28,Linear LED light module,"A linear light emitting diode (“LED”) light fixture includes LED modules that interface with one another to provide a substantially continuous array of LED's. This continuous array allows for substantially uniform light output from the LED light fixture. The LED modules can interface with one another via one or more connectors, which allow two or more LED modules to be electrically and mechanically coupled together. The connectors may be disposed beneath the LED's so that the connectors are not visible when the LED modules are coupled together. The connectors may be disposed along opposite ends of the modules to allow for end-to-end configurations of the modules and/or along side ends of the modules to allow for angled or curved configurations of the modules. The LED modules can be powered via one or more wires, magnets, or clips, which are coupled to a power source.",CHAN CHUN WAH;;CARNEY ANTHONY JAMES;;TICKNER JEROLD ALAN;;MENARD PETER J;;LADEWIG CHRISTOPHER;;GRIGORE VALERICA;;GARRETT BRADLEY STEPHEN;;BOYLE TRAVIS WILLIAM FRANCIS;;COOPER TECHNOLOGIES CO,CHAN CHUN WAH;;CARNEY ANTHONY JAMES;;TICKNER JEROLD ALAN;;MENARD PETER J;;LADEWIG CHRISTOPHER;;GRIGORE VALERICA;;GARRETT BRADLEY STEPHEN;;BOYLE TRAVIS WILLIAM FRANCIS,EATON INTELLIGENT POWER LIMITED (2017-12-31);;SIGNIFY HOLDING B.V (2020-03-02);;COOPER TECHNOLOGIES COMPANY (2011-08-01),https://lens.org/135-994-048-094-106,Granted Patent,yes,110,79,6,22,0,F21K9/20;;F21K9/20;;F21S2/005;;F21S2/005;;F21S4/20;;F21S4/28;;F21S4/28;;F21V15/013;;F21V15/013;;F21V17/164;;F21V17/164;;F21V19/003;;F21V19/003;;F21V21/088;;F21V21/088;;F21V21/096;;F21V21/096;;F21V21/30;;F21V21/30;;F21V23/06;;F21V23/06;;F21V29/51;;F21Y2103/10;;F21Y2103/10;;F21Y2113/13;;F21Y2113/13;;F21Y2115/10;;F21Y2115/10,F21V1/00,362/217.02,2,0,,,"International Search Report and Written Opinion for PCT/US2011/034138 mailed on Nov. 21, 2011.;;International Search Report and Written Opinion for PCT/US2011/034133 issued on Nov. 21, 2011.",ACTIVE
379,US,A1,US 2011/0286207 A1,044-160-932-798-390,2011-11-24,2011,US 201113095349 A,2011-04-27,US 201113095349 A;;US 32887510 P;;US 41020410 P,2010-04-28,Linear LED Light Module,"A linear light emitting diode (“LED”) light fixture includes LED modules that interface with one another to provide a substantially continuous array of LED's. This continuous array allows for substantially uniform light output from the LED light fixture. The LED modules can interface with one another via one or more connectors, which allow two or more LED modules to be electrically and mechanically coupled together. The connectors may be disposed beneath the LED's so that the connectors are not visible when the LED modules are coupled together. The connectors may be disposed along opposite ends of the modules to allow for end-to-end configurations of the modules and/or along side ends of the modules to allow for angled or curved configurations of the modules. The LED modules can be powered via one or more wires, magnets, or clips, which are coupled to a power source.",CHAN CHUN WAH;;CARNEY ANTHONY JAMES;;TICKNER JEROLD ALAN;;MENARD PETER J;;LADEWIG CHRISTOPHER;;GRIGORE VALERICA;;GARRETT BRADLEY STEPHEN;;BOYLE TRAVIS WILLIAM FRANCIS;;COOPER TECHNOLOGIES CO,CHAN CHUN WAH;;CARNEY ANTHONY JAMES;;TICKNER JEROLD ALAN;;MENARD PETER J;;LADEWIG CHRISTOPHER;;GRIGORE VALERICA;;GARRETT BRADLEY STEPHEN;;BOYLE TRAVIS WILLIAM FRANCIS,EATON INTELLIGENT POWER LIMITED (2017-12-31);;SIGNIFY HOLDING B.V (2020-03-02);;COOPER TECHNOLOGIES COMPANY (2011-08-01),https://lens.org/044-160-932-798-390,Patent Application,yes,11,90,6,22,0,F21K9/20;;F21K9/20;;F21S2/005;;F21S2/005;;F21S4/20;;F21S4/28;;F21S4/28;;F21V15/013;;F21V15/013;;F21V17/164;;F21V17/164;;F21V19/003;;F21V19/003;;F21V21/088;;F21V21/088;;F21V21/096;;F21V21/096;;F21V21/30;;F21V21/30;;F21V23/06;;F21V23/06;;F21V29/51;;F21Y2103/10;;F21Y2103/10;;F21Y2113/13;;F21Y2113/13;;F21Y2115/10;;F21Y2115/10,F21V21/00;;F21S4/00,362/217.1;;362/249.02;;362/217.16,0,0,,,,ACTIVE
380,DE,C2,DE 2325854 C2,103-397-583-477-110,1981-10-08,1981,DE 2325854 A,1973-05-22,US 25682772 A,1972-05-25,DE 2325854 C2,,"WESTERN ELECTRIC CO., INC., 10038 NEW YORK, N.Y., US","CARNEY, ADAM CARROLL, MIDDLETOWN, N.J., US;;CICHETTI JUN., MICHAEL PETER, STATEN ISLAND, N.Y., US;;KNEUER, JOSEPH GEORGE, FAIR HAVEN, N.J., US;;RICE, DONALD WESLEY, WANAMASSA, N.J., US",,https://lens.org/103-397-583-477-110,Granted Patent,no,0,0,18,19,0,H04J3/1647;;H04L1/08;;H04L12/525;;H04L12/525;;H04L1/08;;H04J3/1647,H04J3/04;;H04J3/16;;H04L1/08;;H04L12/52,,0,0,,,,EXPIRED
